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I am pleased to introduce the Seven-Year Report 
on the National Cancer Control Programme’s 
(NCCP) implementation of ‘A Strategy for Cancer 
Control in Ireland 2006’ (hereafter referred to as 
the 2006 National Cancer Strategy).
Progress from 2007 to 2014
Cancer Prevention 
The NCCP’s Community Oncology Programme has 
worked collaboratively with the HSE Population 
Health Division and now, the Health and Wellbeing 
Division, to provide a joint approach to the lifestyle 
risk factors common to many chronic diseases.
The focus on smoking cessation for the public 
and cancer patients has involved e-learning and 
training for GPs and Allied Health Professionals, 
development of advice and pharmacotherapy 
approaches for the public.
Alcohol, nutrition, physical activity and obesity 
have all required a shared approach to education 
and support.
Sun exposure is a specific risk factor for cancer. 
The NCCP’s submission to the Department of 
Health contributed to the introduction in 2014 
of legislation banning sunbed use for children 
younger than 19 years.
Information leaflets, including an ABCs for being 
cancer aware, are available on the NCCP website.
Cancer Screening
The National Cancer Screening Service 
commenced in 2007 and built on earlier work in 
rolling out breast and cervical cancer screening.
BreastCheck completed its second round of 
national screening for women age 50-64 years 
in late 2013 and has consistently achieved a 
high uptake (>70%) of invited women. Screening 
is offered every two years in a quality assured 
environment. Patients diagnosed with cancer 
benefit from multidisciplinary assessment and 
integration of surgical services.
CervicalCheck also completed its second round 
of national screening in 2013. Eligible women are 
aged 25-60 years. Uptake has been excellent, 
approaching 83% for younger women less than 30 
years and 74% overall. Smear taking is carried out 
by trained GPs and nurses, cytology is externally 
procured and colposcopy provided on a money-
follows-the patient basis in general hospitals. 
Information technology and quality assurance are 
integrated across the programme.
BowelScreen commenced in the final quarter of 
2012 for men and women aged 60-69 years. The 
programme offers home sampling and FIT testing 
for occult blood, linked to accredited colonoscopy 
centres and surgery for cancer patients, again 
on a multidisciplinary money-follows-the patient 
approach. The programme is on track to complete 
its first national round of screening by the end 
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of 2015 and will then continue to offer screening 
every two years. A programme for follow-up 
colonoscopies for patients with polyps is in place.
Further expansion of screening to ages 55-74 
years is planned after the first national round for 
patients aged 60-69 years is completed, subject to 
resources.
Implementation of Designated Cancer 
Centres
The 2006 National Cancer Strategy and the 2007 
Health Service Executive framework ‘Establishment 
of Managed Cancer Control Networks and 
Designation of Eight Cancer Centres (Appendix 
1)’ led to the implementation of radical change in 
the delivery of hospital-based specialised cancer 
services.
Eight cancer centres were designated, to each 
serve approximately half a million population. Four 
cancer networks were established (two in the East, 
one in the West, and one in the South), each of 
which has two cancer centres. The networks are 
now evolving into the six new hospital groups.
The key characteristics of the designated 
cancer centres are sustainable high volume 
multidisciplinary cancer services spanning the 
range of diagnostics, surgery, radiation oncology 
and medical oncology. Those centres without on-
site radiotherapy facilities have consultant radiation 
oncologists participating in treatment planning. All 
new patients and selected patients with recurrent 
cancer are reviewed at multidisciplinary team 
meetings comprising all diagnostic and therapeutic 
specialists.
Integrated care pathways from primary care into 
consultant oncology services have been developed 
in close collaboration with the Irish College of 
General Practitioners and with hospital consultants. 
Electronic GP referral has been developed and 
implemented for breast, lung and prostate cancer 
clinics and will soon include pigmented lesions.
The centralisation of breast cancer surgery from 
32 hospitals to eight cancer centres (and a satellite 
centre at Letterkenny) was the first big step which 
began in 2008/09 and was finally implemented 
by December 2009. This service was delivered 
in accordance with the Health Information 
and Quality Assurance (HIQA) Standards for 
Symptomatic Breast Disease (2007) and the 
NCCP Standard Operating Procedures (2009). 
Key Performance Indicators were developed 
and reported monthly. Timely access for urgent 
(two weeks) and non-urgent (12 weeks) referrals 
have been maintained, although, in 2014, some 
hospitals have struggled to meet targets, primarily 
due to staffing challenges and patient volumes. In 
2013 the clinics, which offer service for both benign 
and potentially malignant breast diseases, saw 
37,891 new referrals and a similar volume of return 
visits.
Centralisation of breast services has delivered 
timely access to excellent diagnosis and care 
and has replaced the fragmented services in 
32 hospitals prior to 2008, a number of which 
had not consistently offered prompt referral and 
multidisciplinary diagnosis and care.
Building on the successes in centralising breast 
services, the NCCP has progressively moved to 
centralising prostate, lung, pancreas, rectal and 
oesophageal cancer services in specified cancer 
centres.
In 2014, the designated cancer centres offer 
rapid access clinics for GP referrals of suspected 
lung and prostate cancer in all eight centres. 
Prostate surgical services are available in six cancer 
centres. Two other non-cancer centres still provide 
some surgical services and work is ongoing to 
complete their transfer. Lung cancer and upper 
gastrointestinal surgical services are each in four 
cancer centres.
Rectal cancer centralisation is progressing, with 
77% of surgeries taking place in cancer centres 
and the small number of additional services having 
access to MDTs (Appendix 2). This is a radical 
change from the 36 hospitals involved prior to 
2009. 
The national pancreatic cancer programme is 
based in one centre in Dublin with one satellite 
centre in Cork. The national neuro-oncology 
programme has a similar model. The majority 
of gynaecological cancers are referred to seven 
designated cancer centres. 
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Centralisation of uncommon cancers, such as head 
and neck and mouth cancers, neuroendocrine 
cancers, sarcomas and testicular cancers is a work 
in progress.
Work is ongoing with the HSE Divisions of Primary 
Care and Acute Hospitals to expedite GP referral 
for women suspected to have ovarian cancer.
The National Programme for Radiation 
Oncology (NPRO)
Significant investment in staff and facilities for 
radiotherapy has positioned Ireland to address 
the need for radical/curative (60% of treatments) 
and palliative therapy. Two new facilities opened 
in 2011 on the sites of St James’s and Beaumont 
Hospitals in Dublin, each offers Rapid Arc 
Technology and excellent intensity modulated 
therapy. Funding is in place and planning well 
advanced for replacement, expanded facilities 
in Cork and Galway to open in 2017/18 and the 
Republic of Ireland and Northern Ireland have 
collaborated in a cross-border initiative which will 
see patients from Donegal accessing treatment 
in Altnagelvin, Derry, when a new service starts in 
2016. 
Intracranial stereotactic and extracranial 
stereotactic services were launched in Dublin in 
2013 and 2014 respectively. Further investment in 
expansion of facilities in Dublin will be required to 
address demographic growth. 
Expertise in prostate brachytherapy has been 
leveraged to develop and roll out a national 
programme in 2013, with services now available in 
Galway, Cork and Dublin.
 
The National Programme for Medical 
Oncology & Haematology
Following on the successful sequential change 
management of introducing designated cancer 
centres, centralising high volume surgical services 
and developing appropriate multidisciplinary 
teams, the attention of the NCCP turned to the 
development of a national approach to medical 
oncology and haematology. This area of oncology 
expertise was not a feature of the 2006 National 
Cancer Strategy, but nevertheless, has now 
become an absolutely critical component of 
optimal management for cancer patients. 
In 2011, the NCCP embarked on a National 
Oncology Drug Management Programme to 
replace the previous system of 26 hospitals each 
paying for new cancer drugs. The first step was 
the establishment of an NCCP Technology Review 
Committee for new drugs and related predictive 
laboratory tests. This well constituted committee 
provides recommendations to the HSE Drugs 
Committee regarding funding of new drugs 
which exceed the €45,000 per quality adjusted 
life year threshold. In parallel with approval for 
funding for new drugs, the NCCP Chief Pharmacist 
develops treatment protocols in collaboration 
with the Irish Society of Medical Oncology or the 
Irish Haematology Society to provide a national 
protocol and a national physician order set for each 
new product. Since 2012, patients are registered 
by diagnosis for access to each new drug and 
hospitals are reimbursed via the Primary Care 
Reimbursement Service (PCRS) technology process 
on a money-follows-the-patient basis. Prices are 
negotiated by the HSE Corporate Pharmaceutical 
Unit, in collaboration with the NCCP, and national 
discounts are available to PCRS. Hospitals are 
no longer at risk of increasing erosion of their 
revenue base to fund new drugs, and patients are 
better able to transfer from designated cancer 
centre hubs to a number of smaller ambulatory 
chemotherapy services throughout the country.
In addition to new drug funding, in 2013, the 
NCCP initiated a fund for growth in cancer drugs 
to reflect the significant growth in incidence and 
prevalence of cancer. This growth was having an 
impact on hospital base budgets for the top ten 
most expensive drugs which had been approved 
prior to the implementation of the oncology drug 
management system for new drugs. At present, 
hospitals report their utilisation of these ten 
drugs quarterly and are reimbursed proportional 
to growth. In the longer term, work is ongoing 
to develop automated data feeds from hospital 
pharmacy systems to PCRS in order to provide 
real time tracking of drug expenditure and 
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appropriate reimbursement. These significant 
changes in national oncology drug management 
have imbedded quality, safety, audits, consistency 
and access in a money-follows-the-patient model 
supported by national protocols and physician 
order sets. 
In January 2014, the NCCP published its Oncology 
Medication Safety Review Report conducted 
across the 26 hospitals in Ireland involved in 
administering drug therapy in adults and children. 
The recommendations of this report were 
made available to all hospitals and a tracking 
system put in place to monitor compliance with 
these recommendations. A new national Policy 
Development Programme for Cancer Drugs is in 
evolution and will provide national policy direction 
by 2015.
Community Oncology
The Community Oncology Programme expands 
the range of cancer prevention, primary care 
guidelines and educational support, patient 
discharge and survivorship. This Programme has 
been integral to the development of patient 
care pathways from primary care referral into the 
designated cancer centres and has led to the 
development of electronic referral from GP offices 
into the hospitals for breast, lung and prostate 
cancer. Electronic referral of suspected melanoma 
is being piloted.
The Programme has developed a number of 
nursing education programmes including the 
programme for registered nurses in primary 
care which has now been delivered to 700 
nurses through specialist centres and the use 
of video links. An e-learning version is now 
under development. A continuing professional 
development programme for registered nurses 
working in an inpatient setting has focused on a 
three day programme commencing in 2014 which 
will lead to an accredited programme. The skills-
based Community Oncology Nursing Programme 
equips public health nurses to undertake care for 
patients at home who are undergoing systemic 
therapy. This programme, which was initially 
implemented in the Northwest and the West, has 
now been expanded to a university accredited 
programme to be delivered in multiple locations 
across the country.
Cancer Survivorship is now a high priority as 60% 
of diagnosed patients are likely to survive free of 
disease and may, over the course of their lives, 
develop a range of physical and psychological 
needs related to their prior diagnosis of cancer 
and its treatment that can best be addressed 
through an empowered primary care community, 
and through education and information of the 
patients in relation to consequences of cancer or 
its treatment. The initial focus is on development of 
treatment summaries and care plans.
Hereditary Cancer Programme
The Hereditary Cancer Programme has been in 
place for a number of years under the leadership 
of the National Centre for Medical Genetics. 
This service provides excellent guidelines and 
algorithms to determine which patients diagnosed 
with cancer are at risk of having a hereditary 
mutation and which family members should be 
subsequently tested. The original programme 
was under considerable strain in terms of the 
volume of referrals and growth in demand for 
counselling and testing. The NCCP has developed 
a partnership with the National Centre for Medical 
Genetics and they have jointly moved to develop 
a more comprehensive programme for patients 
and public at risk for hereditary cancers. The NCCP 
has funded public services at St James’s Hospital 
and the Mater Hospital, and has developed a 
reimbursement process to these hospitals for the 
costs of the genetic tests. Approval has been 
received in mid 2014 to appoint a national clinical 
lead for the NCCP in hereditary cancer to work on 
a further expansion of this programme. 
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National Guideline Development Groups 
(Tumour Groups)
Oncologists in Ireland have traditionally relied on 
a variety of local or international guidelines to aid 
treatment decisions. As cancer diagnosis, staging 
and treatment continues to grow in variety and 
complexity, the need to develop national evidence-
based clinical practice guidelines was identified as 
a priority.
In 2011, the Royal Colleges of Physicians and 
Surgeons were invited by the NCCP to nominate 
specialists in pathology, radiology, surgical 
oncology, radiation oncology and medical 
oncology to form five National Guideline 
Development Groups for breast, prostate, lung, 
gastrointestinal and gynaecological cancers. Each 
group worked collaboratively with NCCP project 
managers, a methodologist, research support 
and HSE librarians to adopt, adapt or develop 
treatment guidelines which they had critically 
evaluated, based on best published evidence.
The Breast and Prostate National Guideline 
Development Groups completed their work in mid 
2014. Their comprehensive and succinct guidelines 
have been through stakeholder review and are 
proceeding to external review. Publication and 
implementation will be in late 2014.
The Gynaecology Guideline Development Group 
has completed its first guideline and the lung 
and gastrointestinal guidelines have made good 
progress. Once all the Guideline Development 
Groups have completed their tranche of guidelines, 
the NCCP will develop five more national Guideline 
Development Groups to address haematology, skin 
cancers, sarcomas, brain cancers and head and 
neck cancers. 
Guidelines have been developed according to 
the principles and processes of the Department of 
Health National Clinical Effectiveness Committee. 
They will be periodically reviewed and revised as 
necessary.
Cancer Intelligence
The National Cancer Registry of Ireland (NCRI) 
provides comprehensive capture of cancer 
incidence, prevalence, mortality and site-specific 
trends.
This excellent registry is an independent entity 
with its own Board. Its Director works closely 
with hospitals, the NCCP and the National 
Cancer Screening Service to capture data on 
demographics, pathology, staging and the first 
year of treatment. Collaboration and comparison 
of international outcomes is a key element of 
their work. For patients diagnosed up to 2007, 
Ireland has similar outcomes to England, Wales 
and Scotland, but falls short of the better five year 
age-adjusted survivals reported by mature cancer 
control systems, such as some of the Scandinavian 
countries, Australia and Canada.
The reorganisation of cancer services in Ireland 
is expected to show significant improvement in 
survival over the next decade.
The Cancer Intelligence Unit of the NCCP relies on 
NCRI data and HSE hospital data from the Hospital 
Inpatient Enquiry (HIPE) system to evaluate 
workload and plan for revenue, staff and capital 
developments. In addition the NCCP develops 
and implements key performance indicators for 
cancer services, including access times and other 
quality clinical parameters. These are consistently 
monitored by hospitals, screening services, the 
NCCP and the wider HSE. Planning and guidance 
is conducted in partnership with hospitals and HSE 
divisions.
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National Programmes in Quality 
Assurance
Histopathology
Accuracy and consistency in cancer diagnoses 
are the critical elements in determining best 
patient outcomes. The Faculty of Pathology of 
the Royal College of Physicians of Ireland leads in 
the development and implementation of clinical 
audit and quality assurance. The NCCP provided 
sponsorship and collaborative input into this 
programme (from 2009), which spans all tissue 
histopathology, not just cancer. The programme 
has been successfully implemented nationally in 
2013 and published its first report on the initial 3 
benchmarks in February 2014.
Radiology 
The National QA Programme in Radiology 
has been funded by the NCCP since 2010. It 
is managed by the Faculty of Radiology in the 
Royal College of Surgeons in Ireland and has just 
completed the roll out of the supporting ICT in its 
first site. National implementation is expected to 
be complete in 2016.
Endoscopy
In 2011, the conjoint board of the Royal College 
of Physicians and Surgeons in Ireland, in 
association with the NCCP/HSE and its National 
Cancer Screening Service, launched the National 
Quality Assurance Programme in gastrointestinal 
endoscopy. QA Guidelines have been established 
and the programme is in its implementation phase. 
There are currently 18 sites live, with all sites 
expected to be live by 2015.
Overall, these National Quality Assurance 
Programmes, and their data capture and 
information technology infrastructure are available 
in public, private and voluntary hospitals in the 
country. 
Cancer Research
The National Cancer Control Programme does 
not have the mandate to develop strategy or fund 
research, however, it is committed to fostering 
clinical, epidemiology and related translational 
research as an essential element of national cancer 
services. Knowledge development, health services 
evaluation, clinical outcomes and quality of care 
all improve in an active research environment. 
Patients benefit from participation in clinical trials; 
oncologists and allied health staff benefit from 
fostering their intellectual curiosity, developing 
research experience, and engaging in innovative 
studies, all of which favour recruitment and 
retention of excellent staff. Cost savings in health 
services are also facilitated by access to new drugs 
and tests.
ICORG, the All Ireland Cooperative Oncology 
Research Group, conducts the majority of cancer 
clinical trials in Ireland. The cooperative research 
group has participation from most oncologists in 
Ireland. Its funding is principally derived from the 
Health Research Board, as well as the Irish Cancer 
Society and international cooperative groups or 
pharmaceutical sponsorship. ICORG has been 
very successful: in 2013, over 70 clinical trials were 
open to recruitment, 1600 patients were enrolled 
and active collaboration was ongoing with over 
50 pharmaceutical companies and universities 
worldwide.
The National Cancer Registry of Ireland is actively 
involved in research. Its focus is on etiology and 
risk factors, impact of screening and treatment, 
outcomes of care including patient reported 
outcomes, quality of life and long-term sequelae of 
cancer and survival.
Scientists, allied health staff and physicians conduct 
a wide range of basic science, translational, 
epidemiology and clinical research in universities 
and hospitals, which are beyond the scope of this 
document. 
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Challenges in 2014
The burgeoning incidence and prevalence of 
cancer, driven by both the demographics of an 
aging population and the success of long-term 
treatments in improving survival, will more than 
double demands on services in the next 25 years.
The exciting innovations in cancer diagnostics and 
therapeutics come with rapidly rising costs.
The current financial recession and its consequent 
recruitment moratorium impede the smooth 
planning for growth in highly specialised 
human resources or timely investment in capital 
equipment and new technologies. Investment in 
information technology to support clinical systems 
and performance management is a priority. 
National health services reform and restructuring 
are well underway but the impact on the relatively 
“young” National Cancer Control Programme 
must be carefully managed to leverage ongoing 
commitment to the focus of cancer services in 
designated cancer centres.
Opportunities
Research in molecular oncology has led to an 
explosion of knowledge of the genetic behaviour 
and chemical pathways of cancer cells. The 
consequent growth in sophisticated diagnostics 
and therapeutics has steadily improved both the 
curability of cancer and the ability to moderate 
the growth of advanced cancers. Now, more than 
60% of cancers are cured. Advanced cancers are 
evolving into chronic diseases which require long 
term treatment, but some cancers remain refractory 
to current therapies.
The major focus of the next decade will be on 
personalised medicine where drugs target specific 
features of cancer cells. 
Cancer prevention and screening will be a long-
term priority and cancer survivorship will emerge 
as a dominant theme. The future of cancer control 
will reflect innovation and priority setting for cost 
effective interventions.
The progress the NCCP has achieved so far 
in implementing the National Strategy was 
contingent on the strong leadership and support of 
the following people and organisations:
•	 The	Minister	and	the	Department	of	Health
•	 The	HSE
•	 The	Royal	Colleges	of	Medicine	and	Surgery	
in Ireland and the Irish College of General 
Practitioners
•	 The	CEOs	of	hospitals	and	groups,	especially	
those with designated cancer centres
•	 The	oncology	consultant	community	and	
their leaders in specific disciplines or cancer 
diagnoses
•	 The	National	Clinical	Advisors	to	the	NCCP,	
especially Professor Arnold Hill (Surgery), 
Dr Jerome Coffey (Radiation Oncology) and 
Dr Maccon Keane (Medical Oncology) and 
the Chairs and Clinical Leads of the National 
Guideline Development Groups and Clinical 
Services
Special thanks to:
•	 Professor	Tom	Keane,	the	first	Director	of	the	
NCCP
•	 Mr	Tony	O’Brien,	first	CEO	of	the	National	
Cancer Screening Service and former Deputy 
Director of the NCCP and now the Director 
General of the HSE
•	 Dr	Harry	Comber,	recently	retired	Director	of	
the National Cancer Registry of Ireland
•	 The	excellent	staff,	both	past	and	present,	of	
the National Cancer Control Programme
Finally, it’s a privilege to work with the public, 
patients, their advocacy groups and charitable 
bodies such as the Irish Cancer Society, in the 
pursuit of improving the survival and quality of life 
for patients with cancer. 
Dr. Susan O’Reilly MB, BCh, BAO, FRCPC, FRCPI 
National Director 
National Cancer Control Programme
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The Context
Ireland developed its first national Cancer Strategy 
in 1996. This strategy aimed to reduce the death 
rate from cancer in the under-65 age group by 
15%in the ten-year period from 1994. Prior to the 
development of the first Cancer Strategy, there 
had been little dedicated investment in cancer 
services. This 1996 strategy resulted in a definite 
focus, prioritisation and investment (over €400m) in 
cancer services and gave rise to the appointment 
of 85 new cancer consultants (including 15 medical 
oncologists,, 14 breast surgeons, 6 general 
surgeons, 19 histopathologists, 12 radiologists) and 
245 clinical nurse specialists. 
The first Cancer Strategy was evaluated by Deloitte 
in 2003. Their overall review was very positive 
noting that the 1996 National Cancer Strategy 
had raised the profile of cancer services across 
the health system and provided a clearer focus 
and direction in terms of planning processes. It 
concluded that the implementation of a new cancer 
strategy would ultimately be reliant on an ability to 
reconfigure existing structures, enhance system co-
ordination and interaction and redefine accepted 
working practices and service management.
The review coincided with the publication of a 
National Cancer Registry of Ireland (NCRI) report in 
2004, which found significant regional variations in 
treatment and, in the case of breast and colorectal 
cancer, significant differences in regional survival 
rates.
In 2006, the second national cancer strategy, ‘A 
Strategy for Cancer Control in Ireland 2006’, was 
developed by the second National Cancer Forum, 
an advisory body to the Minister for Health and 
Children. It aimed to address the rising burden 
of cancer in the Irish population at a time when 
Ireland compared poorly with other developed 
countries in terms of cancer risk, cancer incidence 
and deaths from cancer. 
The 2006 National Cancer Strategy advocated 
a comprehensive cancer control approach i.e. 
a whole population, integrated and cohesive 
approach to cancer that involves prevention, 
screening, diagnosis, treatment, and supportive 
and palliative care. It also placed major emphasis 
on the measurement of need and on addressing 
inequalities as well as on reform and reorganisation 
of the delivery of cancer services. The aim of 
this new approach was to ensure that future 
services are consistent and are associated with 
a high-quality experience for patients and their 
families. The report highlighted concerns on the 
considerable variation in cancer survival between 
regions and the fragmentation of services for 
cancer patients. 
The 2006 National Cancer Strategy’s vision was 
that “Ireland will have a system of cancer control 
which will reduce our cancer incidence, morbidity 
and mortality rates relative to other EU15 countries 
by 2015. Irish people will know and practice health 
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promoting and cancer-preventing behaviours and 
will have increased awareness of and access to 
early cancer detection and screening. Ireland will 
have a network of equitably accessible state-of-the-
art cancer treatment facilities and we will become 
an internationally recognised location for education 
and research into all aspects of cancer.”
The 2006 National Cancer Strategy envisaged 
the establishment of four geographic networks 
of cancer services, each covering a population of 
about one million people. Each network was to 
have a lead cancer institution /specialist cancer 
hospital with access to radiotherapy services. These 
centres were to deliver a full range of cancer care, 
and to oversee the delivery of cancer services at 
the other institutions in the network. Each cancer 
network was also to have regional centres dealing 
with cancers where a high degree of specialisation 
is not required. 
‘A Strategy for Cancer Control in Ireland 2006’ 
identified a number of key shortcomings in the 
way cancer services were delivered in Ireland. The 
analysis in the report noted that while there had 
been a transformation in the range and capacity 
of cancer services as a result of the 1996 National 
Cancer Strategy, there continued to be a need 
for significant expansion in all aspects of cancer 
service capacity in order to meet the cancer needs 
of the population. With some exceptions, such as 
paediatric cancer, Ireland was performing poorly 
by international standards in relation to cancer 
risks, incidence and survival. The fragmented 
arrangements for the delivery of cancer services 
were not in accordance with best practice. 
Cancer services were spread across thirty six 
hospitals, many with small volumes and lacking full 
multidisciplinary teams. There was poor access as 
well as inequity in the provision, availability and 
performance of cancer services when examined by 
region, gender and by social class. The aim was to 
develop a cancer control system with the potential 
to achieve population and individual outcomes 
on a par with the highest international standards. 
The 2006 National Cancer Strategy included 55 
recommendations including the development of a 
cancer control framework. 
In response to the publication of the 2006 National 
Cancer Strategy, the Health Service Executive 
(HSE) established the National Cancer Control 
Programme (NCCP) in 2007. The role of the NCCP 
was to provide a comprehensive programme of 
cancer control in Ireland, to transform how cancer 
care is delivered, and ensure that cancer services 
meet the highest standards. The programme was 
to provide the necessary governance, integration 
and leadership to create the essential framework 
for a successful transformation of cancer control 
activities in Ireland. 
The establishment of the NCCP came at a time 
when the reputation of cancer services in Ireland 
had been undermined following a series of high 
profile breast cancer missed diagnoses, long 
waiting lists for colonoscopy, missed cancers 
as well as delayed diagnostics and treatment. 
Notwithstanding, the investment made since the 
publication of the 1996 Strategy, cancer services 
were still fragmented and disorganised with limited 
or no accountability. In 2007 breast cancer surgery 
was undertaken in 32 hospitals while rectal cancer 
surgery was undertaken in 36 hospitals. 
The Deloitte report highlighted that while the 
concept of supra-regional centres had been 
accepted by policy-makers, limited progress has 
been made on their establishment on the ground. 
Clinical pathways from secondary services to 
tertiary services had not been clearly defined. 
Specifically the report noted that in some health 
boards, cancer services were spread across a 
number of hospital sites which was attributable to 
geographic and demographic considerations as 
well as a result of political influence and the desire 
to have “all services in all hospitals”. 
There were many positive features of the cancer 
services including the development of regional 
and supra-regional cancer centres, approval for 
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expansion of Radiation Oncology facilities (outlined 
in the Hollywood Report1), additional funding for 
cancer services, high participation in clinical trials, a 
cadre of well-trained oncologists, clinicians, nurses, 
technicians and therapists skilled in oncology, 
early introduction of breast and cervical screening 
programmes (albeit not with national coverage) 
establishment of regional directors of cancer and 
approval for cancer liaison nurses. 
However, at the time, there were few national 
standards, treatment guidelines, quality indicators, 
monitoring of targets or assurance processes in 
place for cancer services. Apart from the Hospital 
In-Patient Enquiry Scheme (HIPE), the only cancer 
data available related to incidence, treatment and 
survival rates from the National Cancer Registry of 
Ireland (NCRI). 
Cancer was not managed as a function and there 
was no co-ordinated national plan for cancer 
prevention, early detection, diagnosis, treatment, 
survivorship and end-of life care. 
Another key impetus for change was the 
publication of the EUROCARE results2, which 
showed cancer outcomes in Ireland were not as 
good as other European countries.
In September 2007, in response to the publication 
of the 2006 National Cancer Strategy, the HSE 
published a plan which provided an outline of the 
proposed configuration of cancer care services. 
This plan, ‘Establishment of Managed Cancer 
Control Networks and for the Designation of Eight 
Cancer Centres’ (Appendix 1) specified that eight 
hospitals were to be designated as cancer centres 
for the purpose of providing primary curative 
surgery in the context of full multidisciplinary care. 
A cancer centre was to be characterised by 
the geographic concentration of all oncology 
disciplines with sub specialised expertise on a 
tumour specific/discipline basis to provide the 
critical mass and support to achieve best practice 
in cancer care. Designated cancer centres were 
anticipated to address the needs of a 500,000 
population base. Four of the eight designated 
centres were in Dublin: The Mater Hospital, 
Beaumont Hospital, St. Vincent’s University 
Hospital, St. James’s Hospital; the other four 
centres were Waterford Regional Hospital, Cork 
University Hospital, Mid Western Regional Hospital 
Limerick and University College Hospital Galway. It 
was also agreed that Letterkenny, because of the 
unique geographical circumstances would become 
a satellite of University College Hospital Galway 
subject to certain conditions on patient volumes, 
governance and outcomes. Apart from designating 
the eight cancer centres, this document also 
recommended further centralisation of certain 
types of cancer surgery. 
The NCCP was established with a remit to lead 
and implement the change management process 
required to reorganise cancer services and set 
up a system of quality assurance and oversight 
designed to improve the care and outcomes for 
cancer patients. It was to adopt a population based 
approach to planning and would integrate all 
aspects of cancer care and oversee all activities.
Prof. Tom Keane was seconded from his role 
as provincial radiation programme leader for 
the British Columbia Cancer Agency in Canada 
and appointed Interim Director of the NCCP in 
September 2007 for a two year period to oversee 
its implementation. He engaged widely with 
radiation, surgical and medical oncologists, GP 
and nursing representatives and voluntary agencies 
across the country. He appointed part-time 
advisers to the NCCP in surgical oncology, medical 
oncology and radiation oncology and established 
the community oncology team. Following the 
completion of Professor Keane’s contract in 
February of 2010, Mr. Tony O’Brien (CEO of the 
National Cancer Screening Service (NCSS) and 
current Director General of the HSE) was appointed 
Interim Director until the commencement of Dr. 
Susan O’Reilly as Director of the National Cancer 
Control Programme in September 2010.
1 The Development of Radiation Oncology Services in Ireland, 2003, http://www.dohc.ie/publications/expert_working_group_
on_radiation_oncology_services.html 
2 The Lancet Oncology, Volume 8, Issue 9, Pages 784 - 796, September 2007
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Change management and leadership of this 
complex strategy initially focused on: 
1. Delivering radical change in the centralisation 
of surgical services for selected common 
diagnostic categories (breast, prostate 
and lung cancers) and for selected 
clinical diagnoses requiring complex 
treatments (rectal, pancreatic and upper 
oesophageal cancers) in high volume, expert 
multidisciplinary centres. 
2. Planning and building radiation oncology 
capacity.
3. Improving quality assurance in diagnostic 
specialities. 
4. Developing evidence based referral pathways 
from primary care to specialist services.
Building on this logical sequence, national 
programmes in medical oncology and 
haematology, and their essential national drug 
management were next developed. 
Simultaneously, the establishment of a quality 
assurance system which incorporated the 
development and monitoring of key performance 
indicators and the establishment of national tumour 
groups as well as guideline development and 
evaluation of patient safety were prioritised.
This report will assess the impact of the 
establishment of the National Cancer Control 
Programme in implementing the 2006 National 
Cancer Strategy. This is particularly important as 
Ireland looks to develop a new cancer strategy. 
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In 2007, the HSE established a National Cancer 
Control Programme (NCCP) in response to the 
publication of the new 2006 National Cancer 
Strategy. 
The Interim Director, Prof. Tom Keane, was 
seconded to oversee its implementation. The 
agreed approach taken for the implementation of 
the Strategy was one of a step-wise, sequential 
implementation with the identification of a number 
of key priority areas which could be significantly 
progressed. The immediate priority was the 
centralisation of symptomatic breast disease 
services along with the expansion of radiation 
oncology facilities, and improving access to 
diagnostic services for some common cancers. 
The development of evidence-based GP referral 
pathways was another early initiative. Centralisation 
of rectal cancer surgery was also a high priority as, 
similar to breast surgery, this service was widely 
dispersed. Other cancer priorities were to be 
addressed in sequence subsequently. The focus on 
medical oncology commenced in earnest in 2012 
along with the establishment of the hereditary 
cancer programme.
In its plan ‘Establishment of Managed Cancer 
Control Networks and the Designation of Eight 
Cancer Centres’ published in September 2007, 
the HSE had provided the blueprint for the 
configuration of cancer services. It had already 
identified the eight designated cancer centres 
which were to be characterised by the geographic 
concentration of all oncology disciplines, with 
sub specialised expertise on a tumour specific/
discipline basis, to provide the critical mass and 
support to achieve best practice in cancer care 
(Appendix 1). 
Priority was initially given to centralising the 
surgery for high volume cancer cases with the 
transfer of breast surgery as the main priority in 
the first two years. Commencing with the lowest 
volume hospitals, services were to be moved in 
sequence from hospitals which did not meet the 
defined criteria for delivery of surgical care into 
the eight designated cancer centres. In parallel 
to the centralisation of hospital services, work 
was undertaken with the Irish College of General 
Practitioners to ensure prompt and appropriate 
referrals. 
 
Symptomatic Breast Disease
In 2007, the Health Information and Quality 
Authority (HIQA) approved the National Quality 
Assurance Standards for Symptomatic Breast 
Disease which were subsequently mandated by 
the Minister for Health and Children. Around this 
time a series of investigations were undertaken 
into serious incidents of delayed or missed breast 
cancer diagnosis which raised concerns about the 
quality and safety of breast cancer services. These 
events gave urgency and momentum to efforts 
to improve the quality and safety of symptomatic 
Overview of Key 
Service Developments
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breast disease services. The then Minister for 
Health and Children convened a special meeting 
of experts in breast cancer care in November 2007, 
an indication of the widespread level of concern 
about the services at that time. 
In 2007, there were 32 hospitals providing some 
level of symptomatic breast disease surgery. 
Between September and November of that year, 
breast cancer surgical services were discontinued 
in hospitals which were carrying out fewer than 
20 breast cancer surgeries per annum. There 
remained 22 hospitals providing a service. It was 
agreed that by the end of 2009, 90% of all breast 
cancer surgeries would be concentrated in the 
eight designated centres (and a satellite centre at 
Letterkenny General Hospital). 
Over 2008-2009, transition plans were developed 
for consolidating the remaining symptomatic breast 
disease services into the eight designated centres. 
Most transitions involved a combination of transfer 
of resource and some additional funding to the 
designated cancer centre. Arrangements were put 
in place for patient follow up and details of the 
new arrangements were communicated to GPs and 
the public. By December 2009, all symptomatic 
breast disease surgery was provided only in the 
eight designated centres and the satellite unit at 
Letterkenny General Hospital. The centralisation of 
breast cancer surgery was controversial particularly 
in parts of the West of Ireland. Strong leadership 
from key clinicians and managers, the backing of 
patient groups and unwavering political support 
were key factors in implementing this change 
within the target time-frame. 
In 2010, the Health Information and Quality 
Authority published the Quality Review of 
Symptomatic Breast Disease Services, the 
culmination of two and a half years of interaction 
with the services since the launch of the National 
Quality Assurance Standards in 2007. This 
involved self-assessment, validation of the self-
assessment process, feedback to designated 
centres and a quality review visit with in-depth 
review of performance prior to publication of the 
findings. While identifying many areas for further 
improvement, the Review acknowledged the 
progress that had been made “From a position in 
2007 when symptomatic breast disease services 
in Ireland were dispersed, unspecified and 
unmonitored, there are now eight designated 
centres established, albeit the last of these became 
operational in December 2009”.
A review of the National Quality Assurance 
Standards for Symptomatic Breast Disease 
Services was carried out in 2013. This review took 
into account the substantial reform programme 
for cancer services over recent years, the HIQA 
national quality review of symptomatic breast 
disease services, published in 20103, and the 
subsequent development of key performance 
indicators (KPIs) and clinical guidelines by the 
National Cancer Control Programme. The review 
also took into account the National Standards for 
Safer Better Healthcare4, published in 2012. 
Since February 2014, symptomatic breast disease 
services are monitored by HIQA under the 
National Standards for Safer Better Healthcare 
as the National Quality Assurance Standards for 
Symptomatic Breast Disease Services have been 
stood down. 
There have been significant improvements in 
the care of patients with breast cancer since the 
establishment of the NCCP. A national clinical 
governance system is in place with designated lead 
clinicians from the eight cancer centres meeting on 
a regular basis to improve the implementation and 
standardisation of evidence based practice across 
the centres. Key performance indicators have 
been developed to monitor access, processes and 
outcomes for those referred to symptomatic breast 
disease clinics. As a result of the establishment 
of these clinics, over 95% of all women with an 
urgent referral are seen promptly within two weeks 
of referral, treatment is consultant-delivered, with 
a multidisciplinary team in place and outcomes 
monitored and KPIs measured. Partnership with 
general practitioners and the ICGP has been key in 
improving the referral pathway. 
3 http://www.hiqa.ie/system/files/Symptomatic_Breast_Disease_Services_National_report_2010%20.pdf
4 http://www.hiqa.ie/standards/health/safer-better-healthcare
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Since all breast disease may be referred (not just 
suspected cancers) these clinics also see a high 
volume of non urgent benign cases within a target 
time of 12 weeks. 
Additional information on breast cancer is available 
in Section 6.1 
Colorectal Surgery
Following the successful transfer of breast cancer 
surgery to the eight designated cancer centres in 
2008-2009, the attention of the NCCP turned to 
colorectal cancer surgery. In 2008, colon cancer 
surgery was performed in 32 hospitals and rectal 
cancer surgery in 29 hospitals. The 2006 National 
Cancer Strategy envisaged that primary surgery 
for colorectal cancer would take place in the 
designated cancer centres. The ‘Establishment 
of Managed Cancer Control Networks 
and Designation of Eight Cancer Centres’ 
recommended that rectal cancer surgery would be 
confined to four designated centres. 
These proposals were discussed at a large 
meeting of the colorectal surgical community at 
the Royal College of Surgeons in Ireland’s (RCSI) 
annual Charter Day in 2008. The importance 
of maintaining competent surgeons in acute 
hospitals to deal with acute surgical cases was 
stressed. Concern was expressed that centralising 
experienced colonic surgeons into eight centres 
would result in a deficit in provision of emergency 
care in the non-designated general hospitals. In 
addition the relative frequency of presentation 
of colon cancer gave rise to concerns that cancer 
centres would struggle to deal with the needs 
of such a large group of patients. It was also 
recognised that there was not a strong evidence 
base indicating that outcomes were likely to be 
improved substantially by centralisation of colon 
cancer surgery. In view of these factors, it was 
agreed that colon cancer surgery would remain in 
all acute hospitals with Emergency Departments. 
However, the international literature was very clear 
that rectal cancer surgery should be carried out in 
high volume centres. 
The Irish Association of Coloproctology (IACP) 
met with Prof. Tom Keane in 2008, indicating 
their support for improving standards of care 
in colorectal cancer surgery and confirming 
willingness to participate in an audit of rectal 
cancer surgery. Following this the RCSI began 
an audit of all rectal cancer surgery performed in 
public hospitals Ireland in 2007. While retrospective 
in nature, the audit provided independent 
verification of the number of rectal cancer 
operations performed in the audited hospitals as 
well as some data relating to quality of surgery and 
pathology. Following the audit, the IACP made a 
number of detailed recommendations:
•	 Rectal	cancer	surgery	should	not	be	
performed in hospitals where fewer than 
20 rectal cancer surgeries are carried out 
annually
•	 Rectal	cancer	surgery	should	be	performed	
in all eight designated cancer centres with 
provisos in relation to number of operations, 
adherence to guidelines, surgeon training, 
nomination of a lead surgeon, discussion of 
patients at multidisciplinary team meetings 
and participation in audit
•	 Rectal	cancer	surgery	could	be	performed	in	a	
small number of high volume non-designated 
centres, with similar provisos as the cancer 
centres, on an interim basis. 
The IACP considered that implementation of these 
recommendations would immediately reduce the 
number of hospitals providing rectal cancer surgery 
to 14.
Prof. Keane met with the four HSE Regional 
Director of Operations, early in 2010, outlining 
the findings of the audit, the rationale for the 
proposed changes and recommending that they 
be implemented in the acute hospital system. The 
transfer to the designated cancer centres was to 
be resourced through inter-hospital transfer of 
resources within the HSE Regions, proportionate 
to the volume of surgery being transferred. The 
Interim Director held separate discussions in 
Letterkenny General Hospital and agreed that 
subject to certain conditions including linkage with 
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the multidisciplinary team in Galway and routine 
monitoring, rectal cancer surgery could continue to 
be performed at the hospital. Some patients with 
particularly complex surgery would be transferred 
to Galway for surgery. 
Subsequent to the audit, many low volume 
surgeons ceased their rectal cancer surgery. 
Some surgeons with moderate volume elected to 
transfer that part of their practice to a designated 
cancer centre. At the end of 2009, 51% of rectal 
cancer surgery took place in the eight designated 
cancer centres and Letterkenny; by the end of 
2012 (last complete year of data), this had risen 
to 72%. However, rectal cancer surgery continued 
to be performed in six other hospitals. Preliminary 
information in relation to 2013 indicates that 
there has been continued transfer of rectal cancer 
surgery to the designated centres from a number 
of smaller hospitals. However, there is a substantial 
rectal cancer surgery practice remaining in two 
non-designated hospitals. 
The national colorectal screening programme 
BowelScreen began at the end of 2012 and is 
currently being rolled out nationally. Under the 
programme all surgery for screen detected cancers 
must be carried out in the eight designated cancer 
centres.
The slow progress and lack of completion of 
transfer of rectal cancer surgery to the designated 
centres over a four year period 2010-2014 is in 
sharp contrast to the rapid, complete transfer of 
breast cancer services in a two year period 2008-
2009. There are a number of contributing factors 
in addition to the resistance to change which is 
also present. This transfer coincided with a period 
of financial retrenchment in Ireland, when the HSE 
experienced budget reductions and a recruitment 
moratorium was in place with resulting reductions 
in staffing levels. The anticipated transfer of 
resources into the designated centres, and the 
export of intermediate level benign surgery to the 
non-designated centres could not be effected. 
The designated centres therefore were trying to 
absorb an increased workload at a time when not 
only did they not receive additional resources but 
their own budget and workforce were reduced. A 
number of cancer centres were also impacted by 
acute hospital reconfiguration, where the role of 
other hospitals in their region changed, and more 
complex non-cancer work was also being diverted 
to the cancer centre. At the end of 2013, rectal 
cancer surgery was undertaken in 19 hospitals. 
The NCCP has identified the continuation of the 
process of rectal cancer centralisation in its service 
plan priorities for 2014. 
Additional information on rectal cancer is available 
in Section 6.4. 
Prostate Cancer
The ‘Establishment of Managed Cancer Control 
Networks and Designation of Eight Cancer 
Centres’ concluded that there is a need for four 
centres nationally, one within each Network, for the 
curative surgical treatment of primary urological 
cancer. 
The original intention has been reconsidered and 
the NCCP now intends to centralise all prostate 
cancer surgery into six centres (University College 
Hospital Galway, Cork University Hospital, the 
Mater, Beaumont, St. James’s and St. Vincent’s 
University Hospitals). Two non designated hospitals 
are also undertaking significant volumes of prostate 
cancer surgery (Appendix 2). Efforts to centralise 
prostate cancer surgery remain a work in progress 
with the transfer of existing surgery from two large 
non cancer centres identified as a priority of the 
NCCP in 2014. 
Joint working with the ICGP takes place to ensure 
best practice in relation to prostate assessment in 
primary care and appropriate referrals. E-learning 
in prostate disease has been developed by the 
ICGP, in collaboration with the NCCP. 
Additional information on prostate cancer services 
is available in Section 6.2 
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Lung Cancer 
The document ‘Establishment of Managed Cancer 
Control Networks and Designation of Eight 
Cancer Centres’ published by the HSE in 2007 
recommended that four centres nationally were 
required, for the curative surgical treatment of 
primary thoracic cancers. 
In recent years, significant advances have been 
made towards the integrated delivery of lung 
cancer services with the introduction of rapid 
access lung clinics in each of the designated cancer 
centres and the establishment of four designated 
surgical lung cancer centres (Mater Hospital and St. 
James’ Hospital Dublin, University College Hospital 
Galway, and Cork University Hospital,) staffed with 
multidisciplinary teams.
Smoking prevalence in Ireland is now 22%. 
Partnership with GPs and HSE prevention services 
is critical in relation to lung cancer prevention and 
early detection. E-learning in smoking cessation 
has been developed for GPs, in collaboration with 
the ICGP, and for allied health professionals.
Additional information on lung cancer services is 
available in Section 6.3. 
Centralising Other Cancers 
As outlined above, the priority for the NCCP was to 
centralise the high volume cancer surgeries into the 
designated centres. With all breast cancer surgery 
undertaken in a designated centre by December 
2009, the focus turned to less common cancers 
and the expansion of radiotherapy facilities. 
Upper Gastrointestinal Cancers
The ‘Establishment of Managed Cancer Control 
Networks and Designation of Eight Cancer Centres’ 
recommended that “there is a need for two centres 
nationally for the curative surgical treatment of 
primary upper gastrointestinal cancers”. In 2007, 
there were nine hospitals (four of them designated 
cancer centres) undertaking oesophagectomies 
for upper gastrointestinal cancer and 28 hospitals 
(including all of the designated cancer centres) 
undertaking gastrectomies for gastric cancer. 
The NCCP undertook an examination of the 
activity in these hospitals, looking at volumes, 
bed utilisation, intensive care usage and the 
geographical patterns of patient referral for both 
oesophageal and gastric resections. Cognisant 
of the strong association between volume and 
outcomes for oesophageal resections and in 
consultation with clinical advisors, it was agreed 
to designate four hospital units to undertake the 
primary surgical management of oesophageal 
cancer. A more in-depth audit of these hospitals 
would be undertaken prior to final determination of 
surgical centres. 
In 2010, Beaumont Hospital, St James’s Hospital, 
University College Hospital Galway and Cork 
University Hospital were designated as the four 
candidate units and a national lead was appointed 
for Upper Gastrointestinal Cancer. At that time, 
surgical activity in Cork was undertaken in the 
Mercy University Hospital; it is however planned 
to transfer this activity to Cork University Hospital. 
This remains a priority in the NCCP’s operational 
plan for 2014. 
Additional information on upper gastrointestinal 
cancer is available in Section 6.5. 
Pancreatic Cancer
In 2008, there were nine hospitals (six of them 
designated cancer centres) undertaking excision of 
pancreatic tumours. A process was undertaken in 
2009 to identify the optimal location for a national 
centre – this resulted in St. Vincent’s University 
Hospital (SVUH), Dublin being designated the 
national centre in late 2009. 
During 2010, the NCCP reviewed the data in 
relation to the units that provided pancreatic 
cancer surgery at that time. Based on this review 
it was then proposed that a satellite unit be 
established in the Mercy University Hospital 
pending transfer of the service to the designated 
cancer centre in Cork University Hospital. 
All cancer surgeries were to be concentrated in 
the new national centre (incorporating the Cork 
satellite service), with patients continuing to 
undergo diagnostic and staging investigation and 
non-surgical management in other hospitals and 
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designated cancer centres. Significant additional 
funding was transferred to St. Vincent’s University 
Hospital in 2010 to support the centralisation of 
pancreatic cancer surgery. Casemix costings for 
the surgical episode of care was transferred from 
those hospitals that had previously carried out 
resections, with funding for work up, diagnostics 
and non-surgical treatments remaining in the 
referring hospitals. Some surgeons who previously 
undertook pancreatic surgery in other Dublin 
hospitals had their contracts adjusted to enable 
them to operate in St. Vincent’s University Hospital. 
Members of the national surgical team for 
pancreatic cancer met with their colleagues 
around the country to discuss and agree patient 
pathways, referral criteria and patient information 
for pancreatic cancer surgery. A national lead 
surgeon was appointed for pancreatic cancers 
and a National Pancreatic Imaging Network was 
also established to agree standards for diagnostic 
imaging prior to referral to the national pancreatic 
centre.
The transfer of pancreatic surgery from the Mercy 
Hospital to the designated cancer centre in Cork 
took place in June 2012. 
Additional information on pancreatic cancer 
services is available in Section 6.6. 
Gynaecological Cancers
In 2007, there were 27 hospitals undertaking 
surgery for cervical, ovarian or uterine cancer. The 
NCCP undertook an examination of the activity in 
these hospitals, looking at volumes, bed utilisation, 
intensive care usage and the geographical 
patterns of patient referral for gynaecological 
resections. In consultation with clinical advisors, 
a decision was taken early in 2012 to centralise 
surgical gynaecology oncology services into seven 
designated cancer centres (the existing cancer 
centres apart from Beaumont Hospital). Improving 
quality of Surgical Gynaecology Oncology Services 
in Ireland is a key priority for the National Cancer 
Control Programme (NCCP), in conjunction with 
the appointed lead consultant for gynae oncology. 
The more complex gynae cancer surgery and 
surgery for rarer tumours is carried out in St James’s 
Hospital and the Mater Hospital. The development 
of a GP referral guideline for ovarian cancer is at an 
advanced stage. 
Additional information on gynaecological cancers 
services is available in Section 6.8. 
Pigmented Lesions and Melanoma
The NCCP developed a national melanoma 
GP referral guideline to assist GPs in the early 
recognition of suspicious pigmented lesions and 
to provide advice on evidence-based referral. 
Following a pilot study in Cork, a pigmented lesion 
referral form was circulated to GPs nationally in 
2013 and in 2014 electronic referral commenced 
on a phased basis. 
In 2014 a review of pigmented lesion referrals was 
undertaken. This recommended the introduction 
of a national standardised approach to managing 
urgent pigmented lesions together with standard 
operating procedures (SOPs) for multidisciplinary 
team meetings, including the diagnoses to 
be discussed, procedures for listing cases and 
attendance requirements. In addition, measurable 
key performance indicators are being developed. 
There are currently 15 hospitals with specialist 
services (including dermatology, oncology and 
plastic surgery) providing services for melanoma. 
It is envisaged that this arrangement will continue, 
but all non-cancer centres will have formal 
arrangements with a designated cancer centre with 
respect to the MDM process. 
Rarer Cancers
While there is already a considerable degree of 
centralisation of the diagnosis and management 
of cancers to the cancer centres, work to complete 
the centralisation of cancer is still underway 
particularly for rarer cancers. Work has commenced 
to develop a plan for the management of head and 
neck cancers and discussions have commenced 
with lead clinicians in the areas of sarcomas, neuro-
endocrine tumours and early upper GI mucosal 
programmes. 
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Progress by the NCCP in relation to centralising 
these services has to date been modest. The 
available resources reside within the acute hospitals 
which provide these services and in the current 
economic circumstances, additional new resources 
are unlikely become available in the foreseeable 
future. The NCCP has reviewed available data on 
incidence and distribution of services and engaged 
with clinicians involved. The process of identifying 
lead clinicians, establishing national networks and 
planning future configuration of services is in train. 
Any further consolidation can be achieved only 
by collaboration and through transfer of existing 
resources. A plan to complete the centralisation 
is being finalised and will be implemented 
in conjunction with the HSE Acute Hospitals 
Directorate. 
A recent analysis of data from the Hospital In-
Patient Enquiry System (HIPE) has demonstrated 
the impact of the NCCP cancer surgery 
centralisation policy - ‘Cancer surgery activity, 
within and without cancer centres 2007-2013’ 
(Appendix 2). This reflects the successes achieved 
in the centralisation of many cancer surgeries; 
55% of breast cancer surgery was undertaken in a 
cancer centre in 2007 – in 2013 this had increased 
to 99.8%; 43% of all rectal cancer surgeries had 
been undertaken in a cancer centre in 2007, by 
2013 this has increased to 77%. 
Rapid Access Clinics
Part of the explanation for poor cancer survival in 
Ireland related to late diagnosis. Comparison with 
other jurisdictions showed that advanced state 
of disease at presentation was more common in 
Ireland. Early diagnosis is an issue that is wider 
than the hospital setting as it necessitates primary 
care involvement and education of both the public 
and family doctors to enable them to recognise 
symptoms and signs of cancer. The NCCP 
prioritised the establishment of Rapid Access 
Clinics in 2009 focusing on lung and prostate 
cancers. 
Prostate Rapid Access Clinics
In 2007/8, access to diagnosis for prostate cancer 
was considered particularly problematic. The 
pathway for the diagnosis of prostate cancer was 
through referral of patients suspected of having 
prostate cancer to general urology clinics in over 
20 hospitals with variation in wait times around 
the country. In many cases, there was no formal 
triage in clinics and this produced unacceptable 
delays in diagnosis. The first two Rapid Access 
Diagnostic Clinics for Prostate Cancer opened in 
St James’s and Galway University Hospitals in June 
2009. They were developed by the two hospitals 
with the National Cancer Control Programme 
and the All Ireland Cancer Foundation Ltd. The 
Foundation specifically targeted prostate cancer 
and provided the initial two clinics with capital 
funding which started the implementation of this 
national initiative. The aim was to provide rapid 
access to a consultant opinion, and prostate biopsy 
if appropriate, to patients likely to have prostate 
cancer, with discussion at a multidisciplinary 
specialist cancer meeting following definitive 
diagnosis to establish appropriate management 
of care. Given the large number of suspect 
cases, it was agreed that patients at higher risk 
based on agreed high risk criteria should be fast 
tracked directly into Rapid Access Diagnostic 
Clinics in the designated cancer centres. Targets 
were set whereby patients were to have access 
to a specialist opinion within four weeks of initial 
appointment; those confirmed as having cancer 
have immediate access to a multidisciplinary 
cancer care team to arrange appropriate treatment. 
In 2012, a system was established by the NCCP’s 
Cancer Intelligence Unit to monitor patient access 
to these clinics and the clinics’ cancer detection 
rate. 
The NCCP supported the other designated 
centres in developing and opening clinics. Funding 
was provided for the recruitment of consultant 
urologists, radiologists, pathologists, radiographers 
and medical laboratory scientists as well as some 
administrative funding. By the end of 2010, there 
were six rapid access prostate clinics operating in 
designated cancer centres. All eight clinics were 
operational by April 2012.
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In parallel to the establishment of the clinics, 
the Community Oncology division of the NCCP 
developed National Prostate Cancer GP Referral 
Guidelines and a National Rapid Access Prostate 
Clinic Referral Form. Educational meetings were 
also held across the country providing GPs with 
the opportunity to hear at first hand how the clinics 
operated. 
Additional information on prostate cancer services 
is contained in Section 6.2. 
Lung Rapid Access Clinics
Lung cancer is the leading cause of cancer deaths 
in Ireland and survival compares poorly with best 
international outcomes. Historically patients with 
respiratory problems suspicious of cancer were 
referred to respiratory clinics and had a series of 
investigations following the first consultation, often 
with delays at each step along the way. These 
clinics were present in some 20 hospitals and 
only a small number were specifically organised 
to address the diagnostic challenge of lung 
cancer. The majority of referrals related to general 
respiratory ailments and only a small minority of 
referrals had an eventual diagnosis of lung cancer. 
As a consequence, it was possible for a lung cancer 
patient to wait months to be seen unless such 
patients were triaged on the basis of symptoms or 
radiological findings.
The Irish Thoracic Society (ITS) developed 
guidelines with a view to improving outcomes 
for lung cancer patients in Ireland. The Society 
pointed out that earlier diagnosis, efficient and 
correct diagnosis and staging, and modern 
multidisciplinary management lead to improved 
short and long term survival with good quality of 
life. Improvements in the delivery of care were 
necessary through earlier diagnosis, rapid access to 
diagnostic and staging procedures, and provision 
of co-ordinated multidisciplinary treatment.
In consultation with the ITS, it was agreed that 
patients with sentinel symptoms or radiological 
findings with a high index of suspicion of lung 
cancer should be fast tracked to lung cancer 
diagnostic clinics in one of the eight designated 
cancer centres. These clinics would provide 
comprehensive clinical assessment and enhanced 
access to diagnostic investigations such as imaging 
and bronchoscopy to reduce multiple hospital 
visits, reduce patient anxiety and shorten the 
time period to diagnosis. The NCCP provided 
funding for the recruitment of consultant 
respiratory physicians, radiologists, pathologists, 
radiographers and medical laboratory scientists 
as well as some administrative funding. By the 
end of 2010 there were functioning rapid access 
lung clinics in six of the designated cancer centres 
with all eight in place by March 2011. Targets 
were set whereby patients were to have access 
to a specialist opinion within two weeks of initial 
appointment; those confirmed as having cancer 
have immediate access to a multidisciplinary 
cancer care team to arrange appropriate treatment. 
In 2012, a system was established by the NCCP’s 
Cancer Intelligence Unit to monitor patient access 
to these clinics and the clinics’ cancer detection 
rate. 
Endobronchial ultrasound (EBUS) is a diagnostic 
technique which improves localisation and 
diagnostic yield when sampling mediastinal or 
hilar lymph nodes and paratracheal masses. This 
may provide essential staging information and may 
provide a tissue diagnosis where the primary lesion 
is not visible within the airway. This technique was 
not available in the majority of designated cancer 
centres in 2009. Over €1.3m was made available 
nationally to fund EBUS ultrasound bronchoscopes 
and ancillary equipment for those centres which 
did not already have this service in place.
In parallel with the development of the clinics, 
the Community Oncology division of the NCCP 
developed National Lung Cancer GP Referral 
Guidelines and a National Lung Cancer Rapid 
Access Service Referral Form. As the Rapid Access 
Clinics became operational, these documents were 
circulated to GPs. Educational meetings were also 
held where GPs had an opportunity to hear at first 
hand how the clinics operated and to have their 
questions answered directly by personnel running 
the clinics. 
Additional information on lung cancers services is 
available in Section 6.3. 
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Radiation Oncology
The publication in 2003 of the report ‘The 
Development of Radiation Oncology Services in 
Ireland’, known as the Hollywood Report, provided 
a blueprint for the future provision of radiation 
oncology services nationally (TD 12). The report 
outlined the significant deficit that existed at that 
time in relation to meeting the radiation oncology 
needs of cancer patients. 
The implementation of this national radiation 
oncology plan became a major focus for the 
NCCP in 2007 following its establishment. It was 
agreed that the first phase, the commissioning 
of four Linear Accelerators each in St James’ 
and Beaumont Hospitals would be procured 
and funded by the HSE, with the tender process 
beginning in 2008. At that time, it was still planned 
that Phase 2 encompassing developments in Cork 
and Galway and their integrated satellite units 
at Waterford and Limerick, would be developed 
under a Public Private Partnership (PPP). 
The two new radiotherapy centres in St James’ 
and Beaumont Hospitals were completed and 
became operational in 2011. From 2008 onwards, 
the economic outlook in Ireland changed 
significantly. Following a detailed internal review, 
the Department of Health decided to meet further 
patient needs in radiotherapy by traditional means 
from within existing capital resources. Funding has 
been made available from the existing HSE Capital 
Plan to replace and expand the current facilities at 
Cork University and Galway University Hospitals 
and enabling works have already commenced 
on both sites. Both units will be relocated and 
expanded and the new facilities are due to open in 
2017/2018. 
In the meantime, radiation oncology services have 
been contracted from two private providers in 
Waterford and Limerick, thus improving access for 
patients in those areas.
It had been intended to deliver additional 
radiotherapy capacity in Dublin through a Public 
Private Partnership (PPP) to design, build, finance, 
maintain and partially operate the facility. However 
the changed economic environment resulted in 
a decision to progress expansion by traditional 
means. In recent weeks (June 2014) approval has 
been given by the Minister for Health to expand 
the radiotherapy facilities in St. Lukes’ hospital 
which will provide capacity until 2018 based on 
NCRI patient projections and private radiotherapy 
continuing at the current level. Funding approval 
for long term expansion in Dublin has yet to be 
agreed.
Planning is underway for the development of a 
radiation therapy facility at Altnagelvin Hospital, 
Derry, with capacity to treat the majority of patients 
residing in Donegal. It is anticipated that this 
facility will come on stream in 2016. The HSE is to 
provide both a capital contribution and ongoing 
revenue funding.
A full review of expansion plans and development 
of radiation oncology services from 2006-2013 is 
addressed in Section 7 of this report. 
Community Oncology 
In parallel to the centralisation of cancer surgery 
and the establishment of rapid access clinics, 
significant engagement was undertaken to support 
GPs and primary care providers in ensuring that 
patients were referred in a timely manner to the 
designated cancer centres. 
A GP was employed to liaise with the Irish College 
of General Practitioners. General practice referral 
guidelines and standardised referral forms to the 
designated cancer centres have been developed 
for suspected lung, prostate, breast cancers and 
melanoma. Considerable work has been done 
on the development of an ovarian cancer referral 
guideline.
National electronic referrals were introduced to 
facilitate referrals with suspected lung, prostate, 
or breast cancer to designated centres. Electronic 
referral of pigmented lesions is currently being 
introduced on a phased basis. These electronic 
referrals have now been embedded in all ICGP 
accredited software systems (see community 
oncology Section 9) and standards are in place and 
monitored to ensure that referrals are addressed in 
a timely manner.
A full review of the work undertaken by the 
Community oncology division of the NCCP is 
covered in Section 9 of this report. 
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Medical Oncology 
The NCCP established a National Medical 
Oncology and Haemato-oncology Programme in 
2012 to ensure that the needs of the anticipated 
increased incidence in cancer diagnosis and 
requirements for treatment continue to be met. 
The national Medical Oncology and Haemato-
oncology Programmes incorporate a number of 
initiatives aimed at coordinating and managing 
cancer drug services, ensuring appropriate 
access to and monitoring of cancer drug use and 
ensuring that appropriate forward-planning is 
undertaken. This included the establishment of a 
Technology Review Committee in early 2011 which 
is responsible for reviewing proposals received 
from industry or expert groups in Ireland for 
funding of new cancer drugs, expanded indications 
for existing cancer drugs or related predictive 
laboratory tests. The recommendations of the 
Technology Review Committee are based on the 
degree of clinical effectiveness, the acute and 
chronic toxicity and the cost effectiveness of the 
proposed technology.
A comprehensive Cancer Drug Management 
Programme was established in 2012 to develop 
and improve the care provided to patients 
receiving treatment with cancer drugs. This national 
medications management system for cancer drugs 
was set up so that the health service can continue 
to provide quality cancer treatment to patients 
within difficult budgetary conditions. The national 
management system facilitates:
•	 National	oversight	of	the	spend	on	high-
cost cancer drugs, allowing for coordinated 
planning and, potentially, national approaches 
to provision of cancer drugs.
•	 Detailed	information	about	drug	utilisation	as	
well as cancer incidence and prevalence.
•	 A	mechanism	for	assuring	adherence	to	
national drug protocols, which is a key quality 
and patient safety objective for the NCCP.
•	 A	coordinated	system	for	HSE	and	
NCCP, hospitals and the Primary Care 
Reimbursement Service (PCRS) in relation to 
high-cost cancer drugs.
A national Oncology Medication Safety Review 
Report was undertaken in 2012 which assessed the 
oncology medication policies and practices in day 
units nationally, from a patient safety and quality 
perspective. The report, which was conducted 
across the 26 hospitals in Ireland involved in the 
administration of systemic cancer therapy in adults 
and children, was published in January 2014. 
The report made a total of 93 recommendations, 
the implementation of which is currently being 
monitored. National safety policies are currently in 
development. 
Detailed information on the National Medical 
Oncology and Haemato-oncology Programme is 
available in Section 8 of this report. 
Hereditary Cancer 
Building on the work in cancer genetics 
carried out by the National Centre for Medical 
Genetics (NCMG), the NCCP established a 
national hereditary cancer programme in 2011 
in collaboration with NCMG. The aim of the 
programme is to improve access to assessment 
and genetic testing for those patients and their 
families whose cancer may have a hereditary 
component. Dedicated out-patient clinics have 
been established and funded by the NCCP in 
St James’s and the Mater Hospitals. Demand 
for the programme, which is primarily focused 
on hereditary breast, ovarian and bowel cancer 
has been increasing significantly since its 
establishment. 
The NCCP has also identified the need to 
expand this diagnostic programme and embed 
standardised surveillance for the high risk 
population. 
Additional information on the hereditary cancer 
programme is contained in Section 10 of this 
report. 
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Cancer Screening
The National Cancer Screening Service Board 
was originally set up under statute in 2006. Under 
the leadership of Tony O’Brien (current Director 
General of the HSE) it transferred into the Health 
Service Executive under the National Cancer 
Control Programme (NCCP) in 2010. 
There are three national cancer screening 
programmes in operation: BreastCheck - The 
National Breast Screening Programme for women 
aged 50-64 was implemented on phased basis 
commencing in 2000. It completed its first round 
of national screening in late 2011 and its second 
round in 2013. CervicalCheck - the National 
Cervical Screening Programme for women aged 
25 to 60 became available to all eligible women 
in September 2008. It completed its first three-
year round of screening in August 2011 and a 
second round in 2013. A national bowel screening 
programme (BowelScreen) was introduced in the 
final quarter of 2012. The programme offers home 
faecal immunochemical testing (FIT) to men and 
women aged from 60 to 69 every two years.
The National Cancer Screening Service (NCSS) 
transferred to the Health and Wellbeing Directorate 
of the Health Service Executive in January 2014. 
There is joint governance between the NCCP and 
the Health & Well Being Directorate in relation to 
the strategic direction of cancer screening and the 
development and monitoring of cancer screening 
key performance indicators. 
Detailed information on the national cancer 
screening programme is available in Section 11 of 
this report. 
Criteria for Success 
The 2006 National Cancer Strategy for cancer 
control provided a clear vision and focus for 
change. Strong political, policy and HSE support, 
combined with effective clinical leadership across 
disciplines and tumour site specific diseases, were, 
and remain essential. 
Broad based communication strategies including 
briefings, interviews and the development of 
literature and a dedicated website were crucial in 
establishing links with all stakeholders, including 
the public, cancer patients, politicians, the media, 
professional bodies (Royal Colleges of Medicine 
and Surgery), the Irish College of General 
Practitioners, other divisions within the HSE, 
hospital leaders and cancer charities such as the 
Irish Cancer Society. 
Financial investment in staffing, technology and 
equipment are essential to ensure state of the 
art diagnostics and therapeutics appropriate to 
the anticipated patient volumes. Modest new 
investment was required to scale up screening 
programmes for the population and diagnostic 
therapy for patients. The ability to transfer hospital 
resources and staff to designated cancer centres 
was essential to mitigate costs. 
Persistence in working across stakeholder groups 
and local interest groups (whether public, political 
or professional) remains a key focus. Ensuring that 
each patient’s cancer is optimally managed by a 
multidisciplinary team in an expert cancer centres is 
central to the aim of improving cancer outcomes. 
The Challenges 
While considerable progress has been made in the 
implementation of many of the recommendations 
of the 2006 National Cancer Strategy (Appendix 3) 
there are a number of priorities which remain work-
in-progress. 
Key challenges include: 
•	 Increasing	incidence:	Ireland	because	of	its	
relatively young population and inevitable 
“boom” in the number of ageing people will 
have the highest growth of cancer incidence 
in Europe. The National Cancer Registry of 
Ireland predicts there will be a doubling in 
the incidence of cancer by 2040. 
•	 The	Current	financial	climate	leading	to	
capacity constraints in beds, theatre and ICU 
and uncertainty re availability of development 
funding at a time of rising incidence and 
prevalence of cancer.
•	 Drug	costs	and	related	laboratory	testing	
which are predicted to rise sharply in the 
coming years.
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•	 Challenges	for	hospitals	and	their	cancer	
centres in managing competing priorities, 
including access for cancer patients, 
improving A&E waiting times and reducing 
surgical waiting lists. 
•	 Current	HR	environment	–	retirements	
and voluntary redundancy, recruitment 
moratorium, lack of clerical support, 
cumbersome recruitment processes, lack 
of key grades e.g. physicists, radiation 
therapists, theatre nurses, mammographers, 
sub specialist pathologists and medical 
oncologists. 
•	 Rapid	growth	and	service	pressures	in	cancer	
centres without transfer out of many benign 
disease services. 
•	 Need	for	a	policy	decision	regarding	Phase	2	
of the National Plan for Radiation Oncology 
in Dublin so that there is adequate capacity to 
meet growing demands beyond 2019.
•	 Delays	in	finalising	centralisation	of	rectal,	
prostate and upper GI services.
•	 Diagnostic	services	in	general	hospitals	need	
to continue in accordance with current clinical 
pathways in order to ensure patient centred 
care and the retention of clinical skills outside 
of the cancer centres. 
•	 Achievement	of	targets	stipulated	by	the	
Key Performance Indicators in a challenging 
financial and human resources environment. 
Risks
•	 The	reorganisation	of	hospitals	into	Groups	
may undermine the existing national policy in 
relation to centralisation of cancer surgeries 
into the eight designated centres; there is a 
need to develop a national framework within 
which Groups are aligned to develop and 
deliver services such as cancer services in 
accordance with national policy. 
•	 Serious	risk	re	future	funding	of	necessary	
radiation oncology development inclusive 
of capital plan for extending facilities and 
equipment replacement and related staffing 
revenue resources.
•	 Constraint	on	growth	of	oncology	drugs	
budget may impact patient access to new 
evidence based, clinically beneficial and 
appropriately cost effective drugs.
•	 May	not	recruit	specialist	staff	in	sufficient	
numbers (e.g. mammographers, 
physicists, theatre and critical care nurses, 
histopathologists, breast radiologists), 
with consequences for patient care and 
reputational damage to NCCP and the cancer 
centre.
•	 May	not	attract	or	retain	consultants,	
with consequences for patient care and 
reputational damage to NCCP and host 
hospitals.
•	 Competing	demands	for	hospital	beds	may	
impact timely access for cancer patients.
•	 May	not	be	able	to	fulfil	data	requirements	
due to loss of clerical administrative support 
and poorly developed ICT infrastructure.
Good strategy implementation requires constant 
reiteration of taking action followed by thoughtful 
analysis which subsequently modifies further 
actions. It is timely to review the implementation 
undertaken to date by the NCCP, celebrate the 
successes and identify the gaps that remain NCCP 
challenges. 
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4
The National Cancer Control Programme was set 
up to implement the National Cancer Strategy 
2006 with three goals:
•	 To	reduce	cancer	incidence,
•	 To	reduce	cancer	mortality	and	morbidity,	and	
•	 To	improve	the	quality	of	life	of	people	living	
with cancer.
The Programme was given the terms of reference 
to manage, organise and deliver cancer control on 
a whole population basis. Its remit was:
•	 To	control all cancer activities
•	 To	integrate all elements of cancer control 
through a variety of settings, and ensure a 
programmatic approach to cancer control 
through the application of evidence-based 
policy to clinical practice and all other 
components of cancer control.
•	 To implement regional cancer centres and 
their networks
Since its establishment, the NCCP has been 
afforded a unique identity and role within the 
health services to enable it to achieve its aims. 
With the agreement of Government and the Health 
Service Executive (HSE) the NCCP was formed as a 
separate directorate within the HSE to implement 
the National Cancer Strategy. It was provided with 
its own corporate identity, office, branding and 
key functions including HR, communications and 
finance as well as dedicated clinical and support 
staffing. The Director was appointed to the HSE 
senior management team reporting to the CEO 
and was supported with part time clinical advisors 
for surgery oncology, medical oncology and 
radiation oncology. These advisors were appointed 
members of the NCCP Executive. 
In the period from 2007 to 2014, the NCCP 
was allocated considerable financial investment 
(€56.8m revenue) to support the establishment and 
resourcing of the eight designated cancer centres 
and the new oncology drug management system 
(Appendix 4). This funding supplemented that 
which was already within the base funding of the 
acute hospitals and was allocated towards agreed 
service priorities. 
Significant funding was also provided to support 
the expansion of radiotherapy capacity: in addition 
to €25.9m in revenue, €65m was invested in the 
development of two new units in Dublin and an 
additional €100m has been approved under the 
HSE capital plan for expansion in Cork and Galway. 
Recently, funding of approximately €6m has been 
approved to support the refurbishment of bunkers 
and purchase of additional linear accelerators in St. 
Luke’s hospital. 
How the 
NCCP Works
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Both the BreastCheck and CervicalCheck 
programmes were fully funded when they 
transferred to the HSE. Between 2012 and 2014, 
the National Cancer Screening Service (NCSS) 
was provided with an additional €19m to support 
the implementation of the new bowel cancer (and 
diabetic retinopathy) screening programmes. 
The role and structure of the NCCP has evolved 
over time to reflect the changes related to the 
ongoing restructuring of the health services. The 
current governance structure of the HSE is outlined 
below.
When the NCCP was first established it had both 
a strategic/planning and an operational remit. 
The St. Luke’s Radiation Oncology Network 
(SLRON) and the National Cancer Screening 
Service (NCSS) were both directly managed by the 
NCCP. However, arising from changes within the 
HSE structures in January 2014, operational and 
financial responsibility for the NCSS transferred 
under the governance of the Health & Wellbeing 
Directorate of the HSE while the St. Luke’s 
Radiation Oncology Network (SLRON) transferred 
to the Dublin Midlands Hospital Group.
The NCCP’s role is now predominantly focused 
on planning, quality assurance and performance 
management of publicly delivered cancer services 
nationally. 
The current organisational structure of the NCCP 
and the roles are outline in Figure 4.2. 
Figure 4.1 HSE Directorate and Leadership Team
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Figure 4.2 Overview of the NCCP Structure and reporting relationship
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Programme Overview
Director
The Director of the NCCP is responsible for the 
planning and implementation of the National 
Strategy for Cancer Control in Ireland, across the 
spectrum of prevention, screening programmes, 
surgical oncology, radiation oncology and 
medical oncology as well as the development of 
national treatment guidelines and performance 
management. 
The Director is a member of the HSE leadership 
team reporting to the Director General. The 
Director and relevant NCCP staff meet regularly 
with key cancer service providers and leaders 
including clinicians, professional bodies, the CEOs/
General Managers of the designated cancer 
centres as well as industry, research and academic 
stakeholders. Monthly meetings are also held with 
the Department of Health. 
Deputy Director
The Deputy Director is responsible for 
overseeing the development of national tumour 
guidelines groups, diagnostic quality assurance, 
communications, radiation oncology and 
supporting the development, delivery, monitoring, 
quality assurance and performance management 
of the NCCP for assigned Hospital Groups. The 
Deputy Director also has oversight, and provides 
support, of the development, delivery, monitoring, 
quality assurance and performance management 
of the St. Luke’s Radiation Oncology Network 
(SLRON).
Head of Cancer Intelligence
The main responsibilities of the Cancer Intelligence 
function are to source and analyse data required 
by the NCCP to perform its functions. Such 
data comes from a variety of data resources 
including HSE data, other sources such as the 
Cancer Registry (NCRI) and the Central Statistics 
Office (CSO). Development of Key Performance 
Indicators is also a key role. In addition, the Cancer 
Intelligence function supports the NCCP in setting 
up new databases and overseeing clinical audits.
Head of Planning, Performance, & 
Programme Management 
The Head of Planning, Performance and 
Programme Management liaises with HSE’s Chief 
Operating Officer (COO) Planning, Performance, 
and Business Functions. They Lead the NCCP’s 
Commissioning and Money Follows the Patient 
activities, liaising with Chief Financial Officer’s 
Business Functions. They have oversight of 
the National Clinical Leads Group and support 
the development, delivery, monitoring, quality 
assurance and performance management of the 
NCCP for assigned Hospital Groups. They also act 
as liaison to the National Screening Service (NSS) 
of the HSE Health & Wellbeing Directorate.
Head of Community Oncology, Primary 
Care, and Prevention 
The Assistant National Director for Community 
Oncology is responsible for leading the community 
oncology team. This includes cancer prevention, 
integration of care between primary and specialist 
services and survivorship. 
Chief Pharmacist 
The Chief Pharmacist is responsible for the 
development of the Medical Oncology and 
Haemato-Oncology Programme focusing on 
Quality & Safety, Drug Approval & Funding, 
Medical Oncology Clinical Information System, 
NCCP Cancer Data Repository and Clinical Audit. 
They Interact with Acute Care, including direct 
clinician interaction, Primary Care Reimbursement 
Services, Transformation and change, Systems 
Reform Unit and ICT Shared Services. 
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The Director and NCCP executives are supported 
by the following: 
National Surgical Oncology Programme 
The clinical advisor and programme manager lead 
on strategic development and implementation of 
surgical oncology services nationally (See Section 6).
National Radiation Oncology Programme
The clinical advisor and programme manager lead 
on strategic development and implementation 
of radiation oncology services nationally (See 
Section 7).
National Medical Oncology and Haemato-
Oncology Programme
The clinical advisor and programme manager lead 
on strategic development and implementation of 
medical oncology and haemato- oncology services 
nationally (See Section 8).
Community Oncology Team 
The work of the community oncology team 
includes cancer prevention, integration of care 
between primary and specialist services, and 
survivorship. An integral component of this work is 
to build Primary Care capacity to care for patients 
with cancer in the community setting. The team 
works within the NCCP, with the wider HSE, general 
practitioners and voluntary agencies to undertake 
research, and to plan, implement and evaluate 
services. Evidence based referral, integration of 
care and appropriate follow up are central to this 
work. The development and implementation of 
a cancer survivorship programme is now a key 
priority (see Section 9). 
Communications
Responsible for the development and management 
of NCCP internal and external communications. 
Clinical Governance for Cancer Care 
In order to ensure that cancer services are 
operated within the agreed standards, there was 
a requirement to put in place robust governance 
arrangements across each of the eight cancer 
centres. 
NCCP receives monthly performance and activity 
reports from each of the eight cancer centres. 
Key Performance Indicators (KPIs) are reviewed 
and discussed at monthly NCCP Executive team 
meetings. Any performance issues which are 
outside of target are subsequently followed up with 
clinicians and management at the relevant cancer 
centres which are responsible for putting in place 
measures to address any non performance. In 
addition KPI data on systemic therapy is received 
from the 26 chemotherapy hospitals nationally
Nationally cancer KPIs are reported by the HSE on 
a quarterly basis as part of the HSE Performance 
Reporting Mechanism (http://www.hse.ie/
performanceassurancereports/ ).
Clinical Leads Group
In line with the recommendations of the 2006 
National Cancer Strategy (Recommendation No. 
23), lead clinicians have been nominated to lead 
the development of cancer care pathways for each 
major site-specific cancer. 
The NCCP developed the role of ‘Lead Clinician’ 
initially in the Symptomatic Breast Service in 
2010, whereby a clinician in each of the cancer 
centres is nominated by the hospital CEO as the 
lead Clinician for Symptomatic Breast Services. A 
National Lead Clinicians Network was established 
for this group of lead Clinicians to meet regularly 
as a group. This network of Lead Clinicians has 
since been extended to a number of tumour 
sites including thoracic (lung), urology (prostate) 
and gastrointestinal (rectal) cancer services in the 
eight designated cancer centres (see TD 10 for 
members). 
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The Lead Clinicians within the designated cancer 
centres are appointed by the hospital managers 
and Clinical Directors in consultation with the 
NCCP for a two year period. The Lead Clinician 
reports directly to the CEO /General Manager/
Clinical Director in their hospital through the 
governance arrangements of the hospital. 
They also have a collegiate relationship with a 
nominated clinical advisor in the NCCP for the 
quality of the services provided. Their role is to 
act as the clinical liaison between the National 
Cancer Control Programme and the relevant cancer 
service. 
The purpose of the national Clinical Lead Network 
is to ensure that the eight centres build on robust 
local clinical governance arrangements, in order 
to operate as a cohesive national clinical network 
for the purpose of clinical audit, sharing of good 
practice and problem solving. Terms of reference 
also include development of key performance 
indicators and informing decision making and 
leading on national multidisciplinary audit, quality 
and risk. Each Network of Lead Clinicians has a 
chairperson who reports to the Director of the 
NCCP (see Figure 4.2). Key projects relating to 
audit and standardisation of services form the basis 
of feedback from the group to the NCCP Director 
and Executive. The Leads groups are supported 
by a project manager from within the NCCP to 
coordinate their work and meetings. 
There are also lead clinicians for upper 
gastrointestinal cancers in the four national centres 
and national leads have been appointed for 
pancreatic cancer, neuro‐oncology, gynaecological 
and neuro‐endocrine cancers. These nominated 
clinicians are responsible for facilitating adherence 
to national standards and key performance 
indicators for the specific service. They play an 
important role in contributing to the continuous 
development and improvement of the service in 
their own cancer centre and nationally, through 
participation in NCCP processes, including annual 
national Audit, Quality and Risk (AQR) meetings. 
National Clinical Guidelines Groups 
(Tumour Groups)
In 2011, the NCCP commenced the development 
of national evidence-based clinical guidelines for 
the diagnosis, staging and treatment of selected 
cancers. These guidelines are being developed by 
a range of consultant specialists (including surgery, 
medical oncology, radiation oncology, radiology, 
pathology) and focus on a particular type of cancer 
with the support of NCCP methodology specialist, 
project managers, researchers and librarians. There 
are currently Guideline Development Groups in 
place for breast, prostate, lung, gynaecological, 
upper gastrointestinal, hepatobiliary and lower 
gastrointestinal cancers. The chairs of each 
individual Guideline Development Group report 
directly to the Director of the NCCP in relation to 
this role. 
For further information see Section 12 of this 
report.
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5
Introduction 
The document ‘A Strategy for Cancer Control in 
Ireland 2006’ reviewed cancer epidemiology in 
Ireland from 1994-2001. On reviewing the cancer 
incidence in the intervening years, an average of 
28,668 new cases of cancer were registered every 
year in Ireland between 2002 and 2011, an increase 
of over 40% since the period 1994-2001 (Table 
5.1). Over 17,000 of those cases were invasive 
cancers, an increase of one third since 1994-2001.
Reviewing the annual figures, there were over 
34,700 new cases of cancer registered in Ireland 
in 2011 an increase of 57% since 2001, when 
22,175 cases were documented. Over 28,700 of 
these were invasive cancers in 2011, compared to 
almost 19,500 in 2001, a 48% increase. Excluding 
the commonest invasive cancer, non melanoma 
skin cancer, all other invasive cancers are now 
close to the 20,000 mark with over 19,500 cases 
of invasive cancer registered in 2011, a 39% 
increase from 2001.
Table 5.1: Annual Average Numbers of Cases
Source: NCRI, 2013
Both sexes Females Males
1994-2001 2002-2011 1994-2001 1994-2001 1994-2001 1994-2001
All cancers 20,211 28,668 10,323 14,849 9,887 13,819
All invasive 
cancers 
(excluding non 
melanoma skin 
cancer)
12,838 17,165 6,178 8,068 6,660 9,096
Cancer Epidemiology 
in Ireland 
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Looking at the period 2008-2010, non melanoma 
skin cancer (NMSC) is still the commonest invasive 
cancer representing 29% of cancers in women and 
31% of cancers in men, a higher proportion than 
in the period 1994-2001 when the percentages 
were 23% for women and 28% for men respectively 
(Figure 5.1). Between 1994 and 2001, the next 
commonest cancers in women were breast (16%), 
colorectal (8%) and lung (5%). The order has not 
changed in 2008-2010, but breast cancer is now 
22% of all cancers in women and lung cancer has 
risen to 7%. 
For men, the commonest cancers apart from 
NMSC were prostate (14%), colorectal (10%) and 
lung (10%) between 1994 and 2001. More recent 
data (Figure 5.1) show that the order remains the 
same but prostate cancer now accounts for 21% of 
all cancers in men.
 
Cancer Projections
Ireland has an unusual demographic profile 
compared to many of its European neighbours. A 
high birth rate and the deep and lasting period of 
emigration in the 1950s along with further egress 
of the population in the 1980s had resulted in a 
population with a very young profile up to recent 
decades. Immigration in recent years as well as the 
return of emigrants who left in the 1980s has meant 
that the population is only now experiencing the 
rapid aging seen in our neighbouring countries 
in earlier decades. As cancer is predominantly a 
disease of older people, the NCRI projections for 
cancer based on the population projections from 
the Central Statistics Office make sober reading 
(Figure 5.2). 
Figure 5.1 Relative frequency of the main invasive cancers diagnosed, 2008 - 2010
Source: NCRI, 2013
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Models predict that the number of cases of 
invasive cancers in women will increase by 86%-
125% between 2010 and 2040. Cases are thus 
predicted to rise from 13,185 in 2010 to between 
24,548 and 29,715 in 2040. For men, invasive 
cancers are predicted to increase by 126%-133% in 
the same period so cases are predicted to rise from 
15,295 in 2010 to between 34,511 and 35,561. 
Thus, the total annual number of new cases of 
cancer is predicted to increase from 28,480 in 2010 
to between 59,059 and 65,256 in 2040.
Cancer Mortality
In 2010, there were 8,316 deaths from cancer 
reported, which was about 30% of all deaths 
in Ireland that year. Cancer was the second 
commonest cause of death after cardiovascular 
disease. This compares to 7,500 cancers deaths 
each year in the period 1994-2001, which was 
about 25% of all deaths during that period.
Lung cancer was the commonest cause of cancer 
death in both women and men in 2010 (Figure 5.3) 
representing 18% of cancer deaths in women and 
22% of cancer deaths in men.
For women, lung cancer was followed by breast 
(16%) and colorectal cancer (10%). This represents 
a significant change from the 1994-2001 period, 
when breast cancer was the commonest cause of 
cancer deaths in women (18%) followed by lung 
(15%) and colorectal (11%) cancers. The order of 
cancer deaths remains the same in men with lung 
cancer remaining the commonest cause of cancer 
deaths at 22%, though the proportion has fallen 
from 24% in the 1994-2001 period. Prostate and 
colorectal cancer were the next commonest cause 
of cancer deaths in both the 1994-2001 period 
where each was 13% compared to 12% to 2010. 
Figure 5.2: Projected Numbers of Invasive Cancers
Projected numbers of all invasive cancers, based on M1F0 population projections 2015-2040, with actual numbers
 
 
 
Source: NCRI, 2013
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Females Males
Cancer Hospital Activity 
The initial phase of cancer diagnosis and treatment 
takes place in the hospital setting. Further 
admissions to hospital can be generated by 
treating morbidity brought on by the disease itself 
or by earlier treatments and for end of life care. 
The increasing number of cases is thus reflected 
in increasing utilisation of hospital facilities. The 
Hospital Inpatient Enquiry System (HIPE) is the only 
national hospital information source that can give a 
breakdown of hospital activity by diagnosis, but 
this system covers inpatient and day case activity 
only. There is no national source of data on 
outpatient or emergency department activity that 
can break down activity by diagnosis. Between 
2005 and 2012, there was a 53% increase in the 
number of inpatient and day case discharges from 
the public hospital sector for cancer. Much of this 
increase occurred in the day case setting which 
increased by 67% over the time period (Table 5.2).
Table 5.2: All Cancer Activity in Acute Public Hipe-Reporting Hospitals in Ireland, 2005-2012
Source: HIPE, 2014
Year 2005 2006 2007 2008 2009 2010 2011 2012
Inpatient 41,270 42,483 44,346 45,880 45,451 44,944 44,273 45,020
Day cases 135,867 187,974 200,987 220,008 222,327 228,727 223,874 226,369
Total 
discharges
177,137 230,457 245,333 265,888 267,778 273,671 268,147 271,389
Figure 5.3: Relative Frequency of the Main Cancer Deaths 2010 
 
Source: NCRI, 2013
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Cancer Prevalence
The NCRI have matched all cancers registrations 
from 1994-2010 to a respective death certificate, 
where available. This enables an estimate to be 
made of the prevalence of patients who have 
survived cancer in Ireland. Between 1994 and 
2010, there were 242,058 patients diagnosed with 
cancer. At the end of 2010, over 104,300 of these 
patients were still alive. The largest group of cancer 
survivors are patients who have been treated for 
breast cancer (24,383) followed by patients who 
have been treated for prostate cancer (21,551). 
This population can be very disparate. Many are 
well and do not require any further interventions. 
Some have sequelae from their cancer diagnosis 
and treatment which require further care and yet 
others will develop recurrent disease. Because 
the NCRI can only follow patients for the first year 
after their cancer diagnosis, it is not possible to 
enumerate how many patients are on active cancer 
treatment at any one time. 
Cancer Survival
Improvements in cancer detection and treatments 
have resulted in substantially better relative survival 
in the Irish population. For all cancers excluding 
non melanoma skin cancer, the five year relative 
survival in men has increased from 52.7% for those 
diagnosed in the period 2000-2004 to 60.3% 
for those diagnosed in 2008-2010. Equally for 
women, the five year relative survival has increased 
from 57.3% in 2000-2004 to 62.5% in 2008-2010. 
This global figure for all cancers masks some 
considerable differences between the tumour types 
(Table 5.3).
1994-1999 2000-2004 2005-2009 2008-2010
Cohort Cohort Cohort Hybrid
Female breast 72.6% 78.1% 82% 81.7%
Lung 9.3% 10.2% 13.7% 14.2%
Colorectal 49.9% 53.8% 59% 60.2%
Prostate 69.4% 85.2% 90.1% 90.7%
Melanoma 83.3% 85.7% 86.1% 84.7%
Table 5.3: Five Year Relative Survival by Cohort and by Tumour Type
Source: NCRI, 2013
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Figure 5.4: Five Year Relative Survival 1994-1999, 2000-2004 and 2005-2009 
Source: NCRI, 2013
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6Centralisation & Progress 
on Individual Cancer Sites
6.1 Breast cancer 
The 2006 National Cancer Strategy 
recommended that “The HSE should conduct 
a review of the number of centres required 
for the management of symptomatic breast 
disease to bring them into line with designated 
Cancer Centres”.
Breast Cancer in Ireland 
Between 2009 and 2011, there were 2,805 cases 
of invasive breast cancer registered in Ireland every 
year. This represents a rate of 124/100,000 for 
females and 1.1/100,000 for males (NCRI 2014). 
Most cases of breast cancer occur in women aged 
over 50 years. In addition to invasive cancer, there 
are approximately 340 in situ cancers registered 
annually (Table 6.1.1) 
Excluding non-melanoma skin cancer, breast cancer 
is the most commonly diagnosed cancer in women 
in Ireland, comprising 31% of female invasive 
cancers (NCRI 2013). There was a significant 
upward trend in breast cancer incidence rates for 
females between 1994 and 2011 of 1.8% per year 
for invasive cancers and 9.4% for in situ cancers 
(Cancer Factsheet: Female Breast NCRI 2013). 
Much of this increase can be attributed to the roll 
out of a national screening programme during this 
time period.
The most recent relative survival estimates are 
a hybrid estimate for the 2008-2010 cohort of 
cancers and five-year relative survival for this cohort 
is 85% with a 95% confidence interval of between 
83.9%-86% (Cancer Factsheet: Female Breast NCRI 
2013). 
Recent cancer projections from the NCRI predict 
the number of female breast cancers to increase 
by 55- 152% between 2010 and 2040 (Cancer 
Projections for Ireland: 2015-2040. NCRI 2014).
Types of Breast Cancer Females Males Total 
Breast (C50) invasive 2,781 23 2,805
Breast (D05) in situ 340 1 341
Table 6.1.1: Annual Average Incidence for Breast Cancer in Ireland, 2009-2011
Source: NCRI 2013
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Cancer Strategy Implementation – 
Surgical Centralisation
The document ‘Establishment of Managed Cancer 
Control Networks and Designation of Eight 
Cancer Centres’ published by the HSE in 2007 
recommended that “treatment of symptomatic 
breast disease will take place in all eight cancer 
centres with a satellite unit in Letterkenny”. 
In 2007, breast cancer surgery was undertaken 
in 32 public hospitals. Based on the 
recommendations of the National Cancer Strategy 
(2006) and its implementation document, the 
NCCP completed the centralisation of breast 
cancer surgery to eight designated Symptomatic 
Breast Disease (SBD) Units and one satellite unit, 
by December 2009. 
Summary of achievements of the National 
Cancer Control Programme in relation to 
Symptomatic Breast Disease
1.  Establishment of the National Cancer 
Control Programme Symptomatic Breast 
Service  
In 2000, the Department of Health (DOH) 
published the report of the subgroup to the 
National Cancer Forum ‘Development of 
Services for Symptomatic Breast Disease’. This 
report outlined the recommended structure for 
specialist breast units, diagnostic principles, 
treatment principles and quality assurance 
standards. 
The National Cancer Strategy (2006) built on 
these principles and recommended that the 
HSE should conduct a review of the number 
of centres required for the management of 
symptomatic breast disease.
The 2006 National Cancer Strategy 
recommended (no. 24) that “The HSE 
should develop care pathways for cancer 
care to link primary care services, hospital 
services and other relevant services”
The National Cancer Control Programme 
(NCCP) was established in 2007 to manage, 
organise and deliver cancer services on a 
whole population basis. Breast Cancer was 
a key area of focus of the NCCP since its 
inception. Rapid Access Clinics with triple 
assessment were established in each of the 
eight designated cancer centres, with GP 
referral guidelines and standardised referral 
forms. 
The 2006 National Cancer Strategy 
recommended (no. 47) that “general 
practitioners should have comprehensive 
information that enables informed referral 
and other management decisions”. 
The 2006 National Cancer Strategy 
recommended (no. 25) that “Improved 
cancer information services should be 
available to primary care”.
The scope of the clinics is symptomatic breast 
disease. For any patient with breast disease, 
there is one overall service, whereas for 
other cancers there are rapid access clinics 
for suspected cancers and parallel general 
clinics for other benign conditions e.g. 
general urology clinics for benign prostatic 
hypertrophy (BPH). This significantly increases 
the cohort of patients using the breast service. 
In view of the increasing volumes attending 
these clinics it is vital that access is prioritised 
for those with suspected cancers. This is 
achieved by triaging patients on receipt of 
referral into urgent and routine appointments.
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2.  National Quality Assurance Standards 
for Symptomatic Breast Disease (SBD) 
Services
In May 2007, the Health Information and 
Quality Authority (HIQA) adopted the National 
Quality Assurance Standards for Symptomatic 
Breast Disease Services, developed by an 
expert group in 2006, chaired by Professor 
Niall O’Higgins. The standards define what 
is expected of the providers of symptomatic 
breast disease services and provide the 
basis for service planning, development 
and continuous improvement. Since the 
publication of these standards, Symptomatic 
Breast Disease (SBD) services have evolved 
and developed. Multidisciplinary team 
working, triple assessment, image-guided 
biopsy, assessment of the axilla, collecting 
and using data to monitor performance and 
ensuring that sufficient numbers of patients 
are treated by clinicians in order that they 
maintain their expertise are now inbuilt into all 
SBD services nationally.
3. NCCP framework to implement the 
National Cancer Strategy 
•	 The	2006	National	Cancer	Strategy	
recommended (no. 21) that “All cancer 
care should be delivered through 
a national system of four managed 
cancer control networks, each serving a 
population of approximately one million 
people”. 
•	 The	2006	National	Cancer	Strategy	
recommended (no. 32) that “The HSE 
should conduct a review of the number 
of centres required for the management 
of symptomatic breast disease to bring 
them into line with designated cancer 
centres”.
•	 The	2006	National	Cancer	Strategy	
recommended (no. 31) that “Patients 
should have their diagnosis established 
and their treatment planned by site 
specific multidisciplinary teams”. 
In line with the recommendations of the 
National Cancer Strategy, the HSE developed 
a framework for the ‘Establishment of 
Managed Cancer Control Networks and 
Designation of Eight Cancer Centres’ in 
September of 2007’ (Appendix 1). This 
framework defined the criteria for the 
delivery of cancer services, and specifically 
recommended that the treatment of 
symptomatic breast disease should be 
delivered at eight Cancer Centres, with 
Letterkenny General Hospital providing a 
satellite service for Galway (Appendix 5). 
The report mandated that Breast Services be 
sequentially withdrawn from hospitals which 
did not meet the defined criteria for delivery 
of symptomatic breast care, commencing with 
the lowest volume hospitals and ultimately 
including all hospitals which did not meet the 
guideline standards. Hospitals with low case 
volumes were directed to no longer provide 
symptomatic breast services and surgical 
treatment with immediate effect.
Under the NCCP the centralisation of 
Symptomatic Breast Disease services from 
32 acute hospitals into 8 designated cancer 
centres (and a satellite unit at Letterkenny 
General Hospital) was completed in December 
2009 (table 6.1.2). These designated centres, 
with multidisciplinary teams, have provided 
a significant advancement towards the 
integrated delivery of cancer services.
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4. Development of patient information 
With the designation of cancer centres, patient 
information booklets were developed for 
each of the Symptomatic Breast Units in 2009. 
These booklets contained standard, important 
information for patients on what to expect 
at their appointment in the Symptomatic 
Breast Clinic, including information on triple 
assessment, mammography and biopsy. These 
booklets also included details on who to 
contact in the breast clinic with any queries or 
concerns. 
Additional information has been developed 
for patients on breast examination, breast pain 
and general health promotion messages for 
cancer prevention and early detection. 
5. Development of Standard Operating 
Procedures (SOPs) for Breast Disease
The 2006 National Cancer Strategy 
recommended that “the HSE ensure that 
systems are in place to identify and support 
a designated health professional as a 
contact person for each individual cancer 
patient who may require it”. 
The NCCP established Standard Operating 
Procedures for Symptomatic Breast Disease in 
2009 for the following areas: 
•	 Overview	of	Symptomatic	Breast	Disease	
Service
•	 Monitoring	and	updating	of	key	
performance indicators
•	 Triage	and	Referral	
•	 Multidisciplinary	teams	
•	 Patient	pathway	of	care	including	the	
designation of the Most Responsible 
Physician 
•	 Communication	and	confidentiality	
•	 Patient	experience	
•	 Facilities	
•	 Data	collection	and	information	
governance 
•	 Adverse	events	reporting	and	
management with particular reference to 
delayed diagnosis of cancer 
The report from the HIQA quality review 
(2010) recommended that “the HSE together 
with the designated centres should formally 
evaluate the implementation of Standard 
Operating Procedures on a phased and 
prioritised basis, to ensure that they are fully 
embedded and being applied consistently 
within and between designated centres”. 
Four SOPs were prioritised for evaluation: 
triage and referral, multidisciplinary teams, 
patient pathway through the pathway of care 
and adverse events reporting. All units scored 
highly, with little variability found between 
hospitals. Areas noted for improvement 
included GP access for annual follow-up 
mammogram, promotion of increased use of 
standardised GP referral form and audit of 
patients who did not attend appointments. A 
number of quality improvement plans are in 
development in the hospitals, linked to these 
areas of improvement. 
2007 2008 2009 2010 2011 2012 2013*
Total number of procedures 2263 2550 2456 2480 2431 2446 2213
Number of procedures undertaken 
in a cancer centre
1237 1490 1917 2465 2421 2423 2209
% of procedures undertaken in a 
designated cancer centre.
54.7% 58.4% 78.1% 99.4% 99.6% 99.1% 99.8%
Table 6.1.2: Resection of Breast Cancers by Designation of Hospital and by Year 2007-2013
Source: NCCP.    *2013 is provisional data only. Includes screen detected cancers.
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Individual hospitals have undertaken initiatives 
to assess compliance in their breast units with 
the remaining SOPs (e.g. communication and 
confidentiality, patient experience). 
6. Development of Key Performance 
Indicators (KPIs)
 
The 2006 National Cancer Strategy 
recommended that “the HSE should put in 
place arrangements to monitor inequalities 
in cancer risks, cancer occurrence, cancer 
services and cancer outcomes”.
A suite of Key Performance Indicators (KPIs) 
for breast disease were developed by the 
NCCP in 2009, along with data definitions, 
based on the national standards for 
Symptomatic Breast Disease (HIQA 2007). 
Data collection of KPIs commenced in 2010, 
with a total of 28 KPIs for breast across the 
following areas: 
•	 Access,	Imaging,	Diagnosis,	
Multidisciplinary working, Time to 
treatment (surgery, chemotherapy, 
radiation therapy) Surgery and Pathology
Some Key Performance Indicators for Breast 
Disease include: 
•	 Number	of	urgent	attendances	to	the	
Breast Clinic and the percentage of those 
offered an appointment within two weeks
•	 Number	of	non	urgent	attendances	to	
the Breast Clinic and the percentage 
offered an appointment within 12 weeks 
•	 Number	of	patients	newly	diagnosed	
with breast cancer in the cancer centre 
and the percentage discussed at 
multidisciplinary team meeting (MDM)
Table 6.1.3: Key Performance Indicators 2010-2013
Source: NCCP.  *2013 data has not been validated. **Does not include no. of cancers diagnosed Oct-Dec 2013 
for Mater Hospital
SBD KPIs Target 2010 2011 2012 2013*
URGENT ACCESS >95% 95.1% 98.7% 97.8% 98.0%
Total number of urgent attendances; 
and of those 12,553 13,759 14,102 14,978
No. and % offered an appointment 
within 2 weeks 11,943 13,576 13,797 14,679
NON URGENT ACCESS >95% 97.6% 95.5% 94.9% 95.6%
Total number of non-urgent 
attendances; and of those 25,078 24,196 24,277 22,913
No. and % offered an appointment 
within 12 weeks
24,474 
(97.6%)
23,103 
(95.5%)
23,029 
(94.9%)
21,896 
(95.6%)
Total referrals 37,611 37,955 38,329 37,891
MDM DISCUSSION >95% 100.0% 100.0% 100.0% 100.0%
Total no. of patients newly diagnosed 
in the cancer centre; and of those 2,012 2,145 2,130 2,109**
No. and % discussed at MDM. 2,012 2,145 2,129 2,109**
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A total of 37,891 women attended the 
Symptomatic Breast Disease Clinics in 2013. 
Of these 14,978 were deemed urgent and 
14,679 (98%) were offered an appointment 
within two weeks of GP referral (Table 6.1.3). 
A further 22,913 were non urgent referrals and 
21,896 (96%) of these were seen within the 
target of 12 weeks. 
The Symptomatic Breast Disease Service 
in Ireland has developed significantly. The 
National Cancer Control Programme has 
been working in partnership with clinical, 
administrative and managerial staff in the 
cancer centres to consolidate the service into 
a standardised national programme, with 
comprehensive standards and targets. An 
annual report of KPIs for Symptomatic Breast 
Disease has been published on the NCCP 
website for 2010 and for 2011. A three year 
composite report was published in 2014 for 
the years 2010-2012. (TD2: SBD KPI report 
2010-2012). 
Each cancer centre reports on this set of 
Key Performance Indicators (KPIs), which are 
also published on the NCCP website. These 
KPIs are designed to assist patients, staff 
and the NCCP in assuring themselves that all 
designated cancer centres are adhering to 
the required standards of practice. Prompt 
access to cancer services has been one of the 
main deliverables for this service. The KPIs are 
presented and discussed at the annual NCCP 
multidisciplinary breast forum for audit, quality 
and risk.
Approximately one in 20 women presenting 
are found to have a primary diagnosis of 
breast cancer. 
A review of KPIs was carried out by the Breast 
Clinical Leads group in 2011. A number of 
KPIs that were consistently being met and are 
now integrated as standard practice will no 
longer be routinely reported. The remaining 
21 Breast KPIs will continue to be reported by 
all units. 
The 2006 National Cancer Strategy 
recommended that “opportunistic testing of 
asymptomatic individuals for cancer is not 
recommended”.
The 2006 National Cancer Strategy stated 
that “opportunistic testing of asymptomatic 
individuals for cancer is not recommended”, 
which includes mammograms in asymptomatic 
women outside of the BreastCheck 
programme. Risk aversion and the cautious 
management of breast conditions, many of 
which are benign, are having an impact on 
the numbers referred to Symptomatic Breast 
Clinics and the volume of diagnostic imaging 
being performed. 
Despite many challenges and an overall 
increase in numbers of patients attending the 
service, SBD centres continue to provide a 
high quality service. Priority is given to those 
with suspected cancers and these patients 
Year Benign Cases Breast Cancers Cases detected Total Cases
2009 30,370 1,879 32,249
2010 35,619 2,012 37,631
2011 35,810 2,145 37,955
2012 36,249 2,130 38,379
2013 35,715 2,176 37,891
Table 6.1.4: Attendances at Symptomatic Breast Disease Units 
Source: NCCP 2014
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are seen within two weeks of GP referral. Non 
urgent referrals are seen within 12 weeks 
where possible, however with increasing 
numbers of benign referrals, there are 
challenges meeting this target for all patients. 
Additional resources were invested in 
Radiation Oncology and Medical Oncology 
in 2011 and these measures are beginning 
to show distinct improvements in these vital 
areas of patient care.
7. HIQA National Quality Review of 
Symptomatic Breast Disease Services
In 2009, the Health Information and Quality 
Authority (HIQA) carried out a national 
quality review of Symptomatic Breast Disease 
Services. Individual reports were published 
for each breast unit in addition to an overall 
national report ‘Report of the National Quality 
Review of Symptomatic Breast Disease 
Services in Ireland, February 2010’. The HIQA 
national report set out 18 recommendations 
on clinical governance, standards, audit, 
system assurance and the role of the Clinical 
Lead for Symptomatic Breast Disease services 
in each centre. The NCCP worked with each 
of the designated centres to implement 
the individual hospital recommendations 
and the overall national recommendations. 
Review meetings were held with hospitals 
quarterly and with HIQA twice yearly to 
monitor progress. The recommendations of 
the HIQA Quality Review are outlined below. 
The majority of recommendations have been 
completed, while others are ongoing.
HIQA Recommendation Status 
1 The HSE should formally establish a national network of the SBD lead 
clinicians with a view to identifying and addressing mutual development and 
support needs.
ü
2 The HSE together with the designated centres should formally evaluate the 
implementation of Standard Operating Procedures on a phased and prioritised 
basis, to ensure that they are fully embedded and being applied consistently 
within and between designated centres.
Ongoing
3 The HSE should ensure that designated centres have robust governance 
arrangements in place, including a Service Level Agreement, to effectively 
manage relationships with third party providers. Such arrangements for the 
outsourcing of radiation oncology should be established promptly. These 
should cover the requirements of the Standards and in particular quality,  
safety and the formalised exchange of information.
ü
4 The HSE should put in place formal national clinical governance 
arrangements, to ensure that the eight centres build on robust local clinical 
governance arrangements, in order to operate as a cohesive national clinical 
network for the purposes of clinical audit, sharing of good practice and 
problem solving.
ü
5 The HSE should put specific actions in place to ensure that its new 
directorate structure incorporates a clear mandate for describing and 
implementing the National Cancer Control Plan. In particular this should 
include clarity in the governance, accountability, responsibility, authority and 
resource allocation for the eight designated centres.
ü
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HIQA Recommendation Status 
6 The HSE should work with designated centres, to assess the organisational 
development needs of the newly established designated centres and introduce 
focused support as required.
Ongoing 
7 The HSE together with the designated centres should carry out a risk 
assessment to identify areas in the designated centres where service 
continuity and sustainability, or the ongoing meeting of Standards, could be 
threatened by the absence of key staff and ensure that contingency plans are in 
place as needed.
Ongoing 
8 The HSE should work with the designated centres, and the relevant training 
bodies, to develop a standardised framework for assuring the skills, education 
and training of staff in the centres are maintained at the necessary levels.
Ongoing 
9 The HSE, with the designated centres, should establish effective ways of 
enhancing the continuity of patient care. This should include the introduction of 
the “Most Responsible Clinician” for patients within the SBD service. This should 
also be inclusive of aspects of care provided by third party providers.
ü
10 The HSE should require all centres to have in place robust arrangements for 
ensuring that all information relevant to patients’ care is accessible as needed 
by patients and clinicians, irrespective of where the care is provided or the 
information is generated.
ü
11 The HSE should identify those designated centres where data management 
capability, and the use of data, are still in development and instigate ongoing 
evaluation and, where needed, provide focused support for those designated 
centres. This should include targeted support and development for SBD 
clinicians in the capture and use of data as an intrinsic facet of clinically effective 
care.
ü
12 The HSE together with the designated centres should coordinate, as part 
of its wider development of clinical audit systems, a review of referral and 
triage processes, aimed at understanding and addressing any unnecessary 
variations in referral or triaging practices between the designated centres and 
their referring clinicians.
ü
13 The HSE should coordinate, with the designated centres and the wider health 
system, the development of a differentiated service response that reflects the 
profile of patients being referred to the service, whereby patients with a lower 
risk of breast cancer are seen in a timely way and with the necessary clinical 
assessment.
Ongoing 
14 The HSE together with the designated centres should develop mechanisms 
for monitoring the numbers of newly diagnosed patients seen and treated by 
individual clinicians with a view to developing benchmarks for the relevant 
clinical specialties.
ü
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8. Establishment of a national governance 
model for Symptomatic Breast Disease
In May 2010, the NCCP held a Governance 
Forum for Symptomatic Breast Disease with 
the CEOs, clinicians and clinical directors 
of the designated cancer centres. This 
forum developed a national governance 
model for the SBD services, based on the 
recommendations of the National Quality 
Review of Symptomatic Breast Services (HIQA 
2010). This governance model recommended 
the establishment of a national group of lead 
clinicians for Symptomatic Breast Disease 
and the establishment of a national Guideline 
Development Group for the development of 
clinical guidelines. 
9. Establishment of a National Clinical Leads 
Network
The 2006 National Cancer Strategy 
recommended (no. 23) that “A lead clinician 
for each cancer centre should be appointed. 
In addition, a clinician should be appointed 
to lead the development of cancer care 
pathways for each major site-specific cancer 
in partnership with all stakeholders within 
the network”.
The HIQA report on the national quality 
review of Symptomatic Breast Disease services 
(2010) recommended that the HSE should 
formally establish a national network of SBD 
Lead clinicians with a view to identifying and 
addressing mutual development and support 
needs. 
HIQA Recommendation Status 
15 The HSE should develop, with the designated centres, a national clinical audit 
programme for SBD services that includes as a minimum: patients triaged as 
non-urgent and subsequently diagnosed with breast cancer, delayed diagnoses, 
longer term clinical outcome and survival rates. The national key performance 
indicator set should be reviewed regularly based on the outcomes of these 
audits.
ü
16 The HSE together with the designated centres should put in place 
arrangements to begin publicly reporting performance against the NCCP Key 
Performance Indicators during 2010.
ü
17 The HSE should undertake a formal evaluation of the change programme that 
has created the eight designated centres with a view to identifying lessons for 
future similar programmes of change. The changes that have been made in 
improving the symptomatic breast disease services should be used as a template 
to be adapted and modified for other services.
Ongoing 
18 The HSE should nominate a national director to be responsible for developing 
and monitoring an implementation plan for these recommendations and should 
ensure that these actions are delegated as necessary. It should put in place 
arrangements for reporting progress with implementation to the HSE Board and 
the public.
ü
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The SBD Clinical Leads group was established 
in July 2010 to ensure that the eight centres 
build on robust local clinical governance 
arrangements, in order to operate as a 
cohesive national clinical network for the 
purpose of clinical audit, sharing of good 
practice and problem solving. The group 
meets quarterly and the work is facilitated by 
an NCCP project manager. 
The terms of reference for the clinical leads 
group are as follows: 
•	 Contribute	to	the	development	and	
continuous improvement of SBD service.
•	 Share	good	practice	and	innovation	
in SBD service and ensure that non 
evidence based practice is discontinued.
•	 Inform	decision	making	and	
standardisation of service delivery across 
the centres. 
•	 Ensure	adherence	to	National	Standards	
and Key Performance Indicators.
•	 Review	the	quality	and	completeness	of	
data, recommending corrective action 
where appropriate and necessary.
•	 Lead	national	multidisciplinary	audit,	
quality and risk (AQR) meeting for SBD.
•	 Input	into	selection	of	Key	Performance	
Indicators (KPIs) for Symptomatic Breast 
Disease Services. 
The group has completed several significant 
projects in relation to standardisation of breast 
services, including: 
•	 Protocol	for	follow-up	after	breast	cancer	
•	 Family	history	of	breast	cancer
•	 Management	of	interval	cancers	
•	 Review	of	Key	Performance	Indicators	
(KPIs) 
•	 HR	census	of	breast	unit	staffing	
•	 Management	of	mastalgia	(breast	pain)
•	 Review	of	GP	referral	guidelines	and	
referral form for breast disease
The Symptomatic Breast Disease services are 
now led by a lead clinician in each designated 
cancer centre and are supported by a 
multidisciplinary team of cancer specialists. 
Through this national network, best practice 
models are identified and shared, to ensure 
standardisation and service improvement 
nationally. 
10. Annual Audit Quality and Risk Forum for 
Symptomatic Breast Disease
Based on the recommendations of the HIQA 
Quality review (2010), the NCCP established 
an annual audit quality and risk forum for the 
Symptomatic Breast Services. The purpose of 
the SBD forum is to: 
•	 Provide	an	annual	multidisciplinary	
forum for audit, quality and risk in the 
Symptomatic Breast Services.
•	 Build	on	local	clinical	governance	
arrangements, in order to operate as a 
cohesive national clinical network for the 
purpose of clinical audit, sharing of good 
practice and problem solving.
•	 Identify	best	practice	models	and	ensure	
standardisation and service improvement 
nationally. 
•	 Examine	and	agree	referral	criteria	for	
the Symptomatic Breast Disease Units. 
This is a decision making forum. Each year, 
the KPIs from each unit are presented and 
any variation is discussed at this forum. The 
first Breast Forum was held in October 2010 
and they have been held annually since. The 
5th annual NCCP Breast Forum was held in 
October 2014 in Limerick. 
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Key themes of the Breast Forum in previous 
years included: 
2010 Follow up after breast cancer, family risk 
of breast cancer. 
2011 Breast imaging, genetic testing, surgical 
management of the axilla, breast 
reconstruction and radiation treatment. 
2012 Hereditary cancer programme, staging 
investigations, GP referrals, quality 
assurance in pathology. 
2013 Quality Assurance for Symptomatic 
Breast Disease services, breast cancer 
clinical guidelines, neoadjuvant 
treatment, surgical margins, and 
specialist breast care nursing. 
The forum also encompasses evidence 
based practice debates and multidisciplinary 
workshops for the purpose of problem solving 
and sharing of best practice models - each 
clinical discipline identifies and agrees key 
areas requiring standardisation and national 
protocols for service improvement. 
11. National clinical guidelines for diagnosis, 
staging and treatment of breast cancers
The 2006 National Cancer Strategy 
recommended that “HIQA should establish 
site-specific multidisciplinary groups at a 
national level to develop guidelines for 
quality in major cancers”. 
The 2006 National Cancer Strategy 
recommended the development of evidence 
based guidelines and standards. The 
NCCP commenced the development of 
evidence based clinical guidelines for the 
diagnosis, staging and treatment of breast 
cancers in 2011. These guidelines include 
recommendations relating to the patient 
pathway in the areas of pathology, radiology, 
surgery, medical oncology and radiation 
oncology. There are 29 clinical questions 
for breast cancer covered in this guideline. 
Nominations for each group were sought 
from the relevant clinical faculties. The breast 
clinical guideline was completed in December 
2014 and is available on the NCCP website.
12.  Revised national standards for 
Symptomatic Breast Disease
In June 2012, the HIQA published the 
National Standards for Safer Better Healthcare. 
These describe how a service provides high 
quality, safe and reliable care, centred on the 
service user and are structured around eight 
themes for quality and safety including: Person 
centred care and support, Effective care and 
support, Safe care and Support. 
A framework on quality assurance for 
Symptomatic Breast services was developed 
by the NCCP in 2013, based on the HIQA 
National Standards for Safer Better Healthcare; 
‘Symptomatic Breast Service – Quality 
Assurance for Safer Better Healthcare, NCCP 
2013’ (TD 3).
In September 2013, the Health Information 
and Quality Authority recommended that the 
2007 National Quality Assurance Standards 
for Symptomatic Breast Disease be subsumed 
into the National Standards for Safer Better 
Healthcare (HIQA 2012). In October 2013, 
this decision was endorsed by the Minister 
for Health. Monitoring of standards for 
Symptomatic Breast Disease Units by HIQA 
has now been subsumed into their monitoring 
programme for the National Standards for 
Safer Better Healthcare. 
13. Audit and Research 
An audit and research report on breast cancer 
referrals in Ireland is included in TD 11.
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14. Workforce planning
The 2006 National Cancer Strategy 
recommended that “the HSE should 
develop a national cancer Workforce Plan 
designed to fully implement national cancer 
policy” 
The projections from the NCRI show an 
increase in incidence and prevalence of breast 
cancer (TD 1). Based on demographic trends 
only, the NCRI predict an 84% increase in 
breast cancer incidence in females and a 107% 
increase in males by 2040. 
The NCRI have also reported the number of 
breast cancers requiring treatment in 2010 
and the estimated number of breast cancers 
requiring treatment in 2025, for the first year 
following patient diagnosis (NCRI 2014). 
These projections will form the basis for NCCP 
workforce planning for breast cancer. 
A surgical oncology workforce planning 
project commenced in 2013 in the National 
Cancer Control Programme and will inform 
long term service planning. The NCCP 
developed a workforce plan for oncology 
for the HSE Medical Education and Training 
Unit (MET) in 2013 to inform the training and 
human resource requirements for oncology, 
including requirements for breast cancer in the 
areas of surgery, radiology, pathology, medical 
oncology and radiation oncology (a copy of 
this report is available). 
15. Community Oncology 
In parallel with the restructuring and 
centralisation of breast surgical services 
a range of initiatives were undertaken to 
strength and support the integration of the 
primary and secondary care interface. These 
include:
•	 Development	of	GP	referral	guidelines	
and standardised referral form (TD 4)
•	 Development	of	electronic	GP	referral	
systems 
•	 Development	of	GP	algorithm	on	
mastalgia (breast pain)
•	 Development	of	patient	booklet	and	
smartphone App’ for mastalgia 
•	 Establishment	of	a	follow-up	protocol	
for patients when their treatment is 
complete 
•	 Development	of	information	materials	
for GPs and patients on follow-up after 
breast cancer 
•	 Development	of	an	e-learning	module	
for GPs on breast disease 
•	 Training	for	GPs	through	CME,	ICGP	and	
hospital study days 
•	 Training	of	hospital	and	community	
nurses on cancer prevention and 
treatment
Female breast 2010 2025 projections (based on demography only)
Surgery 2,541 3,461
Chemotherapy 1,388 1,890
Radiotherapy 2,058 2,803
Source: NCRI 2014 – includes screen detected cancers. 
Table 6.1.5: Projected Breast Cancer Treatment numbers
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•	 Prevention	of	secondary	lymphoedema	
in cancer patients
•	 Cancer	Survivorship	initiatives
These initiatives and programmes are further 
discussed in the community oncology, 
Section 9.
16. Hereditary cancers / genetics / molecular 
Work within the NCCP includes the following 
initiatives: 
•	 Health	Technology	Assessment	for	
women <50 at increased risk of breast 
cancer was undertaken by HIQA at the 
request of the NCCP
•	 Establishment	of	a	Hereditary	Cancer	
Programme
•	 Advice	for	GPs	on	referral	of	patients	
with family risk of breast cancer 
•	 Working	group	to	examine	options	for	
surveillance of women at increased risk of 
breast cancer 
•	 Breast	Cancer	Family	Risk	forum	2014	
•	 Provision	of	Oncotype	DX	testing	
These are further described in the hereditary 
cancer (Section 10) and community oncology 
(Section 9) of this report.
Challenges for Breast Cancer Services 
•	 With	the	development	of	Hospital	Groups,	
it is important that the autonomy of hospital 
groups does not compromise national cancer 
policy in terms of designated centres. Patients 
with breast cancer should continue to have 
their treatment in the appropriate designated 
sites, with the relevant multidisciplinary 
teams. 
•	 The	cessation	of	surgical	services	outside	
of the designated SBD Units, risk aversion 
and the cautious management of breast 
conditions, many of which are benign, are 
having an impact on the numbers referred to 
Symptomatic Breast Clinics and the volume 
of diagnostic imaging. Referrals to the 
Symptomatic Breast Disease Units in Ireland 
have increased from 23,575 in 2006 to 37,891 
in 2013, without a corresponding increase 
in breast cancers detected. This increasing 
volume of referrals has resulted in increasing 
challenges for cancer centres in meeting 
the target waiting times for the non-urgent 
referrals. 
•	 There	has	been	some	reluctance	from	
some medical organisations to support the 
discharge of well women to their GP five 
years post cancer surgery. 
•	 There	is	a	lack	of	IT	systems	and	data	
management staff to automatically capture 
the range of work in the breast service, 
particularly of multidisciplinary teams. 
•	 The	current	HR	environment	with	retirements,	
voluntary redundancy and recruitment 
moratoria has exacerbated the lack of clerical 
support, mammographers and theatre nurses 
in the breast service. 
•	 Competing	demands	for	acute	hospital	
beds may impact on timely access for cancer 
patients. The NCCP plans to monitor access 
times for cancer patients for elective surgery. 
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•	 Management	of	women	at	increased	risk	
of breast disease remains controversial. 
Following a HTA, HIQA made several 
recommendations in relation to surveillance 
of women at increased risk of breast cancer. 
The surveillance of women at moderate 
and at high risk of breast disease will 
place additional demands on the system 
if implemented. The level of evidence 
for cost and clinical effectiveness for the 
implementation of a surveillance system for 
the moderate risk group is weak.
•	 The	increasing	demand	for	predictive	testing	
and for new medicines for the treatment 
of breast cancer has significant resource 
implications. 
•	 The	National	Cancer	Registry	predictions	
of an increase in breast cancer incidence in 
females and a 107% increase in males by 
2040 will have a significant impact on the 
existing services for breast cancer. 
Opportunities for Breast Cancer Services
•	 It	is	opportune	to	re-examine	the	scope	and	
structure of the breast clinics in relation to 
suspected cancers and benign / non urgent 
referrals, to ensure that suspected cancers are 
seen quickly and non urgent referrals are seen 
in the most appropriate setting. 
•	 The	numbers	of	women	attending	breast	
rapid access clinics rose rapidly when the 
clinics were first established and although 
attendances have remained stable at 38,000 
since 2010, the proportion of women who 
are diagnosed with cancer remains at just 
over 5% which is at the lower end of the 
range internationally. A variety of initiatives 
to optimise care in the community are being 
progressed to ensure appropriate referrals 
to specialist centres e.g. management of 
mastalgia, smartphone App’, family risk and 
benign breast conditions. (Discussed under 
community oncology Section 9).
•	 There	are	opportunities	to	look	at	a	diversity	
of roles in the Symptomatic Breast Clinics, 
such as Advanced Nurse Practitioner and 
GP clinics to manage selected non urgent 
referrals.
•	 Clear	information	for	patients	and	for	GPs	on	
risks associated with family history of breast 
cancer assist the streamlining of the referral 
process. 
•	 The	development	and	implementation	of	the	
clinical guidelines for breast cancer will assist 
in standardisation of practice e.g. diagnostic 
imaging, surgical management of the axilla, 
surgical margins, rates of breast conservation 
surgery and reconstruction. 
•	 The	Health	Information	Bill,	when	enacted	
should provide provision for protected 
disclosure for audit. 
•	 The	NCCP	has	a	remit	for	developing	cancer	
services and monitoring its volume and 
quality in the Irish public hospital system only. 
Private hospitals are outside this remit and 
activity there is not subject to NCCP scrutiny.
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6.2 Prostate Cancer 
Epidemiology 
There was an annual average of 3,267 prostate 
cancers diagnosed in Ireland 2009-2011, making 
prostate cancer the commonest invasive cancer 
in Ireland, excluding non-melanoma skin cancer. 
Prostate cancer accounts for 31.9% of all invasive 
cancers. In 2011, there were 563 deaths from 
prostate cancer, making it the 3rd most common 
cause of invasive cancer deaths. Between 1994 
and 2011, there has been an annual increase in 
incidence rate of 5.3% per year; much of this 
increase can be attributed to an expansion of PSA 
testing. The most recent relative survival estimates 
are a hybrid estimate for the 2008-2010 cohort of 
cancers and five-year relative survival for this cohort 
is 93% with a 95% confidence interval of between 
92.2%-94.4% (Cancer Factsheet: Prostate NCRI 
2013). 
Recent cancer projections from the NCRI predict 
that the number of prostate cancers will increase 
by 104%-288% between 2010 and 2040 (Cancer 
Projections for Ireland: 2015-2040. NCRI 2014). 
Cancer strategy implementation – 
surgical centralisation
The document ‘Establishment of Managed Cancer 
Control Networks and Designation of Eight 
Cancer Centres’ published by the HSE in 2007 
recommended that “curative surgical treatment of 
primary urological cancers will be provided in four 
centres” (Appendix 1).
In 2007, there were nine hospitals (five of them 
designated cancer centres) undertaking radical 
prostatectomy for prostate cancer. The NCCP 
undertook an examination of the activity in these 
hospitals, looking at volumes, bed utilisation, ITU 
usage and the geographical patterns of patient 
referral. Beaumont Hospital, St. James’s Hospital, 
the Mater Hospital, St Vincent’s University Hospital, 
Cork University Hospital and University College 
Hospital Galway were designated as the six surgical 
centres for prostate cancer. Rapid Access Prostate 
Cancer Clinics have been established in each of 
the eight designated cancer centres where patients 
are treated by cancer specialists in multidisciplinary 
teams.
Figure 6.2.1: Age profile at diagnosis & death
Source: NCRI, 2013 
Cases  
median age = 67 yrs
Deaths  
median age = 80 yrs
<50 yrs 2.4%
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<50-64 yrs 6.8%
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Summary of achievements of the National 
Cancer Control Programme in relation to 
Prostate Cancer 
1. Establishment of the National Cancer 
Control Programme Prostate Service & 
Rapid Access Clinics 
Prostate Cancer has remained a major area of 
focus of the NCCP since its inception. Rapid 
Access Clinics (RACs) were established in 
each of the eight designated cancer centres, 
with GP referral guidelines and standardised 
referral forms. The first prostate rapid access 
clinics were opened in 2010 and by 2012 all 
eight clinics had opened. Referrals to the 
RACs have increased from 2,466 in 2011 to 
2,870 in 2013.
2. NCCP framework to implement the 
National Cancer Strategy
Recommendation 
28
Cancer Centres that each 
serve a minimum population of 
500,000 should be designated 
by the HSE as soon as possible. 
Ireland will require about eight 
such centres. 
The document ‘Establishment of Managed 
Cancer Control Networks and Designation of 
Eight Cancer Centres’ published by the HSE in 
2007 concluded that there was a need for four 
Centres nationally, one within each Network, 
for the curative surgical treatment of primary 
urological cancer (Appendix 1). 
3. Centralisation of Primary Surgical Activity
In 2007, there were nine hospitals undertaking 
radical prostatectomy for prostate cancer and 
just five were designated cancer centres – 
Beaumont, Mater, St Vincent’s, St James’s and 
University College Hospital Galway. Between 
2007 and 2013, radical prostate cancer surgery 
commenced in Cork University Hospital, with a 
major increase from 2012 onwards. However, 
the centralisation of radical prostatectomy has 
only risen by about 10% between 2007 and 
2013. This is predominantly due to two large 
surgical services in the Adelaide, Meath and 
National Children’s Hospital (Tallaght Hospital) 
and the Mercy University Hospital, Cork which 
have not yet transferred to neighbouring 
designated cancer centres (Table 6.2.1). 
 
2007 2008 2009 2010 2011 2012 2013*
Total number of procedures 256 254 260 303 350 341 290
Number of procedures undertaken 
in a cancer centre 
45 58 44 65 45 76 80
Number of procedures undertaken 
in one of the six designated surgical 
centres for prostate cancer 
156 139 150 186 241 247 199
% of procedures undertaken in 
one of the six designated surgical 
centres for prostate cancer
61% 55% 58% 61% 69% 72% 69%
Table 6.2.1: Resection of Prostate Tumours by Designation of Hospital and by Year, 2007-2013
Source: HIPE data, Healthcare Pricing Office 2014
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4. Development of NCCP GP Referral 
Guidelines and Referral Form for  
Prostate Cancer
Recommendation 
24
The HSE should develop 
care pathways for cancer 
care to link primary care, 
services, hospital services 
and other relevant services. 
Recommendation 
25
Improved cancer 
information services should 
be available in primary 
care. 
National GP Referral Guidelines for prostate 
cancer were developed to support the NCCP 
Rapid Access Prostate Clinics in conjunction 
with the national multidisciplinary prostate 
cancer teams and the Irish College of General 
Practitioners.
These were the first in a series of national 
GP referral guidelines to be developed. The 
evidence based guidelines were developed in 
consultation with all the relevant stakeholders. 
The guidelines however, do not override the 
individual responsibility of health professionals 
to make decisions appropriate to the 
circumstances of the individual patient. (TD 18)
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 Development of information booklet 
for patients on ‘Having your prostate 
checked’ 
Once the cancer centres had been designated, 
a patient information booklet was developed 
for men called ‘Having your prostate checked: 
what you should know’. This booklet provides 
key information for patients on what to expect 
when having their prostate checked. 
 
Meeting the Needs of GPs
Education of GPs with respect to referral 
direction and timing can have an important 
bearing on the process and outcome of care 
that a patient may experience. The needs of 
GPs in relation to cancer were identified in the 
report ‘Early Detection of Cancer, A Needs 
Assessment of General Practitioners’ which 
was published in 2007 by the Irish Cancer 
Society (www.cancer.ie) and the Irish College 
of General Practitioners (www.icgp.ie) 
The common barriers that were identified 
included:
•	 Delay	in	patient	presentation
•	 Lack	of	clear	recommendations
•	 Inequity	of	access
•	 Long	waiting	lists	and	inadequate	access	
for investigations
•	 Referral	of	patients	who	cannot	pay	
privately
•	 Lack	of	direct	access	to	hospital-based	
diagnostics
•	 Communication	difficulty	with	referral	
to hospital services for investigation/
assessment
The development of national GP referral 
guidelines, referral forms and electronic 
systems (developed in conjunction with the 
National Healthlink Project [www.healthlink.
ie]) are aimed at supporting GPs to recognise 
suspicious symptoms and expedite referral of 
patients to the rapid access clinics. It is hoped 
that these referral guidelines, standardised 
referral forms and electronic referral systems 
will increase the number of patients diagnosed 
at an earlier stage in order to maximise 
outcome and survival.
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5. Development of Key Performance Indicators (KPIs)
Recommendation 55 The HSE should present a report on policy indicators each year to the National 
Cancer Forum. 
A suite of Key Performance Indicators (KPIs) for prostate cancer were developed in 2011, along 
with data definitions. Data collection of KPIs concerning the functioning of the Rapid Access Clinics 
commenced in 2012. A full suite of KPIs concerning access, multidisciplinary working, pathology 
reporting and quality of surgery were piloted in 2013 with national rollout to commence in 2014 (Table 
6.2.2):
Access 90% of referrals to the rapid access prostate clinic shall be offered an appointment 
within 20 working days of the date of receipt of a letter of referral in the cancer 
centre 
Time to treatment – 
surgery 
For 90% of patients diagnosed with a primary prostate cancer, the interval between 
the date of decision to treat and date of first surgical intervention where surgery is 
the first treatment, shall be less than or equal to 30 working day 
Time to treatment – 
radiation oncology 
90% of new patients with primary prostate cancer who undergo radical therapy will 
be treated within 15 working days of the date of ready to treat 
Multidisciplinary 
discussion
All patients who are diagnosed with prostate cancer shall be discussed at MDM prior 
to their first therapeutic intervention
Timeliness of 
pathology reporting
The histology report following a first prostate biopsy should be available within 10 
working days of the procedure being carried out in 80% of cases
Surgery For patients who have a radical prostatectomy for prostate cancer and the specimen 
is classified as a pathological stage pT2, the positive margin status should not 
exceed 15%
For patients who have a radical prostatectomy for prostate cancer and the specimen 
is classified as a pathological stage pT2, post-operative PSA at three months will be 
below detection levels in 90% of cases
For patients who have a radical prostatectomy for prostate cancer and the specimen 
is classified as a pathological stage pT3, the positive margin status should not 
exceed 40%
For patients who have a radical prostatectomy for prostate cancer and the specimen 
is classified as a pathological stage pT3, post-operative PSA at three months will be 
below detection levels in 70% of cases
Table 6.2.2: Key Performance Indicators
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A new KPI relating to the rate of urinary tract 
infections (UTI) and blood stream infections 
(BSI) will pilot in 2015 to monitor the new 
national policy on TRUS biopsies. 
Each cancer centre reports on this set of Key 
Performance Indicators (KPIs), which are also 
published on the NCCP website. The KPIs are 
presented and discussed at the annual NCCP 
Prostate Cancer Quality and Audit Forum.
Prostate cancer services in Ireland have 
developed significantly. The National Cancer 
Control Programme has been working in 
partnership with clinical, administrative and 
managerial staff in the cancer centres to 
consolidate the service into a standardised 
national programme, with comprehensive 
standards and targets. 
INDICATOR Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Total
Patients referred 
to RAC shall 
be offered an 
appointment to 
attend within 20 
working days of 
receipt of referral 
52% 55% 55% 54% 56% 51% 59% 53% 52% 51% 59% 71% 55%
The no. of patients 
that attended a 
Prostate RAC within 
reporting calendar 
month
225 278 211 264 296 215 227 200 231 244 279 200 2870
The no. of patients 
that attended or 
received an appt. 
to attend RAC 
within 20 working 
days of receipt 
of referral in the 
cancer centre
117 153 115 143 165 109 133 105 121 124 165 141 1591
% new patients 
diagnosed. with 
PRIMARY prostate 
cancer
42% 33% 39% 32% 36% 33% 38% 28% 40% 39% 34% 40% 36%
Table 6.2.3: NCCP Rapid Access Prostate Clinics 2013
Source: NCCP 2014
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2,870 men attended the eight NCCP Rapid 
Access Prostate Clinics in 2013. Of these 
1,591 were offered an appointment within 20 
working days. On average, 36% of patients 
who attended the clinic were subsequently 
diagnosed with cancer in 2013. Access to 
clinics continues to be an issue with just 55% 
of patients who were referred being seen 
within the target time (Table 6.2.3). 
Access to prostate RACs has deteriorated 
further in the first half of 2014. 
Significant challenges exist within some of 
the prostate cancer Rapid Access Clinics in 
meeting the KPI targets. Galway, Limerick 
and Waterford Hospitals have continuously 
struggled to reach their KPIs. A contributory 
factor to the delays in accessing these clinics 
is a lack of consultant urologist posts locally. 
Since January targets are not being met in 
some Dublin centres arising from cancellation 
of clinics over holiday periods and staffing 
challenges. There is an underlying vulnerability 
in the lack of surge capacity which is evident in 
many RACs. The NCCP has been assured that 
all referrals to these centres are triaged, urgent 
cases are prioritised and appointments offered 
to all appropriate patients in the first instance. 
Recruitment is underway to appoint an 
additional consultant urologist in Galway 
and in June 2014 approval was given by 
the Director General of the HSE to appoint 
another cancer urologist at Cork University 
Hospital with a commitment also to the South 
East. Two new general urology posts have also 
been approved for the South East and the 
recruitment process is underway. 
INDICATOR Jan Feb Mar Apr May Total
Patients referred to RAC shall be offered an appointment 
to attend within 20 working days of receipt of referral 42% 44% 52% 38% 42% 44%
The number of patients that attended a Prostate RAC 
within reporting calendar month; of those 230 248 200 197 225 1100
The number of patients that attended or received an 
appointment to attend RAC within 20 working days of 
receipt of referral in the cancer centre 96 110 104 75 94 479
% new patients diagnosed with PRIMARY prostate cancer 37% 38% 43% 40% 38% 39%
Table 6.2.4: Rapid Access Prostate Clinics 2014
Source: NCCP 2014
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 5. Establishment of a National Clinical Leads 
network for Prostate Cancer
Recommendation 
23
A lead clinician for each 
Cancer Centres should be 
appointed. In addition, a 
clinician should be appointed 
to lead the development 
of cancer care pathways 
for each major site-specific 
cancer in partnership with 
all stakeholders within the 
network. 
The purpose of the national NCCP Prostate 
Cancer Clinical Lead Network is to ensure that 
the eight centres build on robust local clinical 
governance arrangements, in order to operate 
as a cohesive national clinical network for 
the purpose of clinical audit, sharing of good 
practice and problem solving. 
The terms of reference for the clinical leads 
group are as follows: 
•	 Contribute	to	the	development	and	
continuous improvement of the prostate 
cancer service.
•	 Share	good	practice	and	innovation	
in prostate cancer service and ensure 
that non evidence based practice is 
discontinued.
•	 Inform	decision	making	and	
standardisation of service delivery across 
the centres. 
•	 Ensure	adherence	to	National	Standards	
and Key Performance Indicators.
•	 Review	the	quality	and	completeness	of	
data, recommending corrective action 
where appropriate and necessary.
•	 Lead	national	multidisciplinary	audit,	
quality and risk (AQR) meeting for 
prostate cancer.
•	 Input	into	selection	of	Key	Performance	
Indicators (KPIs) for Prostate Cancer 
Services. 
The NCCP Prostate Cancer Clinical Leads 
group was established in 2011 and meets 
quarterly. The group has completed several 
key projects in relation to standardisation 
of PSA, developed a national policy on 
management of infection post TRUS prostate 
biopsy, functional outcome surveys submission 
to the Irish Medicines Board and European 
Medicines Agency to request that PSA home 
testing kits be banned and the development 
and review of KPIs.
The prostate cancer services are now led by a 
lead clinician in each designated cancer centre 
and are supported by a multidisciplinary team 
of cancer specialists. Through this national 
network, best practice models are identified 
and shared, to ensure standardisation and 
service improvement nationally. 
6. Annual NCCP Prostate Cancer Quality 
and Audit Forum 
The NCCP established an Annual Prostate 
Cancer Quality and Audit Forum for Prostate 
Cancer Services. The purpose of the forum is 
to provide an annual multidisciplinary forum 
for audit, quality and risk for Prostate Cancer 
Services.
This is a decision making forum. Each year, 
the KPIs from each unit are presented and 
any variation is discussed at this forum. The 
forum also encompasses multidisciplinary 
workshops for the purpose of problem solving 
and sharing of best practice models - each 
clinical discipline identifies and agrees key 
areas requiring standardisation and national 
protocols for service improvement. 
The first Prostate Cancer Forum was held in 
Farmleigh in November 2012 and it has been 
held annually since. 
Key themes of the previous fora included: 
2012:  Guest Speaker Professor Damian 
Greene, UK: Presented on setting up 
prostate cancer    
centre of excellence.
2013:  Guest Speaker, Mr. Rick Popert, UK: 
Presented on Trans Perineal Prostate 
Biopsy. 
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7. National clinical guidelines for diagnosis, 
staging and treatment of prostate cancer.
The NCCP has commenced the development 
of evidence based clinical guidelines for 
the diagnosis, staging and treatment of 
prostate cancer. These guidelines will include 
recommendations relating to the patient 
pathway in the areas of pathology, radiology, 
surgery, medical oncology and radiation 
oncology. Nominations for each group were 
sought from the relevant clinical faculties. 
The prostate cancer clinical guideline is due 
for completion in 2014 and will be available 
on the NCCP website. Further information is 
available is Section 12. 
8. NCCP PSA Standardisation Project Board 
2013-2014
The NCCP sought to address the lack of 
standardisation of PSA measurements around 
the country as indicated in a recent publication 
in British Journal of Urology International 
(BJUI). It was proposed that harmonisation 
of PSA assays around the country will lead to 
better decision-making particularly for PSA 
results in the narrow 3-7 ug/L range where 
a decision to perform prostate biopsy may 
be taken and where it is thought that lack of 
standardisation may contribute to unnecessary 
biopsies. 
The project board agreed to the establishment 
of a PSA Harmonisation Group which would 
further consider the issue and recommend 
the best approach to achieving optimal 
standardisation. 
The project was divided into the following 
three phases:
Phase 1: National Online Survey: To collate 
data on the current practice in relation to 
pre-analytical, analytical and post-analytical 
aspects of PSA analysis and reporting in 
Irish laboratories, in particular in the NCCP 
designated cancer centres. 
Phase 2: Cross-Laboratory Review: A 
questionnaire was circulated to the eight 
designated cancers and AMNCH and Mercy 
Hospital Cork.
Phase 3: Internal Quality Control (IQC) 
and External Quality Assurance (EQA) 
sampling: Phase three of the project involves 
running common IQC materials to facilitate 
intensive management of PSA measurement. 
Stability testing of PSA samples has also been 
completed as well as an audit of distribution 
timelines of PSA blood samples.
Three NCCP PSA Harmonisation Workshops 
were held during 2013 and 2014 to update 
laboratory personnel about the project.
Limiting of Free to Total PSA Testing:
As part of the work of the NCCP PSA 
Standardisation Project Board, a decision was 
agreed in conjunction with the Irish College of 
General Practitioners to limit the use of Free to 
Total PSA testing to hospital based Consultant 
Urologists. The limiting of Free to Total PSA 
testing to Consultant Urologists will result in 
an estimated annual cost saving of one million 
euros. 
9. Development National Policy for the 
‘National Policy on the Prevention 
and Management of Infection Post 
Trans Rectal Ultrasound (TRUS) Guided 
Prostate Biopsy’
A project team was established in May 2013 
with agreed terms of reference:
a. To conduct an online survey of the 
eight designated NCCP prostate cancer 
centres, Mercy Hospital, Cork and 
Tallaght Hospital, Dublin to determine 
current national practice in relation to the 
prevention and management of infection 
post prostate biopsy.
b. To conduct a literature search for the 
clinical questions raised by the board. 
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c. To draft and agree a national prostate 
biopsy surveillance form and protocol, 
and circulate to relevant stakeholders for 
their review and feedback.
d. To present the findings of the national 
survey at the NCCP Prostate Cancer 
Quality and Audit Forum meeting in 
Dublin Castle on the 8th November 2013.
The national policy for prevention and 
management of infection post TRUS guided 
biopsy has now been published and circulated 
to the designated cancer centres and all 
relevant national stakeholders. The guidelines 
are also available on the NCCP website. 
http://www.hse.ie/eng/services/list/5/nccp/
pubs/guidelines/guidelines.html. A new key 
performance indicator is being piloted in Q4 
of 2104 to monitor the implementation of the 
national policy. 
10. Development of information booklet for 
patients on ‘Having your Prostate TRUS 
Biopsy: What you Should know’
Another output of the NCCP Prostate TRUS 
Infection Project Board is the development of 
a patient information booklet for men called 
‘Having your Prostate TRUS Biopsy: What 
you should know’. This booklet provides key 
information for patients on what to expect 
when having their prostate TRUS biopsy. 
The NCCP was awarded the National Adult 
Literacy Agency Plain English mark for this 
booklet.
11. Development of electronic GP referral 
systems for prostate, lung (and 
other) Cancers - Electronic referral: 
(2010-ongoing)
The NCCP, in collaboration with a broad range 
of stakeholders has developed electronic 
referrals for breast, prostate and lung cancer. 
This award winning initiative commenced 
in 2008 and enables GPs to send a prompt 
referral to the relevant designated cancer 
centre. The referrals are available on-line and 
a breast, prostate and lung cancer referral 
form are available as an integrated referral 
form in GP practice management systems. 
Referrals are acknowledged and the cancer 
team sends a response to the GP with the 
date of the patients’ appointment within five 
working days. The numbers of prostate cancer 
referrals have increased from 186* in 2010 to 
1,042 in 2013. This project was awarded an 
eGovernment award in 2012. 
Further information is available in the 
community oncology Section 9 of this report. 
*only three hospitals were live in 2010.
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12. Submission to the Irish Medicines Board 
and the European Medicines Agency to 
request the banning of PSA home testing 
kits
Recommendation 
18
Population based prostate 
screening should not be 
introduced in Ireland at 
present. The Nation Cancer 
Forum should keep emerging 
international evidence on 
population screening for 
prostate cancer under review. 
The National Cancer Control Programme 
considers that the use of home self-test kits for 
Prostate Specific Antigen (PSA) constitutes an 
unnecessary risk to the health of men. For this 
reason the NCCP is calling for a ban on the 
importation, distribution, marketing and sale 
of such home self-test PSA kits. The NCCP 
have made a submission to the Irish Medicines 
Board and the European Medicines Agency to 
request the banning of PSA home testing kits. 
 
13. Community Oncology 
Additional achievements relating to prostate 
cancer have been achieved in Community 
Oncology and these are discussed in Section 9 
of this report, including:
•	 Development	of	GP	referral	guidelines	
and standardised referral form for 
prostate (and other) cancers. 
•	 Establishment	of	a	follow-up	protocol	
for patients when their treatment is 
complete. 
•	 Development	of	an	e-learning	module	
for GPs on prostate cancer.
•	 Training	for	GPs	through	CME,	ICGP	and	
hospital study days.
•	 Ongoing	development	of	information	
materials for GPs and for patients on 
follow-up. 
•	 Training	of	hospital	and	community	
nurses on cancer prevention and 
treatment.
Opportunities and Challenges 
•	 Timely	access	to	prostate	rapid	access	clinics	
continues to be a challenge. Some of the 
difficulties relate to capacity, particularly in 
the West where there are large numbers of 
referrals. Surgeons from Galway and Cork 
travel to Limerick and Waterford respectively 
to run a weekly clinic in those hospitals. 
However, there is little or no surge capacity 
in the outlying hospitals if the surgeon is on 
leave or a clinic is cancelled.
•	 Completing	the	centralisation	of	prostate	
cancer surgery remains a challenge. Prostate 
cancer surgery continues to be undertaken 
in Tallaght & the Mercy hospitals where there 
has been a historically high volume of urology 
cancer surgical activity. 
•	 In	order	to	address	increasing	reports	of	
cancellations of cancer surgeries, the NCCP 
intends to commence monitoring of waiting 
times for admission for elective cancer 
surgery in 2014. 
•	 There	is	a	lack	of	data	management	staff	and	
IT systems to automatically capture the work, 
particularly of multidisciplinary teams. 
•	 The	current	HR	environment	with	retirements,	
voluntary redundancy and moratoria has 
exacerbated the lack of data management 
support, and theatre nurses in the prostate 
service. 
•	 Robotic	Surgery	is	one	method	of	performing	
radical prostatectomy. HIQA undertook a 
request of the NCCP. The conclusion of 
the HTA was that robot-assisted keyhole 
surgery has benefits to patients compared to 
conventional open radical prostatectomy, but 
that the quality of the evidence to support 
clinical effectiveness was poor and the cost of 
its introduction would be significant. 
•	 Potential	innovation	in	diagnostics	such	
as a move from TRUS prostate biopsies to 
Transperineal Prostate Biopsies would have a 
significant impact on resources such theatre 
and day-ward time, nursing and medical 
personnel.
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•	 The	development	and	implementation	of	
the clinical guidelines for prostate cancer 
will assist in standardisation of practice e.g. 
diagnostic imaging, surgical management. 
•	 PSA	testing	is	best	undertaken	within	NCCP	
guidelines. Home tests currently available risk 
patients undergoing unwarranted tests with 
their associated anxiety. The NCCP has made 
a submission to the Irish Medicines Board and 
the European Medicines Agency to request 
the banning of PSA home testing kits.
•	 Development	of	a	national	policy	for	the	
prevention and management of infection 
post transrectal ultrasound (TRUS) guided 
prostate biopsy will standardise anti-microbial 
prophylaxis for men undergoing TRUS and 
should result in a reduced rate of infections.
•	 NCCP	PSA	Standardisation	seeks	to	
address the lack of standardisation of PSA 
measurements around the country. It was 
proposed that harmonisation of PSA assays 
around the country will lead to better 
decision-making particularly for PSA results in 
the narrow 3-7 ug/L range where a decision 
to perform prostate biopsy may be taken and 
where it is thought that lack of standardisation 
may contribute to unnecessary biopsies.
•	 The	NCCP	has	a	remit	for	developing	cancer	
services and monitoring its volume and 
quality in the Irish public hospital system only. 
Private hospitals are outside this remit and 
their activity is not subject to NCCP scrutiny.
6.3 Lung Cancer 
Epidemiology 
There was an annual average number of 2,165 lung 
cancers diagnosed 2009-2011 in Ireland, making 
lung cancer the 4th most common invasive cancer 
in Ireland, excluding non-melanoma skin cancer. In 
2011, there were 1,858 deaths from lung cancer, 
making it the most common cause of invasive 
cancer deaths. Between 1994 and 2011, there 
has been an annual increase in incidence rate of 
2.2% per year in females and an annual decrease 
of 0.8% in males. The most recent relative survival 
estimates are a hybrid estimate for the 2008-2010 
cohort of cancers and five-year relative survival for 
this cohort is 13.3% with a 95% confidence interval 
of between 12.2%-14.3% (Cancer Factsheet: Lung 
NCRI 2013). 
Recent cancer projections from the NCRI predict 
that the decrease in incidence rate will be reversed 
in the future in men and that growth will accelerate 
in women. Models for lung cancer predict the 
number of cancers to increase by 88%-124% 
between 2010 and 2040 (Cancer Projections for 
Ireland: 2015-2040. NCRI 2014).
Over 90% of lung cancer in Ireland may be 
attributed to smoking tobacco and is therefore 
theoretically preventable. Other known risk 
factors are exposure to radon, asbestos and other 
occupational carcinogens. The prevalence of 
smoking in Ireland remains over 23%, with peak 
prevalence of 31% in the 25-34 year old age group.
The success rate for smoking cessation among 
established smokers is approximately 20% with 
pharmacological therapy. Some smokers who wish 
to quit will attempt many times before succeeding. 
This and the long lag time between beginning 
smoking and the development of lung cancer 
mean that lung cancer will continue to be a major 
cause of cancer mortality for the foreseeable future. 
Earlier diagnosis, efficient and correct diagnosis 
and staging, and modern multidisciplinary 
management lead to improved short and long term 
survival with good quality of life. Improvements 
in the delivery of care are necessary through 
earlier diagnosis, rapid access to diagnostic and 
staging procedures, and provision of co-ordinated 
multidisciplinary treatment.
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Summary of achievements of the National 
Cancer Control Programme in relation to 
Lung cancer
1. Establishment of the National Cancer 
Control Programme Lung Cancer Service 
There is substantial body of evidence 
supporting the hypothesis that volume of 
service and surgeon specialisation makes a 
difference with respect to outcomes for lung 
cancer surgery. The document ‘Establishment 
of Managed Cancer Control Networks 
and Designation of Eight Cancer Centres’ 
published by the HSE in 2007 recommended 
that “four (4) centres nationally will be 
required, for the curative surgical treatment of 
primary thoracic cancers”. 
In 2007, there were six hospitals (all of them 
designated cancer centres) undertaking 
excision of primary lung tumours. Following 
an NCCP review of activity, volumes, bed 
utilisation, ITU usage, surgical outcomes and 
the geographical patterns of patient referral, 
a decision was made to centralise lung cancer 
surgery into four hospitals. 
In 2008, the Mater Hospital, St James’ 
Hospital, Cork University Hospital and 
University Hospital Galway were designated 
as the four surgical centres for primary lung 
cancer treatment. In 2007, 79% of all primary 
lung cancer surgery took place in one of these 
four centres and by 2013 that percentage 
had increased to 96%. Due to capacity 
issues in the Mater Hospital, a small number 
of resections are carried out in St Vincent’s 
University Hospital (Table 6.3.1).
In 2009, the NCCP prioritised funding and 
additional staffing for lung cancer services to 
support the establishment of Lung Cancer 
Rapid Access Clinics in all eight designated 
cancer centres. The aim is of these clinics 
is to accelerate the diagnostic process for 
patients with highly suspicious signs and/or 
2007 2008 2009 2010 2011 2012 2013*
Total number of procedures 241 272 282 297 321 401 385
Number of procedures undertaken 
in a cancer centre 241 272 282 297 321 401 385
% of procedures undertaken in a 
cancer centre  100% 100% 100% 100% 100% 100% 100%
Number of procedures undertaken 
in one the four designated cancer 
centres
191 221 254 277 308 389 370
% of procedures undertaken in one 
the four designated cancer centres
79% 81% 90% 93% 96% 97% 96%
Table 6.3.1: Resection of Primary Lung Cancers in Irish Public Hospitals by Designation of Hospital 
and by Year, 2007-2013
Source: HIPE data, Healthcare Pricing Office, 2014 *Data for 2013 is provisional
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symptoms of lung cancer and improve access 
to treatment to optimise patient outcomes. 
Funding was provided for a considerable 
number of staff including respiratory 
physicians, pathology and radiology posts 
together with nursing, radiographer, medical 
laboratory scientist and administrative support. 
Funding was also provided for endoscopic 
ultrasound equipment. By March 2011, all 
designated centres had established a Rapid 
Access Lung Cancer Clinic and were returning 
monthly data on the clinic to the NCCP. 
GP referral guidelines and standardised 
referral forms were developed in tandem 
with the establishment of the rapid access 
clinics. Patient information booklets have been 
developed for each of the rapid access clinics 
with key information for patients on what to 
expect at their appointment including what 
tests they may undergo. These booklets also 
include details on who to contact in the clinic 
with queries or concerns. 
These structures have provided a significant 
advancement towards the integrated delivery 
of cancer services. In 2013, 91% of patients 
were assessed in a rapid access clinic by a 
respiratory physician within 2 weeks of receipt 
of request from GP or Emergency Department 
for assessment (the target is 95%). (Table 
6.3.2).
While 40% of patients with lung cancer are 
referred to a Rapid Access Clinic, other 
patients are diagnosed through other referral 
streams (acute hospital admission, referral 
to respiratory physicians). Such patients are 
discussed and their management planned at 
lung cancer MDTs (Figure 6.3.1).
 Attendances 2011 2012 2013*
All attendances 1,920 2,751 2,980
Number of primary cancers diagnosed 733 909 868
% of attendances who had a primary 
cancer diagnosed
38% 33% 30%
Table 6.3.2: Lung Rapid Access Clinics
Source: NCCP 2014. *2013 is provisional data
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2. NCCP Rapid Access Lung Clinic Booklet 
wins Crystal Clear Award for Plain English
The NCCP won the 2012 Crystal Clear Award 
for ‘Best Project in a Hospital’ for development 
of eight NCCP Rapid Access Lung Clinic 
Patient Booklets.
This award has been developed to increase 
focus on health literacy in conjunction with 
the National Adult Literacy Agency (NALA). 
This booklet provides information on what 
to expect when you attend the Rapid Access 
Lung Cancer Clinics in the eight NCCP 
designated cancer centres. They also provide 
local information such as contact details for 
the lung cancer team.
 Best Project in a Hospital
‘NCCP Rapid Access Lung Clinic Patient 
Booklets’ The National Cancer Control 
Programme (NCCP) developed the Rapid 
Access Lung Clinic patient booklet to provide 
information for patients about what to expect 
when they attend their Clinic. GPs can refer 
patients with suspected Lung Cancer to a 
Rapid Access Lung Clinic.
Early diagnosis of Lung Cancer increases 
the chance for a cure. The typical lung 
cancer patient is often from the lower socio 
– economic groups, and therefore may have 
low literacy levels. The deliverable of this 
project was to produce and distribute the 
patient booklets to the eight designated 
cancer centres around the country. The 
core information in all eight booklets is 
standardised, and there is hospital specific 
information in the individual booklets. This was 
to ensure that clear information is available to 
all patients irrespective of which hospital they 
attend. As well as informing the patients about 
their visit to the clinic, they include health 
promotion information, in particular a focus on 
encouraging patients to quit smoking. 
Figure 6.3.1 Lung Cancer Care pathway
Initial presentation 
GP / A&E
Urgent CXR
Rapid Access Clinic 
assessment
Clinical Assessment - PS 
PFTs 
CT theras/upr abd 
Bronchoscopy 
Other tests as indicated
Multi-disciplinary 
conference
Lung cancer 
care pathway
Tissue diagnosis 
Stage of disease 
Performance status 
Weight loss 
PFTs
Primary 
treatment
Surgery 
Combined chemo/RT 
Chemo 
Palliative care
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3. Key Performance Indicators 
A suite of Key Performance Indicators (KPIs) for lung disease was finalised in 2012, along with data 
definitions. These KPIs were piloted in 2013 and rolled out nationally in 2014.
Table 6.3.3: Key Performance Indicators 
Referral 95% of referrals to the rapid access lung clinic (RALC) shall be offered an 
appointment to be seen at clinic within 10 working days of the date of 
receipt of a letter of referral in the cancer centre 
Multidisciplinary 
discussion
All patients with a diagnosis of primary lung cancer shall be discussed at a 
multidisciplinary meeting (MDM) 
For patients referred to the rapid access clinic and subsequently diagnosed 
with a primary lung cancer, the interval between the receipt of referral and 
first discussion at a multidisciplinary meeting (MDM) shall be monitored 
Diagnostics For patients diagnosed with a primary lung cancer, clinical TNM stage is 
recorded at MDM in 95% of cases 
Time to treatment – 
surgery
Patients diagnosed with a primary lung cancer where surgery is the first 
treatment shall be offered an appointment for surgery within 30 working days 
of the date of the decision to operate by the multidisciplinary team
Time to treatment – 
systemic therapy
For patients receiving their first cycle of systemic therapy for lung cancer 
in the day ward setting, the timeline between the date of receipt of the 
finalised treatment plan in the day ward and the administration of the first 
cycle of intravenous systemic therapy will not exceed 15 working days
Time to treatment – 
radiation oncology
90% of new patients with a primary lung cancer who have radical therapy will 
be treated within 15 working days of date of being deemed ready to treat 
Time to treatment – 
small cell lung cancer
Patients diagnosed with a small cell lung cancer have treatment initiated 
within 10 working days of the histological diagnosis
Surgery For those patients with primary lung cancer who have a resection, 
pathological TNM stage is recorded
Volume and type of surgical resections for primary lung cancer will be 
recorded
For those patients with primary lung cancer who have a resection, intra-
operative mediastinal lymph node staging is undertaken and recorded
Source: NCCP 2014
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Data for the year 2014 suggest that the 
proportion seen within 10 working days of 
receipt of referral is remaining stable at about 
90%. However, the target is 95%. 
Each cancer centre reports on the Key 
Performance Indicators (KPIs), which are also 
published on the NCCP website. These KPIs 
are designed to assist patients, staff and 
the NCCP in assuring themselves that all 
designated cancer centres are adhering to 
the required standards of practice. Prompt 
access to cancer services has been one of the 
key deliverables for this service. The KPIs are 
presented and discussed at the annual NCCP 
multidisciplinary Lung audit and quality forum. 
4. Establishment of a National Clinical Leads 
Network for Lung Cancer Services 
Each of the designated cancer centres has 
identified lead clinician for lung cancer 
supported by a multidisciplinary team of 
cancer specialists. Their role is to monitor key 
performance indicators within the hospital, 
standardise processes and promote models of 
good practice. 
The Lung Cancer Leads group was established 
in 2011 and meet quarterly. This group of 
lead clinicians from the eight cancer centres 
now operates as a cohesive national clinical 
network for the purpose of clinical audit, 
sharing of best practice and problem solving. 
Through this national network, best practice 
models are identified and shared, to ensure 
standardisation and service improvement 
nationally. 
Jan Feb Mar Apr May Total
Patients referred to RAC shall be offered an appointment 
to attend within 10 working days of receipt of referral 
(target is 95%) 90% 94% 87% 92% 86% 90%
The number of new patients that attended a Lung RAC 
within reporting calendar month; of those 271 285 273 246 245 1320
The number of new patients that attended or received 
an appointment to attend RAC within 10 working days of 
receipt of referral in the cancer centre 244 267 237 226 210 1184
The number of attendances (excluding 
DNAs) at lung rapid access clinics during the 
month: 
New 271 285 273 246 245 1320
Return 321 356 358 346 325 1706
Total 592 641 631 592 570 3026
% new patients diagnosed with PRIMARY lung cancer 43% 34% 30% 36% 36% 36%
Number PRIMARY lung cancer diagnosed 116 97 83 89 88 473
Access to clinics is monitored on an ongoing basis (Table 6.3.4)
Table 6.3.4: Indicator 2014
Source: NCCP 2014
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The terms of reference for the clinical leads 
group are as follows: 
•	 Contribute	to	the	development	and	
continuous improvement of lung cancer 
service.
•	 Share	good	practice	and	innovation	in	
lung cancer services and ensure that non 
evidence based practice is discontinued.
•	 Inform	decision	making	and	
standardisation of service delivery across 
the centres. 
•	 Ensure	adherence	to	National	Standards	
and Key Performance Indicators.
•	 Review	the	quality	and	completeness	of	
data, recommending corrective action 
where appropriate and necessary.
•	 Lead	national	multidisciplinary	audit	and	
quality meeting for lung cancer services.
•	 Input	into	selection	of	Key	Performance	
Indicators (KPIs) for lung cancer services. 
5. Lung Cancer Quality and Audit forum 
An Inaugural National Lung Cancer Quality 
and Audit forum was held on May 10th 2013 
and the second took place in May 2014. 
The purpose of this forum is to establish an 
annual multidisciplinary meeting focusing 
on quality and audit of lung cancer services 
around the country. The meeting builds 
on local clinical governance arrangements 
in order to operate as a cohesive national 
clinical network for the purpose of clinical 
audit, sharing of good practice and problem 
solving. It also identifies best practice models 
and ensures standardisation nationally of lung 
cancer services. The format of the day includes 
presentations, workshops and discussion of 
key service issues and developments. Lung 
cancer screening was discussed in depth at 
2014 meeting, the consensus from the Audit 
and Quality Forum was that a national lung 
cancer screening programme should not be 
established at this time.
Challenges and Opportunities
•	 2011	was	the	establishment	year	for	the	
Rapid Access Lung Clinics. The growth in new 
attendances between 2012 (the first full year 
of activity) and 2013 was 5%. The number of 
returns visits to the clinics is also monitored 
to ensure that the clinics remain primarily 
diagnostic clinics as they were designed 
to be. There was a 20% increase in return 
patients between 2012 and 2013. This trend 
is of concern, as if it continues, it will limit the 
capacity of the clinic to function properly as a 
rapid diagnostic clinic. 
•	 The	proportion	of	patients	attending	who	
were diagnosed with primary lung cancer 
fell from 38% to 30% between 2011 and 
2013. While this figure suggests a highly 
appropriate referral pattern, the trend will 
continue to be monitored.
•	 Six	of	the	eight	designated	centres	see	
over 95% of patients within two weeks of 
referral. Two centres have not achieved this. 
Cork University Hospital in particular has 
experienced challenges in providing timely 
access to CT scanning. While a second 
CT scanner has been commissioned, the 
recruitment of radiographers, a scarce grade, 
has also posed difficulties. 
•	 The	diagnostic	processes	in	the	RAC	result	
in the diagnosis of a relatively high number 
of lung nodules. These require follow-up 
monitoring; how best to manage this with 
efficient use of resources is a matter of some 
discussion.
•	 The	aim	is	to	increase	survival	from	lung	
cancer. Timely access to curative treatment 
for suitable patients is vital to achieve this. If 
there is undue delay to surgery, the disease 
can progress within a short time frame to 
becoming inoperable. The NCCP is planning 
to monitor time from decision to operate to 
date of surgery from 2014 onwards. 
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•	 Lung	cancer	is	to	a	large	extent	a	preventable	
disease, related primarily to smoking. Efforts 
to reduce levels of smoking initiation and 
to support smoking cessation continue 
to be strengthened. Levels of smoking 
among young women and in more deprived 
communities require particular attention to 
prevent widening inequality in relation to this 
disease. 
•	 The	emergence	of	e-cigarettes	is	a	relatively	
recent phenomenon. There has been rapid 
market penetration despite unanswered 
questions about their safety, efficacy for harm 
reduction and cessation, and overall impact 
on public health. To minimise potential 
impacts on prevention and cessation and 
the undermining of existing tobacco control 
measures, there is a need to regulate the 
availability of these nicotine delivery devices. 
The HSE does not endorse the use of 
e-cigarettes.
•	 The	ongoing	debate	and	emerging	evidence	
in relation to lung cancer screening will be 
monitored. 
•	 The	NCCP	has	a	remit	for	developing	cancer	
services and monitoring its volume and 
quality in the Irish public hospital system only. 
Private hospitals are outside this remit and 
activity there is not subject to NCCP scrutiny. 
6.4  Colorectal Cancer
Epidemiology 
There was an annual average 2,468 colorectal 
cancers diagnosed 2009-2011 in Ireland, making 
colorectal cancer the 3rd most common invasive 
cancer in Ireland, excluding non-melanoma skin 
cancer. In 2011, there were 1,040 deaths from 
colorectal cancer, making it the 2nd most common 
cause of invasive cancer deaths. Between 1994 
and 2011, incidence rates have been stable. The 
most recent relative survival estimates are a hybrid 
estimate for the 2008-2010 cohort of cancers and 
five-year relative survival for this cohort is 60.6% 
with a 95% confidence interval of between 59%-
62.1% (Cancer Factsheet: Colorectal NCRI 2013). 
Recent cancer projections from the NCRI predict 
that this stability in incidence rates will change 
in future with models for colon cancer predicting 
number of cancers to increase by 110%-138% 
between 2010 and 2040 and predictions for rectal 
cancer increasing by 89%-97% in the same time 
period (Cancer Projections for Ireland: 2015-2040. 
NCRI 2014. TD 1).
Cancer strategy implementation – 
Surgical Centralisation
The document ‘Establishment of Managed Cancer 
Control Networks and Designation of Eight 
Cancer Centres’ published by the HSE in 2007 
recommended that “the curative surgical treatment 
of primary colon cancers will be delivered at all 
Eight (8) Cancer Centres” but that “there is a need 
for four centres nationally for the curative surgical 
treatment of primary rectal cancers”. 
In 2007, there were 35 hospitals undertaking 
colectomies for colon cancer and 33 hospitals 
undertaking resections for rectal cancer. The NCCP 
undertook an examination of the activity in these 
hospitals, looking at volumes, bed utilisation, ITU 
usage and the geographical patterns of patient 
referral for colorectal resections. In consultation 
with clinical advisors, a decision was taken to audit 
the surgical management of rectal cancer in public 
hospitals in Ireland. 
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Audit
In 2008, the RCSI in collaboration with the NCRI 
and funded by the NCCP undertook a retrospective 
audit of all rectal cancers that underwent surgery 
in 2007 in a public hospital in Ireland. Data were 
collated retrospectively on individual patients by 
the NCRI and RCSI staff on patient characteristics, 
multidisciplinary decision making, management 
plan for all patients, processes and outcomes 
of surgery and whether patients received 
chemotherapy or radiation treatment. 
The major elements that were examined included 
hospital volumes, surgeon volumes, patterns of 
care, type of operation undertaken and surgical 
outcomes including negative margin resection 
rates, 30 day mortality, clinical leaks, return to 
theatre, length of stay, readmission rates and 
timing and use of radiotherapy.
Following the audit, the Irish Association of 
Coloproctology recommended that:
•	 Rectal	cancer	surgery	should	not	be	
performed in hospitals where fewer than 
20 rectal cancer surgeries are carried out 
annually.
•	 Rectal	cancer	surgery	should	be	performed	
in all eight designated cancer centres with 
provisos in relation to number of operations, 
adherence to guidelines, surgeon training, 
nomination of a lead surgeon, discussion of 
patients at multidisciplinary team meetings 
and participation in audit.
•	 Rectal	cancer	surgery	could	be	performed	in	a	
small number of high volume non-designated 
centres, with similar provisos as the cancer 
centres, on an interim basis.
Following consideration of the audit report, the 
NCCP decided that rectal surgery would be 
centralised to all eight of the cancer centres. For 
colon cancer, in view of the high proportion of 
such cancers that present outside cancer centres 
as emergencies and the importance of maintaining 
surgical competence in the provision of emergency 
care outside the cancer centres, it was decided not 
to actively centralise colon cancer surgery. It was 
recommended that all patients should be discussed 
at the cancer centre multidisciplinary meeting. 
Centralisation of Primary Surgical Activity
Although colon cancer has not been actively 
centralised, there has been some movement 
towards the cancer centres between 2007 and 
2013 with about half of all cancers being surgically 
treated in a cancer centre compared to 41% 
in 2007 (Table 6.4.1). It is anticipated that this 
percentage will increase in coming years with the 
roll out of BowelScreen across the country and 
the establishment of hospital groups. Cancers 
diagnosed under the BowelScreen programme will 
be treated in one of the designated cancer centres. 
There has been a moderate level of success in 
centralising rectal cancer to the eight cancer 
centres and Letterkenny, the proportion being 
treated in a cancer centre rising from 43% in 2007 
to 77% in 2013 (Table 6.4.2). A further 23% of 
activity was performed in one of four hospitals – 
Tallaght Hospital, the Mercy University Hospital, 
Cork, Kerry General Hospital and Mayo General 
Hospital. Capacity and resource issues in the 
receiving cancer centres have delayed the transfer 
of these services. 
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Leads Group
A national Rectal Cancer Clinical Leads group, comprising of the lead rectal cancer clinician from each of the 
eight cancer centres has been established. The role of the leads is to develop a cohesive national clinical 
network for the purpose of clinical audit, sharing of good practice and problem solving. 
2007 2008 2009 2010 2011 2012 2013*
Total number of procedures 906 903 958 895 822 901 830
Number of procedures undertaken 
in a cancer centre 
371 382 462 445 445 434 417
% of procedures undertaken in a 
cancer centre 
41% 42% 48% 50% 54% 48% 50%
Table 6.4.1: Resection of Colon Cancers by Designation of Hospital and by Year, 2007-2013
Data Source; HIPE Portal, Healthcare Pricing Office. *Data is provisional for 2013
2007 2008 2009 2010 2011 2012 2013*
Total number of procedures 438 405 458 459 420 432 414
Number of procedures undertaken 
in a cancer centre 190 199 237 249 279 311 317
% of procedures undertaken in a 
cancer centre 43% 49% 52% 54% 66% 72% 77%
Table 6.4.2: Resection of Rectal Cancers by Designation of Hospital and by year, 2007-2013
Data Source; HIPE Portal, Healthcare Pricing Office. *Data is provisional for 2013
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Key Performance Indicators
A suite of Key Performance Indicators (KPIs) for rectal cancer was developed in 2012, along with data 
definitions. This suite concerning access, multidisciplinary working, timeliness of interventions, staging, 
pathology reporting and quality of surgery was piloted in 2013 with national rollout in 2014 (Table 6.4.3).
Activity Number of rectal cancer patients referred to the cancer centre 
Diagnostics Every patient should have a rigid sigmoidoscopy performed to determine the position 
of the tumour prior to any therapeutic intervention.
Time to treatment – 
surgery
For patients diagnosed with a primary rectal cancer, the interval between the 
discussion at the multidisciplinary meeting (MDM) and date of first surgical 
intervention where surgery is the first treatment shall be monitored.
Time to treatment – 
radiation oncology 
90% of new patients with primary rectal cancer who undergo radical therapy will be 
treated within 15 working days of the date of ready to treat 
Time to treatment – 
systemic therapy
90% of new patients with primary rectal cancer who require systemic therapy will be 
treated within 15 working days of the date of the finalised treatment plan 
Multidisciplinary 
discussion
All patients who are diagnosed with rectal cancer shall be discussed at MDM prior to 
their first therapeutic intervention
Staging For patients with a primary rectal cancer, clinical TNM stage is recorded at prior to 
commencement of treatment
Surgery The proportion of patients with rectal cancer who undergo a radical surgical procedure 
that have an abdominoperineal resection (APR). 
Distal margin status will be documented for all patients who have a radical surgical 
procedure for rectal cancer
Radial margin status will be documented for all patients who have a radical surgical 
procedure for rectal cancer
The percentage of patients whose marginal status is clear will be documented for all 
patients who have a radical surgical procedure for rectal cancer
Number of lymph nodes that are harvested from all newly diagnosed rectal cancer 
patients will be recorded
The number of newly diagnosed rectal cancer patients who have to return to theatre 
for any surgical procedure during their hospital stay
Radiotherapy The proportion of newly diagnosed rectal cancer patients who receive radiotherapy 
pre or post operatively
Length of stay Following surgery for rectal cancer, the percentage of patients with unscheduled re-
admission to hospital within 30 days of discharge following surgery
Table 6.4.3: Key Performance Indicators 
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Opportunities and Challenges
•	 The	national	roll	out	of	BowelScreen,	the	
national colorectal screening programme 
will increase the caseload of adenomas 
and colorectal cancers in the cancer 
centres, particularly in the early years of the 
programme. This will require careful planning 
and management to ensure that patients are 
treated in a timely manner.
•	 The	completion	of	the	centralisation	of	rectal	
cancer surgery remains a challenge. 
•	 Monitoring	of	the	quality	of	colon	cancer	
management has not commenced and will 
prove challenging because of the wider 
dispersal of cases around the hospital system.
•	 There	is	a	lack	of	data	management	staff	to	
enable ongoing collection of data to monitor 
the quality of the colorectal service. 
•	 The	NCCP	has	a	remit	for	developing	cancer	
services and monitoring its volume and 
quality in the Irish public hospital system only. 
Private hospitals are outside this remit and 
activity there is not subject to NCCP scrutiny. 
6.5 Oesophageal and Gastric Cancers
Epidemiology 
There was an annual average of 526 gastric cancers 
diagnosed 2009-2011 in Ireland, making gastric 
cancer the seventh (7th) most common invasive 
cancer in Ireland, excluding non-melanoma skin 
cancer. In 2011, there were 327 deaths from gastric 
cancer, making it the seventh (7th) most common 
cause of invasive cancer deaths. Between 1994 
and 2011, there has been an annual decrease in 
incidence rates of 1.6% per year in both females 
and males. The most recent relative survival 
estimates are a hybrid estimate for the 2008-2010 
cohort of cancers and five-year relative survival for 
this cohort is 23.9% with a 95% confidence interval 
of between 21.2%-26.6% (Cancer Factsheet: 
Stomach NCRI 2013). 
Recent cancer projections from the NCRI predict 
that this decrease in incidence rate will be reversed 
in the future with models for gastric cancer 
predicting number of cancers to increase by    
29%-64% between 2010 and 2040 (Cancer 
Projections for Ireland: 2015-2040. NCRI 2014).
On average 384 oesophageal cancer cancers 
have been diagnosed annually between 2009 
and 2011. This makes oesophageal cancer the 
fourteenth (14th) most common invasive cancer in 
Ireland, excluding non-melanoma skin cancer. In 
2011, there were 359 deaths and oesophageal 
cancer was ranked as the sixth (6th) highest cause 
of invasive cancer death. Between 1994 and 2011, 
there has been an annual decrease in incidence 
rates of 1% per year in females and an annual 
increase of 0.2% per year in males. For the 2008-
2010 cohort, the five-year relative survival is 
estimated as being 15.1% with a 95% confidence 
interval of between 12.6%-17.8% (Cancer 
Factsheet: Oesophagus NCRI 2013). 
Recent cancer projections for oesophageal cancer 
predict that this cancer will increase by 116%-134% 
between 2010 and 2040 (Cancer Projections for 
Ireland: 2015-2040. NCRI 2014).
Cancer strategy implementation – 
surgical centralisation
The document ‘Establishment of Managed Cancer 
Control Networks and Designation of Eight Cancer 
Centres’ published by the HSE in 2007 was the 
first outline of an implementation plan for the 
‘A Strategy for Cancer Control in Ireland 2006’ 
(Appendix 1). The Working Group concluded that 
“there is a need for two centres nationally for 
the curative surgical treatment of primary upper 
gastrointestinal cancers”. 
In 2007, there were nine hospitals (four of 
them designated cancer centres) undertaking 
oesophagectomies for upper gastrointestinal 
cancer and 28 hospitals (including all of the 
designated cancer centres) undertaking 
gastrectomies for gastric cancer. The NCCP 
undertook an examination of the activity in these 
hospitals, looking at volumes, bed utilisation, 
ITU usage and the geographical patterns of 
patient referral for both oesophageal and gastric 
resections. Cognisant of the strong association 
between volume and outcomes for oesophageal 
resections and in consultation with clinical advisors, 
it was agreed to designate four hospital units to 
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undertake the primary surgical management of 
oesophageal cancer. A more in-depth audit of 
these hospitals was to be undertaken prior to final 
determination of surgical centres. 
In 2010, Beaumont Hospital, St James’s Hospital, 
University Hospital Galway and Cork University 
Hospital were pre-designated as the four candidate 
units subject to audit of performance and safety. At 
present surgical activity in Cork is undertaken in the 
Mercy University Hospital; it is however planned to 
transfer this surgical work to the designated cancer 
centre in Cork University Hospital.
Audit
In 2011, a retrospective audit of all oesophageal 
and junctional cancers that underwent surgery 
between 2008 and 2010 was undertaken in the 
four candidate oesophageal cancer surgical centres 
and James Connolly Memorial Hospital (Dublin), 
utilising the methodology adopted by the National 
Oesophago-Gastric Audit in England and Wales. 
Data were collated retrospectively on individual 
patients by the participating centres on patient 
characteristics, pre-treatment tumour stage, the 
staging process, the patient management plan, the 
processes and outcomes of surgery and whether 
patients received chemotherapy or radiation 
treatment. Data analysis was undertaken by the 
NCCP.
The major elements that were examined included 
hospital volumes, type of staging investigations 
carried out, documentation of pre-operative 
staging, patterns of care, type of operation 
undertaken and surgical outcomes including in-
hospital mortality, anastomotic leaks, haemorrhage, 
acute renal failure, wound infection and cardiac 
and respiratory complications. Other outcomes 
examined included unplanned return to theatre 
rates, pathological margins and lymph node yields.
The main conclusions of this audit were that there 
was evidence of a volume/outcome differential with 
the highest volume centre having better surgical 
outcomes in terms of in-hospital mortality, reduced 
post-operative complications and fewer unplanned 
return to theatre. However, all four units achieved 
an international standard compatible with the 
volume of patients treated in the centre.
Following consideration of the audit report, in 
2012, the NCCP designated St James’s Hospital as 
the National Centre for Oesophageal and Gastric 
Cancer with Beaumont Hospital, University Hospital 
Galway and Cork University Hospital designated as 
the three satellite centres for oesophageal cancer 
surgery. 
The four surgical units all continue to contribute 
to a national database, based in St James’s 
Hospital, which enables ongoing detailed audit 
of the management and outcomes of upper 
gastrointestinal cancers.
Clinical Leads Group
In 2011, the clinical lead surgeons of the four 
hospitals formed a Clinical Leads Group chaired by 
the national clinical lead. The terms of reference for 
the clinical leads group are as follows: 
•	 Contribute	to	the	development	and	
continuous improvement of upper 
gastrointestinal cancer surgical service.
•	 Share	good	practice	and	innovation	in	upper	
gastrointestinal cancer surgical service 
delivery and ensure that non evidence based 
practice is discontinued.
•	 Inform	decision	making	and	standardisation	
of service delivery across the centres. 
•	 Ensure	adherence	to	National	Standards	and	
Key Performance Indicators.
•	 Review	the	quality	and	completeness	of	
data, recommending corrective action where 
appropriate and necessary.
•	 Lead	national	multidisciplinary	audit,	
quality and risk (AQR) meeting for upper 
gastrointestinal cancer surgical service.
•	 Input	into	selection	of	Key	Performance	
Indicators (KPIs) upper gastrointestinal cancer 
surgical service.
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Key Performance Indicators
The four clinical lead surgeons of the candidate hospitals for the surgical management of oesophageal 
cancer agreed a number of Key Performance Indicators which were identified as being an appropriate part 
of the quality monitoring programme that the NCCP in conjunction with the lead clinicians was putting 
in place. As well as monitoring activity in the national centre and its three satellite units, agreement was 
reached to monitor other quality parameters such as access, staging, multidisciplinary discussion, timely 
treatment, surgical outcomes and use of resources (Table 6.5.1). 
Access New patients referred with a histology report that indicated an oesophago-gastric 
cancer shall be offered an appointment at the oesophago-gastric cancer centre 
within 10 working days of the date of receipt of the referral letter in the centre
Staging Patients newly diagnosed with an oesophageal or G-O junction cancer will have a 
PET-CT scan where it is clinically indicated within 15 working days of the date of 
diagnosis at the cancer centre
Patients newly diagnosed with a malignant neoplasm of the oesophagus or G-O 
junction or malignant neoplasm of the stomach with predicted early cancer (T1 or 
T2) should undergo endoscopic ultrasound.
Surgery Patients newly diagnosed with a malignant neoplasm of the oesophagus, G-O 
junction or rest of the stomach, with predicted high grade dysplasia (HGD) or T1a 
cancer should undergo endoscopic mucosal resection.
Multidisciplinary 
discussion
For patients with a newly diagnosed oesophago-gastric cancer, the interval 
between the date of diagnosis and the date of discussion at a multidisciplinary 
meeting (MDM) shall not exceed 25 working days.
Time to treatment – 
systemic therapy 
Initial systemic/combination therapy in a curative setting will be carried out 
promptly.
Time to treatment – 
radiation therapy
Initial radiation therapy in a curative setting will be carried out promptly. 
Time to treatment – 
surgery
Surgical intervention, where surgery is the first treatment, will be carried out within 
15 working days of the MDM decision in 90% of cases. 
Surgical intervention, following neoadjuvant treatment, will be carried out within 40 
working days of completion of neoadjuvant treatment in 90% of cases
Surgery 75% of patients will have a complete resection (R0).
75% of patients will have 15 or more lymph nodes removed.
Use of Resources Following surgery, patients will be discharged within 21 calendar days after the 
date of the surgical procedure.
Following surgery, <15% percentage of patients will be re-admitted to hospital 
within 30 days of discharge following surgery.
Table 6.5.1: Key Performance Indicators 
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The KPI suite of indicators was agreed in 2011 
and the suite was piloted nationally in 2012. A 
full report of the pilot of the Key Performance 
Indicators for that year is found in TD 5 but some 
highlights include:
•	 In	2012,	over	600	patients	were	referred	to	
one of the four centres. 
•	 Overall	58%	of	patients	referred	to	the	
designated surgical centres were treated with 
curative intent.
•	 91%	of	patients	referred	to	the	designated	
cancer centre with a histology report that 
indicated an oesophago-gastric cancer were 
offered an appointment at the oesophago-
gastric cancer centre within 10 working days 
of the date of receipt of the referral letter in 
the centre.
•	 79%	of	patients	newly	diagnosed	with	an	
oesophageal or G-O junction cancer and 
assessed at the oesophago-gastric cancer 
centre regarding suitability for treatment with 
curative intent had a PET-CT scan where it 
was clinically indicated within 15 working days 
of the date of diagnosis at the cancer centre. 
•	 84%	of	patients	newly	diagnosed	with	a	
malignant neoplasm of the oesophagus or 
G-O junction and 72% of patients newly 
diagnosed with a malignant neoplasm of the 
stomach with predicted early cancer (T1 or 
T2) underwent endoscopic ultrasound.
•	 84%	of	patients	with	a	newly	diagnosed	
oesophago-gastric cancer were discussed 
at a multidisciplinary meeting (MDM) within 
25 working days of the date of the initial 
diagnosis.
•	 The	target	for	timely	surgery	was	changed	
to 20 working days as it was deemed to be a 
more achievable target without compromising 
patient outcomes.
•	 For	patients	who	underwent	surgery,	the	
target for a complete resection was exceeded 
for both oesophageal and gastric cancers.
•	 For	patients	who	underwent	surgery,	the	
target for lymphadenectomy was exceeded 
for oesophageal cancer and was 74% for 
gastric cancer (target is 75%).
•	 Examining	length	of	stay	following	surgery,	
it was identified that there was room for 
improvement, particularly for oesophageal 
surgery. 
•	 Readmission	rates	following	surgery	were	low.
Centralisation of Primary Surgical Activity
Although the four surgical centres for upper 
gastrointestinal cancers were not formally 
designated until 2012, it is clear from Table 6.5.2 
that patients began to be referred to one of the 
eight designated cancer centres shortly after the 
establishment of the NCCP. A higher proportion 
of patients who required oesophageal resections 
were attending designated cancer centres in 
2007 (65%). This has risen to 78% in 2013. The 
Mercy University Hospital still has surgical activity 
ongoing there, pending transfer of the service to 
Cork University Hospital and there is some surgery 
taking place in Tallaght Hospital – which accounts 
for the procedures outside of cancer centres. 
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Gastric cancer surgery was more widely dispersed in 2007, with just 43% of activity being performed in 
one of the four designated surgical units and 56% of activity occurring in any of the eight cancer centres. In 
2013, this has increased to 60% and 66% respectively (Table 6.5.3).
Table 6.5.3: Gastric Resection for Gastric Cancers by Designation of Hospital and by Year, 2007-2013
Data Source; HIPE Portal, Healthcare Pricing Office. *Data is provisional for 2013
2007 2008 2009 2010 2011 2012 2013*
Total number of procedures 132 133 141 142 155 127 120
Number of procedures undertaken 
in a cancer centre 85 97 104 104 114 96 93
% of procedures undertaken in a 
cancer centre 65% 73% 74% 73% 74% 76% 78%
Number of procedures undertaken 
in a designated surgical unit 
79 93 100 103 113 96 93
% of procedures undertaken in a 
designated surgical unit 
60% 69% 71% 73% 73% 76% 78%
Table 6.5.2: Oesophageal Resections for Upper Gastro-Intestinal Cancers by Designation of Hospital 
and by Year, 2007-2013
Data Source; HIPE Portal, Healthcare Pricing Office. *Data is provisional for 2013
2007 2008 2009 2010 2011 2012 2013*
Total number of procedures 144 154 167 182 143 149 131
Number of procedures undertaken 
in a cancer centre 81 99 98 125 90 90 87
% of procedures undertaken in a 
cancer centre 56% 64% 59% 69% 63% 60% 66%
Number of procedures undertaken 
in a designated surgical unit 62 83 80 107 76 80 79
% of procedures undertaken in a 
designated surgical unit 43% 54% 48% 59% 53% 54% 60%
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Challenges and Opportunities
•	 Completing	the	centralisation	of	oesophageal	
surgery remains a challenge as capacity 
within the receiving centres is constrained. 
The NCCP has entered into discussions with 
the Acute Hospital Directorate and individual 
hospitals to expedite the transfer of upper 
GI cancer surgery from the Mercy into the 
designated cancer centre in Cork University 
Hospital and to cease the remaining surgical 
activity in Tallaght Hospital (Dublin).
•	 The	NCCP	in	conjunction	with	the	national	
clinical lead needs to formalise a strategy 
for the surgical management of gastric 
cancers particularly in terms of volume and 
distribution.
•	 For	oesophageal	cancers,	there	are	plans	
in place to expand the programme to 
encompass early mucosal endoscopic lesions. 
•	 The	establishment	of	a	national	clinical	
database provides a unique opportunity for 
detailed national audit over and above the 
collation of the KPIs. It enables local and 
national research and facilitates patient access 
to international clinical trials. 
•	 The	Clinical	Surgical	Leads	Group	does	not	
have a NCCP project manager assigned to 
it. This makes co-ordination of the group 
somewhat haphazard and has led to delays in 
the group processes. 
•	 The	NCCP	has	a	remit	for	developing	cancer	
services and monitoring volume and quality 
in the Irish public hospital system only. Private 
hospitals are outside this remit and activity 
there is not subject to NCCP scrutiny.
6.6 Pancreatic Cancer 
Epidemiology 
An average of 478 pancreatic cancers were 
diagnosed annually 2009-2011 in Ireland, making 
pancreatic cancer the eleventh (11th) most 
common invasive cancer in Ireland, excluding 
non-melanoma skin cancer. In 2011, there were 
478 deaths from pancreatic cancer, making it the 
fifth (5th) most common cause of invasive cancer 
deaths. Between 1994 and 2011, there has been 
an annual increase in incidence rate of 0.4% per 
year in females and 0.9% per year in males. The 
most recent relative survival estimates are a hybrid 
estimate for the 2008-2010 cohort of cancers and 
five-year relative survival for this cohort is 7.0% with 
a 95% confidence interval of between 5.4%-8.8% 
(Cancer Factsheet: Pancreas NCRI 2013). 
Recent cancer projections from the NCRI predict 
the number of pancreatic cancers to increase by 
147% between 2010 and 2040 (Cancer Projections 
for Ireland: 2015-2040. NCRI 2014).
Cancer Strategy Implementation – 
Surgical Centralisation
The document ‘Establishment of Managed Cancer 
Control Networks and Designation of Eight 
Cancer Centres’ published by the HSE in 2007 
recommended that curative pancreatic surgical 
treatment should be concentrated in one national 
centre (Appendix 1). The decision to centralise 
pancreatic all surgery was based on actual activity 
data prior to 2007. 
Pancreatic cancer surgery in Ireland was relatively 
widely dispersed with no one particular high 
volume hospital. In 2008, there were nine 
hospitals (six of them designated cancer centres) 
undertaking excision of pancreatic tumours. 
Preparatory work and consultation with clinical 
leadership commenced in 2008/2009 and a 
process was undertaken in 2009 to identify the 
preferred location for a national centre - this 
resulted in St. Vincent’s University Hospital (SVUH), 
Dublin being designated the National Centre in 
late 2010. 
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During 2010, the NCCP reviewed the data 
in relation to the surgical units that provided 
pancreatic cancer surgery at that time. Based on 
this review it was proposed that a satellite unit 
be established in the Mercy University Hospital 
pending transfer of the service to the designated 
cancer centre in Cork University Hospital. 
As obtaining pre-operative histology is not always 
possible a decision was taken to centralise the 
surgical treatment of all pancreatic tumours 
suspected of being malignant as well as those 
with proven malignancy. All cancer surgeries 
were concentrated in the new national centre 
(incorporating the Cork satellite service), with 
patients continuing to undergo diagnostic 
and staging investigation and non surgical 
management in other hospitals and designated 
cancer centres. 
Significant additional funding was transferred to 
St. Vincent’s University Hospital in 2010 to support 
the centralisation of pancreatic cancer surgery. 
Casemix costings for the surgical episode of care 
were transferred from those hospitals that had 
previously carried out resections, with funding for 
work up, diagnostics and non-surgical treatments 
remaining in the referring hospitals. Some surgeons 
who previously undertook pancreatic surgery in 
other Dublin hospitals had their contracts adjusted 
to enable them to operate in St. Vincent’s Hospital. 
Members of the national surgical team for 
pancreatic cancer in consultation with their 
colleagues nationally agreed patient pathways, 
referral criteria and patient information for 
pancreatic cancer surgery. A National Pancreatic 
Imaging Network was also established to agree 
standards for diagnostic imaging prior to referral to 
the national pancreatic centre in SVUH.
It was deemed essential that Pancreatic Cancer 
surgery transfer from the Mercy University Hospital 
to the designated cancer centre at Cork University 
Hospital (CUH). This took place in July 2012. 
Governance
A series of arrangements, including governance, 
multidisciplinary team and clinical effectiveness 
arrangements, were put in place in order to 
establish this single national service in SVUH with a 
satellite unit in CUH. These included: 
•	 Designation	of	one	National	Clinical	Lead	for	
the National Surgical Centre for Pancreatic 
cancer
•	 Practitioners	operating	at	CUH	to	participate	
and be subject to all elements of the audit 
and quality processes of the national 
programme
•	 An	oversight	group	to	be	established	to	
monitor implementation consisting of 
representatives from both sites and the NCCP
•	 A	single	national	set	of	referral,	diagnostic	
and treatment guidelines, protocols and 
audit parameters to be implemented at the 
National Centre and the Satellite centre 
The main objectives of the Pancreatic Cancer 
Oversight Committee are to:
•	 Establish	a	joint	multidisciplinary	meeting
•	 Develop	clinical	guidelines	and	standards
•	 Develop	and	implement	key	performance	
indicators for Pancreatic Cancer Surgical 
Services
•	 Review	patient	pathways	and	referral	
protocols
•	 Agree	clinical	and	corporate	governance	
mechanisms 
This Committee agreed and piloted a suite of 
Key Performance Indicators which have now been 
adopted nationally. The first Audit and Quality 
Forum for Pancreatic Cancer was held in 2014. This 
included presentation and discussion of audit data 
from 2012 and activity data from 2013.
In 2013, 91% of all resections of pancreatic tumours 
took place in the National Surgical Centre including 
its satellite in Cork University Hospital and 93% of 
activity took place in a cancer centre (Table 6.6.1).
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Key Performance Indicators 
The establishment of a suite of Key Performance Indicators (KPIs) was an essential part of the quality 
monitoring programme established by the NCCP. A suite of KPI indicators was agreed in 2011 and piloted 
nationally in 2012. As well as monitoring activity in the national centre and its satellite unit, agreement 
was reached to monitor other quality parameters such as diagnostics, multidisciplinary discussion, timely 
treatment, surgical outcomes and use of resources (Table 6.6.2). 
Table 6.6.2: Key Performance Indicators 
2007 2008 2009 2010 2011 2012 2013*
Total number of procedures 76 89 79 90 77 95 86
Number of procedures undertaken 
in a cancer centre 45 58 44 65 45 76 80
% of procedures undertaken in a 
cancer centre 
59% 65% 56% 72% 59% 80% 93%
Number of procedures undertaken 
in the National Surgical Centre for 
Pancreatic Cancer 
9 11 16 51 40 71 78
% of procedures undertaken in 
the National Surgical Centre for 
Pancreatic Cancer
12% 12% 20% 57% 52% 75% 91%
Table 6.6.1: Resection of Pancreatic Tumours by designation of hospital and by year, 2007-2013
Data Source; HIPE Portal, Healthcare Pricing Office. *Data is provisional for 2013
Diagnostics Number of newly diagnosed proven or suspected pancreatic cancer patients referred from 
other hospitals who require a repeat triphasic CT following initial MDT discussion at the 
NSCPC.
Multidisciplinary 
discussion
For patients with newly diagnosed proven or suspected pancreatic cancer, the interval 
between referral to the NSCPC and discussion at multidisciplinary conference (MDM) shall 
not exceed 10 working days.
Time to treatment – 
systemic therapy 
Neo-adjuvant systemic therapy will be carried out within 15 working days of the finalised 
treatment plan.
Time to treatment – 
surgery
Surgical intervention in new patients with proven or suspected pancreatic cancer, where 
surgery is the first treatment, will be carried out within 20 working days of the MDM 
decision.
80Report on the implementation of ‘A Strategy for Cancer Control in Ireland 2006’
A full report of the pilot of the Key Performance 
Indicators for 2012 is found in TD 6, but some 
highlights include:
•	 In	2012,	almost	600	patients	were	referred	to	
the National Surgical Centre for Pancreatic 
Cancer (NSCPC). 
•	 Forty	four	percent	or	260	patients	were	
diagnosed with pancreatic cancer and 96 of 
these patients underwent either a Whipple’s 
procedure or a distal pancreatectomy in 
either St. Vincent’s University Hospital or in 
the Cork centre. 
•	 This	indicates	that	260	out	of	478	or	54%	of	
patients diagnosed with pancreatic cancer in 
Ireland were referred to the NSCPC in that 
year. 
•	 Eighty	four	percent	of	referrals	were	discussed	
at a multidisciplinary meeting (MDM) within 
10 working days of receipt of referral and 
20% of referrals required a repeat triphasic 
CT following the MDM discussion, which 
indicates that there is room for improvement 
in the referral process. 
•	 Seventy	one	percent	of	those	deemed	to	
have an operable tumour went on to surgery 
within 20 working days of the decision to 
operate. 
•	 Of	those	with	pancreatic	cancer,	almost	70%	
had an R0 resection and almost 89% had at 
least 10 lymph nodes removed. 
•	 The	30	day	in-hospital	mortality	rate	following	
a Whipple procedure was 2.8%. 
•	 Parameters	looking	at	use	of	resources	
indicate a continuous shortening of length of 
stay in 2012 with few hospital readmissions.
All of these parameters are within international 
standards. 
Annual audit quality and risk forum for 
pancreatic cancer
In line with the management of other cancers 
and based on the recommendations of the HIQA 
Quality Review (2010), the NCCP established an 
annual audit quality and risk forum for pancreatic 
cancer. The purpose of the forum is to: 
•	 Provide	an	annual	multidisciplinary	forum	for	
audit, quality and risk in pancreatic cancer 
services.
•	 Build	on	local	clinical	governance	
arrangements, in order to operate as a 
cohesive national clinical network for the 
purpose of clinical audit, sharing of good 
practice and problem solving.
Surgery The number of patients with operable pancreatic cancer who do not undergo surgical 
resection and have a have documented valid reason why not.
If the patient with pancreatic cancer has surgery, then the margin-negative resection rate 
(R0) should be measured.
If a patient has a Whipples (pancreaticoduodenectomy) for pancreatic cancer, then the 
regional lymph node dissection should encompass 10 or more lymph nodes.
Use of Resources Length of inpatient hospital stay of patients who undergo a Whipple 
(pancreaticoduodenectomy) or distal pancreatectomy procedure.
Number of patients following a Whipple (pancreaticoduodenectomy) or distal 
pancreatectomy procedure who are readmitted to hospital within 30 days of discharge 
following surgical procedure.
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•	 Identify	best	practice	models	and	ensure	
standardisation and service improvement 
nationally. 
•	 Examine	and	monitor	referral	criteria	to	
the National Surgical Centre for Pancreatic 
Cancer. 
The inaugural forum for pancreatic cancer was held 
in the NCCP Offices in February 2014. 
Challenges and Opportunities
•	 Completing	the	centralisation	of	pancreatic	
tumour surgery remains a challenge as 
capacity within the receiving centres 
continues to be a limiting factor. 
•	 Establishment	of	a	joint	multidisciplinary	team	
meeting between St. Vincent’s University 
Hospital and Cork University Hospital is still 
outstanding.
•	 There	are	opportunities	for	both	units	
delivering pancreatic surgical services to 
work together to develop and standardise 
in-hospital clinical management pathways, 
and to work with community oncology in 
developing patient information.
•	 The	centralisation	of	surgical	services	
and data capture offers an opportunity to 
establish a national clinical database, which 
would provide a unique opportunity for 
detailed national audit over and above the 
collation of the KPIs, enable local and national 
research and facilitate patient access to 
international clinical trials. 
•	 Both	centres	continue	to	cite	challenges	
in ensuring adequate work up and staging 
of patients prior to referrals to the national 
centre for surgery. 
•	 The	NCCP	has	a	remit	for	developing	cancer	
services and monitoring its volume and 
quality in the Irish public hospital system only. 
Private hospitals are outside this remit and 
activity there is not subject to NCCP scrutiny
6.7 Neuro-Oncology: Cancers of the 
Brain and Central Nervous System
Epidemiology 
An annual average of 345 cancers of the brain 
and central nervous system (including benign 
intracranial and intraspinal tumours) were 
diagnosed nationally 2009-2011 in Ireland. These 
cancers account for 1.8% of all invasive cancers 
excluding non-melanoma skin cancer and are 
the thirteenth (13th) most common category of 
cancer in Ireland. In 2011, there were 262 deaths 
from brain and central nervous system cancer, 
making it the ninth (9th) most common cause of 
invasive cancer deaths. Between 1994 and 2011, 
there has been no change in incidence rates of 
these tumours. The most recent relative survival 
estimates are a hybrid estimate for the 2008-2010 
cohort of cancers and five-year relative survival for 
this cohort has remained unchanged since 1994 
at 20% with a 95% confidence interval of between 
17.12%-23.1% (Cancer Factsheet: Brain and 
Central Nervous System NCRI 2013). 
Recent cancer projections from the NCRI predict 
that the incidence rate will increase in the future 
with models for brain and central nervous system 
cancer predicting the number of cancers to 
increase by 46%-95% between 2010 and 2040 
(Cancer Projections for Ireland: 2015-2040. NCRI 
2014).
Cancer strategy implementation – 
Surgical Centralisation
The document ‘Establishment of Managed Cancer 
Control Networks and Designation of Eight 
Cancer Centres’ published by the HSE in 2007 
recommended that “the curative surgical treatment 
of primary brain and other central nervous system 
(CNS) cancers will be provided at one national 
centre” (Appendix 1). 
In 2007, there were two hospitals undertaking 
the primary surgical treatment of brain and CNS 
tumours – Beaumont and Cork University Hospitals. 
The NCCP undertook an examination of the 
activity in these hospitals, looking at volumes, 
bed utilisation, ITU usage and the geographical 
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patterns of patient referral for brain and central 
nervous system resections. Following this review 
and in consultation with clinical advisors, a decision 
was taken to establish a national neuro-oncology 
service on two sites for adults - the national site in 
Beaumont, with a satellite unit in Cork.
Annual Report
The first annual report on the national neuro-
oncology service was published in 2012 and 
encompassed both adult and paediatric tumours. 
The full report is found in TD 7 but some highlights 
include:
•	 822	neuro-oncology	operations	performed	
with 751 adult procedures and 71 paediatric 
procedures.
•	 Of	the	adult	procedures,	680	or	91%	were	
intracranial procedures and 71 (9%) were 
spinal. 
•	 552	(74%)	of	all	of	the	adult	procedures	were	
performed in Beaumont and 199 (26%) were 
undertaken in Cork. 
•	 89%	of	intrancranial	procedures	and	87%	of	
spinal procedures were on primary tumours, 
the remainder were on metastases.
•	 Glioma	was	the	commonest	adult	intracranial	
primary tumour that an operation was 
performed upon (324 or 54% of all operations 
on primary tumours).
Of those gliomas, 191 were WHO Grade 4.
•	 Looking	at	those	who	were	operated	on	for	
metastases, 25 (32%) of the primary cancers 
were lung in origin.
•	 Expansion	of	awake	craniotomies	in	
Beaumont and Cork University Hospital. 
•	 Introduction	of	immunoflouresence-guided	
surgery.
•	 Development	of	fully	refurbished	suite	of	
laboratories specifically for the molecular 
genetic analysis of brain tumour in Beaumont. 
Key Performance Indicators
In 2014 a number of Key Performance Indicators 
were developed which will be part of an ongoing 
quality monitoring programme.
Challenges and Opportunities
•	 Improvements	to	the	service	in	recent	years	
include the opening of the new Intracranial 
Stereotactic Radiosurgery Service at the St 
Luke’s Radiation Oncology Unit at Beaumont 
Hospital in May of 2013. In the initial year it 
is expected that up to 50 patients will benefit 
increasing to around 200 annually over the 
coming years as the service develops. 
•	 Data	management	staff	are	not	available	to	
the National Neuro-Oncology Service which 
will pose a challenge to the collation of a 
suite of Key Performance Indicators.
•	 The	expansion	of	awake	craniotomies	has	
resulted in an increased requirement for the 
expertise of Speech and Language therapists. 
This is currently being met on an ad hoc basis 
in Beaumont Hospital. 
•	 There	is	currently	no	administrative	support	
to the multidisciplinary team meeting in 
Beaumont which is a challenge to support this 
essential component of cancer care.
•	 There	is	inadequate	specialist	community	
rehabilitation staff to support patients upon 
discharge. 
•	 The	NCCP	has	a	remit	for	developing	cancer	
services and monitoring its volume and 
quality in the Irish public hospital system only. 
Private hospitals are outside this remit and 
activity there is not subject to NCCP scrutiny.
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6.8 Gynaecology Cancer 
Epidemiology 
Gynaecological cancers can be broadly subdivided 
into uterine body, ovarian, cervical and other rarer 
cancers such as cancers of the vulva, vagina and 
placenta.
Uterine Cancer (Corpus Uteri)
There was an annual average of 400 uterine 
cancers (corpus uteri) diagnosed 2009-2011 
in Ireland, making uterine cancer the 5th most 
common invasive cancer in women in Ireland, 
excluding non-melanoma skin cancer. In 2011, 
there were 83 deaths from uterine cancer, making 
it the 15th most common cause of invasive cancer 
deaths in women. Between 1994 and 2011, 
incidence rates have increased by 2.4% per year. 
The most recent relative survival estimates are a 
hybrid estimate for the 2008-2010 cohort of uterine 
cancers and five-year relative survival for this cohort 
is 78.4% with a 95% confidence interval of between 
75%-81.5% (Cancer Factsheet: Corpus Uteri NCRI 
2013). 
Recent cancer projections from the NCRI predict 
that this increase in incidence rates will continue 
in future with models predicting number of uterine 
cancers to increase by 62%-90% between 2010 and 
2040 (Cancer Projections for Ireland: 2015-2040. 
NCRI 2014).
Ovarian Cancer
For ovarian cancer, there was an annual average 
of 344 cancers diagnosed 2009-2011 in Ireland, 
making ovarian cancer the 6th most common 
invasive cancer in women in Ireland, excluding 
non-melanoma skin cancer. In 2011, there were 
278 deaths from ovarian cancer, making it the 4th 
most common cause of invasive cancer deaths 
in women. Between 1994 and 2011, incidence 
rates have demonstrated a slight decrease of 
0.8% per year, though this decrease was not 
statistically significant. The most recent relative 
survival estimates are a hybrid estimate for the 
2008-2010 cohort of ovarian cancers and five-year 
relative survival for this cohort is 39.4% with a 
95% confidence interval of between 36.0%-42.8% 
(Cancer Factsheet: Ovarian NCRI 2013). 
Recent cancer projections from the NCRI predict a 
moderate increase in incidence rate in future with 
models for ovarian cancer predicting number of 
cancers to increase by 34%-44% between 2010 and 
2040 (Cancer Projections for Ireland: 2015-2040. 
NCRI 2014).
Cervical Cancer
There was an annual average of 328 cervical 
cancers diagnosed 2009-2011 in Ireland, making 
cervical cancer the 7th most common invasive 
cancer in women in Ireland, excluding non-
melanoma skin cancer. In addition, there has 
been an average of 2,847 cervical carcinomas in 
situ diagnosed every year. In 2011, there were 78 
deaths from cervical cancer, making it the 12th 
most common cause of invasive cancer deaths 
in women. Between 1994 and 2011, incidence 
rates have increased by 2.1% per year for invasive 
cancers and 7% per year for in situ cancers, the 
latter increase particularly reflecting the national 
roll out of the cervical screening programme. The 
most recent relative survival estimates are a hybrid 
estimate for the 2008-2010 cohort of invasive 
cervical cancers and five-year relative survival for 
this cohort is 72.2% with a 95% confidence interval 
of between 68.7%-75.4% (Cancer Factsheet: 
Cervical NCRI 2013).
Recent cancer projections from the NCRI predict 
that this increase in incidence rates will continue 
in future with models for cervical cancer predicting 
number of cancers to increase by 77%-88% 
between 2010 and 2040 (Cancer Projections for 
Ireland: 2015-2040. NCRI 2014).
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NCCP and Gynaecological Cancers 
The document ‘Establishment of Managed Cancer 
Control Networks and Designation of Eight 
Cancer Centres’ published by the HSE in 2007 
recommended that “the curative surgical treatment 
of primary gynaecological cancers will be delivered 
at four centres nationally” (Appendix 1). 
In 2007, there were 27 hospitals undertaking 
surgery for cervical, ovarian or uterine cancers. The 
NCCP undertook an examination of the activity in 
these hospitals, looking at volumes, bed utilisation, 
ITU usage and the geographical patterns of 
patient referral for gynaecological resections. 
In consultation with clinical advisors, a decision 
was taken early in 2012 to centralise surgical 
gynaecology oncology services into 7 designated 
cancer centres: Mater Hospital, St James Hospital, 
St Vincent’s Hospital in Dublin; Cork University 
Hospital, University Hospital Limerick, University 
Hospital Galway and Waterford Regional Hospital 
outside Dublin. 
Complex gynaecological cancer surgery will be 
carried out in St James’s Hospital and the Mater 
Hospital. 
Establishment of a National Clinical Leads 
network for Surgical Gynaecology Oncology 
The Surgical Gynaecology Oncology Clinical Leads 
group was established in January of 2012. The 
purpose of the National Leads group is to ensure 
that the seven centres build on robust local clinical 
governance arrangements, in order to operate as a 
cohesive national clinical network for the purpose 
of clinical audit, sharing of good practice and 
problem solving. This group meets on a quarterly 
basis and is supported by a project manager from 
the NCCP. 
The terms of reference for the clinical leads group 
are as follows: 
•	 Contribute	to	the	development	and	
continuous improvement of surgical 
gynaecological services.
•	 Share	good	practice	and	innovation	in	
surgical gynaecological services and 
ensure that non evidence based practice is 
discontinued.
•	 Inform	decision	making	and	standardisation	
of service delivery across the centres. 
•	 Develop	and	ensure	adherence	to	National	
Standards and Key Performance Indicators.
•	 Review	the	quality	and	completeness	of	
data, recommending corrective action where 
appropriate and necessary.
•	 Lead	national	multidisciplinary	audit,	quality	
and risk (AQR) meeting.
•	 Input	into	selection	of	Key	Performance	
Indicators (KPIs) for Gynaecology Oncology 
Services. 
Gynae Oncology Standards
The following standards have been set by the 
NCCP and Leads Group in Surgical Gynaecology 
Oncology:
•	 All	patients	diagnosed	with	or	with	a	strong	
suspicion of having a cancer (with an 
ovarian mass) should be referred to a Gynae 
Oncologist pre-operatively.
•	 All	radical	gynaecological	surgery	will	be	
performed by Gynae oncology surgeons only, 
including laparoscopic and robotic surgery if 
appropriate.
•	 Low	grade	cases	of	uterine	cancer	with	
no evidence of myometrial invasion on 
MRI do not require surgery under a Gynae 
Oncologist. 
All patients will be discussed at MDM, and 
recommendations recorded in the patients’ chart.
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Centralisation of Primary Surgical Activity
There has been a moderate level of success in 
centralising uterine and ovarian cancer to the eight 
cancer centres since the decision was made in 
early 2012(Table 6.8.1 and 6.8.2). The proportion 
of women being treated in a cancer centre rose 
from 68% in 2009 to 79% in 2013 for uterine cancer 
(Table 6.8.1) and from 68% in 2009 to 87% in 2013 
for ovarian cancer (Table 6.8.2). Colposcopy 
services for cervical cancer are not being 
centralised and about 30% of radical surgery for 
cervical cancer is still being conducted outside of 
the cancer centres with no significant change in the 
proportion since 2009 (Table 6.8.3).
Table 6.8.1: Resection of Uterine Cancers by Designation of Hospital and by Year, 2009-2013
2009 2010 2011 2012 2013*
Total number of procedures 325 290 264 272 276
Number of procedures undertaken in a 
cancer centre 222 193 175 192 219
% of procedures undertaken in a cancer 
centre 68% 67% 66% 71% 79%
Data Source: HIPE Portal, Healthcare Pricing Office. *Data is provisional for 2013
Table 6.8.2: Resection of Ovarian Cancers by Designation of Hospital and by Year, 2009-2013
2009 2010 2011 2012 2013*
Total number of procedures 229 185 174 219 149
Number of procedures undertaken in a 
cancer centre 157 138 118 173 130
% of procedures undertaken in a cancer 
centre 68% 75% 68% 79% 87%
Data Source: HIPE Portal, Healthcare Pricing Office. *Data is provisional for 2013
Table 6.8.3: Resection of Cervical Cancers by Designation of Hospital and by Year, 2009-2013
2009 2010 2011 2012 2013*
Total number of procedures 171 151 152 121 90
Number of procedures undertaken in a 
cancer centre 117 107 98 79 62
% of procedures undertaken in a cancer 
centre 68% 71% 64% 65% 69%
Data Source: HIPE Portal, Healthcare Pricing Office. *Data is provisional for 2013
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Development of Key Performance 
Indicators (KPIs) for Surgical Gynaecology 
Oncology 
A suite of Key Performance Indicators (KPIs) for 
Surgical Gynaecology Oncology are currently 
being developed by the NCCP in co-operation 
with the Leads Group for Gynaecology Oncology. 
It is expected that these will be agreed by the end 
of 2014 and will be piloted in 2015. 
Commencement of national Clinical 
Guidelines for Diagnosis, Staging and 
Treatment 
The 2006 National Cancer Strategy recommended 
the development of evidence based guidelines 
and standards. The NCCP has commenced the 
development of evidence based clinical guidelines 
for Gynaecology Services. These guidelines will 
include recommendations relating to the patient 
pathway in the different Gynaecology areas. 
The following subgroups have been identified: 
Cervical Cancer, Ovarian Cancer, Vulval Cancer, 
Endometrial Cancer, Uterine and Fallopian Cancer 
and Gestational Trophoblastic Disease. 
The Gestational Trophoblastic Disease subgroup 
was the first to start and this guideline is due for 
completion in 2014 and will be available on the 
NCCP website following stakeholder review. 
Annual Quality Safety and Risk meeting
The first Surgical Gynaecology Meeting will take 
place in 2015 when KPI data becomes available. 
The purpose of this forum will be to: 
•	 Provide	an	annual	multidisciplinary	forum	for	
audit, quality and risk. 
•	 Build	on	local	clinical	governance	
arrangements, in order to operate as a 
cohesive national clinical network for the 
purpose of clinical audit, sharing of good 
practice and problem solving.
•	 Identify	best	practice	models	and	ensure	
standardisation and service improvement 
nationally. 
Community Oncology 
(These initiatives are further discussed in the 
Community Oncology Section 9 of this report)
•	 The	Development	of	Ovarian	Cancer	GP	
referral guidelines and a standardised referral 
form are being progressed by the Community 
Oncology division of the NCCP in co-
operation with the Leads Group in Surgical 
Gynaecology. 
•	 Following	completion	of	these	guidelines	
electronic GP referral forms may be 
developed. 
•	 Access	to	diagnostic	tests	needs	to	be	
strengthened and developed throughout the 
country in line with the implementation of the 
guidelines.
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6.9 Neuroendocrine Cancer
Epidemiology 
Neuroendocrine tumours arise from cells of the 
endocrine (hormonal) and neural (nervous) system. 
These cells can be found throughout the body 
but neuroendocrine tumours are most frequently 
diagnosed in the digestive tract and the lungs. 
Many are benign, but some are malignant. 
Neuroendocrine tumours are defined as per the 
RARECARE definitions (TD 8). Table 6.9.1 outlines 
the number of cases recorded by the National 
Cancer Registry every year. Table 6.9.2 is an 
estimate of the current number of prevalent cases. 
Table 6.9.1: Neuroendocrine Cancers in Ireland: Total Cases Diagnosed per Year, 1994-2011
By tumour behaviour By site
Year of 
diagnosis
Borderline/ 
uncertain
Invasive Total Gastro- entero- 
pancreatic*
Other Total
1994 26 283 309 55 254 309
1995 25 301 326 60 266 326
1996 23 277 300 46 254 300
1997 33 296 329 71 258 329
1998 24 318 342 57 285 342
1999 22 343 365 72 293 365
2000 21 350 371 72 299 371
2001 37 349 386 98 288 386
2002 29 351 380 76 304 380
2003 25 374 399 79 320 399
2004 31 388 419 85 334 419
2005 27 425 452 94 358 452
2006 29 449 478 105 373 478
2007 40 487 527 124 403 527
2008 36 493 529 128 401 529
2009 40 563 603 154 449 603
2010 38 535 573 166 407 573
2011 ** 33 486 519 147 372 519
Source: NCRI 2012
* gastroenteropancreatic defined as all tumours located in the digestive system (ICD10: C15 – C26 inclusive) ** 
data for 2011 is not yet complete
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While the incidence of the disease in Ireland is on 
a par with other countries (around four per 100,000 
per year), since 1994 there has been a steady 
increase in numbers being diagnosed.  A total of 
55 gastro-entero-pancreatic cases were diagnosed 
in 1994, while in 2010, 166 cases were reported 
representing an annual percentage increase of 
eight per cent. 
Hospital Activity 
As demonstrated in Table 6.9.3, about half of all 
intestinal neuroendocrine tumours are currently 
treated in a cancer centre. 
Cancer strategy implementation
In 2013, the NCCP established a neuroendocrine 
network which is aimed at establishing an 
integrated and coordinated national approach 
to handling the diagnosis and treatment of 
gastroenteropancreatic Neuroendocrine Tumours 
(NETS) in Ireland.  The priority is to increase 
collaboration between specialists treating such 
tumours. 
The National Programme aims to build a network 
involving the designated cancer centres in Dublin, 
Cork and Galway. This will improve service levels 
for Irish patients with increased exposure to new 
treatments and approaches, inclusion in drug and 
other trials, as well as other benefits. A minority of 
patients may still be referred for treatment abroad 
in rare circumstances and it is anticipated that lung 
NETS will still be managed by the specialist lung 
oncology centres.
The National Clinical Lead for Neuroendocrine 
Tumours leads a weekly dedicated multidisciplinary 
outpatients NET clinic in St Vincent’s University 
Hospital. Input is also provided by specialists 
with endocrinology and pancreatic/hepatobiliary 
surgical expertise. Plans are well underway to 
set up a special clinic for patients and families 
with hereditary neuroendocrine tumours and it is 
expected that a national MDT will be operational 
later in 2014. Strong links have also been 
established with the NET patient support group. 
Table 6.9.2: Prevalence of Neuroendocrine Cancers in Ireland
Gastroenteropancreatic* 1,009
Other 1,016
Total 2,025
Source: NCRI 2012.Total prevalence (17 year: 1994-2010) = number of patients diagnosed between 1994 & 2010 
that were still alive on 31/12/2010
Table 6.9.3: Distribution of Gastroenteropancreatic Neuroendocrine Tumours by Hospital of 
Treatment 
Total Cases Attending The Hospital Had Tumour Directed Surgery 
2006 2007 2008 2009 2010 Annual 
Average
2006 2007 2008 2009 2010 Annual 
Average
Cancer 
Centre 60 76 73 76 103 77.6 21 35 39 35 45 35
Other 
Hospital 63 69 75 99 87 78.6 32 30 41 53 45 40.2
Data Source; HIPE Portal, Healthcare Pricing Office
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6.10 Sarcomas
Epidemiology 
Between 1994 and 2012, there were 671 cases 
of invasive primary bone cancer diagnosed in 
Ireland, an annual average of 35 cases per year. 
Approximately 85% of these cancers are sarcomas. 
In addition to the bone tumours, there were on 
average 42 cancers of connective tissue registered 
every year between 2009 and 2011. These are rare 
tumours and due to the small numbers involved it 
is difficult to establish any trend in incidence. There 
were seven deaths in 2011 from a primary bone 
cancer and 22 deaths from a soft tissue cancer. 
(Cancer Trends No 22: Primary bone cancer, NCRI 
2014). Because soft tissue sarcomas can occur in 
any anatomical site, they may be assigned to the 
code of the site organ rather than to the connective 
tissue code. For this reason, it has been shown 
internationally that registry data can underestimate 
soft tissue sarcomas by as much as 50%. 
The most recent relative survival estimates are 
a hybrid estimate for the 2008-2010 cohort of 
primary bone cancers and five-year relative survival 
for this cohort is 57.3% with a 95% confidence 
interval of between 45.4%-69.0% (http://www.ncri.
ie/data/survival-statistics downloaded May 2014). 
For soft tissue sarcomas, the five-year relative 
survival for the equivalent cohort is 64.4% with 
a 95% confidence interval of between 57.7%-
71.0% (http://www.ncri.ie/data/survival-statistics 
downloaded May 2014). 
Hospital Activity
The NCCP undertook a review of the hospital 
activity associated with the treatment of sarcoma in 
2012. The main findings were: 
•	 There	are	approximately	1,000	patient	
discharges from public hospitals every year 
following treatment for bone cancer. 
•	 Approximately	one	quarter	of	these	patients	
are children.
•	 Looking	specifically	at	surgical	treatment	of	
bone tumours of the limb (C40), Cappagh 
and St Vincent’s Hospitals and Beaumont 
Hospital are the main providers for the 
adult population and Cappagh and Crumlin 
Hospitals are the main providers for children 
with these cancers. St. Vincent’s University 
Hospital is the largest service provider 
for surgical procedures for these types of 
tumours.
•	 For	surgical	treatment	of	bony	sites	other	than	
limbs, St James’s Hospital is the main service 
provider.
•	 There	are	on	average	2,248	discharges	
recorded on the HIPE system every year 
following treatment of a soft tissue tumour. 
NCCP Plans 
The NCCP has convened two national meetings to 
discuss and agree a process to develop pathways 
for the management of suspected sarcoma 
diagnosis. Agreement was reached at the meeting 
that the surgical management of these sarcomas is 
to be within designated cancer centres with other 
cancer care delivered locally. Treatment planning 
should be agreed in a designated centre by a 
multidisciplinary team.
It is intended to develop pathways to ensure that 
patients with suspected sarcomas are referred 
for diagnosis and treatment to a cancer centre. 
While additional considerations will be required to 
agree the treatment location of certain sarcomas, 
it has been agreed that the treatment of Musculo-
skeletal sarcomas will be centralised in St. Vincent’s 
University Hospital and Cappagh Hospitals. Chest 
wall and gastrointestinal stromal tumors (GIST) will 
be treated in St. James’s Hospital. 
The NCCP has yet to agree an implementation 
plan with local clinicians and hospital managers 
on the reconfiguration of services and clinical 
pathways to enact these proposals. 
The Inaugural Meeting of the Irish Sarcoma Group 
(ISG) has been scheduled for the end of November 
2014. 
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6.11  Head and Neck Cancers 
Epidemiology 
Between 1994 and 2009, there were 411 cases 
of invasive head and neck cancer diagnosed in 
Ireland every year. The most common cancer site 
was the larynx, with 127 cases registered every 
year, followed by tongue cancer at 62 cases per 
year (Cancer Trends No 10: Head and Neck cancer, 
NCRI 2011). Incidence rates have been increasing 
by 7.9% per year for females and 5.2% per year for 
males since 2001. 
The most recent relative survival estimates are a 
hybrid estimate for the 2008-2010 cohort of head 
and neck cancers and five-year relative survival for 
this cohort is 47.9% with a 95% confidence interval 
of between 42.8%-52.9% (http://www.ncri.ie/data/
survival-statistics downloaded May 2014). 
Recent cancer projections from the NCRI predict 
that incidence rates will continue to increase with 
models for head and neck cancer predicting the 
number of cancers to increase by 60%-114% 
between 2010 and 2040 (Cancer Projections for 
Ireland: 2015-2040. NCRI 2014).
Cancer Strategy Implementation – 
Surgical Centralisation
The document ‘Establishment of Managed Cancer 
Control Networks and Designation of Eight 
Cancer Centres’ published by the HSE in 2007 
recommended that “the curative surgical treatment 
of head and neck cancers will be delivered in one 
national centre” (Appendix 1). 
Hospital Activity
In 2013, the NCCP undertook a review of the 
hospital activity associated with the treatment of 
head and neck cancers between 2008 and 2012. 
The main findings were: 
•	 There	are	approximately	2,027	patient	
discharges from public hospitals every year 
following treatment for head and neck cancer. 
•	 Surgical	procedures	were	carried	out	in	over	
30 hospitals.
•	 Over	68%	of	those	discharges	were	from	a	
cancer centre.
•	 A	further	11%	of	discharges	were	from	the	
South Infirmary University Hospital, Cork.
•	 Looking	specifically	at	surgical	treatment,	
68% of procedures were undertaken in a 
cancer centre. Twenty percent of activity was 
undertaken in the South Infirmary University 
Hospital, Cork. 
Centralisation of Primary Surgical Activity
As head and neck cancers have not been actively 
centralised, there has been no change in the 
distribution of the surgical treatment of head 
and neck cancers between 2007 and 2013 (Table 
6.11.1). 
Table 6.11.1: Resection of Head and Neck Cancers by Designation of Hospital and by Year, 2007-2013
2007 2008 2009 2010 2011 2012 2013*
Total number of procedures 391 386 409 446 423 425 438
Number of procedures undertaken 
in a cancer centre 270 250 280 308 280 284 307
% of procedures undertaken in a 
cancer centre 69% 65% 69% 69% 66% 67% 70%
Data Source; HIPE Portal, Healthcare Pricing Office. *Data is provisional for 2013
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Plans for Head and Neck Consolidation 
In November of 2013, the NCCP convened a 
national meeting of all relevant stakeholders and 
clinical experts to develop a national approach 
for head and neck cancer surgery. Priorities 
were agreed in the areas of surgery, primary 
care pathways, radiology, pathology, workforce 
planning, multidisciplinary care and performance 
monitoring. Work is an advanced stage in relation 
to primary care pathways and surgical planning. 
Complex head and neck cancers are to be 
centralised into designated centres where there 
is access to the full multidisciplinary team which 
includes head and neck surgeons, radiation 
oncologist, medical oncologist, pathologists and 
radiologists with special interest in head and neck 
cancers, cancer nurse specialists, data managers 
as well as speech therapists and dieticians. 
Access to restorative dentistry, plastic surgery and 
endocrinology are also required. 
It has been agreed that head and neck sarcomas, 
rare, biologically challenging and hypo-pharyngeal 
head and neck cancers should be treated in one 
national centre. A minimum case volume of twelve 
cases per surgeon will be the initial standard 
increasing to 24 cases over time. Work is currently 
underway to develop a structure for a consolidated 
service. 
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7
Recommendation 
30
The 2006 National Cancer 
Strategy recommended that 
“The National Network for 
Radiation Oncology Services 
should be established by 
the HSE in accordance 
with the timelines set by 
Government”. 
National Radiotherapy Strategy
For the past number of years, the expansion of 
radiation therapy facilities has been progressed 
under The Report on the Development of 
Radiation Oncology Services in Ireland, (known 
as the Hollywood Report) which was published in 
2003 (TD 12). 
The report outlined the significant deficit that 
existed at that time in relation to meeting the 
radiation oncology needs of cancer patients. 
Modern estimates suggest that between 55% and 
60% of patients will require access to radiation 
oncology services during their cancer illness. In 
contrast, at that time, approximately 20% of cancer 
patients in Ireland had radiation therapy as part of 
their primary treatment and approximately 39% of 
patients with invasive cancer had radiation therapy 
at some point during their illness.
In July 2005, the Minister for Health and Children 
announced the Government’s approval for a 
national network for radiation oncology to be put 
in place by 2011. The original intention was for a 
capital investment of over €400m (predominantly 
funded through a Public Private Partnership (PPP)) 
resulting in 23 additional linear accelerators to 
bring the national total to 36. The Network was to 
consist of: 
Four large centres, two in the Dublin Region (in 
St. James’ Hospital and Beaumont Hospital), one 
in Cork University Hospital and one in Galway 
University hospital:
•	 A	single	Eastern	Region	treatment	centre	
serving the southern part of the region 
and adjacent catchment areas, ultimately 
providing a 13-14 linear accelerator capacity 
with appropriate clinical and non-clinical staff. 
•	 A	single	Eastern	Region	treatment	centre	
serving the northern part of the region 
and adjacent catchment areas, ultimately 
providing an 8-9 linear accelerator capacity 
with appropriate clinical and non-clinical staff.
A treatment centre located at Cork University 
Hospital (CUH) was ultimately to provide an 8-9 
linear accelerator capacity with appropriate clinical 
and non-clinical staff.
National Radiation 
Oncology Programme
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The treatment centre located at University College 
Hospital Galway (UCHGI) was ultimately to provide 
a 6 linear accelerator capacity with appropriate 
clinical and non-clinical staff.
The report also recommended the development 
of two integrated satellite centres in Waterford 
and Limerick each with two Linear Accelerators. 
These satellites were to link with the large centres 
in Cork and Galway respectively. In addition the 
report recommended that arrangements be put in 
place with the Northern Ireland health authorities 
for services for patients in the North West of 
Ireland to be referred for treatment initially in 
Belfast City Hospital with further work to pursue 
the joint provision of a satellite centre for the North 
West linked to Belfast. A recommendation was 
also included that the continuity of expertise and 
ethos in St. Luke’s Hospital be maintained for the 
services. 
These recommendations were implemented on a 
phased basis. Phase 1 of the National Programme 
for Radiation Oncology (NPRO), involved the 
provision of new radiation oncology centres on 
the grounds of St. James’s and Beaumont Hospital 
Campuses both with four linear accelerators and 
two CT simulators. These new facilities were 
opened and operational in early 2011. The existing 
radiotherapy centre at St Luke’s and the new 
centres at Beaumont and St James’s together form 
the St Luke’s Radiation Oncology Network (SLRON) 
which operates across the three sites. 
SLRON now operates as a single network with 
patients and staff moving between the centres as 
required. Services are delivered across the three 
sites on a 4-4-4 model (i.e. four linear accelerators 
operational on each site) with all patients booked 
through a central booking office. This ensures 
patients equity of access to the next available 
appointment, subject to site specific tumours and 
consultant availability.
Phase 2 of the national plan involved the design 
and construction of new departments in CUH and 
UHG. Funding for Cork and Galway has been 
fully provided for in the 2012-2016 HSE Capital 
Plan. Funding for Phase 2 expansion in Dublin 
(envisaged to be about €132k in the longer term) 
has yet to be agreed.
Under the original plan, the capital investment for 
Phase 2 was to be provided through a combination 
of exchequer and public private partnership (PPP) 
funding. However, in view of the economic outlook 
in Ireland, the Department of Health decided in 
2012 to fund all expansion via traditional means 
from within the HSE Capital Plan. 
The NPRO was drafted with a view to providing 
sufficient capacity in the public system to treat all 
patients in the Republic of Ireland. However in the 
intervening years radiotherapy facilities were built 
in the private sector and the HSE has since entered 
into Service Level Agreements for the provision of 
radiotherapy by private sector providers in both 
Waterford and Limerick.
In Waterford the Whitfield Hospital operated by 
UPMC (University of Pittsburgh Medical Centre) 
provides radiotherapy to patients from the South 
East while the Mater Private Hospital currently 
operates a facility on the grounds of University 
Hospital Limerick for patients from the Mid West. 
Both facilities have two linear accelerators and 
provide approximately one linear accelerator of 
capacity to the HSE. Future capacity projections for 
public radiotherapy facilities have for the medium 
term included the continuation of this level of 
activity in these private facilities.
There are also private radiotherapy facilities in 
Dublin (St. Vincent’s Private Hospital, the Mater 
Private Hospital, The Hermitage and Beacon 
Hospitals). All of these units have two linear 
accelerators and operate independently of the 
NCCP. 
In 2013 as part of the considerations on expansion 
plans for Phase 2 in Dublin, the Minister for Health 
commissioned Trinity College Dublin to undertake 
a study on the costs of radiation oncology 
provision through the public and private sectors in 
Ireland. The report found that public providers offer 
significant cost advantages over private providers 
particularly as capacity utilisation increases. 
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National Plan for Radiation Oncology 
Phase 2 in Cork and Galway
There are currently four linear accelerators in 
Cork University Hospital and three in University 
College Hospital Galway. Funding for Phase 2 of 
the National Plan for Radiation Oncology provides 
for one additional linear accelerator (and a spare 
bunker) in Cork as well as the replacement of the 
current four linear accelerators over the period 
from 2013-2017 at a projected cost of €52m. In 
Cork considerable enabling works are required 
to decant the identified site and commission 
a purpose built unit. The preliminary site work 
associated has commenced and it is envisaged that 
this project will be completed in late 2017. 
In Galway one additional linear accelerator (and a 
spare bunker) will also be provided, and the three 
existing linacs replaced. The work is scheduled 
to be completed in 2018 at a cost of €48m. 
Significant enabling works are also required. 
The new radiotherapy units in Cork and Galway 
are significant new capital builds encompassing 
additional linear accelerators capacity as well as all 
related onsite facilities including dedicated clinic 
space, planning facilities and support staff offices. 
Contingency plans are being developed in each 
unit in the event of a shortfall in capacity, pending 
completion of the new expanded facilities.
Capacity Planning for Dublin
Based on the flow of patients, the St. Luke’s 
Radiation Oncology Network (SLRON) currently 
treats approximately 55% of all radiotherapy 
patients nationally. 
Capacity planning for the Dublin Region has been 
revised to reflect the amended National Cancer 
Registry of Ireland (NCRI) cancer projections 
(2014) (TD 1). Planning has been based upon the 
following assumptions: 
•	 60%	of	all	cancer	patients	are	expected	to	
receive radiotherapy;
•	 55%	of	all	radiotherapy	patients	nationally	are	
treated in Dublin; and
•	 65%	will	be	treated	through	public	provision	
in the Greater Dublin area.
Dublin Expansion
The medium to longer term plan for Dublin 
involves the provision of seven additional linear 
accelerators at St. James’s and four additional 
linear accelerators at Beaumont Hospital to give 
a total of 19 linear accelerators over time. Four 
of the linear accelerators at St. James’s would 
replace those at St. Luke’s which it is intended will 
ultimately cease to operate as a radiation oncology 
treatment facility. 
The indicative cost for this is €120m (€75m at 
St James’s and €45m at Beaumont). The capital 
allocation for the pre-construction phase in 
2014/15 for Beaumont would total €5m, with 
construction through to 2016/18 costing €40m and 
the facilities being operational from early 2019. 
This required funding is not available from within 
the current HSE capital plan and discussions are 
ongoing with HSE Estates and the Dept. of Health 
to agree and fund expansion to accommodate the 
demand for treatment in the Dublin region.
Table 7.1: Requirement for Linear Accelerators in Dublin up to 2030
Linac requirement Current 2015 2016 2017 2018 2019 2020 2025 2030
65% Public provision 12 14 14 14 15 15 15 17 19
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In June of 2014 ministerial agreement was reached 
to fund the refurbishment of three existing bunkers 
in St. Luke’s hospital to accommodate two/three 
new linear accelerators. The approval for this 
expansion which is funded from the existing HSE 
capital plan has been welcomed as capacity will 
be at reached in the St. Luke’s network by the 
end of 2015. The continuation of services in St. 
Luke’s Hospital will provide the interim treatment 
capacity required, pending agreement on a longer 
term expansion plan. The current priority for the 
NCCP is the development of additional radiation 
oncology capacity at Beaumont Hospital. Funding 
for the design and planning of expansion in the 
Beaumont hospital site is being sought from 
within the existing HSE capital plan to enable 
construction to commence in 2017. Construction 
work on the development of the new National 
Paediatric Hospital on the site of St. James’s will 
delay expansion of the radiotherapy facility until at 
least 2020. Funding for the long term expansion in 
Dublin has yet to be secured. 
The revised plans for additional capacity at St. 
Luke’s and the continued delivery of radiotherapy 
will defer the full transfer of radiation oncology 
services to the Beaumont and James’s campuses 
and the cessation of services on the St. Luke’s site. 
The continuation of the service over three sites 
will pose a continued staffing challenge for the 
network. 
Allied to the opening of the radiotherapy facilities 
on the grounds of Beaumont and St. James’s 
Hospitals, 12 dedicated inpatient radiotherapy 
beds have opened in each of the host hospitals; St. 
James’s (February 2014) and Beaumont Hospitals 
(2012). There has been a commensurate reduction 
in radiotherapy beds in St. Luke’s hospital.
During the period 2010-2012, a total of 54 
additional staffing posts were provided to the 
SLRON network. These posts were primarily 
radiation therapists, physicists and clinical 
engineers and were required to support patients 
across the network. Some of these posts (including 
dietetics and nursing staff) will form part of the 
complement in the host hospital, and provide 
service to radiation patients in the inpatient 
beds and the new centres. Additional consultant 
radiation oncologist posts have also been added 
in recent years, bringing the current total in the St 
Luke’s Network to 16. 
Access to Radiotherapy
Prior to the opening of the new radiotherapy 
faculties on the grounds of St James’s and 
Beaumont Hospitals there had been a significant 
challenge to ensure timely access to radiotherapy 
in Dublin. These delays have improved 
considerably with the opening of the new radiation 
oncology centres on the grounds of St. James’s 
and Beaumont Hospitals. 
Table 7.2: Average Waiting Times (Weeks) for Treatment
 2007 2013
Breast 10 2
Prostate 21 2
H&N 5 2.5
Rectum 4 2
Cervix 5 2
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The increase in linear accelerator capacity in 
Dublin from 2008-2013 has also resulted in an 
80% reduction in treatment of patients treated on 
an out-of-hours basis (i.e. after 10pm). St. Luke’s 
Hospital has moved from treating approximately 
750 patients on an out-of-hours basis per year 
to 150 in 2013. This improvement has not only 
resulted in a better service to patients but has also 
yielded financial savings of €1.2m to the network. 
Timely access to radiotherapy is a key performance 
indicator (KPI) for all radiotherapy units. Since 2012 
the NCCP has published radiotherapy waiting 
times for public patients in all centres (SLRON, 
Cork, UCHG, Waterford and Limerick). Originally 
data was only reported on the number and 
percentage of patients undergoing radiotherapy 
treatment for breast, lung, rectal or prostate cancer 
who commenced treatment within 15 working 
days of being deemed ready to treat by the 
Radiation Oncologist. Since 2013 waiting times 
for all patients undergoing radical treatment are 
monitored by the NCCP each month. 
There has been a notable improvement in the 
number and percentage of patients undergoing 
radical radiotherapy treatment who commenced 
treatment within 15 working days of being deemed 
ready to treat by a consultant radiation oncologist. 
The most recent figures for Quarter 1 in 2014 
indicated that 91.6% of patients are treated within 
the target of 15 working days. This reflects a 
sustained improvement on access in the past two 
years. 
New Technology
There has been a significant investment in new 
technologies for radiotherapy, all of which are 
designed to enable patients to receive more 
effective and precise treatment, frequently over 
a shorter time period. All radiotherapy centres 
in Ireland offer external beam radiotherapy and 
brachytherapy. Intensity modulated and image 
guided radiotherapy is available for specific tumour 
types in all radiotherapy centres. 
The SLRON centres in St. James’s and Beaumont 
Hospital sites are both equipped with MRI scanners 
and with rapid arc capabilities and St James’s 
Centre treated the first patient in Ireland with 
RapidArc™ technology in December 2011. 
Brachytherapy
A national prostate brachytherapy (radioactive 
seed implant) training programme was introduced 
across all public units in 2012. Led by Prof. 
Frank Sullivan from UCHG and applying recently 
published UK and Ireland Prostate QA guidelines, 
four consultants were trained initially and, training 
was provided to two further radiation oncologists 
in 2014. Over 180 patients were implanted in 2013 
and an ongoing quality assurance programme is 
underway. The treatment is a day case procedure, 
as opposed to the traditional seven and half weeks 
of external beam radiotherapy. It is expected that 
approximately 200 men will be provided with this 
treatment in 2014, and that the patient numbers 
will grow significantly in future years. 
Table 7.3: % Undergoing Radical Treatment Who Commenced Treatment within 15 Working Days
Year Q1 Q2 Q3 Q4
2012 79.6% 77% 77.3% 81%
2013 82.0% 77.9% 78.4% 84.2%
2014 91.6%
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An ocular brachytherapy programme for the 
treatment of ocular melanoma was opened in St. 
Luke’s Hospital, Rathgar in 2010 with dedicated 
surgical and nursing support provided by the 
Royal Victoria Eye and Ear Hospital and image-
guided gynae brachytherapy commenced in Cork 
University Hospital in 2013. 
Stereotactic Surgery
Following a significant equipment upgrade, funded 
by the charity Friends of St. Luke’s Hospital a new 
intracranical stereotactic radiotherapy/radiosurgery 
service opened in the SLRON unit at Beaumont 
hospital in August 2013. All patients requiring this 
treatment are jointly managed by site-specialised 
radiation oncologists and neurosurgeons. 
The extracranial stereotactic service (SABR: 
Stereotactic Ablative Radiotherapy) commenced 
in the SLRON unit at St James’s in March 2014, 
with the initial focus on treating early stage non-
small cell lung cancers with curative intent. This 
service will be gradually extended with the result 
that patients no longer have to travel abroad under 
the HSE Treatment Abroad Scheme or depend 
upon the service being contracted from the private 
sector.
A new more efficient, modern and fractionated 
programme for Total Body Irradiation (TBI) patients 
was developed in 2013 and the programme was 
transferred from St Luke’s Hospital to SLRON at 
St James’s in association with the national bone 
marrow transplant unit which is based in St James’s 
Hospital. 
Governance
Prior to the 1st of January 2014 St. Luke’s Radiation 
Oncology Network (SLRON) was under the direct 
governance of the HSE National Cancer Control 
Programme. The Network has since transferred to 
the Dublin Midlands Hospital Group of the HSE. 
The radiotherapy units in Galway and Cork are 
under the direct management of the hospitals. 
The National Radiation Oncology Planning and 
Implementation Committee was established in 
2012 to “Provide support, advice and guidance to 
the Director of the NCCP on radiation oncology 
services to ensure timely and equitable access 
to radiation oncology services of the highest 
international standard”. It comprises of professional 
leads, as well as clinical and managerial 
representation from the public radiotherapy units in 
Dublin, Cork and Galway (Terms of reference and 
membership are available). The group is currently 
progressing the development of national clinical 
radiotherapy guidelines and is overseeing the 
development of local and national contingency 
plans in the event of unavailability of capacity or 
machine failure for a protracted period of time. 
Patients in the South East of the country may be 
referred to the UPMC Whitfield Cancer Centre for 
radiation oncology. The HSE has a service level 
agreement (SLA) with Whitfield for the provision 
of services to public patients referred through the 
designated cancer centre at Waterford Regional 
Hospital. 
Similarly patients in the Mid West are referred to 
the Mater Private facility on the grounds of the 
Mid Western Regional Hospital in Limerick under a 
SLA. The SLA covers quality & clinical governance, 
access, the patient referral process, patient 
discharge, patient-centred care, interdisciplinary 
communication, adverse incident reporting, 
data requirements and a review process and 
dispute resolution. Regular meetings are held 
between both operators and the HSE to discuss 
performance matters. 
Although UPMS has divested its ownership and 
management responsibilities at Beacon Hospital 
in Dublin, it has confirmed to the NCCP in April 
2014 that it intends to continue to operate the 
radiotherapy facility in Waterford. 
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Quality Key Performance Indicators
All radiotherapy units nationally report the 
number of patients (excluding palliative patients) 
who completed radical radiotherapy treatment 
in the preceding quarter. During 2013 a total of 
3,951 patients completed their care in public 
radiotherapy facilities. 
Radiotherapy units also report on the number and 
% of patients undergoing radical radiotherapy 
treatment who commenced treatment within 15 
working days of being deemed ready to treat by 
the radiation oncologist (palliative care patients 
not included). The target is that 90% of patients 
are treated within this 15 day period. During 2013 
an average of 81% of patients (3,181) were treated 
within this timeframe. For the first quarter of 2014 
over 90% of patients are being treated within the 
target timeframe. 
In 2011 SLRON has established a Quality 
Assurance in Radiotherapy (QART) Committee 
which is responsible for coordinating, overseeing 
and integrating quality assurance and continuous 
quality improvement initiatives across St Luke’s 
Radiation Oncology Network (SLRON) and to 
advise nationally if required. The QART committee 
has developed a quality and audit system for 
the network which provides assurance that the 
specified requirements relating to the quality of 
patient care are satisfied and that the appropriate 
quality control mechanisms and procedures are 
in place. This has included the development of 
clinical protocols and an on line documentation 
system which is in line with international best 
practice. The SLRON clinical guidelines are 
currently being reviewed by Cork and Galway with 
the intention of endorsing and adopting these 
for national use. This is being progressed under 
the auspices of the National Radiation Oncology 
Planning and Implementation Committee 
(NROPIC). Once agreed these guidelines will 
form the basis of future contracted services and of 
clinical audit. 
National radiotherapy meetings are held annually 
to discuss key performance indicators, advances in 
technology and clinical services as well as and new 
service developments. 
Progress on Cross Border Provision of 
Radiation Oncology Services
Agreement with Belfast City Hospital for the 
provision of radiation oncology services to patients 
from Donegal, particularly those with breast or 
prostate cancer, was reached in 2006. A very small 
number of patients continue to avail of this service 
annually.
Access for patients from the North West to 
radiotherapy will be improved under a North/
South agreement to refer cancer patients from Co. 
Donegal to the new unit in Altnagelvin which is 
scheduled to open in 2016. The HSE will provide 
both a capital contribution and ongoing revenue 
funding. The new unit will also treat patients 
needing palliative radiotherapy and will provide a 
much reduced travel time. 
Research & Development 
Current research in SLRON is included in the 
areas of clinical trials, translational research and 
developmental research. St Luke’s Institute of 
Cancer Research (SLICR) provides funding to the 
Clinical Trials Unit (CTU) in SLRON from funding 
SLICR receives from the Friends of St Luke’s, the 
Health Research Board and the St Luke’s Cancer 
Research Fund. In 2013 SLRON recruited 103 
patients to clinical trials, the highest accruals to 
cancer treatment trials of all HRB funded sites. 
SLRON also attained the highest credits of all HRB 
funded sites during 2013. The work of the CTU is 
multidisciplinary and involves clinicians, radiation 
therapists, physicists, nurses, statistician and 
administrative staff. The list of trials open to patient 
accrual in SLRON during 2013 and due to start in 
2014 is included in TD 9.
There are two academic chairs at present (UCD & 
TCD), and there are strong academic links to the 
Faculty in the RCSI. 
Three Translational research studies in the areas of 
Rectal Prostate and Pancreatic cancer also started 
in 2013 in collaboration with RCSI, UCD and 
DCU. The trials have provided five publications, 
five publications in progress and nine conference 
presentations during 2013. 
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Other areas of research and development involve 
the range of links which exist with Trinity College, 
University College Dublin and RCSI. These include 
PhD and MSc programmes, TCD Division of 
Radiation Therapy and the Institute of Molecular 
Medicine Cancer Research Laboratory also in TCD, 
UCD Conway Institute, SpR training programmes 
and nursing degree and education programmes. 
There is a strong programme of PhD research 
in the physics department of SLRON together 
with UCD and DIT. There are at present four PhD 
students and a postdoctoral researcher working in 
areas contributing to clinical work in stereotactic 
and intensity modulated radiotherapy, the 
promising clinical field of Adaptive Radiotherapy, 
radiobiology of high dose treatments in lung and 
a national dosimetric audit system. Funding for 
the PhD research has come from SLICR, the Dublin 
Graduate Physics Programme and the NCCP 
medical physics training programme. 
Cork University Hospital has recently secured 
funding for a full time radiation therapist post to 
support the Oncology Clinical Trials Unit.  This will 
allow the department to establish radiotherapy 
trials which, to date, have not been achievable.  
The radiation oncology department in Galway 
University Hospital is closely involved with the 
Prostate Cancer Institute at NUI Galway. With the 
planned expansion of the unit, it is anticipated that 
there will be increased involvement in research 
projects and improved co-ordination with the 
NUIG.
Challenges for Radiation Oncology
The main challenge for radiotherapy relates to the 
significant capital costs of development and the 
long lead in time to build and then commission 
new equipment (this can be up to four years). 
Securing a timely decision to allow for completion 
of developments in line with projected demands 
remains a concern for the Dublin region. 
Agreement and funding of the longer term 
expansion for the remainder of Phase 2 expansion 
in Dublin (indicative cost of €120m) has yet to be 
secured. 
In the event that the radiotherapy service at the 
UPMC Whitfield Cancer Centre or the Mater 
Centre in Limerick was discontinued the existing 
public facilities in Dublin, Cork or Galway are not 
in a position to absorb the public demand (or a 
proportion of the private patients from either of 
these centres). In addition to limited linac capacity 
in the existing public system there would be 
patient access/satisfaction issues around travel 
times as well as revenue costs for additional 
in-patient and hostel beds, diagnostics and 
chemotherapy. In terms of contingency planning 
for this scenario there are a limited number of 
alternative scenarios available to the HSE for the 
delivery of this care. 
The existing linacs in Cork and Galway are almost 
at full capacity and there may be challenges 
accommodating demand pending completion of 
the new facilities. Contingency plans are currently 
under development in all radiotherapy centres 
nationally in the event of a machine breakdown. In 
the absence of local alternatives some contingency 
plans may include transfer of patients off site for 
treatment.
The recently agreed expansion of St. Luke’s will 
result in the continued delivery of radiotherapy 
across three sites in Dublin. This poses a challenge 
for clinical staff and medical cover. 
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Significant numbers of highly trained staff are 
required to run a radiotherapy unit. In recent 
years the availability of suitably trained physics 
staff has posed a challenge in commissioning 
new equipment. While a training programme 
(accredited by the Commission on Accreditation of 
Medical Physics Educational Programs (CAMPEP) 
has been developed between the radiotherapy 
units in SLRON and UCHG availability of qualified 
staffing remains a challenge. 
The NCCP has a remit for developing cancer 
services and monitoring its volume and quality 
in the Irish public hospital system only. Private 
hospitals are outside this remit and activity there is 
not subject to NCCP scrutiny
Opportunities
Should the UPMC Whitfield Cancer Centre come to 
market the HSE/DOHC could consider a purchase 
or lease arrangement, retaining existing staff and 
protecting the clinical service, as well as gaining 
an opportunity to review revenue costs in order 
to secure the continuation of local treatment for 
patients from the South East. 
Activity Tables
The following tables outline radiotherapy activity 
in SLRON, UCHG and CUH from 2008 to 2013. 
Total body irradiation and stereotactic treatment 
are not available in UCHG or CUH. Data are also 
presented on public patients treated in Whitfield 
Radiotherapy and Limerick (Mater Private) Units. 
Table 7.1: Radiation Activity 2009-2013 
Radiotherapy Annual Activity SLRON 2008-2013 
Total Number of Patients (New 
Starts)
2008 2009 2010 2011 2012 2013
St Luke’s Hospital 3366 3462 3685 2970 2331 1651
Beaumont Centre - - - 449 935 1187
St James Centre - - - 342 823 1160
Total 3366 3462 3685 3761 4089 3998
Radical Patient Numbers 2008 2009 2010 2011 2012 2013
St Luke’s Hosp 2040 2217 2564 2011 1604 1139
Beaumont Centre  -  -  - 320 686 834
St James Centre  -  -  - 267 601 800
Total 2040 2217 2567 2598 2891 2773
Palliative Patient Numbers 2008 2009 2010 2011 2012 2013
St Luke’s Hosp 1326 1245 1121 959 727 512
Beaumont Centre - - - 129 249 353
St James Centre - - - 75 222 360
Total 1326 
(39%)
1245 
(36%)
1121 
(30%)
1163 
(31%)
1198 
(29%)
1225 
(31%)
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Radiotherapy Annual Activity SLRON 2008-2013 
 Brachytherapy Activity (SLH) 2008 2009 2010 2011 2012 2013
Gynae Patients 173 153 159 158 142 166
Ocular Patients - - 8 26 38 42
Prostate Patients - - - - 22 30
Total Brachy Patients 173 153 167 184 202 238
 Number of Total Body Irradiation 
(TBI) Patients
2008 2009 2010 2011 2012 2013
St Luke’s Hospital 29 32 48 28 27 16
St James Centre - - - - - 25
Total 29 32 48 28 27 41
 Number of Stereotactic Patients 2008 2009 2010 2011 2012 2013
St Luke’s Hospital 12 12 15 14 27 11
Beaumont Centre - - - - - 25
Total 12 12 15 14 27 36
Percentage of Patients treated 
using IMRT Technique (Step & 
Shoot and RapidArc)
2008 2009 2010 2011 2012 2013
St Luke’s Hospital 1% 2% 4% 7% 19% 30%
Beaumont Centre - - - - 11% 37%
St James Centre - - - - 10% 27%
Total 1% 2% 4% 7% 15% 31%
Table 7.2 Radi
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otherapy Annual Activity for UCHG Hospital 2008 – 2013
Table 7.2: Radiotherapy Annual Activity for UCHG Hospital 2008-2013
Total Number of Patients (New 
Starts)
2008 2009 2010 2011 2012 2013
Total 1287 1393 1320 1303 1358 1262
Radical Patient Numbers 2008 2009 2010 2011 2012 2013
Total 862 977 924 904 998 860
Palliative Patient Numbers 2008 2009 2010 2011 2012 2013
Total 425
33%
416
30%
396
30%
399
31%
360
27%
402
32%
 Brachytherapy Activity 2008 2009 2010 2011 2012 2013
Gynae Patients 74 81 59 67 51 55
Ocular Patients 0 0 0 0 0 0
Prostate Patients 38 71 78 94 111 94
Total Brachy Patients 112 152 137 161 162 149
Percentage of Patients treated 
using IMRT Technique (Step&Shot 
and RapidArc)
2008 2009 2010 2011 2012 2013
Total 0 5% 8% 8% 13% 11%
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Table 7.3: Radiotherapy Annual Activity for Cork University Hospital 2008-2013
Total Number of Patients (New Starts) 2008 2009 2010 2011 2012 2013
Total 1246 1261 1412 1339 1276 1277
Radical Patient Numbers 2008 2009 2010 2011 2012 2013
Total 1041 1226 1308 1321 1123 1139
Palliative Patient Numbers 2008 2009 2010 2011 2012 2013
Palliative courses 359 317 412 383 424 438
Single sessions 185 157 193 161 150 143
Brachytherapy Activity 2008 2009 2010 2011 2012 2013
Gynae Patients - - - - - 56
Prostate Patients - - - - - 31
Total Brachy Patients - - - - 87
Percentage of Patients treated using IMRT 
Technique
2008 2009 2010 2011 2012 2013
Total - - - - - 7
Table 7.4: Radiotherapy Annual Activity Whitfield Radiotherapy Unit Public Patients 2008-2013
2008 2009 2010 2011 2012 2013
Total Number of Patients (New Starts) 480 553 481 543 541 554
Total Radical Patient Numbers 244 313 263 307 317 297
Palliative Patient Numbers Total 236 240 218 236 224 252
Palliative patients as % of Total Pts. 49% 43% 45% 43% 41% 46%
Table 7.5: Radiotherapy Annual Activity Limerick (Mater Private) Public Patients 2008-2013
2008 2009 2010 2011 2012 2013
Total Number of Patients (New Starts) 338 315 308 416 397 369
Total Radical Patient Numbers 287 222 233 302 292 250
Palliative Patient Numbers Total 51 93 75 114 105 119
Palliative patients as % of Total Pts. 15% 29% 24% 27% 26% 32%
Key performance indicators for radiation therapy are included in TD 19
104Report on the implementation of ‘A Strategy for Cancer Control in Ireland 2006’
8
The 2006 National Cancer Strategy did not 
make any direct recommendation in relation to 
medical oncology or haematology. 
Recommendation 
49
HIQA should establish a 
Cancer Health Technology 
Assessment Panel.
Introduction
The 2006 National Cancer Strategy contained little 
in the way of recommendations relating directly 
to medical oncology and haemato-oncology 
services. At the time of the publication of the 2006 
National Cancer Strategy, the specialties of medical 
oncology and haemato-oncology were growing. In 
2000, there were 13 consultant medical oncology 
posts in Ireland and 22 consultant haematology 
posts5 in the public health system. By 2005, this 
had increased to 23 consultant medical oncology 
posts and 40 haematology posts6. Currently there 
are 34 consultant medical oncology posts and 
58 consultant haematology posts. There are at 
least a further four medical oncology specialists 
and at least two haematology specialists working 
exclusively in the private sector. However, the 
number of medical oncology and haematology 
consultants in Ireland still falls far short of 
international norms based on population and 
cancer incidence.7 
Medical Oncology & Haemato-
oncology Services
The last ten years have witnessed a huge increase 
in the complexity and volume of chemotherapy. 
Data suggests that the number of patients 
receiving chemotherapy has increased substantially. 
The growth in both incidence of cancer and 
prevalence of patients on active treatment with 
new drugs drives growth of volume and complexity 
of work.
5 Comhairle na nOspidéal, Consultant Staffing, January 2000. Available www.lenus.ie.
6 Note: haematology posts referred to here cover all areas of haematology, including, for example, blood and clotting 
disorders, transfusion medicine, paediatric haematology etc. There is no approved sub-specialty of haemato-oncology in 
Ireland.
7 (Unpublished) Internal NCCP working document on medical oncology manpower planning, Dr. Maccon Keane.; The 
shortage of medical oncologists: The Australian Medical Oncologist Workforce Study, MJA 196(1) 2012.
Medical Oncology & 
Haemato-Oncology 
Programme
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Medical oncology and haemato-oncology services 
are provided in 25 acute adult hospitals and one 
paediatric hospital in Ireland. These services 
operate mainly on a hub and spoke model, with 
the oncologist and haematologists based at a 
designated cancer centre, travelling to provide 
agreed services to satellite centres. Complex 
chemotherapy and services are provided at 
designated cancer centres and complex haemato-
oncology services are provided at specialist centres 
where there is access to in-patient beds. 
There is wide variation in the management of 
oral chemotherapy with the majority of patients 
receiving prescriptions for dispensing in their local 
retail pharmacy business.
Impact of Hospital Groups on Medical 
Oncology and Haemato-Oncology 
Services
The organisation of cancer services in eight cancer 
networks was an important outcome of the 2006 
National Cancer Strategy. The Report on the 
Establishment of Hospital Groups as a transition to 
Independent
Hospital Trusts, known as the Higgins Report 
(health.gov.ie/wp-content/uploads/2014/03/
IndHospTrusts.pdf) sets out the planned 
structure of hospital groups, in anticipation of 
the establishment of hospital trusts. A criterion 
for each group was the inclusion in each of an 
NCCP-designated cancer centre and the report 
stated that the recommendations contained in 
the report “are not in conflict with existing NCCP 
arrangements and do not propose to dismantle any 
of the existing NCCP centres or radiation oncology 
services”. 
The structure of the hospital groups has a varying 
impact on the existing structure of medical 
oncology and haemato-oncology services. 
•	 In	the	Dublin	Northeast	Group,	there	are	
existing linkages (on the basis of shared 
consultant posts and linked services) 
between Beaumont/Connolly and Beaumont/
Drogheda, which fall within the hospital group 
structure. However, there is an existing link 
between the Mater and Cavan hospitals, 
with the Mater Hospital acting as the hub 
for services in Cavan, an arrangement which 
is now outside of the new hospital group 
structure.
•	 In	the	Dublin	Midlands	Group,	there	are	
existing links between Tallaght and Naas 
hospitals, which are unaffected by the hospital 
group structure. There are shared consultant 
medical oncology posts between Tallaght 
and St. Vincent’s hospitals but the services 
provided are separate so this is not a major 
cause for concern in relation to continuity 
of patient care. Medical oncology and 
haematology services at St. James’s Hospital 
and Tullamore Hospital are largely unaffected, 
except in relation to the traditional referring 
patterns to these hospitals. Within the 
Midland Hospitals, clinics are provided by the 
Tullamore-based haematologists to Mullingar 
and Portlaoise, both of which are now in 
a different hospital group. There are also 
concerns regarding the impact of the hospital 
group structure on existing diagnostic service 
provision for currently linked hospitals.
•	 Existing	shared	posts	and	services	in	Dublin	
East will be largely unaffected, with the 
exception of the Mater/Cavan link mentioned 
above. The other significant change in this 
area is the new association of Kilkenny and 
Wexford with the cancer centres in the 
Dublin East Group (i.e. St. Vincent’s & Mater 
Hospitals).
•	 In	the	South/South	West	Group,	the	change	
to existing links between the hospitals in the 
Southeast (Waterford / Kilkenny / Wexford) is 
a significant one and excellent links between 
these services have been built up over several 
years. These associations also reflect the 
traditional routes of patients for treatment. 
The Higgins Report states that: “Waterford 
Regional Hospital will continue to be an 
NCCP centre, retaining its current population 
referral base for cancer patients. Joint 
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consultant appointments, such as general 
surgery shared with Wexford, across the 
groups will continue to support the specialist 
cancer services it provides.”
•	 The	links	in	place	between	hospitals	in	the	
West/North West hospitals do not pose 
any significant issues in relation to the new 
hospital group structure.
•	 The	cancer	services	provided	in	the	Midwest	
region will be unaffected by the new hospital 
group structure.
•	 The	Higgins	Report	did	not	address	services	
at St. Luke’s Hospital Rathgar. 
Establishment of national NCCP 
programmes for medical oncology 
and haemato-oncology
The NCCP formally established national 
programmes for medical oncology and haemato-
oncology programmes in late 2012. A consultant 
medical oncologist was appointed national 
lead for the programme while clinical advice on 
haemato-oncology is provided by the Chair of the 
Irish Haematology Society. The programmes are 
supported by a Chief Pharmacist and a Programme 
Manager.
Approximately 33,000 people receive treatment 
with cancer drugs each year, both oral drugs 
delivered in the community and delivered by 
injection in hospital settings. NCRI predicts that the 
number of new patients receiving chemotherapy 
will increase by 42%-48% in the period 2010 to 
2025. The total number of patients per year being 
treated is expected to grow even faster as new 
drugs and longer duration of treatment drives 
demand for services.
The medical oncology and haemato-oncology 
programmes aim to ensure that the needs of 
the anticipated increased incidence in cancer 
diagnosis, prevalence of cancer and requirements 
for treatment continue to be met. These 
programmes provide a framework for national 
oversight and audit of drug use, adherence to 
protocols and drug spend. The programmes 
incorporate a number of evolving, inter-related 
work streams. Current areas of focus are listed 
below and are discussed in more detail in the 
sections that follow:
•	 Development	of	chemotherapy	protocols
•	 Enhancement	of	patient	safety	and	quality
•	 Technology	Review	Committee	
•	 Oncology	Drugs	Management	System	(for	
new cancer drugs)
•	 Funding	programme	for	growth	in	cancer	
drugs
•	 The	development	of	a	business	case	for	
a national Medical Oncology Clinical 
Information System
•	 Diagnostic	molecular	testing	
•	 The	development	of	key	performance	
indicators for medical oncology and haemato-
oncology services
•	 Clinical	Trials
•	 Workforce	planning	for	medical	oncology	and	
haemato-oncology
•	 Increased	availability	of	information	about	the	
work of the programmes, principally through 
the development of the NCCP website
107 Report on the implementation of ‘A Strategy for Cancer Control in Ireland 2006’
Chemotherapy protocols
Adherence to protocols is a key patient safety and 
quality measure in the use of chemotherapy for 
the treatment of cancer. NCCP has commenced a 
major programme of drug protocol development, 
which will eventually cover over 300 cancer drug 
protocols. Since 2012, protocols for 23 different 
indications have been completed and made 
available on the NCCP website, at www.hse.ie/
nccpchemoprotocols. The process of protocol 
development involves the review of international 
evidence and consultation with medical oncologists 
and haematologists in Ireland. The Irish Society 
for Medical Oncologists (ISMO) and the Irish 
Haematology Society (IHS) are responsible for 
contributing to and signing off the content of the 
protocols for relevant drugs. 
Patient Safety and Quality
In January 2014, NCCP published its Oncology 
Medication Safety Review Report8. The report 
presented the findings of the review which was 
conducted across the 26 hospitals in Ireland 
involved in the administration of systemic cancer 
therapy in adults and children. The aim of the 
review was to assess the oncology medication 
policies and practices in day units nationally, from a 
patient safety perspective. The report made a total 
of 93 recommendations, all of which were cross-
referenced with the HIQA Safer Better Healthcare 
Standards9.
The NCCP is now focussed on the implementation 
of the report’s recommendations. A national 
implementation steering group is in place and 
an action plan has been produced to guide 
implementation at national and local level. All 
hospitals are required to report regularly to NCCP 
on implementation of the recommendations. Work 
has commenced on the development of national 
policies and procedures to address areas raised by 
the report.
The Oncology Medication Safety Review revealed 
that approximately half of the 26 hospitals involved 
in providing chemotherapy services had a written 
patient consent process in place. In 2013, NCCP 
developed a national consent process and 
template consent form for systemic therapy. All 
hospitals are required to include the minimum 
parameters set out in the NCCP template into their 
local consent processes.
Technology Review Committee 
In 2011 the NCCP established a Technology 
Review Committee which is responsible for 
reviewing proposals received from industry or 
expert groups in Ireland for funding of new drugs, 
or expanded indications for existing drugs or 
related predictive laboratory tests. The Committee 
incorporates the consideration of clinical benefit, 
pharmacoeconomic evaluation from the National 
Centre for Pharmacoeconomics, value for money 
and National Clinical Practice Guidelines in its 
review processes. 
The committee comprises nominees from the 
Irish Society of Medical Oncologists (ISMO), 
the Irish Haematology Society (IHS), HIQA, 
the National Centre for Pharmacoeconomics 
(NCPE), a pathologist, a public health specialist 
and pharmacy expertise. The committee reports 
to the Director of the National Cancer Control 
Programme and makes recommendations on the 
priority for consideration or implementation of 
a new treatment or test. The recommendations 
are based on the degree of clinical effectiveness, 
the acute and chronic toxicity and the cost 
effectiveness of the proposed technology. 
A positive recommendation from the Technology 
Review Committee is brought to the HSE 
Drugs Committee. HSE/Department of Health 
management makes the final decision for funding 
on all new drugs and technologies.
8 www.hse.ie/nccponcsafetyreview
9 HIQA. National Standards for Safer Better Healthcare. 2012.
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Since 2012, 11 new cancer drugs and one 
diagnostic	test	(OncotypeDX)	have	been	
recommended for approval for funding in 
Ireland through this process. These drugs are 
Abiraterone (Zygiga®), Axitinib (Inlyta®), Bosutinib 
(Bosulif®), Cabazitaxel (Jevtana®), Decitabine 
(Dacogen®), Eribulin (Halaven®), Ipilimumab 
(Yervoy®), Mifamurtide (Mepact®), Ruxolitinib 
(Jakavi®) Pertuzumab (Perjeta®) and Vemurafenib 
(Zelboraf®). Updates on the list of drugs approved 
are available at www.hse.ie/nccpdrugprogramme. 
NCCP is fully engaged with the National Centre 
for Pharmacoeconomics (NCPE) and the HSE 
Corporate Pharmaceutical Unit (CPU) on rapid 
reviews, health technology assessments (HTAs) 
and company price negotiations. NCCP is also 
engaged in the horizon scanning process with drug 
companies in relation to expected new cancer 
drugs.
Oncology Drugs Management System
The demand for the introduction of new cancer 
drugs is growing internationally and Ireland is no 
different. These drugs are expensive and their 
introduction presents a particular challenge during 
difficult budgetary circumstances. Several new 
cancer drugs have been introduced in Ireland and 
their effectiveness will be reviewed as sufficient 
data becomes available.
The HSE has put a robust assessment process 
in place for new medicines, including cancer 
medicines, through the HSE Drugs Committee. The 
intention of this process is to ensure that the HSE 
can provide access to as many new and existing 
medicines as possible, at sustainable prices and 
from within the resources available. 
As each new drug is approved by the HSE Drugs 
Committee, a protocol is developed and made 
available to ensure standardisation in the use of the 
drug.
In order to provide a mechanism for reimbursement 
of costs associated with newly approved cancer 
drugs, the NCCP collaborated with the Primary 
Care Reimbursement Service (PCRS) to develop the 
Oncology Drug Management System (ODMS). This 
system consists of a web portal which is accessible 
by approved users in the hospitals involved in 
providing chemotherapy services. To date (July 
2014), this system relates to reimbursement 
for six newly approved high-cost cancer drugs 
delivered by injection in hospital settings, namely, 
Cabazitaxel (Jevtana®), Decitabine (Dacogen®), 
Eribulin (Halaven®), Ipilimumab (Yervoy®), 
Mifamurtide (Mepact®) and Pertuzumab (Perjeta®).
Hospitals are required to input data into the 
Oncology Drug Management System to claim 
reimbursement from the NCCP for approved drugs. 
Use of the drugs must be in line with the nationally 
agreed protocol for the drug. The process of 
reimbursement for new cancer drugs facilitates 
the implementation of the Government’s policy on 
money following the patient.
The information provided on the use of new drugs 
will allow the NCCP to audit the use of these 
drugs in line with protocols and to assess their 
effectiveness over time and it will allow for research 
into patient outcomes and cost benefits realisation.
The NCCP maintains an oversight role, primarily to 
monitor the rate of growth and spending on listed 
drugs in addition to monitoring compliance with 
the approved indications. The collection of data 
through this system also provides for audits to be 
carried out to ensure quality and adherence to 
protocols. 
The NCCP is currently working on an IT solution 
which will allow for the direct extract of data from 
hospital systems, without the need for manual 
entry. This work is ongoing.
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Funding for growth in cancer drugs
Many patients receive cancer drugs with curative 
intent. In situations where a patient’s cancer is 
not considered curable, it is treated as a chronic 
disease, with patients often remaining on ongoing 
treatment with cancer drugs. Advances in new 
technologies are producing targeted therapies for 
specific cancers and the number of drugs being 
approved for use is growing steadily.
As the demand for cancer drug treatment grows, 
increasing pressure is being placed on hospitals to 
meet this demand. Hospital based cancer drugs 
account for approximately 50% of overall cancer 
drug expenditure. The cost of hospital cancer 
drugs has been rising significantly in recent years. 
This is expected to continue to increase along with 
complexity of chemotherapy provision due to the 
following factors:
•	 Predicted	increase	in	cancer	incidence	due	to	
population growth and ageing
•	 Steady	improvements	in	treatment	outcome
•	 Acceleration	in	the	rate	of	introduction	of	new	
drugs
•	 More	patients	being	treated	closer	to	home
National Medical Oncology Clinical 
Information System
The 2006 National Cancer Strategy recommended 
the development of information systems 
and information technology to support the 
management and delivery of cancer services. 
In late 2013, NCCP established a steering group 
to develop a business case for a national medical 
oncology clinical information system. The objective 
of the steering group is to develop a framework 
for the procurement and implementation of a 
Medical Oncology Clinical Information System 
(MOCIS) for the optimal and safe delivery of 
systemic cancer treatment, including e-prescribing 
and e-administration of chemotherapy, for the 
treatment of cancer, in publicly funded hospitals. 
Diagnostic molecular Testing
Increasingly, medicines are being developed which 
are targeted towards specific patient groups and 
their cancer type. Suitability for these medicines 
necessitates a range of molecular testing to 
identify those patients likely to respond. Numerous 
molecular biology findings have potential 
therapeutic impact and are potential contributors 
to changes in clinical practice. Some mutations 
Figure 8.1: Cost of Medicines Used in the Treatment of Cancer in Ireland 2009 - 2013
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have been shown to predict dramatic responses 
to certain treatments. In contrast other mutations 
confer a negative effect. 
Prior to 2012, many of the newer molecular 
tests (e.g. KRAS, EGFR) were undertaken in the 
UK funded by the pharmaceutical industry. The 
pharma companies subsequently provided start up 
funding to three Irish laboratories to enable them 
to undertake testing locally. The support funding 
was withdrawn once testing became established 
and the funding requirements have since been 
transferred to the HSE/NCCP. 
The Faculty of Pathology, at the request of the 
NCCP, developed guidelines for predictive cancer 
molecular diagnostic services in Ireland in 2011. 
The guidelines refer to laboratory accreditation, 
participation in molecular QA programmes, 
key performance indicators for test quality and 
reporting, minimum volume requirements and cost 
effectiveness/value for money. 
The priority for the NCCP is to deliver a quality 
assured service of high volume and technical 
expertise which provides value for money and 
meets demands. There are considerable economic 
and quality indications to support centralisation 
of testing in one (or no more than two centres). 
Given the potential cost implication to the 
NCCP, it is critical that there is minimal to no 
redundancy of expertise or infrastructure across 
multiple laboratories. The NCCP is now funding 
two laboratories (RCSI/Beaumont Hospital and St. 
James’s Hospital) to undertake public RAS, EGFR, 
BRAF and ALK cancer molecular testing nationally. 
University College Hospital Galway has also 
recently commenced a molecular testing service 
which is funded locally. 
The NCCP is currently in consultation with the 
Faculty of Pathology to develop a sustainable plan 
for molecular testing. The Faculty has established a 
committee which will provide guidance and advice 
to the HSE in relation to molecular testing; this 
work is expected to be completed in the autumn of 
2014. 
Cytogenetics testing
A national cytogenetics service is available in 
Ireland provided by the National Centre for 
Medical Genetics. As a result of funding and 
resource limitations many samples are sent to the 
UK for testing, often using the hospital’s internal 
funding. Discussions are ongoing with the Irish 
Haematology Society to determine how best to 
identify and progress requirements for cytogenetics 
testing. Further information on cytogenetics 
activity, challenges and updates is available at 
http://www.genetics.ie/documents/5-year-NCMG-
report-2007-2011.pdf. 
Key performance indicators
A suite of KPIs in medical oncology and haemato-
oncology were developed by clinicians to monitor 
access to, and quality of, services and to address 
areas such as waiting time for consultation and 
treatment, attendance at MDMs and triple 
signature of prescriptions. 
The first national KPI was introduced in 2012 across 
the 25 adult acute hospitals providing cancer 
treatment and addressed a key service access area 
relating to the waiting time for receipt of treatment:
“For patients receiving their first cycle of 
intravenous systemic therapy in the day ward 
setting, the timeline between the date of receipt 
of the finalised treatment plan in the day ward and 
the administration of the first cycle of intravenous 
systemic therapy will not exceed 15 working days.”
All but one hospital have been reporting on this 
KPI regularly and work is continuing to ensure 
100% compliance. Data for 201310 show that 
many hospitals are reaching the target of receipt 
of treatment within 15 days of finalisation of the 
treatment plan. Of the designated cancer centres, 
in five of the six centres that reported, 89%-
100% of patients received treatment within the 
target time. Of 15 out of 17 satellite centres that 
reported, between 91% and 100% of patients 
received treatment within the target timeframe.
10 NCCP Cancer Intelligence, December 2013.
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Table 8.1: KPI for Time to Treatment - 2013 Data
Year to date Average number of patients receiving 
first dose of new systemic therapy 
regimen in the day ward setting every 
month*
% commenced treatment within 
target timeframe
Beaumont Hospital No data received
Mater Hospital 26.1 90%
St. Vincent’s Hospital No data received
St. James’s Hospital 53.2 100%
Cork University Hospital 32.1 68%
Limerick University 
Hospital
27.8 89%
Waterford Regional 
Hospital
18.4 94%
Galway University Hospital 34.5 87%
Connolly Hospital No data received
St. Luke’s Rathgar 19.4 100%
Tallaght Hospital 24.4 100%
OLLH Drogheda 20.0 91%
Cavan General Hospital 7.0 98%
Naas Hospital 3.6 98%
Tullamore Hospital 19.2 97%
St. Luke’s Kilkenny 9.0 92%
South Tipperary Hospital 7.2 94%
Wexford General Hospital 4.7 80%
Mercy Hospital 14.3 64%
South Infirmary Victoria 
Hospital
18.4 100%
Kerry General Hospital 20.2 100%
Sligo General Hospital 18.6 100%
Mayo General Hospital 19.3 93%
Portiuncula Hospital 7.7 86%
Letterkenny General 
Hospital
16.3 Insufficient data
Source: NCCP Cancer Intelligence, May 2014.
*Note: These data relate only to patients receiving their first dose of a new treatment regimen in the day 
ward. NCCP does not collect key performance data on all chemotherapy administrations. 
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A pilot project is currently underway in relation 
to the implementation of the remaining KPIs in 
the agreed suite. Work is underway to develop a 
solution which would minimise additional manual 
collection of data. Implementation of this approach 
will be contingent on the outcome of the pilot and 
IT developments.
Information & Communications 
As the medical oncology and haemato-oncology 
programmes have developed, every effort has 
been made to make information available to all 
relevant stakeholders in a timely and accessible 
fashion. Our approach includes:
•	 Regular	updates,	through	the	National	
Director, to HSE management and leadership.
•	 Regular	updates	to	hospital	CEOs	/	
management on drugs, programmes and 
initiatives.
•	 Regularly	updated	sections	on	the	NCCP	
website for patients/public and health 
professionals.
•	 Appointment	of	hospital	liaison	people	for	
specific projects, to ensure direct links with 
NCCP.
•	 A	national	annual	multidisciplinary	medical	
oncology and haemato-oncology meeting to 
discuss areas of strategic development.
•	 Informal	links	with	clinicians,	oncology	nurses	
and pharmacists on the range of activities 
within the medical oncology and haemato-
oncology programmes.
Clinical Trials
Cancer clinical trials are essential for continued 
progress towards even more effective treatments 
and care for patients with cancer. Trials often 
involve local collaboration (with other academic 
groups or hospitals) or national/international 
collaboration (with research organisations or 
biotech/pharmaceutical industry). In 2013, more 
than 1,600 patients were on cancer clinical trials 
in Ireland11. Clinical trial studies are run by a team 
of consultants (medical oncology, haematology, 
radiation oncology, surgery, paediatric oncology 
etc.), supported by clinical research nurses and 
pharmacists and others where feasible (e.g. clinical 
research radiographers, data managers, clinical 
pharmacology, clinical trials radiology service and 
administrative staff). 
NCCP strongly supports the provision of clinical 
trials in Irish public hospitals. Clinical trial activity 
is not affected by NCCP funding streams. The 
lack of data management staff has been raised 
by hospitals as a significant barrier to progressing 
clinical trials. 
Workforce planning
Cancer services are provided by a range of 
health professionals who work within a climate 
of increasing patient numbers and treatment 
complexities and decreasing resources. The 
health professionals who provide cancer services 
are highly trained and qualified and this level of 
training has a lead-in time of several years. The lack 
of a multidisciplinary workforce planning model 
and the inability of the current funding system to 
allow for meaningful multi-year workforce planning 
make the process of planning the workforce 
requirements extremely challenging. 
11 ICORG: All-Ireland Cooperative Oncology Research Group. www.icorg.ie. Accessed March 11th 2014.
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Consultant Posts
Since 2007, when the National Cancer Control 
Programme was established, nine additional 
consultant medical oncologist posts have been 
approved, in addition to five replacement posts. 
The NCCP provides advice on the structure of 
these posts and in several cases, the posts include 
a designated contractual commitment to NCCP. 
In the same period, twelve additional consultant 
haematology posts have been approved 
(although not all of these have a significant cancer 
component), in addition to 10 replacement posts. 
In the case of any posts which have a considerable 
cancer commitment, NCCP provides advice on the 
structuring of the posts.
While the number of consultant posts has 
increased, Ireland compares poorly against 
international norms for consultant staffing in 
medical oncology and haematology.12 Based 
on international staffing levels, it is suggested 
that 60-80 consultant medical oncologists and 
approximately 75 consultant haematologists would 
be required13. There are currently 34 medical 
oncology and 58 consultant haematology posts in 
publicly funded hospitals in Ireland. 
There remain several areas of particular concern 
in terms of consultant staffing. In medical 
oncology, there is one single-handed service, 
which is not recommended in terms of patient 
safety or workload for the consultant involved. 
In haematology, there are a number of single-
handed consultant services. Additionally, there 
are a number of larger services which are under 
considerable pressure owing to significantly 
increased workload. In some cases, this situation is 
heightened where delays have been experienced 
in replacing consultants who have retired or 
resigned from post.
On a number of occasions the NCCP has 
repeatedly sought funding and approval for the 
appointment of additional consultant oncology 
posts in its annual Service Plan submissions. 
Current pressures are in the Midlands, St. James’s / 
Tallaght, Cork, Galway and the Southeast. To date, 
these requests have not been funded.
A higher specialist training programme in medical 
oncology commenced around the time that the 
2006 National Cancer Strategy was published, 
producing a pipeline for specialists in medical 
oncology to contribute to the growing role of the 
specialty in the treatment of cancer. However, 
some hospitals have reported difficulties in 
recruiting to permanent consultant posts, despite 
a significant number of specialists emerging 
each year from the State-funded higher specialist 
training programmes. Each year, 2-4 medical 
oncology specialists complete training, along with 
approximately 5 specialists in haematology. 
At the request of the HSE’s Medical Education & 
Training Unit, the NCCP made a submission in late 
2013 in relation to expected training requirements 
in cancer-related specialties, including medical 
oncology and haemato-oncology. This submission 
highlighted the growing pressures on existing 
services and staffing levels and advocated for an 
increase in consultant posts in medical oncology 
and haematology.
Workforce requirements for nursing, pharmacy, 
allied health professionals, data management and 
clinical trials staff are handled directly by hospitals 
but NCCP provides advice on these areas, as 
appropriate.
12 (Unpublished) Internal NCCP working document on medical oncology manpower planning, Dr. Maccon Keane
13 (Unpublished) NCCP Submission to HSE Medical Education & Training Unit, November 2013.
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Oncology Nursing 
There have been many positive developments in 
oncology nursing in Ireland over the past decade 
most notably the introduction of specialist roles, 
Clinical Nurse Specialist and Advanced Nurse 
Practitioners, as well as initiatives such as nurse 
led clinics and nurse prescribing all of which have 
enhanced patient care. 
The NCCP and the HSE Office of the Director 
of Nursing and Midwifery Services (ONMSD) 
developed a partnership to identify and advise 
on priorities for cancer nursing nationally. This 
resulted in the establishment of the Strategic 
Nursing Reference Group in 2008 which developed 
a Strategy and Educational Framework for Nurses 
Caring for People with Cancer in Ireland. The 2006 
National Cancer Strategy prioritised nineteen 
recommendations under the themes of patient 
centred cancer care, leadership in cancer nursing, 
cancer education, knowledge skills and experience 
of the nurse delivering evidence based practice 
and cancer research.
The education framework has been prioritised 
which will enable all nurses (generalist and 
specialist) to participate in cancer control. It will 
ensure the professional development of nurses 
in cancer control is consistent with the national 
framework for the profession and cancer care. The 
role of nurses and the competencies they require 
have been defined to meet the objectives of the 
2006 National Cancer Strategy. 
The 2006 National Cancer Strategy and 
Educational Framework will facilitate and guide 
the development of new roles, multidisciplinary 
working and will positively impact on the quality 
and safety of care delivered by nurses to patients 
and their carers in Ireland.
The introduction of defined nursing competencies 
and the introduction of the cancer module at 
undergraduate level will better prepare nurses 
to meet the needs of their patients. Further 
information is available in the Community oncology 
Section 6 of this report.
Achievements
•	 Development	of	23	indication	specific	cancer	
drug protocols since 2012, which are available 
on the NCCP website, at www.hse.ie/
nccpchemoprotocols. Several more protocols 
are in development.
•	 Completion	of	the	oncology	drug	
medication safety review, development 
of an implementation action plan and 
commencement of implementation of the 
recommendations.
•	 Introduction	of	a	national	patient	consent	
process for systemic therapy.
•	 Implementation	of	the	oncology	drugs	
management system for six drugs (to date) 
which were newly approved for funding. 
Reimbursement of costs for these drugs in 
conjunction with the PCRS.
•	 Implementation	of	the	“Money	Follows	
the Patient” model of funding utilising the 
Oncology Drug Management System.
•	 Introduction	of	national	patient	information	
for collection of data for the oncology drugs 
management programme.
•	 The	completion	of	a	baseline	survey	of	
current haemato-oncology services in Ireland.
•	 First	annual	multidisciplinary	medical	
oncology & haemato-oncology meeting held 
in early 2014.
•	 The	implementation	of	a	national	key	
performance indicator for medical oncology 
and haemato-oncology, relating to the time 
from approval of the patient’s treatment 
plan to receipt of treatment and a reported 
compliance of 90% to 100% for most 
hospitals. Additional KPIs are currently in pilot 
stage.
•	 Recognition	by	the	Department	of	Social	
Protection of the cancer drugs management 
programme for the collection of the PPSN.
•	 Recognition	of	the	NCCP	as	a	health	
information resource by HIQA.
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Strengths
•	 Strong	support	amongst	enthusiastic	and	
committed stakeholders for the work of the 
programmes, particularly clinicians, oncology 
nurses and hospital management.
•	 Equitable	provision	of	services	and	funding	of	
new drugs and growth in drug costs.
Challenges
•	 Demographics	–	the	ageing	population	will	
increase the incidence of cancer. The number 
of newly diagnosed cancers is increasing 
by 4.5% annually and the National Cancer 
Registry estimate that new cases of cancer 
will increase by 84% for females and 104% 
for males by 2040. Most of these patients will 
require treatment with chemotherapy.
•	 Lack	of	IT	and	data	management	systems	to	
support optimal delivery of care and planning 
of services.
•	 Uncertainty	regarding	availability	of	ongoing	
funding for cancer drugs and inability to plan 
services accordingly.
•	 Development	and	approval	of	a	business	
case for the introduction of a national medical 
oncology clinical information system.
•	 The	impact	of	the	HSE	recruitment	
moratorium on all staff involved in the 
provision of cancer services, including 
medical, nursing, pharmacy and data 
collection.
•	 Lack	of	multi-annual	multidisciplinary	
workforce planning to address the 
burgeoning growth in cancer incidence. 
•	 National	coordinated	and	resourced	approach	
to cytogenetics testing.
•	 The	rapid	evolution	of	personalised	medicine	
and its impact on resources.
Opportunities
•	 Implementation	of	a	money	follows	the	
patient approach.
•	 Alignment	of	medical	oncology	and	haemato-
oncology programmes to a commissioning of 
services approach.
•	 Legislative	developments	–	Health	Identifiers	
Bill and Health Information Bill.
•	 Clinical	review	of	funded	cancer	drugs	and	
audit of cancer drug use and spending.
•	 Standardisation	of	haemato-oncology	MDMs.
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9Community Oncology 
Programme
Introduction
The Community Oncology programme was set up 
in 2008 with the overall aim of supporting primary 
care professionals in the provision of cancer 
services with better integration of care. It set out to 
address the recommendations of the 2006 National 
Cancer Strategy. In this regard it has built solid 
relationships with both statutory and voluntary 
bodies and had many successes in relation to:
•	 Developing	evidence	based	pathways	of	care	
for common cancers in collaboration with the 
Irish College of General Practitioners (ICGP) 
and specialist services
•	 Building	capacity	and	enhancing	knowledge	
of cancer among health professionals who 
work in community settings by developing 
specific training programmes for doctors, 
nurses and allied health professionals
•	 Embarking	on	innovative	technological	
initiatives e.g. electronic cancer referral, 
e-learning and an App for patients
•	 Implementing	cancer	prevention	initiatives	
especially in relation to smoking cessation
•	 Commencing	a	survivorship	care	programme	
to support patients, families and health 
professionals 
•	 Providing	evidence	based	information	for	the	
public and health professionals
In this chapter, we will present the key 
recommendations from the 2006 National 
Cancer Strategy and briefly outline the ways in 
which the Community Oncology programme has 
addressed these recommendations. Supplementary 
information on the community oncology 
programme is available in a separate report. 
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The NCCP Community Oncology Division 
collaborates with the HSE Directorates, in particular 
Health and Wellbeing (and its predecessor the 
HSE Population Health Division of the HSE), on 
a number of cancer prevention initiatives. While 
the focus involves a joint approach to lifestyle risk 
factors that are common to many chronic diseases, 
smoking cessation has been a priority. This has 
included work programmes with the Office of 
Tobacco Control and the HSE Tobacco Control 
Implementation Framework group on:
•	 Training	of	health	personnel	in	Brief	
Interventions for smoking cessation
•	 E-learning	in	smoking	cessation	for	GPs	and	
Allied Health Professionals
•	 Development	of	smoking	cessation	advice	for	
patients e.g. pre-surgery and after a diagnosis 
of cancer
•	 Research	on	the	impact	of	brief	interventions	
and counselling on quit rates
•	 Development	of	a	national	pharmacotherapy	
smoking cessation algorithm
No. 2  The recommendations of the review of 
the National Health Promotion Strategy 
should be implemented across all 
sectors. 
No. 3 Compliance with all provisions of the 
Public Health (Tobacco) Acts, 2002 and 
2004 should be monitored.
No. 4  Excise duty on cigarettes should be 
substantially increased each year above 
the rate of inflation. To this end the 
National Cancer Forum should produce 
a pre-Budget submission to the Minister 
for Finance each year in order to 
continue advocating for price increases 
on tobacco. 
No. 5  Nicotine replacement therapy should 
be made available free of charge to all 
medical card holders.
No. 6  The Report of the Strategic Task force on 
Alcohol, 2002 should be implemented in 
full.
No. 7  The recommendations of the Report 
of the National Task Force on Obesity, 
2005 should be implemented in full. In 
particular there is a need for measures 
that raise awareness of the links between 
diet and cancer.
No. 8  The health services should work with the 
food industry in order to encourage it to 
produce, market and improve access to 
attractive and healthy options.
No. 9  The recommendations of The Report 
of the National Task Force on Obesity 
in relation to physical activity should be 
implemented in full.
No. 10 In conjunction with campaigns to 
promote safe sun practices and to 
reduce exposure to ultraviolet radiation, 
regulation of sun bed use, including 
restriction to use by adults only should 
be put in place. 
No. 11  The public should be made aware that 
radon measurements can be undertaken 
by the Radiological Protection Institute of 
Ireland. Consideration should be given to 
providing financial support for testing in 
high-radon areas and for any necessary 
remedial work, on a means tested basis. 
No. 12  The HSE should put in place 
arrangements to monitor inequalities in 
cancer risks, cancer occurrence, cancer 
services and cancer out comes. 
Cancer Prevention 
The 2006 National Cancer Strategy had 11 recommendations related to cancer prevention:
118Report on the implementation of ‘A Strategy for Cancer Control in Ireland 2006’
The appointment of a part-time Health Promotion 
Officer has also facilitated NCCP involvement in 
health promotion initiatives including: 
•	 Training	of	nursing	personnel	on	lifestyle	
measures for cancer prevention, including the 
role of motivational interviewing techniques
•	 Collaboration	with	HSE	led	initiatives	on	
obesity, physical activity, alcohol and nutrition
•	 Training	supports	for	community	pharmacists	
in relation to cancer prevention 
•	 Submission	of	a	Position	Paper	to	the	
Department of Health on the evidence of the 
risks of sunbeds, which contributed to the 
introduction of legislation in 2014
Information on cancer prevention has been 
developed for patients and the public in leaflet, 
wallet card and electronic form. These have been 
widely distributed in a number of healthcare 
settings and during NCCP educational courses. 
They are available to download from the NCCP 
website and include: 
•	 ABCs	for	being	cancer	aware
•	 Quit	before	your	surgery	and	get	better	faster
•	 Smoking	cessation	after	a	cancer	diagnosis
•	 Testicular	cancer	awareness
Additional lifestyle advice is provided on the NCCP 
website.
The NCCP has undertaken a number of joint 
initiatives with the wider health sector and 
academic bodies. The role of the Community 
Oncology programme includes advocating for 
disease prevention, developing prevention 
strategies and implementing cancer prevention 
initiatives. We have collaborated with the Irish 
College of General Practitioners (ICGP), Royal 
College of Physicians (RCPI), Royal College of 
Surgeons (RCSI), Irish Cancer Society (ICS) and 
other cancer charities. Specific outputs in relation 
to cancer prevention include the RCPI policy on 
alcohol, the RCPI policy on obesity, collaboration 
with the ICS on skin cancer prevention and the 
ICGP on smoking cessation e-learning.
Community oncology has acted as a resource 
in relation to expert advice on the aetiology of 
various cancers. This has included provision of 
advice on environmental risks (real or perceived), 
e.g. water fluoridation, responding to consultations 
(e.g. the National Radon Strategy) and contributing 
to the broader disease prevention efforts. 
The national approach to disease prevention, 
particularly in relation to lifestyle risk factors, is the 
Healthy Ireland strategy.14 
Supporting GPs and Primary Care 
The 2006 National Cancer Strategy 
recommended that:
No. 24 The HSE should develop care pathways 
for cancer care to link primary care 
services, hospital services and other 
relevant services.
No. 25  Improved cancer information services 
should be available to primary care.
No. 26 The HSE should develop programmes 
that support primary care professionals in 
the provision of cancer services.
No. 47 General practitioners should have 
comprehensive information that enables 
informed referral and other management 
decisions.
No. 48 Information systems and information 
technology should be developed by the 
HSE to support the management and 
delivery of cancer services.
In 2009, the NCCP appointed a GP advisor to 
develop links between Community Oncology and 
the Irish College of General Practitioners (ICGP) 
and to identify new means of collaboration and 
support for GP colleagues. A large component of 
this work is collaboration on GP guidelines and 
referral pathways. The GP advisor also plays an 
essential role in the implementation of all NCCP 
guidance – linking with GP study days hosted by 
hospitals, attending GP Continuing Medication 
Education (CME) groups and conferences, while 
also feeding back concerns or suggestions from 
14 Healthy Ireland. A Framework for Improved Health and Wellbeing 2013-2025 http://www.hse.ie/eng/health/hl/hi/
119 Report on the implementation of ‘A Strategy for Cancer Control in Ireland 2006’
the GP community to the NCCP. Novel ways of 
providing education and information for GPs 
include e-learning, which has been used to 
develop modules on breast disease and breast 
cancer, prostate cancer and smoking cessation, in 
conjunction with the ICGP. 
One of the key aims of the National Cancer 
Strategy is early referral of patients with clinical 
findings suggestive of cancer. The need for clear 
recommendations on the investigation and referral 
of patients presenting to their GP with possible 
signs of cancer has been well recognised.15 The 
Community Oncology programme has to date 
developed GP referral guidelines for suspected 
breast (2009), lung (2010), prostate cancer (2011) 
melanoma (2011) and ovary (2014 - expected) 
cancers. These guidelines take account of existing 
published evidence-based referral guidelines and 
are applicable to the Irish healthcare setting and 
service configuration. A GP referral tool-kit is being 
developed to assist GPs in recognising urgent 
clinical features of less common cancers, e.g. head 
and neck. 
While the primary focus is on when to urgently refer 
a patient, information is also included on actions 
that should appropriately be taken in primary care 
(e.g.	referral	for	an	urgent	Chest	X	Ray)	or	indeed,	
practices that should be discouraged in primary 
care (e.g. aspiration of a breast lump, excision 
of a pigmented lesion). A standardised referral 
form was also developed in tandem with each 
guideline. The forms were designed to actively 
seek the information required for triage, plus other 
clinical information of relevance if patients were to 
undergo certain investigations on the day of clinic 
attendance, e.g. anticoagulant use. In addition, the 
dependencies of other HSE services are addressed 
before a guideline can be released. For example, 
an assessment of CA125 and ultrasound services 
has been carried out prior to the implementation of 
the ovarian cancer referral guideline. 
The process of development of the guidelines and 
forms is outlined in detail in the supplementary 
information on the community oncology 
programme. The development and consultation 
process provided an opportunity to make links 
with both primary and secondary care and 
opened communication as to the challenges 
faced in different parts of the service. Completed 
guidelines and forms have been circulated to 
each GP nationally and copies are available on 
the NCCP website, to which the ICGP, Healthlink 
and other websites can direct GPs. The agreed 
national referral forms for breast, lung, prostate 
and melanoma have also been developed 
into electronic formats, in collaboration with 
the General Practice Information Technology (GPIT 
group) and HSE ICT Directorate. 
Use of Information Technology
The 2006 National Cancer Strategy included 
recommendations that:
No. 26 The HSE should develop programmes 
that support primary care professionals in 
the provision of cancer services.
No. 47 General practitioners should have 
comprehensive information that enables 
informed referral and other management 
decisions.
No. 48 Information systems and information 
technology should be developed by the 
HSE to support the management and 
delivery of cancer services.
A number of innovative community oncology 
projects have harnessed new capabilities in 
information technology, for the betterment of 
cancer services. 
An excellent example of this is the 
development of an electronic referral system 
for GPs.  This award-winning project (2012 
Winners: Ireland eGovernment Awards http://
irishegovernmentawards.ie/) has taken agreed 
national standardised referral forms for breast, 
lung, prostate cancer and melanoma and 
developed electronic versions in association with 
Healthlink, an electronic messaging system, and 
the four ICGP accredited software systems. 
15 H Daly, C Collins Barriers to Early Diagnosis of Cancer in Primary Care: A Needs Assessment of GPs Ir Med J. 2007 Nov-
Dec;100(10):624-6
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The NCCP Electronic Cancer Referral Project 
commenced in 2008, with the objective of 
developing an online system for GPs to refer 
patients directly to the cancer centre. This ensures 
rapid referral of patients with suspected cancer in 
a secure manner. Once the GP sends an electronic 
cancer referral, an immediate acknowledgment 
is given. In addition the cancer teams send a 
response to the GP, with the date of the patient’s 
appointment within five working days. It builds on 
existing technologies already deployed in GPs’ 
surgeries and the wider Health Service, namely 
the Healthlink infrastructure (www.healthlink.ie ) 
and accredited GP practice management systems. 
Details of the system development are included 
in the supplementary information on community 
oncology (TD 17).
Referrals are currently available as an online referral 
form (Healthlink Online) from the GP directly to 
the cancer teams, or an integrated referral form 
for ICGP accredited GP practice management 
systems. which also goes directly to the cancer 
teams. Work has commenced on the development 
of an integrated web services browser, which 
will facilitate the creation of additional electronic 
cancer referrals forms in a more seamless manner, 
via the National General Electronic Referral Project. 
The NCCP electronic referral model has been 
adopted to develop a platform for a National 
General Electronic Referral Form. 
The number of electronic cancer referrals (Breast, 
Prostate and Lung Cancer) is increasing each year, 
with 2,070 referrals in 2010 (first year of go live), 
4,360 electronic referrals in 2011.  In 2013 there 
were 13,361 electronic referrals which was a 44% 
increase in referrals from 2012. Currently 35% of all 
breast, prostate and lung cancer referrals are sent 
electronically nationwide. Melanoma electronic 
referral commenced as a pilot exercise in 2014 and 
will be available nationally by the end of the year.
Demonstration of effectiveness and success:   
The number of electronic cancer referrals (Breast, 
Prostate and Lung Cancer) has increased by 795% 
for the five years 2010 to 2014.  Table 9.1 provides 
further details.
Table 9.1: Electronic Cancer Referrals (Breast, 
Prostate and Lung – with the inclusion of 
Pigmented Lesion for 2014)
Year Number of Electronic Referrals
2010 2,070
2011 4,360
2012 9,303
2013 13,381
2014* 16,453
Data Source: National Healthlink Project, NCCP
The NCCP Electronic Cancer Referral Project is 
a good example of how different agencies can 
work together to pool their resources to achieve 
innovation and better quality healthcare.
Another innovative use of technology has been 
the development of a smartphone App, with 
information for patients on breast pain and an 
interactive patient diary.  While breast pain is 
not a symptom concerning for breast cancer, 
it was recognised as a major cause for referral 
to symptomatic breast clinics (14.5% of all GP 
referrals in a one month study in 2011) and a 
source of anxiety for patients.  The information 
and completed diary are designed to support GPs 
in their reassurance of young women with benign 
bilateral cyclical breast pain. Additional means 
of harnessing technology have included the use 
of e-learning to improve the reach of existing 
educational programmes (e.g. with the ICGP) and 
of the website as an information resource for health 
care professionals, patients and the public.
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Nursing Developments 
The 2006 National Cancer Strategy 
recommended that:
No. 25 Improved cancer information services 
should be available to primary care.
No. 26 The HSE should develop programmes 
that support primary care professionals in 
the provision of cancer services.
No. 50 The HSE should develop a National 
Cancer Workforce Plan designed to fully 
implement national cancer policy.[The 
2006 National Cancer Strategy noted the 
need for “a focus on the development of 
cancer nursing roles that reflects recent 
successful developments in oncology 
nursing and maximises the potential 
role that nurses can play in all aspects of 
cancer care”.]
‘A Strategy and Educational Framework for Nurses 
Caring for People with Cancer in Ireland’16 was 
launched in May 2012 and is for all nurses caring 
for people with cancer in Ireland. It was developed 
in conjunction with the Office of the Nursing 
and Midwifery Services Director (ONMSD) and 
following comprehensive consultation with nurses 
in Ireland. It aims to guide and support nurses in 
the provision of quality cancer care to people with 
cancer in Ireland, specifically by:
•	 Enabling	all	nurses	to	participate	in	cancer	
control whether specialist or generalist and 
irrespective of where they work 
•	 Ensuring	the	professional	development	of	
nurses in cancer control is consistent with the 
national framework for the profession and 
cancer care
•	 Defining	the	role	of	nurses	and	the	
competencies they require to meet the 
objectives of the 2006 National Cancer 
Strategy 
•	 Proposing	a	formal	structure	whereby	
nurses who care for people with cancer are 
represented at policy making level and have 
leadership roles that ensure the maximum 
contribution of nursing to evidence based 
cancer care
Its recommendations cover themes of patient 
centred cancer care, leadership in cancer nursing, 
cancer education, skills, knowledge and experience 
of the nurse and delivering evidence based 
practice and cancer nursing research. The 2006 
National Cancer Strategy implementation group 
has overseen the following developments to date:
•	 A	formal	partnership	has	been	established	
between the NCCP and the Office of the 
Nursing and Midwifery Services Director 
(ONMSD)
•	 Three	nurse	education	programmes	have	
been developed to address the needs of 
various nursing groups (further detail below)
•	 There	has	been	collaboration	with	services	
and academic intuitions such as NUIG 
and NMBI (Nursing and Midwifery Board 
of Ireland) in relation to programme 
developments
•	 Approval	of	a	Health	Research	Board	(HRB)	
Nursing Development Research grant 
Future plans include national roll out of the three 
education programmes; development of a nursing 
leadership programme to meet the needs of nurses 
working in cancer care; to continue to promote 
cancer nursing research initiatives and to better 
integrate nursing care between specialist hospital 
oncology services and primary care services.
16  NCCP (2012) A strategy and educational framework for nurses caring for people with Cancer in Ireland http://hdl.
handle.net/10147/233454
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NCCP Cancer Nursing Education 
Programmes
The nursing programmes developed to date to 
meet the educational needs of nurses caring for 
people with cancer in Ireland, in line with the 2012 
strategy are:
•	 Cancer	Education	Programme	for	Registered	
Nurses Working in Primary Care (a two day 
programme)
•	 Education	Programme	for	nurses	working	in	
an inpatient setting (a three day programme) 
•	 Community	Oncology	Nursing	Programme	
(a comprehensive six-month skills based 
programme which has university accreditation) 
1. Cancer Education Programme for 
Registered Nurses Working in Primary Care 
The need for this programme was identified 
following research with nurses who work in the 
primary health care setting, showing they would 
benefit from participating in a short cancer 
programme that incorporated prevention, 
identification of symptoms suggestive of cancer, 
referral pathways, treatment and post acute care. 
Its implementation is supported by the Nursing 
Midwifery Planning Development Units (NMPDU) 
and the Centres of Nurse Midwifery Education 
(CNME). An Bord Altranais (now Nursing and 
Midwifery Board of Ireland, NMBI) approved the 
course as a Category 1 programme.
The programme covers four themes:
•	 Prevention	–	including	motivational	
interviewing and cancer screening 
programmes
•	 Presentation	of	the	patient	in	primary	care,	
guidelines for referral
•	 Treatment	of	common	cancers	–	breast,	lung,	
prostate and skin
•	 Post	acute	care,	survivorship	and	psycho-
oncology
The programme has been delivered in specialist 
cancer centres to almost 700 primary care 
nurses since 2011, using video links to maximise 
participation. The evaluation of the programme has 
been very positive and has also informed a revision 
of the curriculum. An E-learning version of this 
programme is now under development to facilitate 
nurses who cannot attend in person. 
2. Education Programme for Registered 
Nurses Working in an Inpatient Setting
Every nurse at some stage of their career cares for 
patients diagnosed with cancer. This Continuing 
Professional Development (CPD) programme is to 
facilitate nurses who work in acute hospitals, care 
of the elderly units, nursing homes and community 
based hospitals / hospices to enhance their 
knowledge, skills and competence in cancer care. 
The curriculum has been finalised for this three-
day programme and it is due to commence during 
2014. It is proposed to develop it to a Higher 
Education and Training Awards Council (HETAC) 
level 8 and to have it accredited as a category 2 
programme by NMBI. 
3. Community Oncology Nursing Programme 
Traditionally cancer patients who are receiving 
systemic chemotherapy receive all their care in 
an acute cancer unit. This often results in patients 
having to travel long distances to hospital for short 
procedures e.g. disconnection and flushing of 
venous lines. This Community Oncology Nursing 
Programme was developed to facilitate community 
nurses to provide shared nursing care to acute 
oncology patients at home. 
These public health nurses undertake a nursing 
education programme which equips them with 
the required knowledge and skills to safely and 
competently provide care at home, to patients 
undergoing systemic cancer therapy. Theoretical 
and skills based training is delivered over six 
months. The programme commenced in 2010 in 
response to a clinical and patient need. It has been 
evaluated and deemed very successful, resulting 
in substantial hospital avoidance by patients who 
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could receive their care at home. A critical success 
factor was the national and local leadership. 
The project was awarded the UK Quality in 
Care Excellence in Oncology award 2012. The 
Programme has received university accreditation 
and will be delivered in multiple locations around 
the country. 
Survivorship
The 2006 National Cancer Strategy described 
cancer control as “a whole population 
approach to cancer care with a strong emphasis 
on integration and holistic care including 
survivorship, support services and palliative care” 
and specifically recommended:
No. 37 The HSE should ensure that access to 
comprehensive psycho-oncology and 
psychosocial support is provided for 
cancer patients and their families in each 
Managed Cancer Control Network.
No. 38 A partnership framework should be 
developed between the HSE and the 
voluntary sector.
No. 39 A code of practice should be developed 
for self-help groups, support groups and 
support centres.
The term “cancer survivor” was used in the 2006 
National Cancer Strategy and the predicted 
growth in cancer survivors was noted, particularly 
in relation to women who have had breast cancer. 
Many of the themes and recommendations of the 
2006 National Cancer Strategy are relevant to 
cancer survivors – e.g. the need for integrated care 
and smooth patient pathways, information needs 
across the spectrum of health care professionals as 
well as for the patient themselves and the need for 
psychological support. Progress has been made in 
terms of long-term follow up of women with breast 
cancer with a policy which addresses information 
needs on keeping well and arrangements for 
ongoing mammography surveillance by hospitals. 
The focus on psycho-oncology needs led to 
research on current availability of services and a 
report on proposed models of care. Following on 
from the publication of the 2006 National Cancer 
Strategy, the Irish Cancer Society established an 
affiliation project and developed a code of practice 
for cancer support services, to which the NCCP 
contributed.17
The complexity of survivors’ needs have been 
better described in recent years, with more 
evidence on long-term side effects and medical, 
psychological and social needs. The NCCP has 
therefore recently adopted a strategic approach 
to cancer survivorship and commenced the 
development of a patient survivorship programme. 
Its aim is to improve the quality of survivorship care 
in Ireland for cancer patients and their families.
The main goal for the NCCP Survivorship 
Programme is to empower patients to achieve their 
best possible health while living with and beyond 
a diagnosis of cancer. This involves providing 
information, guidance and support to survivors 
and families in relation to healthy lifestyle, disease 
prevention and control in order to aim for a good 
quality of life and prolonged survival. 
One of the key priorities of a Survivorship 
Programme is for people with a history of cancer 
to become partners with the health service in 
their post-acute care and to be empowered in this 
regard. 
The development of a Patient Treatment Summary 
and Care Plan is internationally recommended 
and a logical first step towards a sustainable 
Survivorship Programme. 
The NCCP, in collaboration with specialist 
services, GPs and patients has developed a 
Patient Treatment Summary and Care Plan. This 
provides information on the patient’s medical 
history, treatment, specialist providers and ongoing 
disease specific surveillance requirements. In 
addition it highlights the importance of them 
taking charge of their preventive health care, 
how to recognise potential disease recurrence or 
long term complications of disease/treatment. It 
provides links to useful websites e.g. in psycho-
oncology. 
17 The Irish Cancer Society’s code of practice for cancer support services: http://www.cancer.ie/sites/default/files/content-
attachments/ics_support_groups_guidelines_2011.pdf
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This Patient Treatment Summary and Care Plan 
is currently being piloted in one specialist cancer 
centre, prior to national roll-out. 
Meeting the Information Needs of 
Professionals and the Public 
The 2006 National Cancer Strategy 
recommended that: 
•	 Improved	cancer	information	services	should	
be available to primary care.
•	 The	HSE	should	develop	programmes	that	
support primary care professionals in the 
provision of cancer services.
•	 HIQA	should	ensure	that	the	public	has	
access to high-quality up-to-date information 
about all aspects of cancer.
•	 General	practitioners	should	have	
comprehensive information that enables 
informed referral and other management 
decisions.
The Community Oncology Programme has 
developed a suite of information materials for 
health care professionals in the community and 
primary care and to support patients and the 
public. A complete list of materials produced to 
date is provided in the supplementary information 
on community oncology (TD17). The process of 
GP referral guidelines has already been outlined, 
including the emphasis placed on appraising 
current evidence, consultation with all stakeholders 
and supporting implementation. Similarly, the 
community oncology resource booklet has 
been invaluable for those public health nurses 
supporting patients in the community, has won a 
number of awards and been adopted for use in 
other countries.
A similar in-depth process has been applied in 
the development of material for patients or the 
public. At the time of the writing of the 2006 
National Cancer Strategy, it was envisaged that 
this role would be fulfilled by HIQA. Nonetheless, 
the recommendations of the 2006 National 
Cancer Strategy have been followed in terms of 
consultation with voluntary groups and attention 
to detail in ensuring information is “accessible and 
understood by those of different standards and 
cultures”. Members of the team have received 
training by the National Adult Literacy Agency 
(NALA) and materials intended for the public are 
approved by NALA prior to publication. There 
is wide multidisciplinary team input to materials 
that are intended for patients attending a service 
and inclusion of practical information tailored to 
individual hospitals. Voluntary groups are consulted 
in regards to the appropriateness and acceptability 
of material. The patient booklet prepared for those 
attending a rapid access ling clinic appointment 
(Lung Cancer Rapid Access Clinic- what you 
should know) was awarded the Crystal Clear 
Award in 2012, for excellence in plain English 
communication. 
Information materials have also been prepared to 
support cancer prevention and early detection of 
symptoms among the general public. A working 
group was established in 2013 following the 
expressed need by various health professionals 
for resources for use with the general public and 
patients to increase awareness of testicular cancer, 
the early warning signs of cancer in general and 
to convey the benefits of quitting smoking prior to 
cancer treatment and surgery.
•	 Screening	Promotion	Officers	in	the	NCCP	
identified an opportunity to promote 
awareness of the early warning signs of 
cancer with various groups including minority 
ethnic groups. 
•	 Health	Promotion	Officers	in	the	HSE	
expressed a need for resources to use with 
smokers undergoing cancer treatment and 
also undergoing surgery.
•	 Pharmacists	identified	an	opportunity	to	
target young men regarding awareness of 
testicular cancer via their female partners 
attending for contraception. 
Materials for the public are made available in hard 
copy in GP surgeries or pharmacies as appropriate 
and are also accessible on the NCCP website, 
www.cancercontrol.hse.ie. 
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Research & Audit
The 2006 National Cancer Strategy noted that 
“cancer research is an essential component 
in the development, implementation and 
evaluation of a national cancer control 
programme”.
The need for high quality research in all aspects 
of cancer care is a stated aim of the 2006 National 
Cancer Strategy. The National Cancer Forum 
identified research as an essential component in 
the development, implementation and evaluation 
of a National Cancer Control Programme. The 
scope of cancer research includes subjects in which 
Community Oncology can make a contribution. 
This includes areas of epidemiology, prevention, 
audit and health services research. The Community 
Oncology programme recognises the importance 
of research and establishing an evidence base 
for new developments and initiatives. The 
division has health professionals from diverse 
backgrounds including the disciplines of public 
health medicine, general practice, psychology, 
nursing, health promotion, laboratory science and 
health management. This diversity of disciplines 
creates fertile ground for health service research 
and brings a number of perspectives to the work 
we undertake.
Collaboration is an integral part of the work of 
the Community Oncology Division. The division 
actively seeks to be part of networks in the wider 
health service and academic institutions and has 
participated as collaborators as a health service 
partner in large scale and small scale research 
projects that are relevant to cancer control and 
services. The National Cancer Control Programme 
is fortunate to be able to take a national view 
of cancer services, policy and prevention. This 
facilitates the implementation and scaling up 
of any research results that would be beneficial 
to cancer services in Ireland. In developing the 
evidence base, either as a principal investigator or 
as a health service partner, the NCCP can ensure 
that best practice agenda is implemented and 
promoted for cancer services in Ireland.
The NCCP community oncology division also 
collaborates and leads on a number of the work-
streams of the current Ireland-Northern Ireland-
National Cancer Institute Consortium, in cancer 
prevention, nursing and survivorship. 
A comprehensive list of the research and audit 
activities undertaken by community oncology is 
provided in the supplementary information section 
(TD17).
Challenges and Opportunities
The next ten years will see the Community 
Oncology Division strengthen and develop. In 
particular attention will be given to ensuring the 
infra-structure and integrated working relationships 
remain sustainable and focused on meeting patient 
needs. 
The forthcoming challenges include:
•	 The	need	for	great	focus	on	primary	
prevention, particularly in collaboration with 
the Healthy Ireland Strategy, the HSE Health 
and Wellness Directorate and the Chronic 
Disease Programmes, and acknowledging 
the population cancer risk due to the national 
obesity epidemic.
•	 To	make	real	progress	in	preventing	the	highly	
preventable cancers – e.g. through HPV and 
hepatitis B vaccination, and to prevent head 
and neck cancers by reducing smoking and 
alcohol incidence.
•	 Empowering	the	public	to	take	a	role	in	their	
own health and wellbeing, including the 
recognition of early symptoms of cancer.
•	 Ensuring	equitable	access	for	all,	in	particular	
to diagnostic services, while recognising the 
dependencies of NCCP on many other HSE 
services in this regard.
•	 Sustaining	the	existing	good	will	and	
spirit of collaboration, when services feel 
overwhelmed due to the ageing population 
and increasing demand.
•	 Prioritising	the	development	and	
implementation of survivorship initiatives, as 
the cancer survivor population expands.
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10Hereditary Cancer
Programme
The 2006 National Cancer Strategy 
recommended that “A National Cancer 
Genetics Policy should be developed by the 
National Cancer Forum”.  
The 2006 National Cancer Strategy also 
recommended that “The HSE should develop 
specific programmes that promote early 
detection of cancer”. 
Background to Hereditary Cancer 
Services In Ireland
The rapid advances underway in cancer genetics 
were noted in the 2006 National Cancer Strategy, 
with an acknowledgement that “the increasing 
worldwide understanding of the role of genetics 
in the provision of cancer care is leading to 
an increased demand for the development of 
services in the area and presents major medical, 
organisational and financial challenges that need to 
be addressed”. 
Identification of families with hereditary forms 
of common cancers allows better clinical 
management of the affected individuals, and pre-
symptomatic testing of at-risk relatives. Relatives 
found to be at low risk can be reassured and do 
not require ongoing screening, while those found 
to be at high risk can be targeted for increased 
surveillance and prophylactic interventions.
The majority of hereditary cancer cases in Ireland 
are managed directly by the National Centre for 
Medical Genetics (NCMG), which is based in Our 
Lady’s Children’s Hospital, Crumlin (OLCHC). The 
NCMG aims to provide a comprehensive service 
for all patients and families in the Republic of 
Ireland affected by or at risk of a genetic disorder. 
This is a comprehensive service including the 
provision of Clinical Genetics, Cytogenetics and 
Molecular Genetics services. 
The focus of the clinical cancer work of the 
National Centre for Medical Genetics is the 
identification of families with hereditary cancer, 
with the aim of early cancer detection and better 
outcomes for family members at risk, and also the 
reassurance of those found not to be at excess 
genetic risk of cancer. Although the National 
Centre for Medical Genetics provides a national 
service for chromosome analysis of adult and child 
leukaemia, the Centre only carries out molecular 
testing for inherited disorders; it is not involved in 
the analysis of single gene changes in cancer cells 
that may have prognostic or therapeutic relevance 
for the treatment of the individual with cancer. 
Since 1995, the NCMG has provided genetic 
counselling and molecular genetic testing to 
affected and unaffected patients with a family 
history of breast, ovarian or other potentially 
hereditary cancers. A cancer genetics clinic was 
also established in 1998 in St. James’s Hospital 
under the leadership of (the now retired) Prof. Peter 
Daly. 
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Establishment of the Hereditary 
Cancer Programme
There is no comprehensive national policy on 
genetics and genetic testing in Ireland. In response 
to advances in diagnostics and the growing 
demand for services, the NCCP established a 
Hereditary Cancer Programme in collaboration 
with the National Centre for Medical Genetics in 
2012. The aim of the programme is to improve 
access to assessment and genetic testing for those 
patients and their families whose cancer may have 
a hereditary component. The scientific leadership 
is provided by Prof. Andrew Green in the NCMG 
and the programme is designed to build on the 
capacity in NCMG. In line with the standards and 
with the oversight of the NCMG, new dedicated 
hereditary cancer clinics have been established by 
the NCCP in the Mater and St. James’s Hospitals to 
improve access to assessment and genetic testing 
for patients and their families.
The Hereditary Cancer programme primarily 
focuses on hereditary breast, ovarian and bowel 
cancer, but also includes testing for rarer hereditary 
cancer syndromes. The programme formalises the 
relationship between NCCP and NCMG and allows 
for joint planning for a sustainable service and 
oversight of new technology and developments. 
Work progressed to date includes collation 
of hereditary cancer activity data nationally, 
investment in the new hereditary cancer clinics 
in St. James’s and the Mater Hospitals and the 
securing of funding for the laboratory testing 
generated by those clinics. Working groups are 
considering issues related to specific hereditary 
cancers, to agree best practice and management 
pathways and to ensure standardisation of practice 
nationally. Work ongoing includes the agreement 
of criteria for genetic testing among ovarian 
cancer patients and the management of those with 
identified cancer predisposition genes. 
In addition to the above and given the conflicting 
scientific evidence available, the NCCP 
commissioned the Health Information and Quality 
Authority (HIQA) to carry out a health technology 
assessment on breast surveillance among women 
under 50 who are at increased risk, e.g. due to 
family history18. As a result of this, a formalised 
breast surveillance programme is proposed for 
women with an identified genetic mutation, or 
equivalent risk, from the age of 30. A business 
case is currently being developed to progress this 
programme. 
Additional funding has been allocated to provide 
for consultant sessions and nursing staff to support 
clinics in both St James’s and the Mater hospitals 
since 2012. All cancer genetic testing ordered 
from these clinics is also funded by the NCCP. 
Funding to appoint a full-time consultant in cancer 
genetics was sought by the NCCP as part of the 
2014 HSE service planning process but no funding 
was allocated. However, in June 2014 the Director 
General of the HSE agreed to approve a new post 
of national lead for hereditary cancer. Recruitment 
of this new Dublin-based consultant post, which 
will have a clinical and academic component, will 
commence this year. 
Hereditary Cancer Clinics Activity & 
Capacity 
Clinical cancer genetics services are now provided 
in NCMG in Crumlin by two specialists, with a 
team of 2.6 WTE genetic counsellors and 1 WTE 
administrative staff. In St James’s and the Mater 
hospitals in Dublin, two clinics per week are held 
by a medical oncologist/cancer geneticist. The 
NCMG also holds outreach clinics in Cork and 
Galway. 
The NCMG has seen an increase in cancer 
genetic referrals, an increase in the numbers of 
cancer genetics patients seen and an increase in 
hereditary cancer gene testing (see below). From 
a referral rate of 600-700 per annum in the early 
2000s the numbers of cancer genetic referrals 
reached 1,167 in 2011, and 1,283 in 2013, an 
increase of 60%. As a result, the waiting time to 
be seen in the genetics clinic has increased to 12 
months, and the clinical services of the NCMG are 
working at capacity.
18 http://www.hiqa.ie/healthcare/health-technology-assessment/assessments/surveillance-of-women-under-50-with-
increased-risk-of-breast-cancer
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All genetic testing is coordinated by the Molecular 
Genetics laboratory in the National Centre for 
Medical Genetics, whether carried out in house 
or outsourced to the UK. The hereditary cancer 
programme has oversight of clinic and testing 
activity levels. The numbers of tests carried out 
have increased rapidly over recent years (see 
table 10.3 below). The commonest reason for 
testing is for the BRCA1/2 genes, which are 
primarily associated with breast and ovarian 
cancer, followed by HNPCC/Lynch syndrome, 
which predisposes to bowel and other cancers. 
The growth has been seen in both the number 
of cancer patients being tested (undergoing 
‘diagnostic’ testing) and those relatives who are 
being tested for a specific mutation in their family 
(called ‘predictive’ or ‘pre-symptomatic’ testing). 
Data show an overall 73% increase in the number 
of hereditary cancer samples received by the 
NCMG since 2010 (Table 10.3). Essentially all of 
this growth has come from the additional clinical 
activity of the NCCP funded clinics, as clinical 
resources at NCMG do not permit any increase in 
activity.
Table 10.1: NCMG Clinical Activity 2007-2010
Year 2007 2008 2009 2010
Number of appointments (DNA rate) 576 (5.5%) 757 (9.5%) 641 (11%) 724 (6.9%)
Number of patients seen 858 1098 832 985
Source: NCMG, 2014. Note: Referrals not accurately coded as cancer/non-cancer and genetic tests not 
electronically coded before 2011. Therefore these were manually coded by genetic counseling staff. Clinical 
activity affected in 2009/10 due to sick leave.
Table 10.2: NCMG Clinical Activity 2011-2013
Year 2011 2012 2013
Cancer genetic referrals 1167 904 1283
Total appointments (DNA rate) 601 (7.9%) 906 (4.8%) 973 (4.3%)
Total patients seen 811 1226 1,507
Cancer predictive genetic appointments 372 361 538
Diagnostic appointments attended* 187 501 393
Waiting List* 300 345 431
*Source: NCMG, 2014. These figures relate only to the NCMG and do not reflect those who attended the clinics in 
SJH & the Mater which were established in 2012
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Table 10.3: All Cancers – Total Samples since 2010 by Referral Centre
Referral Centre 2010 2011 2012 2013
National Centre for Medical Genetics 864 635 926 830
St James’s Hospital 5 92 340 370
Mater Misericordiae University Hospital 3 3 192 339
Other Hospitals 65 90 109 86
Totals 937 820 1567 1625
Source NCMG 2014
Table 10.4: NCMG Laboratory Activity 2010-2013 – Patients Undergoing BRCA Gene Testing
2010 2011 2012 2013
BRCA Predictive tests 184 173 284 346
BRCA full screen tests 149 115 367 361
Source NCMG 2014; Overall increase since 2010 is 88% for predictive tests and 142% for full screens 
Table 10.5: NCMG Laboratory Activity 2010-2013 – Total Samples* by Disorder
Disease Name 2010 2011 2012 2013
Breast Cancer 651 528 1121 1162
Lynch syndrome 161 144 175 193
Li-Fraumeni Syndrome/p53 gene 7 15 47 83
Phosphatase and Tensin Homolog 26 30 37 41
Tuberous Sclerosis 20 21 33 35
Von-Hippel Lindau 7 9 16 27
Familial Adenomatous Polyposis Coli 25 16 25 22
Multiple Endocrine Neoplasia Type 1 10 8 13 13
MYH polyposis 7 <5 11 12
RET Oncogene (MEN2, FMTC etc.) 14 16 26 8
E Cadherin <5 <5 12 7
Peutz-Jeghers Syndrome <5 5 <5 6
Phaeochromocytoma   24 5
BRAF V600E mutation <5 22 18 <5
Birt-Hogg-Dube Syndrome <5  <5 <5
SDHB Hereditary Paraganglioma (PHMG)   <5 <5
Totals 937 820 1567 1625
Source: NCMG, 2014 * Note: The numbers of samples exceed the number of patients, as multiple tests can be 
carried out per patient
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A far greater number of people undergo an 
assessment of their hereditary risk - in most cases 
requiring attendance at a clinic appointment 
but some may be reassured following remote 
assessment of their family history by questionnaire. 
Again, the number of patients requiring 
assessment at clinic continues to rise, with 1,283 
patients referred directly to NCMG in 2013, 
compared to 600-700 in the mid 2000s (this 
excludes numbers sent directly to the St. James’s 
& Mater Hospital clinics). While this is partly due to 
increased awareness, it also reflects the level of un-
met need over recent years. This is confirmed by 
the high level of pick up of cancer predisposition 
genes among those patients with cancer who 
have diagnostic cancer genetic testing - 14.8% of 
women who have diagnostic breast cancer genetic 
testing are found to have a deleterious BRCA1 or 
BRCA2 mutation.
Hereditary cancer services in Ireland have 
struggled to keep abreast with demands and 
remain considerably under-resourced in terms of 
funding and staffing. Waiting times for an initial 
appointment remain unacceptably high, in NCMG 
in particular, with only about half being seen 
within 6 months. Much of this relates to the need 
for additional genetic counselors and support 
staffing, laboratory staff and resources for genetic 
tests. The additional hereditary cancer clinics in 
St. James’ and the Mater Hospitals are helping to 
meet some of this need but are being run without 
any substantive clinical appointments, which is a 
serious risk in terms of sustainability. Laboratory 
staff numbers at NCMG have decreased over the 
period 2010-2013, while cancer sample numbers 
increased by 73%. This is also unsustainable and 
raises the likelihood of a clinical risk.
Currently the NCMG, in agreement with the NCCP, 
is offering diagnostic breast cancer genetic testing 
to women affected by breast or ovarian cancer, 
who meet high risk criteria. In the UK, revised NICE 
guidelines published in 2013 have recommended a 
significant change in practice, whereby BRCA1 and 
BRCA2 gene testing should be offered to women 
who are at high risk of having a BRCA1/BRCA2 
mutation, regardless of whether they are affected 
by cancer or not. If such a recommendation were 
to be introduced in Ireland, it would require 
significant new investment in clinical and laboratory 
genetic services, to provide for the large number of 
additional women requiring testing.
A further unmet need is the fact that the referral 
of those with potentially hereditary colon cancer is 
under 20% of those for hereditary breast cancer. As 
in many other countries, the detection of hereditary 
colon cancer in Ireland is not being implemented 
sufficiently. If the expected number of hereditary 
colon cancer families were identified, there would 
be a significant increased need for genetic services 
for these families.
Currently the assessment of the likelihood of a 
cancer being hereditary in each cancer clinic is 
not structured or equitable. To ensure equity and 
quality care, each cancer clinic should have a 
family cancer clinic, where family history taking, 
cancer diagnosis validation, and risk assessment 
can be carried out using standardised protocols 
and clinical recommendations. Those at high 
risk can then be seen by cancer genetic services 
for diagnostic or predictive testing, and those at 
moderate risk can be managed at the local service, 
without involvement of cancer genetic services.
The current management of laboratory cancer 
genetic tests for the Mater Hospital and St James’ 
Hospital involves the setting up of individual 
purchase orders and billing for each test for 
each patient seen in those clinics. This process is 
cumbersome and time consuming, and generates 
substantial administrative costs. Solutions are being 
sought to streamline the process, and minimise 
that administrative load.
From 2010 to 2013, there has been a 73% increase 
in samples received for cancer testing. Figures 
for Q1 in 2014 indicate that this level of testing 
continues to increase. Much of this is likely a result 
of un-met need over recent years and increased 
levels of awareness arising from some recent high 
profile cases.
All cancer genetic testing except BRCA predictive 
testing and MSI testing of tumours is sent abroad 
(predominantly to the UK) because of lack of 
resources in the laboratories in the NCMG. This 
results in an outflow of revenue from the NCCP 
and a loss of expertise at NCMG. Recent years 
have seen major advances in DNA sequencing 
technology, with massively parallel (or “Next 
Generation”) DNA sequencing reducing costs 
and increasing the scope of genes that can be 
tested. This technology is now in use in all of the 
laboratories to which NCMG sends cancer samples 
for testing. There is an urgent need to invest in 
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this technology at NCMG to allow the resumption 
of testing for the common cancers in-house. The 
benefits of such investment include:
•	 A	unique	opportunity	to	introduce	modern	
clinically effective and cost efficient DNA 
cancer screening technology to the NCMG to 
support NCCP’s national cancer control remit
•	 Ability	to	substantially	enhance	the	provision,	
access, sustainability and viability of quality 
cancer screening to the Irish population by 
Irish based scientists, with no further loss of 
revenue abroad 
•	 Opportunity	to	realise	annual	cost	savings	
with realistic prospects of more economies 
of scale, as the required capital infrastructure 
and scientific experience for this new 
technology will be in place. Any such growth 
will have to be additionally resourced for 
consumables and staff, and governed by 
service level agreements
The National Cancer Control Programme (NCCP) 
and NCMG will continue to collaborate via the 
hereditary cancer programme to ensure genetic 
testing is carried out in the most cost effective 
and clinically appropriate manner. Future plans to 
help meet the growing need will see the extension 
of hereditary cancer clinics to medical oncology 
services in the South and West. However this will 
necessitate a considerable investment in the overall 
service. 
Challenges 
•	 Challenge	in	keeping	pace	with	new	
technology and emerging clinical evidence
•	 The	era	of	personalised	medicine	brings	
with it new indications for genetic testing, to 
inform individual risk and predicted response 
to treatment 
•	 Lack	of	funding	to	support	appointment	of	a	
dedicated permanent consultant geneticist 
post in cancer genetics
•	 Need	for	additional	nursing,	genetic	
counsellor and administrative support for 
existing cancer clinics 
•	 Growth	in	laboratory	testing	requirements	
without commensurate increase in staffing
•	 Lack	of/need	for	investment	in	laboratory	
equipment and automation 
•	 Lack	of	national	data	base	to	capture	referrals	
and link to clinical findings 
•	 Lack	of	a	national	register	of	those	with	
hereditary cancer - their outcomes, 
treatments, and long term health
•	 Long	waiting	times	for	appointments	
•	 Increased	awareness	and	understanding	of	
genetic testing among the public – increased 
uptake of appropriate testing predicted, 
especially among those with cancer 
themselves, with resultant increase in demand 
on the service
•	 Improved	understanding	among	all	health	
care professionals but also a need for 
enhanced cancer genetics service, with the 
capacity to support other clinical colleagues 
•	 The	NCCP	has	a	remit	for	developing	cancer	
services and monitoring its volume and 
quality in the Irish public hospital system only. 
Private hospitals are outside this remit and 
not subject to NCCP scrutiny 
Opportunities
•	 Further	develop	the	hereditary	cancer	
programme in Ireland 
•	 Recruitment	of	a	dedicated	leader	for	cancer	
genetics in Ireland 
•	 Development	of	a	national	hereditary	cancer	
policy
•	 Evaluation	of	repatriation	of	genetic	testing	
to Ireland from the UK with new models of 
funding genetic tests
•	 Triage	of	patients	in	cancer	clinics	prior	to	
referral to NCMG
•	 Identifying	the	specific	genetic	cause	
of hereditary cancer and offering pre-
symptomatic testing to at risk relatives 
supports the HSE’s objective of a specific 
programme of promoting the early detection, 
and indeed preventing, cancer in this known 
high risk population 
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11The National 
Screening Service
No. 13 Population-based screening programmes 
should only be introduced where 
their population health benefit can be 
demonstrated using the National Cancer 
Forum criteria.
No. 14  Breast screening should be extended to 
include all women aged between 50 and 
69. 
No. 15  The national roll-out of the Irish Cervical 
Screening Programme should be 
completed as a matter of priority.
No. 16  A colorectal cancer programme should 
be established to encompass population 
screening, high risk screening and 
necessary developments in symptomatic 
colorectal cancer services. In preparation 
for this programme, the Department of 
Health and Children should establish 
a working group under aegis of the 
National Cancer Forum to address a 
range of implementation issues. 
No. 17  The Department of Health and 
Children in conjunction with the HSE 
and BreastCheck should plan the 
alignment of population-based screening 
programmes.
No. 18  Population-based prostate screening 
should NOT be introduced in Ireland 
at present. The National Cancer Forum 
should keep emerging international 
evidence on population screening for 
prostate cancer under review. 
No. 19  Opportunistic testing of asymptomatic 
individuals for cancer is not 
recommended. 
No. 20  The HSE should develop specific 
programmes that promote early 
detection of cancer.
 
The 2006 National Cancer Strategy made 8 recommendations in relation to Cancer Screening:
Since the publication of the 2006 National Cancer Strategy the National Screening Service has been 
established and delivers four population-based screening programmes in Ireland. When the four 
programmes are fully rolled out, over two million people in Ireland will be eligible to participate in one or 
more of the programmes. 
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History and background: Population-
based Screening in Ireland
In 1989, a pilot programme of screening for breast 
cancer, known as the ‘Eccles Programme’ was 
established by the Mater foundation. It was part of 
a European initiative and received support from the 
‘Europe Against Cancer’ programme. 
The Eccles programme had a breast cancer 
detection rate of 7.9 cancers per 1,000 screened 
indicating high prevalence of breast cancer and 
demonstrated a case for a breast screening 
programme in Ireland. This heralded the beginning 
of population-based screening in Ireland.
Following an independent evaluation of the Eccles 
Programme in October 1995, the Minister for 
Health announced the phased introduction of the 
national breast screening programme.
In 1996, the Department of Health published 
a document ‘A Strategy for Cancer Services in 
Ireland’. Following this the Minister established 
a National Steering Committee to oversee the 
implementation of Phase 1 of the national breast 
screening programme. Phase 1 of the national 
programme commenced in early 2000.
The Steering Committee oversaw the development 
of the service including development of clinical 
protocols, establishing quality assurance 
mechanisms, and the recruitment of clinical and 
organisational staff. 
The Steering Committee made a number of 
excellent and forward thinking decisions that 
served the new programme well and continue to 
have a positive impact on the quality and delivery 
of the BreastCheck programme today, including:
•	 Two	year	screening	interval
•	 Double	reading	of	mammograms
•	 Triple-assessment
•	 Two	view	mammography	
•	 Inclusion	of	primary	treatment	(surgery)	as	
part of the programme
•	 The	BreastCheck	Women’s	Charter
From inception, the remit of BreastCheck has been 
to provide Ireland’s first quality assured, evidence 
based breast screening programme for women 
aged 50 to 64 years. The aim of BreastCheck 
is to screen women using mammography and 
to detect breast cancer at the earliest possible 
stage. It is a successful model of care consisting 
of mammographic screening, follow up and 
surgical management of women who are detected 
with breast cancer. The pioneering clinical-led 
model leveraged the learning from international 
programmes. 
By the time of the publication of ‘A Strategy for 
Cancer Control in Ireland’ in 2006 by the National 
Cancer Forum and the Department of Health and 
Children, the BreastCheck programme had been in 
place for six years. Planning for Phase 2 - expansion 
of the breast screening service to the 13 counties 
in the West and the South of the country - was well 
underway with a planned commencement date of 
end 2007. 
The ‘A Strategy for Cancer Control in Ireland 2006’ 
made other screening recommendations including: 
•	 The	extension	of	the	upper	age	limit	of	breast	
screening to 69 years following national 
expansion
•	 Alignment	of	screening	programmes
•	 National	roll-out	of	the	Irish	cervical	screening	
programme
•	 Establishment	of	a	colorectal	cancer	screening	
programme
Since January 2014, the national screening 
programme is under the remit of the HSE Division 
of Health and Wellness. The NCCP and Health 
& Wellbeing now collaborate on planning, 
strategy and monitoring of performance of cancer 
screening, the NCCP is no longer engaged in the 
operational delivery of screening programmes.
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Extension of BreastCheck Age Range
This remains as an objective of the Programme 
for Government. It is acknowledged that it is an 
ambitious target in coming years. A business plan 
was submitted to the Department of Health in 
the summer of 2013 and awaits full approval and 
financial commitment. Extension of the age range 
will increase the eligible cohort by over 40%.
Alignment of Screening Programmes
The National Breast Screening Board was dissolved 
on December 31, 2006 and in its place the 
National Cancer Screening Service Board was 
established as a statutory organisation chaired by 
Dr Sheelagh Ryan. Governance of BreastCheck was 
transferred to the board of the National Cancer 
Screening Service (NCSS) on its establishment 
in January 2007. In addition, the Board was 
given responsibility to roll out cervical screening 
nationally. Mr Tony O’Brien (current Director 
General of the HSE) was appointed as the first 
director of the NCSS. 
Cervical Screening
By 2006, the Irish Cervical Screening Programme 
(Phase 1) had been in operation in three 
counties, Limerick, Clare and North Tipperary. 
Governance of the former Irish Cervical Screening 
Programme (ICSP) Phase 1 was transferred to the 
National Cancer Screening Service Board on its 
establishment and it was given the remit to ensure 
the national roll-out of the cervical screening be 
completed as a national priority. CervicalCheck 
commenced on a national basis in September 
2008.
Colorectal Screening
Following the ‘A Strategy for Cancer Control 
in Ireland 2006’, the Minister for Health and 
Children asked the Board of the National Cancer 
Screening Service (NCSS) to explore the potential 
for the introduction of a national colorectal 
cancer screening programme. The programme 
was to encompass population screening, high 
risk screening and necessary developments in 
symptomatic colorectal cancer services. This was 
to follow resolution of a range of implementation 
issues. 
In December 2009, the NCSS recommended 
the phased implementation of a population-
based colorectal cancer screening programme 
for men and women, in line with international 
best practice and consistent with the EU Council 
Recommendation. The format of the programme 
had been agreed based on a Health Technology 
Assessment undertaken by the Health Information 
and Quality Authority (HIQA) on the cost-
effectiveness, health outcomes and resource 
requirements of various options for a population-
based colorectal cancer screening programme. 
This evaluation was completed in October 2009. 
Preparations for the programme commenced in 
late 2010 and continued until 2012.
BowelScreen
The National Bowel Screening Programme started 
in October 2012 with the ultimate aim of reducing 
mortality from colorectal cancer in men and women 
aged 55-74 years in Ireland. The programme 
is being introduced on a phased basis to allow 
for the development of sustainable capacity for 
the full population. The programme is initially 
offering screening to men and women aged 60-69 
years. The first round of screening is on track for 
completion by the end of 2015.
135 Report on the implementation of ‘A Strategy for Cancer Control in Ireland 2006’
Diabetic RetinaScreen
In 2011 the NCSS was tasked with developing 
and delivering a population-based screening 
programme for diabetic eye disease, which 
commenced in February 2013. 
National Cancer Screening Service - 
Role and Evolution 
The role of NCSS included the following:
•	 To	carry	out	or	arrange	to	carry	out	a	
national breast screening service for the early 
diagnosis and primary treatment of breast 
cancer in women.
•	 To	carry	out	or	arrange	to	carry	out	a	national	
cervical cancer screening service for the early 
diagnosis and primary treatment of cervical 
cancer in women. 
•	 To	advise	on	the	benefits	of	carrying	
out other cancer screening programmes 
where a population health benefit can be 
demonstrated.
•	 To	advise	the	Minister,	from	time	to	time,	
on health technologies, including vaccines, 
relating to the prevention of cervical cancer.
•	 To	implement	special	measures	to	promote	
participation in its population-based 
screening programmes by disadvantaged 
people. 
The Board of the NCSS was dissolved when the 
NCSS joined the Health Service Executive National 
Cancer Control Programme (NCCP) in 2010. 
In January 2014, the operational management 
of the National Cancer Screening Programme 
transferred to the new HSE division of Health and 
Wellbeing. The NCCP and Health & Wellbeing now 
collaborate on planning, strategy and monitoring 
of performance of the NCSS.
Current Screening Focus
The National Cancer Screening Service,which will 
now be known as the National Screening Service 
(NSS) is now responsible for implementation and 
delivery of four population-based, call and re-call 
screening programmes in Ireland. These include: 
•	 The	ongoing	provision	of	BreastCheck	service	
and the national expansion of the programme 
targeting women aged 50 to 64 years.
•	 The	roll-out	of	CervicalCheck	–	The	National	
Cervical Screening Programme in September 
2008 targeting over 1.1 million women aged 
25 to 60 years.
•	 The	establishment	of	BowelScreen	–	The	
National Bowel Screening Programme in 
October 2012 and phased introduction 
initially to men and women aged 60 to 69 
years. 
•	 Implementation	of	Diabetic	RetinaScreen	
– The National Diabetic Retinal Screening 
Programme to provide regular screening and 
treatment of diabetic retinopathy, a common 
complication of diabetes, to people with 
diabetes aged 12 years and over. Although 
not a cancer screening programme, this has 
been aligned with the other population-based 
screening programmes. 
Quality Assurance
Quality Assurance (QA) is an integral component 
of each screening programme. The elements 
below are important for the development and 
the ongoing implementation of each screening 
programme. These ensure that preventative action 
and/or corrective action is taken on an ongoing 
basis and that the overall risk management of each 
programme is central. 
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Quality Assurance structures include:
•	 Quality	Assurance	committees	for	each	
programme; these are responsible at the 
outset for development of a set of Quality 
Assurance guidelines and Key Performance 
Indicators (KPIs). Each QA committee 
is involved in the ongoing review of its 
programme and oversees programme 
adherence to guidelines. 
•	 Executive	Management	Team	for	each	
programme to review issues and evolve 
implementation policies. 
•	 Clinical	Advisory	Groups	for	each	programme	
where external expertise is of value. 
•	 Expert	Groups	set	up	to	examine	a	particular	
issue and provide guidance. 
Quality Assurance processes include:
•	 Ongoing	monitoring	and	review	for	
continuous improvement
•	 Clinical	audits
•	 Standard	Operating	Procedures	(SOPs)	-	
comprehensive SOPs are developed for each 
programme and delivery
•	 Peer	review	
•	 Stakeholder	feedback	including	client	
feedback 
•	 MOUs	(memorandum	of	understanding)
•	 Contracts
Figure 11.1: Policy, Management and Quality Assurance Structure 
NCSS Senior Team
Programme Executive 
Management Team
Quality Assurance 
Committee
Operations Group
Management Team
Chair: Head of NCSS 
Organisation service delivery, budget, 
cross-programme development.
Chair: Programme Manager 
Programme policy, implementation, 
service delivery, budget, and 
programme development.
Chair: Independant, external 
Develop and monitoring of Quality 
Assurance guidelines along with 
providing advice to executive.
Chair: Programme Manager 
Operational delivery through 
cross-department support.
Chair: Programme Manager or designee  
Operational management and delivery.
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Quality Standards and Guidelines
A set of comprehensive standards, measurements 
and KPIs for all aspects of each programme has 
been developed. Standards are updated from time 
to time dependent on programme needs. 
•	 BreastCheck - Guidelines for Quality 
Assurance in Mammography Screening (3rd 
Ed. 2008)
•	 CervicalCheck - Guidelines for Quality 
Assurance in Cervical Screening (2nd Ed. 2014)
•	 BowelScreen - Guidelines for Quality 
Assurance in Colorectal Screening (1st Ed. 
2012)
•	 Diabetic RetinaScreen - Standards for Quality 
Assurance in Diabetic Retinopathy Screening 
(1st Ed. 2013)
The guidelines provide standards, KPIs and 
measurements for the programmes which form the 
basis for data reporting and statistical review and 
are included in the published annual reports for 
each programme. 
Quality Assurance Committees 
Each programme has a dedicated Quality 
Assurance Committee.  
•	 Directly	Delivered	Programmes
 BreastCheck 
 As BreastCheck is a directly delivered 
programme, the Quality Assurance Committee, 
chaired by Quality Assurance Director, 
comprising of staff from all disciplines, meets 
quarterly to review and discuss quality issues. 
 
 External Accreditation
 As part of quality assurance, an external quality 
assurance certification process is planned for 
Q3/Q4 2014. It is intended that the European 
Reference Centre for Breast Screening (EUREF) 
will carry out the process. It is a voluntary 
certification process, which when all criteria 
are fulfilled demonstrates adherence to a 
recognised quality system. In 2002 EUREF 
carried out this process for BreastCheck 
which at the time was delivering Phase 1 of 
the programme in the eastern part of the 
country and successfully achieved voluntary 
accreditation. It was envisaged that once the 
programme had completed at least one round 
of the national programme the process would 
be repeated and planning has begun for this. 
Work has begun on the fourth edition of the 
guidelines. Following the external accreditation 
process, the edition will be finalised.
•	 QA	Multidisciplinary	Consultants’	Group
 All consultants either directly employed, 
or involved in delivery of aspects of the 
programme, meet on an annual basis, usually in 
October or November. 
•	 Purchaser-Provider	Programmes	with	MFTP	
elements
 As CervicalCheck, BowelScreen and Diabetic 
RetinaScreen follow a purchaser-provider model, 
Quality Assurance Committees, led by an 
independent chairperson, have been established 
and are in place prior to the commencement 
of the programmes. The membership includes 
representatives nominated by professional 
bodies and associations, or by direct invitation 
from the NCSS. 
 As part of the development of Guidelines for 
Quality Assurance in Cervical Screening, and 
Colorectal Screening, external peer review 
evaluations, including international experts, took 
place.
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NCSS Programme Delivery
The National Cancer Screening Service is 
dedicated to the continued delivery of screening 
programmes, sharing expertise and learning across 
population-based screening programmes and 
driving effectiveness through strengthening the 
single governance model in place for screening. 
Each population-based screening programme is 
evidence based and leverages best international 
practice. Each programme is quality assured, 
clinically unique and each is designed using 
a model appropriate to that programme. All 
programmes are fully audited against a range of 
quality and client-centred criteria as set out in a 
programme Charter. Programme performance 
is continually measured against the respective 
Charter to ensure that the programme is 
performing at optimal level. All programmes 
are managed and supported through a central 
structure and some shared resources. 
Communications, promotional activities and 
screening promotion are co-ordinated centrally to 
increase awareness and participation in the national 
programmes. 
There is a varied range of stakeholders including 
clients, media, charities, lobby groups, patient 
advocacy groups, health professionals, professional 
bodies, clinical and non-clinical service providers, 
clinical community, HSE and voluntary hospitals 
with which the NCSS engages on a regular 
basis. Education and awareness programmes 
and activities are planned to facilitate a mutually 
supportive stakeholder environment and enable 
informed consent and increased participation 
across the programmes.
Population based, call-recall screening, particularly 
in the cancer field, is well established in a number 
of countries internationally. The NCSS has strong 
linkages with bodies and organisations abroad 
which provides an invaluable source of assistance 
and expertise and assist in collaboration. 
Challenges across the National Cancer 
Screening Service
Recruitment and moratorium - over recent years 
the remit of the NCSS has increased from delivery 
of two screening programmes to four programmes 
while at the same time the management and 
support team has reduced. This is against a 
backdrop of a growing and an aging population 
in Ireland and an increasing burden of cancer. 
The ongoing development and delivery of the 
programmes, in particular the focus required 
for the two newer programmes is extremely 
challenging and creates a risk to the timely and 
highly quality assured implementation of the 
programmes.
It is imperative that the continued safe and quality-
assured introduction of the new programmes 
BowelScreen and Diabetic RetinaScreen, together 
with the ongoing management and delivery 
of the current BreastCheck and CervicalCheck 
programmes, retain the appropriate level of 
support required to ensure all programmes 
continue to deliver their objectives. 
When all four population-based screening 
programmes are fully rolled out, over two million 
people in Ireland will be eligible to participate in 
one or more of the programmes. 
The NCSS became part of the Health and 
Wellbeing Division of the Health Service Executive 
in January 2014. There continues to be ongoing 
linkages to the NCCP for cancer screening strategy 
and performance management. 
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BreastCheck
BreastCheck is the National Breast Screening 
Programme, a population-based call re-call 
programme, that offers women aged 50 to 64 a 
free mammogram every two years. BreastCheck is 
a successful and high quality screening service for 
women who have no symptoms of breast cancer. 
The aim of BreastCheck is to reduce the number 
of breast cancer mortalities in these women, by 
detecting breast cancer at the earliest possible 
stage.
The BreastCheck service is different from the 
symptomatic breast services provided at specialist 
breast clinics throughout the country because the 
woman is not referred to BreastCheck by a GP and 
does not have symptoms of a breast cancer. 
Service standards and Quality Assurance systems 
are in place throughout the programme. These 
high level standards are in line with international 
guidelines to ensure that the best service is 
provided to women. While it is internationally 
accepted that no screening system is 100 per cent 
accurate, BreastCheck aims to ensure that the 
screening service is safe and effective. 
A specialist BreastCheck multidisciplinary team 
provides the screening service to women. The 
integrated team involves administration, consultant 
medical and other staff including anaesthetists, 
histopathologists, radiologists, surgeons, 
radiographers and breast care nurses. The team 
is involved in the screening, detection, diagnosis 
and treatment of breast cancer. The success of 
the programme is due to the close working links 
and operations between the administration of 
BreastCheck and the clinical team. 
Programme History 
BreastCheck commenced screening in February 
2000 in the eastern part of the country. Two 
screening units were built, one on the campus of 
St Vincent’s University Hospital and the second 
on the campus of Mater Hospital, each with four 
associated mobile screening units. BreastCheck 
patients requiring surgery are admitted to the host 
hospitals. 
The ‘A Strategy for Cancer Control in Ireland’ 
published in 2006 by the Cancer Control Forum 
and the Department of Health and Children 
recommended that the BreastCheck programme 
be rolled out nationally as quickly as possible. 
Following tendering and planning, the programme 
expanded in the West and South of the country in 
December 2007. Two new units, with state of the 
art digital equipment were built, and a number of 
mobile units were commissioned to facilitate the 
breast screening service to women living in the 
South and West. The BreastCheck Southern Unit is 
located in Cork city. Initially South Infirmary Victoria 
University Hospital was the host hospital. Following 
service configuration in the South, Cork University 
Hospital became the host hospital. The Western 
Unit is based in Galway on the campus of Galway 
University Hospital. To facilitate the expansion, over 
100 staff were recruited and employed in the West 
and the South.
In 2007, at the time of the national expansion to 
the south and west, the programme upgraded 
from using analogue mammography screening 
equipment to digital screening equipment. The 
BreastCheck programme was one of the first 
internationally to provide digital mammography. 
BreastCheck now has four static centres: two in 
Dublin, one in Cork and one in Galway. Each centre 
has four associated mobile units which provide 
screening as close to women’s homes as possible. 
The majority of screening takes place on mobile 
units. Some screening, all assessment and follow 
up takes place at the static centres. The initial 
round of screening of women in 13 counties in the 
West and the South was achieved in 2010. 
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Improving the quality of screening and breast 
disease services in Ireland is a key priority and 
BreastCheck continues to link with the NCCP and 
symptomatic breast disease services and the eight 
designated cancer centres. 
In some locations the programme is now in its 
eighth round of screening. 
The following figures relate to the BreastCheck 
programme, since the start of the programme in 
January 2000 to mid June 2014:
•	 444,585	women	have	been	screened,
•	 1,171,935	mammograms	have	been	
provided, and 
•	 7,184	cancers	have	been	detected.		
The following figures relate to the BreastCheck 
programme in the years 2011, 2012 and provisional 
figures for 2013 and indicate numbers of women 
invited, screened and cancers detected each year. 
(Table 11.1)
Copies of all annual reports and publications 
are available on the NCSS Website: http://www.
cancerscreening.ie/publications/index.html
The most recent BreastCheck programme report 
for 2012/13 is attached in TD 16 
 Table 11.1: Year that the Women’s First Invitation in the Screening Round was Issued
 
2011 2012 2013*
Number invited 172,076 183,632 210,241
Number eligible invited 168,129 179,222 203,312
Number screened 125,329 128,002 144,192
Uptake rate (based on known target 
population i.e. number invited) 72.8% 69.7% 68.6%
Uptake rate (based on eligible invited) 74.5% 71.4% 70.9%
Number of cancers detected 832 858 850
*provisional figures - not yet validated
Source: NCSS 2014
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Challenges and opportunities
•	 Concern	regarding	uptake	–	A	key	challenge	
is maintaining high levels of screening 
over time, particularly with women new 
to the programme. This is experienced 
by population screening programmes 
internationally. A targeted campaign to 
encourage women aged 50-64 to participate 
and to provide additional online resources is 
planned for 2014. An uptake rate of 70% is 
key to achieving the aim of the programme 
in reducing deaths from breast cancer in the 
screening population. A higher than 70% 
uptake rate has always been achieved by 
BreastCheck since start of programme. The 
trend since 2012 shows that the uptake rate is 
reducing especially among new women to the 
programme (initial women). 
•	 The	recruitment	moratorium	within	the	HSE	
continues to pose a key challenge for the 
programme. 
•	 An	ongoing	shortage	of	radiographers	
both nationally and internationally poses a 
significant challenge.
•	 As	set	out	in	the	BreastCheck	KPIs,	hospital	
admission for women with breast cancer 
diagnosis within three weeks can be difficult 
to achieve. 
•	 Age	range	extension	-	the	NCSS	welcomes	
the Government’s commitment to extend 
the age range to include women aged 
65-69 years as outlined in The ‘Strategy for 
Cancer Control in Ireland’ 2006, and in the 
Programme for Government and Future 
Health – A strategic framework for reform 
of the health service’. Approval and funding 
to extend the age range to women aged 
69 years has not been agreed. A business 
plan has been submitted to the Department 
of Health and awaits full approval and 
financial commitment. BreastCheck is 
currently available to women aged 50-64 
years; a cohort of over 380,000. Recruitment 
and training of the required clinical and 
administrative staffing complement will be 
critical. Most notable will be the requirement 
of radiographers, a professional grade 
which remains in short supply in Ireland and 
elsewhere. 
•	 It	is	important	to	note	that	while	the	extension	
has been deferred, continued government 
commitment signals recognition of the value 
of population-based screening programmes 
as worthwhile health initiatives. It has long 
been the intention to extend the programme 
and there is clear evidence to support this.
•	 Ageing	population	and	growth	in	numbers	
- the impact of the ageing population in 
Ireland is that the current cohort together 
with the extended age range will bring the 
total eligible population to over 544,000; an 
increase of over 41 per cent. This presents a 
particular challenge as part of the planning, 
costing and investment for the extended age 
range. 
•	 Equipment	and	capital	investment	-	the	
majority of mammography and medical 
equipment in the current programme is either 
overdue for replacement, or will become due 
within the next few years. The impact is that 
equipment, which is out of warranty, is less 
effective. An approval for capital funding in 
line with the 2014 capital plan was received 
and a plan for replacement of equipment for 
the BreastCheck programme has begun. 
•	 Service	reconfiguration:	South	-	the	
reconfiguration of health services in the South 
a number of years ago changed the host 
hospital from the South Infirmary Victoria 
Hospital to Cork University Hospital. As the 
BreastCheck unit is geographically distant 
from CUH, the additional travel time for 
clinical and nursing staff on a daily basis 
between both sites has created a burden on 
the unit. 
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•	 Ongoing	debate	about	breast	screening - 
there is continued debate about the merits 
of breast screening. An independent breast 
screening review undertaken in the United 
Kingdom was published in late 2012. 
The independent panel assessed both 
the benefits and harms associated with 
population breast screening. The report 
found that breast screening programmes 
in the UK save lives; however the available 
evidence showed that for each breast cancer 
death prevented, about three cases are 
detected by screening that would not have 
become clinically apparent in the woman’s 
lifetime in the absence of screening. Some of 
the abnormalities detected, due to advances 
in diagnostic processes, may not progress to 
affect a woman’s survival. However, it cannot 
be determined which abnormalities fall into 
this category. 
The review recommended that it is vital to give 
women information that is clear and accessible, so 
that they can understand both the potential risks 
and benefits of screening and make an informed 
decision around participation. BreastCheck 
provides a number of information leaflets and an 
additional factsheet is available for women who 
would like further detailed information about DCIS 
(ductal carcinoma in situ). BreastCheck provides 
opportunities, in the small number of cases where 
a cancer is diagnosed by the programme, for the 
woman to explore and fully discuss treatment 
options. 
CervicalCheck
Programme History
In Ireland, during the last thirty years, cervical 
cancer rates have been rising despite the 
widespread availability of opportunistic screening 
with deaths from cervical cancer increasing by an 
average of 1.5% per year since 1978. 
On 1 January 2007, governance of the cervical 
screening programme was moved from the Health 
Service Executive to the National Cancer Screening 
Service (NCSS) Board, established under Statutory 
Instrument 632 of 2006.
On 1 September 2008, CervicalCheck - The 
National Cervical Screening Programme was 
launched, extending the programme nationwide. 
CervicalCheck provides free smear tests through 
primary care settings to the approximately 1.1 
million women in Ireland aged 25-60 years that 
are eligible for screening. A successful national 
programme in Ireland has the potential to cut 
current mortality rates from cervical cancer by up 
to 80%. 
 
Quality Standards 
Quality standards, to address each step of the 
cervical screening process, were developed for 
CervicalCheck by a dedicated quality assurance 
committee with subsequent peer review. The 
Guidelines for Quality Assurance in Cervical 
Screening were originally published in January 
2010 and have recently been updated based 
on learning from the programme over the first 
five years of operation and developments in 
technology. The second edition was published in 
2014. 
CervicalCheck has established, documented, 
implemented and maintains a quality management 
system (QMS) for the Programme Administration 
Office and works to continually improve its 
effectiveness in accordance with the requirements 
of the International QMS Standard IS EN ISO 
9001:2008.
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Programme Activity
During the first five years of the programme, in 
excess of 1.66 million smear tests were performed 
in over 916,000 women. This constituted 73.7% 
of the target population. In general, younger 
women were more likely to participate in screening 
with 82.7% of women aged 25-29 years screened 
compared to 62% of women in the 55-59 year 
old group. Averages of 1,250 smear tests were 
performed daily as part of the programme.
 
Primary Care and Smeartaking 
CervicalCheck through the NCSS contracted for 
the provision of smeartaking services with general 
practitioners and clinics in the primary care setting 
nationwide. The agreement is a legally binding 
contract between the NCSS and the service 
provider (GPs and clinics) and is structured on 
the basis of a fee per service for an eligible client 
in line with CervicalCheck’s quality assurance 
guidelines. 
Figure 11.2: Coverage from 1 September 2008 to 31 August 2013. Percentage of Women Screened as 
Part of CervicalCheck
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Smeartaker Training 
The Smeartaker Training Unit co-ordinates and 
delivers all smeartaker educational initiatives. The 
introduction of cervical screening on a national 
basis led to a demand for training potentially over 
4,600 smeartakers on an ongoing basis. Between 
2003 and 2013, 1,644 smeartakers (GPs, trainee 
GPs, practice nurses) and administrative staff took 
part in smeartaker training programmes organised 
by the Smeartaker Training Unit. 
Cytology
Cytology services are procured through a public 
tendering process. This has resulted in a significant 
reduction in time required for a woman to receive 
her result. In 2013, following a second public 
procurement process, two laboratories (one in 
Ireland and one overseas) provide cytology services 
to the programme. In addition, in 2013 a separate 
training facility was established at a second 
laboratory in Dublin.
Colposcopy 
Quality assured colposcopy services are important, 
ensuring women with a screen-detected 
abnormality are provided with the optimum care. 
Since 2008, fifteen colposcopy services staffed by 
dedicated multidisciplinary teams, work with the 
programme. 
Significant investments were made in providing 
adequate facilities and information technology 
links. It was calculated that 16,500 new patient 
slots would be required per year and service level 
agreements documented the resources provided 
for an agreed quantum of new patients attending 
to ensure adequate capacity. All colposcopists 
were either accredited by the BSCCP or in training 
under supervision and all services agreed to take 
part in regular MDT meetings. The development, 
establishment, and on-going management of 
the service level agreement including the fee per 
treatment feature, a forerunner of Money Follows 
The Patient, contributes to improving service 
delivery for those individuals who had been 
referred for treatment to a colposcopy clinic.
The number of women attending colposcopy 
increased significantly in the first five years of the 
CervicalCheck programme with a peak of 17,500 
new patients attending for the first time in the 
third year of the programme. A marked increase 
in the number of follow up appointments can be 
explained by increasing numbers of women with 
low-grade cytology undergoing surveillance. This 
figure peaked in the fifth year of the programme 
with 43,983 attended follow up appointments.
Figure 11.3: Numbers of Women Attending Colposcopy during the First Five Years of the 
CervicalCheck Programme
Source NCSS 2014
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Long waiting times were a feature of colposcopy 
services before the introduction of CervicalCheck. 
In the fifth year of the programme, the waiting 
times met national standards for all categories of 
smear test abnormalities.
The objective of any cervical screening programme 
is to detect and treat high grade abnormalities, 
which if left untreated, could progress to invasive 
cancer. The numbers of biopsies increased 
markedly during the first five years of the 
programme. Overall for this time period, 25,912* 
women were diagnosed as having CIN2, CIN3 
or adenocarcinoma in situ. Invasive cancer was 
diagnosed in 572* women.
*Figures correct as of the most recent draft of the 
annual report for the fifth year of the programme
Copies of recent annual reports and publications 
are available on the NCSS Website: http://www.
cancerscreening.ie/publications/index.html
A copy of the most recent CervicalCheck 
programme report is included in TD 15. 
Introduction of HPV testing in 
Colposcopy 
The treatment of CIN can reduce the risk of 
invasive cancer by over 90 per cent but the risk of 
recurrence means that treated women still have 
five times the risk of invasive cancer compared to 
women who have always had normal smear tests. 
Careful follow-up measures are required to identify 
treatment failures at the earliest opportunity and 
prevent subsequent cancer. Traditional protocols 
involve more intensive screening with annual 
cytology tests for up to 10 years. 
In recent years attention has focused on ways to 
define the risk of recurrence more accurately and to 
stratify follow up protocols according to the risk. 
On the recommendations of the HPV Scientific 
Advisory Group and subsequent peer review, 
HPV testing was introduced in colposcopy as part 
of the CervicalCheck programme in 2012 as an 
adjunct to cytology in the follow up of women who 
received treatment at colposcopy. Two combined 
cytology and HPV tests are available for women 
post-treatment at colposcopy, one at six months 
post-treatment and the second at 18 months 
post treatment. Women with results categorised 
as low risk at this time are discharged to routine 
screening. 
HPV testing to manage uncertainty at 
Colposcopy 
Women with low-grade cytological abnormalities 
constitute the majority of referrals to colposcopy. 
While some of these women require treatment, 
most do not and probably represent a transient 
infection with the human papillomavirus which will 
resolve spontaneously. 
Management strategies try and balance early 
diagnosis of high grade CIN with the avoidance of 
default and unnecessary treatment and anxiety for 
women. While any management should be tailored 
to the needs of the woman including age, patient 
choice and risk of non compliance, the majority 
of women who do not have high grade disease 
should undergo surveillance. 
Traditionally these women were managed with 
six-monthly colposcopy and cytology without 
conclusive evidence of the value of colposcopy or 
the recommended six-month screening interval. 
A fresh approach has been implemented in 2014 
which uses the negative predictive value of HPV 
testing to return the woman to normal screening in 
a more efficient and effective manner.
HPV Immunised Cohort
The HPV immunisation programme which 
commenced in 2010 for first years in secondary 
school with a catch up programme for girls in the 
sixth year of secondary school means that these 
women will be protected from being infected 
with the high risk HPV types that cause over 70% 
of invasive cancers. The HPV vaccinated cohort 
will start entering the CervicalCheck programme 
in 2019 and the approach to screening for 
these women will have to change significantly. 
CervicalCheck is currently planning to implement 
these changes, part of which includes a HTA 
process later in 2014 in conjunction with The 
Health Information and Quality Authority (HIQA).
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Challenges and Opportunities
Much has been achieved in the first five years of 
the CervicalCheck programme. The challenge 
is to build on these achievements and sustain 
the momentum to enable the fulfillment of the 
ultimate goal – a reduction of cancer incidence 
and mortality from cervical cancer. The most recent 
data from the NCRI shows incidence continuing 
to rise as the prevalent disease is identified. The 
target of reducing mortality by 50% and incidence 
by 30% by 2018 seems ambitious.
Colorectal Cancer
In Ireland, colorectal cancer is the second most 
commonly diagnosed cancer and the second 
most common fatal cancer among both men and 
women. Over the last 15 years, the number of 
cases of colorectal cancer diagnosed in Ireland 
has risen by approximately 20% in both sexes. 
There are over 2,400 newly diagnosed cases 
each year. Approximately 1,040 people die from 
colorectal cancer each year, 610 men and 430 
women. Although the number of cases diagnosed 
continue to rise, the last twenty years has also seen 
a significant 20% increase in five year survival from 
50.1% to 60.6%.
Table 11.2: Colorectal Cancer Key Facts*
Male Female Total
Number of new cases per year (2009-2011 averages) 1,405 1,031 2,436
Number of deaths per year (2011) 610 430 1,040
Number alive with this cancer (2011) 8,212 6,604 14,816
*National Cancer Registry Ireland
Figure 11.4: Trends in Incidence Colorectal Cancer 1994-2011
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Background to the Establishment of a 
National Colorectal Cancer Screening 
Programme 
Following the ‘A Strategy for Cancer Control 
in Ireland 2006’, the Minister for Health and 
Children asked the Board of the National Cancer 
Screening Service (NCSS) to explore the potential 
for the introduction of a national colorectal 
cancer screening programme. The Board of the 
NCSS established an Expert Advisory Group on 
Colorectal Cancer to explore the potential benefits 
of introducing a colorectal cancer screening 
programme in Ireland. The Expert Group, chaired 
by Professor Niall O’Higgins, evaluated the 
clinical and organisational requirements for the 
establishment of an effective, efficient and quality 
assured screening service. The Group presented 
its first (interim) report to the Board of the NCSS in 
December 2007. 
An independent peer review of the report was 
completed in August 2008 by an international 
panel of experts on colorectal cancer screening 
(Prof Wendy Atkin & Prof Robert Steele [UK], 
Professor Jean Faivre [France] and Prof Michael 
O’Brien [USA]). On completion of this evaluation 
in December 2008, the Board of the NCSS 
recommended to the Minister a national, 
population-based, colorectal cancer screening 
programme for men and women aged 55-74 years. 
In June 2009, the Minister requested the Health 
Information and Quality Authority (HIQA) to 
explore a means of delivering a high quality 
colorectal screening programme within existing 
resources. In December 2009, the NCSS 
recommended the phased implementation of a 
population-based colorectal cancer screening 
programme for men and women, in line with 
international best practice and consistent with the 
EU Council Recommendation.
NCSS Recommendations
The Board of the NCSS recommended:
•	 The	eligible	population	for	screening	should	
be men and women aged 55-74 years.
•	 The	programme	to	operate	on	a	two	yearly	
screening round.
•	 The	faecal	immunochemical	test	(FIT)	to	be	
the primary screening tool.
•	 Persons	with	a	positive	result	from	the	primary	
screening test to be offered a colonoscopy.
•	 The	screening	pathway	would	include	primary	
treatment, after which the patient would be 
discharged from the screening programme 
for follow up in the symptomatic service in 
accordance with best clinical practice.
Table 11.3: Trends in Five Year Relative Survival Colorectal Cancer
Period Relative Survival 95% Confidence Interval
1994-1999 50.1 %  (48.8-51.3%)
2000-2004 53.9 %  (52.6-55.1%) 
2005-2009 59.2 %  (57.6-60.7%) 
2008-2010* 60.6 %  (59.0-62.1%) 
* Hybrid estimate
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Screening Programme Preparation 
During 2010 to 2012 the following steps were 
undertaken:
•		Colonoscopy	Capacity
The NCSS focused on immediately 
identifying and building sufficient capacity in 
colonoscopy services nationwide to sustain the 
implementation of the programme, but also 
maintaining and enhancing the symptomatic 
service capability. The NCSS requested 
expressions of interest from all publicly funded 
hospitals that wished to be considered as a 
screening colonoscopy unit as part of a national 
programme. The NCSS undertook a baseline 
analysis of endoscopy facilities that expressed 
interest. It was conducted in partnership with the 
representative professional bodies, the Royal 
Colleges and the UK Joint Advisory Group on 
Gastroenterology (JAG).
•		Recruitment	of	Clinical	Nurse	Specialists	
in Gastroenterology – Colorectal Disease 
Screening and Management
The NCSS received approval for the recruitment 
of 20 Clinical Nurse Specialists to support 
the introduction of a population screening 
programme. 
•	Quality	Assurance	Framework	Development
The NCSS sought and developed a 
multidisciplinary process to agree Quality 
Assurance (QA) processes and standards for 
a national programme. An independent QA 
Chairperson, Chairs (Clinical Consultants) of three 
designated specialist sub-groups (endoscopy, 
laboratory/pathology, surgery) and members of 
each sub-group representing clinical expertise in 
each field were appointed by the NCSS. These 
sub-groups, in addition to a Programme sub-
group developed a full suite of standards.
•		Faecal	Immunochemical	Test	(FIT)	Service
The NCSS completed a tendering process for the 
provision of the FIT service. This is one of the first 
population cancer screening programmes in the 
world using the FIT as the primary screening test 
in a national setting.
•		Population	Communications
Initial market and consumer research and brand 
development were undertaken to inform the best 
population communications approach that would 
support the programme in its aim to achieve an 
uptake of 50-60%.
•		Client	Support
FIT test kits would only be sent to those who 
indicate that they are willing to use it. It was 
necessary to develop easily understandable 
materials and accessible channels of 
communication to potential users. In addition, a 
procurement process took place that led to the 
selection of a call centre with the intention of 
managing calls from those wishing to participate 
in the programme, request a FIT kit and other 
general inquiries. 
•	Population	Register	and	Clinical	Data	
Repository
The population register is a secure electronic 
database managed by the National Cancer 
Screening Service that contains the demographic 
details of men and women who are eligible 
to participate in the screening programme. 
The Health (Provision of Information) Act 1997 
allows the National Screening Service to obtain 
and store demographic details and clinical 
results.
 
149 Report on the implementation of ‘A Strategy for Cancer Control in Ireland 2006’
Designing a commissioning model for a 
colorectal screening programme
During the planning phase it was known that 
approximately 95% of the programme would take 
place outside of a hospital setting (in the patient’s 
home) and in the FIT testing laboratory.
For the approximately 5% of clients who would 
require referral to hospital for a colonoscopy 
and possible surgery, it was decided to design 
a commissioning model of reimbursement for 
all hospital based elements of the programme 
in which money would follow the patient. The 
commissioning is managed via signed memoranda 
of understanding (MOU) with the relevant hospitals.
•	 Screening	colonoscopy	units	would	be	
reimbursed for each screening colonoscopy 
performed.
•	 Histopathology	laboratories	in	designated	
cancer centres would be reimbursed for 
histopathology arising from a screening 
colonoscopy.
•	 Hospitals	providing	CT	colonography	as	part	
of the programme would be reimbursed for 
each scan.
•	 Designated	cancer	centres	would	be	
reimbursed for each screen detected cancer 
referred and treated.
A fundamental principle was that any hospital 
providing screening colonoscopies as part of a 
screening programme would have to demonstrate 
that they could control their symptomatic waits. An 
MOU would allow for performance monitoring of 
each screening colonoscopy unit and ensure that 
any patient presenting symptomatically would not 
be disadvantaged.
Surgery
The management of screen-detected colon and 
rectal cancer is not materially different from that 
of the management of symptomatic disease. All 
screen detected cancers, colon and rectal would be 
referred to one of eight designated cancer centres.
BowelScreen 
Launch of BowelScreen – The National 
Bowel Screening Programme
BowelScreen – The National Bowel Screening 
Programme commenced in October 2012 with the 
ultimate aim of reducing mortality from colorectal 
cancer in men and women aged 55-74 years in 
Ireland. 
In order to allow the development of sustainable 
capacity for the full population, the programme 
is being implemented on a phased basis, starting 
with men and women aged 60-69 years. The first 
round of screening is on track for completion at the 
end of 2015.
Approximately ninety five per cent (95%) of 
participants will have a normal result and will 
be re-invited for screening in two years time. 
Approximately 5% of participants will have a result 
that requires a colonoscopy to be performed as a 
follow up test.
The procedure is carried out in one of the 
programme’s screening 15 colonoscopy units. 
Those with a normal result from colonoscopy are 
re-invited for screening in two years time. Those 
with polyps requiring surveillance are followed 
up with a BowelScreen colonoscopy in one or 
three years depending on the classification of risk. 
Those diagnosed with a cancer are referred to a 
designated cancer centre for treatment and are 
discharged from the screening programme. 
The following figures relate to the BowelScreen 
programme, since the start of the programme 22 
October 2012 to May 2014:
•	 144,000	Invitations	issued
•	 43,000	Normal	FIT	results
•	 2,330	Colonoscopies
•	 83	Cancers
This data is not yet validated and is provisional at 
this time. 
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Challenges and opportunities
BowelScreen – The National Bowel Screening 
Programme has the opportunity to play a part in 
significantly reducing mortality from colorectal 
cancer in Ireland. When the programme is 
operational at full capacity and extended to the 
entire eligible population (aged 55-74), the full 
impact of screening on clinical health outcomes 
and cost-effectiveness will be realised and 
evaluated. 
However significant challenges remain regarding 
the resource impact on the programme and on 
hospital services. 
While 95% of BowelScreen takes place outside of 
a hospital, a main resource constraint is at the level 
of hospital services. Availability of hospital capacity 
is vital to ensure the success of BowelScreen.
The resource impact on endoscopy services is 
perhaps the most challenging. For example, in 
2006 there were 50,470 colonoscopy discharges 
in Ireland in HIPE reporting hospitals. In 2011, 
this rose to 67,678 colonoscopy discharges 
representing a 34.1% increase in that five year 
period. The demand for colonoscopy procedures 
continues to rise, replicating the picture seen in the 
NHS. 
Round one of the BowelScreen programme is on 
track to be delivered by the end of 2015. Over 
time the programme will be extended to the full 
eligible population. 
Diabetic RetinaScreen 
There is currently a global epidemic of diabetes 
(especially Type 2), which means that diabetic 
retinopathy will continue to be a public health 
problem. Untreated sight-threatening diabetic 
retinopathy (DR) is the most common cause of 
blindness in people of working age in Ireland. 
It is estimated that the diabetes prevalence in 
Ireland equates to 190,000 with many case as yet 
undiagnosed.
Diabetic retinopathy is caused when diabetes 
(raised blood glucose levels) damage the small 
blood vessels/capillaries in the back of the retina 
leading to haemorrhages, which can affect vision. 
Diabetic retinopathy may not cause symptoms 
until it is quite advanced and close to affecting a 
person’s sight, therefore screening is essential to 
identify and treat issues early. Diabetic retinopathy 
can be diagnosed at an early stage in people with 
both Type 1 and Type 2 diabetes and evidence 
demonstrates that if detected early enough, 
appropriate treatment can be provided which may 
reduce the risk of sight deterioration. 
All people with diabetes are at some risk of getting 
diabetic retinopathy. People in the categories 
below are at greater risk:
•	 Those	with	diabetes	for	a	long	time
•	 Those	with	diabetes	that	is	poorly	controlled
•	 Those	with	high	blood	pressure
•	 Those	on	insulin	treatment
After 20 years with diabetes, nearly all patients 
with type 1 and over 60% of patients with type 2 
diabetes will have some degree of retinopathy.
Establishment of the Diabetic 
Retinopathy Screening Programme
Due to the experience of the Screening Service in 
delivering high-quality population-based screening 
programmes, it was formally requested by the 
Health Service Executive that the NCSS commence 
the development of a national diabetic retinopathy 
screening programme in 2011 under the auspices 
of the NCCP. 
Following this request, the NCSS committed to 
the development of a national diabetic retinopathy 
screening programme and commenced actively 
preparing for the introduction of the programme 
working closely with the National Directorate 
of Clinical Strategy and Programmes. Following 
a planning stage, Diabetic RetinaScreen - The 
National Retinal Screening Programme was 
launched in February 2013. 
151 Report on the implementation of ‘A Strategy for Cancer Control in Ireland 2006’
Aim of Diabetic RetinaScreen
The aim of the programme is to reduce the risk 
of sight loss amongst people with diabetes, by 
the early identification and effective treatment if 
necessary of sight threatening diabetic retinopathy, 
at the appropriate stage during the disease 
process. 
The national programme is a population-based, 
call-recall programme of screening for sight-
threatening diabetic retinopathy, which will be 
delivered on an annual basis once the first round of 
screening has been completed. Screening will be 
offered to people with diagnosed diabetes, aged 
12 years and over, registered with the programme. 
The programme is delivered locally and provided 
to the highest, internationally comparable, quality 
assurance standards. Systematic screening involves 
digital photography of the retina followed by a 
three-stage image grading process to identify the 
changes of sight-threatening diabetic retinopathy 
in the retina. 
The programme will aim to reach a growing 
eligible population of an estimated 190,000 
people. This is based upon 5.6% of the population 
having diabetes, with a programme uptake rate of 
80%. It is estimated that 25% of those screened 
will require referral for further investigation and 
possible treatment. Of this, 18% will be treated 
for diabetic retinopathy and 7% will be treated for 
non-diabetic retinopathy related conditions. 
Development of a Screening Register for 
Diabetic Retinopathy
A national register of all people with diabetes 
does not currently exist in Ireland. In order to 
facilitate the commencement of a national diabetic 
retinopathy screening programme, an extensive 
register of people diagnosed with diabetes 
was created during the last quarter of 2011 and 
early 2012. This information was compiled from 
national health schemes, such as the General 
Medical Scheme (GMS), Drugs Payment Scheme 
and Long Term illness Scheme in Dec 2012. This 
register is used to invite people to participate in 
the programme. A facility for GPs to verify their 
diabetic patients will be added over time. 
Development of a Quality Assurance 
Framework
A quality assurance framework has been developed 
to ensure that every aspect of the screening 
programme would operate in line with international 
best practice standards. A Quality Assurance 
Committee was established and completed the 
development of standards for quality assurance 
in diabetic retinopathy screening for the national 
programme. 
Procurement of Photography and 
Grading Service Providers
A rigorous public procurement process for the 
selection of the photography and grading service 
provider to undertake the screening test and 
associated grading system was completed. Two 
companies were selected and are providing 
services for the programme.
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Procurement of Treatment Capacity 
The Screening Service together with the National 
Diabetes Programme completed a process to 
determine treatment model and identify the 
necessary treatment capacity requirements in order 
to determine the resources required to manage 
screen-detected abnormalities, without negatively 
impacting symptomatic service capability. 
Governance has been agreed in order to minimise 
delays for those transitioning from screening to 
treatment. 
The treatment aspect of the programme was 
initially under the remit of the HSE Diabetes 
Programme but was included in the remit of the 
Screening Service at the end of 2012. A model 
to determine resources required to address 
capacity was developed. In co-operation with 
the Irish College of Ophthalmologists and 
HSE Clinical Programmes, the initial treatment 
locations were identified and to date Memoranda 
of Understanding (MOUs) are in place with eight 
hospitals in locations through out the country for 
the supply of these services. 
Invitation Targets 
The national programme achieved the target for 
2013 and invited 30% of the eligible population 
on the register to participate in the programme. 
To date, the programme is on track to achieve the 
target and invite the remaining 70% of the register 
by the end of 2014. 
Challenges and opportunities 
•	 Recruitment	and	retention	of	critical	staff.
•	 Achievement	of	the	programme	standard	of	
an 80% uptake participation rate.
•	 Growing	diabetic	population.	
•	 Availability	of	an	increased	number	of	
screening locations to clients for the initial 
screening appointment.
•	 Move	to	annual	screening	in	2015,	once	the	
initial round is complete. 
Round one of the Diabetic RetinaScreen 
programme is on track to be delivered by the 
end of 2014. Once this initial round of screening 
is complete, the programme will introduce and 
deliver annual screening. 
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12 Development of 
National clinical
Guidelines
No. 41: The 2006 National Cancer Strategy 
recommended that “HIQA should establish 
site‐specific multidisciplinary groups at a 
national level to develop guidelines for quality 
in major cancers”.
Development of National Clinical 
Guidelines
‘A Strategy for Cancer Control in Ireland 2006’ 
recommended that “national site-specific 
multidisciplinary groups should be convened to 
develop evidence based guidelines for cancer 
care. These groups should provide guidance for all 
common cancers”. 
In 2011, the NCCP commenced the development 
of national evidence-based clinical guidelines for 
the diagnosis, staging and treatment of common 
cancers. These evidence-based guidelines aim to: 
•	 Improve	the	quality	of	clinical	care,
•	 Prevent	variation	in	practice,
•	 Address	areas	of	clinical	care	with	new	and	
emerging evidence,
•	 Encompass	best	research	evidence	in	
conjunction with clinical expertise, and
•	 Incorporate	the	use	of	evidence	based	
methodology and command the respect 
of stakeholders, including the HSE, the 
department of Health’s National Clinical 
Effectiveness Committee (NCEC) and 
regulatory authorities such as the Health 
Information and Quality Authority (HIQA) 
The National Cancer Control Programme (NCCP) 
has commenced the development of national 
evidence-based clinical guidelines for the 
diagnosis, staging and treatment of five common 
cancers, commencing with: Breast, Prostate, 
Lung, Gastrointestinal (oesophageal, pancreatic 
& colorectal) and Gynaecological (Gestational 
trophoblastic disease (GTD)) Cancers. 
Guideline Development 
Guideline development groups (GDGs) were 
established with nominations received from the 
relevant professional medical colleges (Royal 
College of Physicians, Royal College of Surgeons). 
Chairpersons were agreed by the group members. 
Membership of each Guideline Development 
Group includes representatives from all relevant 
clinical disciplines including Radiology, Pathology, 
Surgery, Medical Oncology and Radiation 
Oncology, a Project Manager, a Methodologist and 
a Clinical Librarian. 
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The work of each GDG was completed in discipline 
specific subgroups (i.e. pathology, surgery, 
radiation oncology etc) to expedite the process 
and to ensure the best utilisation of clinician time. 
It is a labour intensive process and would not be 
possible without the significant contribution of time 
and expertise of all the clinicians and librarians 
involved. 
Governance 
Governance of the guideline development process 
is provided by a multidisciplinary Guideline 
Steering Group, which is chaired by the Director of 
the NCCP. The Steering Group meets quarterly to 
assess progress of each of the individual GDGs and 
to provide oversight and leadership, to address any 
queries as they arise and to ensure all guidelines 
are being developed using an evidence-based 
approach. Members of each GDG have completed 
a conflict of interest form. The current membership 
is listed in TD 10. 
Methodology for Developing 
Evidence-Based Guidelines
Guideline development is a complex multi-year 
project and internationally, it requires on average 
two years to complete an evidence-based clinical 
guideline. 
The principal benefit of developing evidence 
based guidelines is to improve the quality of care 
received by patients. Other benefits include the 
following:
•	 Improvements	in	the	quality	of	clinical	
decisions,
•	 Improvement	in	patient	outcomes,
•	 Potential	for	reduction	in	morbidity	and	
mortality and improvement in quality of life,
•	 Promotion	of	intervention	of	proven	benefit	
and discouragement of ineffective ones, and
•	 Improvements	in	the	consistency	and	
standard of care (NCCP 2012) 
A methodologist qualified in evidence-based 
practice was appointed from within NCCP staff 
to design and oversee the methodology for the 
development of the guidelines. The methodology 
was based on the principles of Evidence Based 
Practice (Sackett et al. 2000) The appointment of a 
dedicated NCCP project manager for each of the 
GDGs to manage, support and co-ordinate each 
aspect of the guideline development has been a 
critical success factor in the development of this 
project. Training in evidence-based guideline 
development was provided by the NCCP for all 
clinicians and librarian participating in the GDGs. 
NCCP Guideline Development 
Methodology 
Step 1 Develop clinical questions 
Step 2 Search for the evidence
Step 3 Appraise the literature for validity and 
applicability (AGREE II instrument for 
existing guidelines and SIGN checklists 
for primary literature)
Step 4 Formulate and grade the 
recommendations (evidence is applied 
in conjunction with clinical expertise and 
applicability to the Irish setting)
Step 5 Draft Guideline (including national 
stakeholders and international expert 
review)
Weekly methodology meetings, chaired by the 
methodologist, are held in the NCCP and attended 
by all project managers and research staff. These 
meetings have provided training in aspects of 
guideline development, peer to peer support for 
the project managers and a forum to resolve issues 
and difficulties. Quarterly meetings are also held 
with this team and the librarians to address issues 
arising. 
Implementation and Audit
The implementation plan is based on the 
Com-B theory of Behaviour Change (Michie 
et al 2011). A multidisciplinary clinical team 
is responsible for the implementation of the 
guideline recommendations.. Audit criteria will be 
established for each guideline (based on KPIs) and 
an audit plan will be developed by the NCCP. 
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National Endorsement
The National Clinical Effectiveness Committee 
(NCEC) was established by the Department 
of Health in September 2010. The NCEC is 
responsible for endorsing all national clinical 
guidelines. Upon completion, the NCCP 
guidelines will be submitted to the National 
Clinical Effectiveness Committee (NCEC) in the 
Department of Health for national endorsement. 
The NCCP has liaised closely with the NCEC to 
ensure that the methodology used will meet the 
standards set out by the NCEC.
Progress to Date
The NCCP has prioritised the development 
of these national clinical guidelines and has 
developed an evidence-based approach to their 
development to ensure delivery of robust national 
clinical guidelines. 
Guidelines for the Diagnosis Staging and 
Treatment of Breast Cancer has been published 
on the NCCP website., The draft guideline for 
Lung Cancer will be available for review in 2015. 
Guidelines for Oesophageal, Pancreatic and 
Colorectal Cancers are underway. Guidelines for 
Prostate Cancer and Gestational Trophoblastic 
Disease are to be published in 2015.
An additional five cancers have been identified 
for future development of guidelines which will be 
progressed pending availability of resources. 
Summary 
The NCCP has implemented the recommendation 
of the 2006 National Cancer Strategy in 
establishing site‐specific multidisciplinary groups 
at a national level to develop guidelines for 
quality in major cancers. These evidence based 
clinical guidelines aim to ensure standardised 
multidisciplinary care for patients, putting evidence 
into practice to improve patient outcomes. 
Table 12.1: Guidelines Development Group Progress – June 2014
Guidelines 
Development 
Group
Ask Search Appraise Apply Guideline
(Tumour Group) Questions Revise Sign Off Library
Sign 
off Guidelines
Primary 
Literature
Extract 
Data
Agree Recom-
mendations
Sign off 
by Tumour 
Group
Breast
Surgery P P P P P P P P P P
Radiology P P P P P P P P P P
Medical Oncology P P P P P P P P P P
Palliative Care P P P P P P P P P P
Radiation Oncology P P P P P P P P P P
Prostate
Active Surveillance P P P P P P P P P
Diagnosis+Radiology P P P P P P P P P
Pathology P P P P P P P P P P
Medical Oncology P P P P P P P P P P
Radiation Oncology P P P P P P P P P P
Surgery P P P N/A P N/A P P P
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Guidelines 
Development 
Group
Ask Search Appraise Apply Guideline
(Tumour Group) Questions Revise Sign Off Library
Sign 
off Guidelines
Primary 
Literature
Extract 
Data
Agree Recom-
mendations
Sign off 
by Tumour 
Group
Palliative Care P P P P P P P P P P
Gynaecological
Gestational 
Trophoblastic 
Disease
P P P P P P P P P P
Lung
Respiratory 
physicians
P P P N/A P N/A P P P
Radiologists P P P P P P P P P P
Pathologists P P P P P P P P P P
Surgical P P P P P P N/A P P P
Medical Oncology P P P P P P P P P
Radiation Oncology P P P P P P P
Palliative care P P P P P P P P P P
Oesophageal & 
OGJ Tumours
Radiology P P P P P P P
Surgery Gastro P P P P P P P P
Pathology P P P P P P P
Radiation Med Onc P P P P P P P
Pancreas
Radiology P P P P P P P
Surgery P P P P
Pathology P P P P P P
Radiation Oncology P P P P
Medical Oncology P P P P P
Colorectal
Radiology P P P P P P P P
Surgery P P P P P P P P
Gastroenterology P P P P P P
Pathology P P P P P P P P P
Radiation Oncology P P P P P P P P
Medical Oncology P P P P P P
Shaded boxes indicates commenced but not completed
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13 Cancer 
Intelligence
The 2006 National Cancer Strategy recommended 
that: 
No. 43.  HIQA should develop cancer surveillance 
systems that will build on the existing 
system of cancer registration. 
No. 45.  HIQA should ensure that a minimum 
national dataset should be collected for 
all cases of cancer. 
No. 48 Information systems and information 
technology should be developed by the 
HSE to support the management and 
delivery of cancer services. 
Many of the oversight/monitoring roles originally 
identified for HIQA have now been adopted by the 
NCCP or the NCRI (inc. recommendations 43, 45,). 
Health care is essentially an information science. 
Data is required at every level in a healthcare 
organisation - to enable clinicians to diagnose 
disease, identify possible intervention opportunities 
and achieve health outcomes; to enable patients to 
make informed choices regarding their treatment 
and to facilitate managers and clinical leaders to 
plan, manage and improve the health service. 
Data and information lie at the core of any quality 
improvement system.
The original strategy document ‘A Strategy for 
Cancer Control in Ireland 2006’ envisaged the 
establishment of a cancer surveillance system, built 
on the existing system of cancer registration which 
had the following main aims: 
•	 monitoring	trends	in	cancer	incidence,	
prevalence and survival
•	 evaluating	the	effectiveness	of	cancer	
prevention and screening
•	 evaluating	the	quality	and	outcomes	of	cancer	
care
•	 evaluating	the	impact	of	environmental	and	
social factors on cancer risk
•	 supporting	investigations	into	the	causes	of	
cancer
•	 providing	information	in	support	of	genetic	
counselling services
Since the publication of the original strategy 
document, the OECD developed a conceptual 
framework to measure system performance in 
cancer. (http://www.oecd.org/els/health-systems/
Focus-on-Health_Cancer-Care-2013.pdf)
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Five main domains of system performance are 
described
•	 Access to cancer care – includes such 
measures as time to access specialist review 
and key procedures, access to cancer drugs, 
equity of access to services 
•	 Effectiveness of cancer care – refers to 
the assessment of clinical effectiveness all 
along the steps of the cancer care path. It 
includes both outcome measures such as 
survival rates, mortality, stage at diagnosis 
and process measures such as adherence to 
agreed guidelines and appropriate use of 
cost effective procedures
•	 Governance of cancer care – relate to 
the organisation of care delivery and the 
relationships that are established between 
different care providers within the care 
structure
•	 Costs of cancer care – hospital and 
community services expenditure on cancer, 
drug costs
•	 Human resources and structures – diagnosis 
and treatment equipment capacity, staff 
capacity and hospital capacity (volume and 
distribution of acute beds, day care beds and 
theatre slots)
In Ireland, as is the case with most jurisdictions, 
data on these domains come from multiple 
sources. 
The major national source of comprehensive cancer 
data is the National Cancer Registry (NCR) www.
ncri.ie. The National Cancer Registry Board was 
first established in 1991 when the then Southern 
Tumour Registry became the National Cancer 
Registry. The NCR has remained an independent 
entity with its own Board since its inception and 
has been led by Dr Harry Comber as Director since 
1992. The NCCP has been represented on the 
NCR Board since 2009 and the Board has been 
chaired by the Director of the NCCP, Dr Susan 
O’Reilly, since early 2013. 
The NCR has captured data on all cancer 
cases in Ireland since 1994. The NCR database 
has information on demographics, tumour 
characteristics, treatment and some follow-
up information on all cancer cases in Ireland, 
irrespective of where patient is diagnosed. As a 
registry, it does not contain comprehensive clinical 
data and is collected retrospectively, often more 
than a year after initial treatment. It is the definitive 
source of information on cancer incidence, 
mortality, prevalence and survival. 
The Hospital Inpatient Enquiry (HIPE) is designed 
to capture hospital activity in the public hospital 
system. It covers all admissions with cancer for a 
particular time period, irrespective of when the 
patient was diagnosed. HIPE captures information 
on diagnosis and detailed surgical treatment data, 
but is limited in radiotherapy coding and has little 
medical oncology data. At a national level it is 
anonymised and unlinked to individual patient 
records, so patients cannot be tracked across 
hospitals. 
The breast and cervical screening programmes 
carry data on all women screened and record 
clinical data on the cancers diagnosed. The breast 
data has been linked to the NCR data and there 
are provisions for doing the same with the cervical 
data.
There is some limited data on outpatient 
attendances at medical oncology and radiotherapy 
clinics. These are collected at local level and 
reported to the HSE’s Business Intelligence Unit.
The utilisation and cost of some intravenous high 
cost cancer drugs is captured by the NCCP Cancer 
Drug Management Programme and some other 
cancer drugs are captured on the Primary Care 
Reimbursement System. 
There are eight symptomatic breast disease 
databases, one in each of the cancer centres.
There are a variety of other local databases, 
including radiation oncology treatment data, 
hospital- and consultant-specific databases, and 
others. In addition to the cancer specific databases, 
there are a variety of hospital databases that are 
current or potential providers of some of the key 
data items (Figure 13.1). 
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Costs and human resources are compiled by the 
relevant hospital financial and HR systems and 
data on access and effectiveness of services are 
extracted from administrative, laboratory, radiology 
systems and clinical systems or notes. Governance 
is monitored with documentation of organisational 
structures, policies, protocols and procedures.
Achievements
•	 To	date,	standards	and	their	associated	
quality measures or key performance 
indicators (KPIs) have been defined for 
symptomatic breast disease, lung, prostate, 
rectal, upper gastrointestinal and pancreatic 
cancers as well as for radiation (access only) 
and medical oncology. 
•	 An	initiative,	led	by	the	NCRI,	to	define	
the national core cancer dataset has been 
completed and the core dataset disseminated 
to all cancer centres. 
•	 A	project	to	transfer	histopathology	data	
electronically to the NCRI and Cervical Check 
is being rolled out to public hospitals with 
histopathology laboratories.
•	 A	cancer	information	system	to	enable	quality	
assurance and clinical audit was provided in 
Cork, Limerick and Waterford hospitals as 
these cancer centres lacked any such facility 
for data capture. 
•	 National	collation	of	the	KPIs	for	symptomatic	
breast disease commenced in 2010 and 
monthly, quarterly and annual reports are 
produced. 
•	 National	collation	of	upper	gastrointestinal	
and pancreatic KPIs as well as access to 
radiation oncology commenced in 2012 
and monthly, biannual and annual reports 
produced. 
Figure 13.1: Potential Data Sources on Patient Pathway
Potential data sources on patient pathway
DIAGNOSIS TREATMENT
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PALL CARE
DEATH CERT
MED ONC
HIPEPHARMACY
MDT
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•	 Monitoring	of	the	rapid	access	clinics	for	lung	
and prostate cancer commenced in 2012 and 
monthly reports are produced.
•	 Lung,	prostate	and	rectal	KPI	suites	were	
piloted in 2012 and 2013. Full national roll 
out of these KPIs commenced in 2014.
•	 Access	to	medical	oncology	has	been	
monitored since 2013 and monthly reports 
produced. The full suite of KPIs is being 
piloted in 2014.
•	 Volume	and	centralisation	of	cancer	surgery	
for all major cancers is monitored using HIPE 
data on a bi-annual basis. The NCRI database 
also provides insight into the centralisation 
of cancer surgery across all service providers 
both public and private. 
•	 NCRI	data	on	cancer	incidence	and	cancer	
projections is invaluable for service planning. 
Challenges
•	 Lack	of	a	unique	identifier	has	made	
duplication of records and reporting 
inevitable and has made tracking of patients 
outside the hospitals where initial treatment 
occurs extremely difficult. However, this 
challenge will hopefully be addressed by 
the legislation that is currently progressing 
through the Houses of the Oireachtas 
regarding a national unique identifier. 
•	 Current	information	governance	legislation	
inhibits sharing of data on an individual level, 
which has resulted in multiple organisations 
extracting similar data on patients for their 
own individual purposes and multiple 
databases.
•	 Current	information	governance	legislation	
inhibits pooling of data on a national level. In 
addition to the legislative barriers, the wide 
variety of databases collecting data in the 
cancer centres would make such a pooling 
exercise extremely expensive. 
•	 A	deficit	of	staff	with	data	management	and/
or data analytical skills continues to impede 
quality measurement.
•	 Further	manipulation	of	existing	
administrative sources (e.g. outpatient data, 
Special Delivery Unit data) to answer specific 
cancer queries has proven to be challenging.
•	 The	two	year	lag	in	reporting	of	cancer	
treatments by the NCRI has limited its utility 
in service planning and evaluation. 
•	 Lack	of	resources	in	the	NCRI	to	provide	
follow up data beyond one year after 
diagnosis has proven problematic when 
trying to estimate disease prevalence for the 
purpose of estimating service requirements 
and planning drug budgets. 
•	 Most	frameworks	that	address	requirements	
for quality improvement recommend linking 
budgets to performance – currently there is 
inconsistent and patchy data available on the 
cost of cancer care at individual or hospitals 
level. While the HSE is introducing measures 
to improve patient level costing, no robust 
data on the comprehensive cost of cancer 
care are available. 
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14 Cancer Diagnostics
and Quality Assurance
No. 31: The 2006 National Cancer Strategy 
recommended that “Patients should have 
their diagnosis established and their treatment 
planned by site‐specific multidisciplinary 
teams”.
Introduction 
Accurate, complete and timely diagnostic reports 
from pathologists and radiologists are a basic 
requirement for a cancer control programme. 
Multidisciplinary care has been highlighted as 
an essential component in the management of 
patients with cancer. A multidisciplinary team 
meeting is a deliberate, regular, meeting involving 
a range of health professionals with expertise 
in the diagnosis and management of cancer. 
The purpose of the meeting is to facilitate best 
practice management of all patients with cancer. 
The key principle of multidisciplinary care is that 
all cancer patients will have the opportunity to 
have prospective treatment and care planning by 
an appropriate multidisciplinary team. Interactions 
between pathology, radiology and clinical 
specialists at meetings add quality to the diagnosis, 
disease staging and patient management 
decisions. Radiologists and pathologists are core 
members of and important contributors to the 
cancer multidisciplinary team. The role of these two 
specialists is different from other multidisciplinary 
team participants in that they often belong to 
several groups and actively contribute in many 
multidisciplinary team meetings. 
In support of the centralisation of cancer services, 
the growth in demand and the need to develop 
quality assured services the NCCP funded over 
thirteen (13.5) additional consultant radiologist 
posts, ten consultant histopathologist and nine 
senior scientist posts in designated cancer centres 
between 2007 and 2009. 
Pathology
Pathology is the medical specialty concerned with 
the study of the nature and causes of diseases.  
It underpins every aspect of medicine, from 
diagnostic testing and monitoring of chronic 
diseases to cutting-edge genetic research and 
blood transfusion technologies.  Pathology is 
integral to the diagnosis of every cancer. Accurate, 
timely diagnosis and information on the extent of 
disease is essential to plan treatment and future 
management of a patient with cancer. 
In recognition of the importance of pathology 
in cancer control, funding was allocated for an 
additional ten consultant pathology posts in 2008-
2009, in the main to support breast, lung and 
prostate cancer services. 
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Radiology
Radiology is defined as the specialty encompassing 
all aspects of medical imaging that yields 
information regarding anatomical, physiological 
and pathological status of disease. It includes 
those interventional techniques necessary for 
diagnosis, as well as minimally invasive therapy, 
which fall under the remit of departments of clinical 
radiology.
Routine clinical, laboratory, and radiologic 
examinations for malignancies are performed for 
the purpose of tumour detection, diagnosis, and 
accurate staging, so as to enable optimal treatment 
planning. Specific radiologic examinations for each 
malignancy depend on the site, histology, grade, 
and pattern and extent of spread based on clinical 
evaluation.
In recognition of the important role of radiology in 
cancer control, 13.5 radiologists were funded by 
the NCCP in 2008-2009.
National Quality Assurance 
Programmes in Histopathology, 
Radiology and Endoscopy
Quality Assurance (QA) plays an important role 
in the delivery of health care services and is a 
useful tool in helping to avoid adverse health 
outcomes by improving practice or quality of care. 
All health practitioners aim to provide excellent 
service to patients and achieve optimal health 
outcomes. Most health practitioners ensure this 
happens by constantly reviewing, assessing 
and monitoring their work through a variety of 
processes including the review of Key Performance 
Indicators, investigation of critical incidents, peer 
review and audit of their service. Regardless of the 
approach taken, the underlying aim of any quality 
assurance activity is to identify ways in which health 
practitioners’ practices and competence can be 
improved and the quality of current services can be 
maintained and improved. 
The Report of the Commission on Patient Safety 
and Quality Assurance (www.dohc.ie/publications/
pdf/en_patientsafety.pdf?direct=1) concluded that 
clinical audit should be viewed as an essential and 
integral component of professional practice which 
will contribute to improved patient outcomes. It 
acknowledges that there are challenges to clinical 
audit including fear of litigation through disclosure 
of data and states that “to encourage participation 
in clinical audit, clinicians need to feel safe with 
the process and to be assured that it will not be 
used against them in a punitive manner”. The 
Commission recommended the introduction of an 
exemption from Freedom of Information legislation 
and the granting of legal protection from disclosure 
to data related to patient safety and quality 
improvement that are collected and analysed by 
healthcare organisations solely for purposes of 
improving safety and quality. Such legal protection 
is provided in a number of countries and it is 
hoped will be included in the forthcoming Health 
Information Bill. 
Following a number of high profile cancer 
misdiagnoses between 2006 and 2008, the Faculty 
of Pathology, Royal College of Physicians of Ireland 
(RCPI), recognised there was an urgent need to 
ensure that diagnostic standards are high, not 
only for cancer but in general and are improving 
continuously with advances in knowledge. 
Following discussion with the NCCP, it was agreed 
that Faculty of Pathology, RCPI would lead on the 
development and implementation of a National 
Quality Assurance Programme in Histopathology. 
The programme management is by RCPI. The 
National QA programmes in Radiology and GI 
Endoscopy followed in 2010 and 2011 respectively. 
The fundamental aim of these QA Programmes is 
to ensure patient safety and enhance patient care 
with timely, accurate and complete pathology, 
imaging and endoscopy diagnoses and reports. 
The NCCP has provided sponsorship of these 
programmes since their inception. As programmes 
are now beginning to mature and their remit is 
much broader than cancer, sponsorship of the 
programmes transferred to HSE Quality and 
Patient Safety Division in 2014 which will fund the 
programmes from 2015 onwards. 
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National Histopathology Quality 
Assurance Programme 
Pathology, like other diagnostic services, involves 
decision-making with a degree of uncertainty 
and a level of error is unavoidable. The National 
Histopathology Quality Assurance Programme 
evolved in response to misdiagnoses in breast 
cancer in Ireland and subsequent investigations by 
the Health Information and Quality Authority. The 
primary aim of the Programme is to improve quality 
and enhance patient care. 
The National Histopathology QA Programme 
is funded by the NCCP and is the result of a 
collaborative process between representatives 
of the Faculty of Pathology, RCPI, NCCP, HSE 
ICT, Acute Hospitals, Directorate of Quality 
and Patient Safety, relevant HSE departments, 
Department of Health, Independent Hospitals 
Association of Ireland, and the Health Information 
and Quality Authority (as an observer). The scope 
of the Programme includes histopathology, 
cytopathology, neuropathology and autopsy. All 
national private, public and voluntary hospitals with 
histopathology laboratories participate.
The quality assurance guidelines have been 
updated regularly since they were first 
issued in 2009. (http://www.rcpi.ie/content/
docs/000001/312_5_media.pdf). They are intended 
for use primarily by consultant pathologists and 
focus mainly on the clinical interpretation and 
reporting of histopathology and also autopsy 
practice. QA data is extracted and encrypted 
from Hospital Laboratory Information Systems 
and submitted regularly to a central database, the 
National Quality Assurance Intelligence System 
(NQAIS). To date 33 public and private laboratories 
are participating and generating local QA reports. 
Data is uploaded and analysed for accuracy on a 
monthly basis. These data are formally reviewed, 
within each hospital, by the clinical lead and 
Quality Committee on at least a quarterly basis to 
examine trends, identify where targets are being 
met and also areas of underperformance with 
a view to developing and implementing quality 
improvement initiatives. 
The current quality monitors are:
•	 Inter	Institutional	consultation
•	 Intradepartmental	consultation
•	 Correlation	of	frozen	section	diagnosis	with	
final diagnosis
•	 Cytology	quality	assurance
•	 Retrospective	review
•	 Multidisciplinary	Team	Meetings
•	 Laboratory	based	non-conformances
•	 Laboratory	based	External	Quality	
Assessment
•	 Turnaround	Time
•	 Addendum	reports
•	 Reports	communicated	directly	to	clinician	by	
pathologist
Targets have been set for intradepartmental 
consultation, turnaround time and frozen section 
correlation. The first national report was published 
in February 2014. (http://www.rcpi.ie/content/
docs/000001/1623_5_media.pdf?1392311091) 
The report shows an improvement over time, with 
targets now being reached. It is planned to set 
targets for the remaining quality activities. 
National Radiology Quality Assurance 
Programme
Radiology, like many diagnostic services, involves 
decision making under conditions of uncertainty 
and a certain degree of error is inevitable. 
The National Quality Assurance Programme in 
Radiology was launched in 2010. It followed on 
reported cases of cancer misdiagnoses which 
reaffirmed the critical role of QA in the delivery of 
patient care. Few formal measures were in place to 
reassure the public that error is kept to an absolute 
minimum and few national benchmarks for key 
aspects of diagnostic services were in place to 
measure performance.
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The Programme is recognised as a key initiative in 
enhancing patient safety and has received wide 
support from organisations within the healthcare 
sector that are driving the agenda of improved 
patient care.
The National QA Programme has been funded 
by the NCCP since 2012 and is managed by RCPI 
and is led by the Faculty of Radiologists of the 
Royal College of Surgeons in Ireland (RCSI), in 
collaboration with:
•	 Royal	College	of	Surgeons	in	Ireland	
•	 Directorate	of	Quality	&	Patient	Safety	HSE	
•	 Independent	Hospitals	Association	of	Ireland	
(IHAI) 
•	 HSE	Information	and	Communication	
Technology 
•	 HSE	Acute	Services	
•	 Department	of	Health	
•	 Health	Information	and	Quality	Authority	-	
observer 
The objective of this QA programme (combined 
for diagnostic and interventional radiology) is to 
provide guidelines for practical and implementable 
QA measures, which, in conjunction with existing 
local quality systems, will enable each hospital to 
monitor and evaluate their own performance in an 
effort to improve patient safety. These guidelines 
have been developed following consultation with 
Radiologists within the Faculty and in a number 
of pilot hospitals. International QA standards 
and guidelines have been reviewed and adapted 
for this QA programme. The Faculty has made a 
number of recommendations within the guidelines 
and will assist in their phased implementation. 
These recommendations include the quality 
activities that should be carried out and how to 
conduct activities. Key quality indicators have 
been identified to collect QA data. As the data 
matures, each hospital will be able to monitor its 
own performance and compare it to the aggregate 
national performance and intelligent targets to be 
set by the Faculty. 
The basic objective of the rollout of this QA 
Programme is to promote patient safety and 
enhancement of patient care with accurate, timely 
and complete Radiology diagnoses and reports. 
Access to diagnostic radiology and interventional 
radiology services is for all patients and therefore 
the benefit to improvements in patient safety 
through this QA programme will be for the whole 
population. 
Guidelines and an Information Governance 
Policy have been published and participating 
departments have begun quality assurance 
activities.
Quality indicators have been developed in relation 
to: 
•	 Retrospective	peer	review
•	 Prospective	double	reporting
•	 Multidisciplinary	Team	meetings
•	 Discrepancy	meetings
•	 Communication	of	unexpected	clinically	
significant, urgent and critical radiological 
findings 
•	 Focused	audit
•	 Report	turnaround	time
•	 Report	completeness
•	 Inter	institutional	review
In addition to the guidelines for diagnostic 
radiology which will apply equally to interventional 
radiology, there are some specific areas of quality 
assurance to interventional radiology which are 
outlined in these guidelines: 
•	 Outcomes	meetings
•	 Multidisciplinary	team	meetings
•	 Communication	of	unexpected	clinically	
significant, urgent and critical radiological 
findings 
•	 Focused	audit
•	 Report	completeness
•	 External	review	–	registries
A sophisticated ICT system has been procured 
to support QA activities in the Radiology 
Departments. Rollout of the system began in 
March 2014 and is envisaged to take two years to 
complete. 
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National Endoscopy Quality Assurance 
Programme
In advance of the introduction of BowelScreen, 
the Conjoint Board of RCPI and the RCSI, in 
association with the HSE, launched the National 
Quality Assurance Programme in Gastrointestinal 
(GI) Endoscopy in 2011. The programme aims 
to establish a quality assurance framework in 
each endoscopy unit that ensures a high-quality, 
consistent and accurate service, translating into a 
quality patient experience.
The programme is managed by the Conjoint Board 
of RCPI and RCSI, in collaboration with:
•	 National	Cancer	Screening	Service	
•	 Quality	&	Patient	Safety	Directorate	
•	 Independent	Hospitals	Association	of	Ireland	
•	 HSE	Information	and	Communication	
Technology 
•	 HSE	Acute	Hospitals
•	 Department	of	Health	
•	 Health	Information	and	Quality	Authority	-	
observer 
The National QA Programme has a defined 
governance structure which comprises of a 
Steering Committee with representation from the 
Conjoint Board of the RCPI and RCSI and other 
stakeholders. 
GI Endoscopy Quality Assurance guidelines were 
developed by a multidisciplinary Working Group 
of endoscopy physicians, surgeons and nurse 
endosocpists who were appointed by the Conjoint 
Board and these guidelines have now been 
distributed to all participating units. They define 
key areas of QA in the delivery of endoscopic 
procedures and how to embed them in routine 
clinical practice. The guidelines ensure that there 
is a consistent and standard method of recording 
Key Quality Data (KQD) across all participating 
hospitals.
For each QA activity, a number of targets, or 
Quality Indicators (QI), have been identified. Where 
there are no quality indicators due to a lack of 
sufficient evidence upon which to base a standard, 
a key recommendation has been made.
Key Quality Data required for the programme are 
collected locally by each unit on their Endoscopy 
Reporting System (ERS). Targets/QIs) have been set 
using best international practice. 
The National Quality Assurance Intelligence 
System (NQAIS), already used by the National QA 
Programme in Histopathology, was adapted from 
the HSE Health Information Unit system. NQAIS is 
the central data repository for the GI Endoscopy 
programme and has been enhanced to store, 
analyse, access and report on key quality data.
The Quality Assurance Programme is entering 
into the implementation phase, with the 
testing of NQAIS-Endoscopy system taking 
place in a number of pilot sites. Once the GI 
Endoscopy Quality Assurance Programme is fully 
implemented, each endoscopy unit will be able 
to create quality assurance reports, from NQAIS, 
based on the quality activity of the unit as set out 
in the guidelines. 
The reports will enable units to monitor, review and 
improve the quality of their work in the context 
of national norms and evidence based quality 
indicators.  
The guidelines have been circulated to all public, 
private and voluntary hospitals in Ireland providing 
endoscopy services. The introduction of this 
programme has many benefits including:
•	 Improved	patient	care	and	increased	public	
confidence in diagnosis 
•	 Standardised	QA	systems	
•	 Data	available	to	individual	units	to	review	
their own performance against national 
targets. 
•	 Identification	of	good	practice	and	areas	of	
improvement 
•	 Improved	communication	within	and	between	
institutions 
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15Research
The 2006 National Cancer Strategy 
recommended that:
No. 51. The third National Cancer Forum, in 
partnership with the HRB, should advise 
on the development of a specific plan for 
cancer research
No. 52. There should be improved clinical trial 
entry for patients, both in terms of the 
number of trials conducted and the 
enrolment to them
No 53. Ireland should establish a national tissue 
biobank to support research and service 
delivery
No. 54. The HRB should establish a national 
cancer research database
Promotion of access to clinical translational and 
health services research in the country makes an 
important contribution to improving the care of 
those with cancer.
The NCCP strongly supports the integration of 
research into clinical practice but is not responsible 
for funding or delivery. There are several key 
players in the promotion of cancer research 
in Ireland. Key amongst these are ICORG (All 
Ireland Co‐operative Oncology Research Group), 
the Health Research Board (HRB), , the Irish 
Cancer Society, the National Cancer Registry of 
Ireland (NCRI) and a number of smaller charities 
who support and promote research and patient 
participation in clinical trials. All of the designated 
cancer centres are linked with Irish universities and 
play an active role in both clinical and translational 
research. 
The majority of cancer clinical trials conducted 
in Ireland are overseen by the All Ireland Co‐
operative Oncology Research Group (ICORG),. This 
is a North‐South organisation that brings clinical 
cancer research to Ireland. In the past fifteen years 
ICORG has succeeded in offering research options 
to over 10,300 patients. ICORG (www.icorg.ie) is 
responsible for scaling up the number of clinical 
trials available and the accrual of patients across 
the academic centres in the country. 
In 2013, ICORG had over seventy cancer 
clinical trials open to recruitment, with more 
than 100 active and collaborated with over fifty 
pharmaceutical companies and universities 
worldwide. During the year 1,600 patients 
nationally enrolled in ICORG clinical trials. In 
addition, access was made available to over twenty 
five new cancer drugs and treatments and there 
were seven publications in high impact medical 
journals. 
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While the NCCP does not directly fund research 
it has provided some financial support to ICORG 
to assist with data management and in moving 
forward a number of clinical trials in order to 
reduce the time from planning stage to start-up. 
The Director of the NCCP, Dr. Susan O’Reilly is a 
member of the Board of ICORG. A detailed report 
on progress achieved in 2013 is available in TD 14. 
Irish Oncologists have typically been well 
represented in international collaborations and 
have been important members of international 
research collaborations designing and leading 
effective clinical research. This undertaking has 
significant benefits not only for patients with 
cancer in Ireland, who have access to innovative 
therapeutics. In addition, the hospital benefits 
where, in some circumstances, the availability 
of free research-based treatment has reduced 
the financial cost of providing drug therapy for 
patients in selected circumstances such as phase 
3 randomised trials. ICORG has estimated that 
participation in cancer clinical trials has saved the 
State over €5m in funding annually.
Ireland is also a participating state in the 
International Agency for Research on Cancer 
(IARC), which provides valuable research into many 
aspects of cancer control.
In translational research, clinical trials are an 
opportunity for tissue acquisition and for the study 
of molecular oncology changes that may either 
be predictive or prognostic in determining the 
underlying nature and behaviour of cancers. The 
establishment of specialised molecular cancer 
laboratories with high volumes of referrals will 
improve quality and facilitate large clinical trials. 
Many hospital laboratories in conjunction with 
academic research centres are now planning to 
acquire next generation sequencers which will 
significantly improve the capacity to process tests 
and to undertake research. 
Cancer research is included within the statutory 
remit of the National Cancer Registry. The primary 
aim of the research programme of the Registry is 
to provide information which will help reduce the 
cancer burden, through understanding of: 
•	 aetiology	and	risk	factor	prevalence	
•	 stage	distribution	of	cancer	and	factors	
affecting this, including screening
•	 patterns	of	care,	their	determining	factors	and	
results
•	 outcomes	of	cancer	care,	including	patient-
reported outcomes, survival and long-term 
sequelae of cancer
The Director of the NCCP, Dr. Susan O’Reilly, is 
also the current Chair of the Board of the National 
Cancer Registry of Ireland. A detailed report of 
the recent research work of the National Cancer 
Registry is included in TD 13.
For the future of research in Ireland the NCCP 
envisages that the considerable advances in 
personalised medicine in determining treatment 
decisions for cancer with specific molecular 
abnormalities and genetic mutations will continue 
to drive the direction of research, both in clinical 
trials and in translational science. Developments 
in these areas will inevitably drive the directions 
of therapeutics for patients and, over time, we 
anticipate that a combination of innovation and 
evidence based best practice along with highly 
organised cancer systems, prompt access to 
screening, diagnosis and care will continually 
improve outcomes for patients in Ireland.
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A Strategy for Cancer Control in Ireland - Vision 
 
 
‘Ireland will have a system of cancer control which will reduce our cancer 
incidence, morbidity and mortality rates relative to other EU15 countries by 
2015.  Irish people will know and practice health promoting and cancer- 
preventing behaviours and will have increased awareness of and access to 
early cancer detection and screening.  Ireland will have a network of 
equitably accessible state-of-the-art cancer treatment facilities and we will 
become an internationally recognised location for education and research 
into all aspects of cancer.’ 
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1. Introduction 
 
In 2006 the government published A Strategy for Cancer Control in Ireland.  The Strategy 
emphasised the association between volumes of certain procedures and patient outcomes, 
stating that it was not in the best interests of patients that hospitals perform small volumes of 
cancer surgery. 
 
Launching the Strategy the Minister for Health Mary Harney, TD said  ‘To ensure that every 
patient gets the best quality care, we need to develop better ways of hospitals and health 
professionals working together based on connection and partnership rather than on isolation and 
self-sufficiency.’ 
 
The Strategy identified an evidence based requirement to establish specialist Cancer Centres, 
each serving a minimum population of 500,000.  Ireland will therefore require eight such centres. 
The strategy recommended that Cancer Centres should be networked together in Managed 
Cancer Control Networks and that there should be a broad aim of equipping each of the HSE’s 
four regions with broad self sufficiency of services in relation to the more common forms of 
cancer. 
 
Cancer Centres within the national Managed Network should be seen as equal partners, but in 
order to ensure adequate case-volume and expertise, some of the Cancer Centres will be 
required to provide a higher level of care for those less common cancers that need larger 
volumes than would present if that form of cancer were to be treated at all Cancer Centres. 
 
In June 2006 the HSE announced its intention to establish a National Cancer Control 
Programme to implement the Strategy.  The HSE had concluded that there was a need for a 
national programme to provide the necessary governance, integration and leadership to create 
the essential framework for a successful transformation of cancer control activities in Ireland. 
 
This Programme will manage, organise and deliver cancer control on a whole population basis, 
through the application of evidence-based policy to clinical practice and all other components of 
cancer control.  The delivery of cancer services on a programmatic basis will serve to ensure 
equity of access to services and equality of patient outcome irrespective of geography. 
 
Delivering on this objective and improving cancer outcomes is about far more than just re- 
organising hospital services, but there are significant and immediate gains to be made from 
changes in the provision of acute cancer services. 
 
A vital step in this process is the identification of eight cancer centres and the re-alignment of a 
number of existing hospital services from their present locations.  In many instances there are 
simply too many hospitals treating too few patients. 
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Given the importance of cancer surgery, in particular, in determining outcomes for patients with 
cancer, this is likely to be a significant reason for Ireland’s relatively poor cancer survival and the 
relatively poor survival for certain cancers outside of Dublin.  This is contrary to patient interests 
and diffuses both resources and expertise in an entirely counter productive way.  This can no 
longer be permitted. 
 
The HSE established an Advisory Group to assist it in designing the Cancer Control Programme 
(See Appendix B) and commissioned a Working Group (See Appendix A) to review the available 
evidence and make informed and expert judgements on the most appropriate configuration of 
the Managed Cancer Control Networks and centres. 
 
At one level the issues which underpin this approach may appear extremely complex.  At 
another level they are in fact quite straightforward.  Ireland has many excellent, highly skilled 
and expert cancer specialists.  We do not at present make best or consistent use of these 
talents and we have not yet created the optimum environment for consistent success. 
 
Ireland already achieves good outcomes by international standards in the field of paediatric 
cancer.  Paediatric Cancer services are already concentrated appropriately to achieve critical 
mass and optimum care. Ireland has developed a successful and effective model of population 
based breast cancer screening.  BreastCheck’s clinical performance is based on a case volume 
related centralised model and it is achieving world class levels of performance. 
 
However, Ireland has not thus far adopted this approach for acute adult cancer services in 
general.  Ireland does not, in general, have good outcomes by international standards, for the 
population as a whole.  The full implementation of the Cancer Strategy will enable us to do much 
better.  The designation of cancer centres and the resulting reorganisation of services is a 
critical step. 
 
I wish to acknowledge the hard work and commitment of all those involved in this process and, 
in particular, the members and other participants of the Advisory and Working Groups. 
 
It is essential that the changes outlined in this Report are implemented if we are to achieve our 
true potential in cancer control. This Report was approved by the Advisory Group on September 
24th 2007 and has been accepted by the Health Service Executive. 
 
 
 
 
 
 
 
 
 
Tony O’Brien 
Chairman 
HSE Managed Cancer Control Networks and Centres Working Group 
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2. Essential Characteristics of a National Cancer Control Programme in order 
to implement a Managed Cancer Network model 
 
The full implementation of the Cancer Control Strategy and the achievement of optimal cancer 
outcomes will require the adoption of a new approach to the management of hospital based 
cancer services across geographical locations and traditional institutional boundaries. 
 
For this reason it will be necessary for the National Cancer Control Programme to become the 
budget holder for all identifiable cancer related HSE expenditure.  In this way it will have the 
capacity to redirect resources between services and the capacity to enter into an appropriate 
blend of governance arrangements ranging from direct management to commissioning and 
performance management models.  The Programme will have the characteristics of an Agency 
within the HSE. 
 
The Director of Cancer Control will require significant authority over cancer control assets to 
ensure that they are used to best effect.  Equally the Director will require the authority to direct 
the discontinuation of any services that do not meet the standards and criteria set. 
 
It is important to stress that the development of the National Cancer Control Programme signals 
a profound change in the approach of the health services to the management of key cancer 
control assets.  Key cancer assets will be managed in the interests of the population as a whole 
in a tightly co-ordinated networked system.  Key services and facilities are therefore no longer to 
be regarded as the prized assets of individual institutions.  It is an essential characteristic of the 
Cancer Control Programme that such assets are understood to be under the ultimate control of 
the Cancer Control Programme itself. 
 
Clarity about the character of the Programme is central to understanding the inter-relationship 
between the different cancer centres and the rationale for the distribution of specific services 
between those centres.  This can be illustrated in the context of radiation oncology. 
 
When completed, the National Plan for Radiation Oncology will ensure the public provision of 
radiotherapy at six (6) public sites in the country.  However access to these services will be 
equal as between all eight (8) managed cancer control centres.  It should not be regarded as 
necessary for each cancer centre to have radiotherapy on its own site in order for its patients to 
have equality of access to the radiation oncology service. 
 
The radiation oncology facilities being developed under the national plan will be controlled by the 
National Cancer Control Programme, will operate to a single set of operational standards and 
protocols, and will provide absolute equality of access based on clinical need.  A similar 
approach will be applied to all other sub-specialties. 
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The National Cancer Control Programme will also1: 
 
• Be committed to regional implementation of interventional cancer control services 
according to nationally derived policies and plans. 
 
• Define national operational standards and ‘best practices’ according to evidence of 
benefit on a tumour by tumour basis. 
 
• Monitor compliance with practices of cancer control according to commonly agreed ‘best 
practices’ based upon evidence for most cost-effective use of public funds. 
 
• Ensure accountability for the delivery of interventional services according to annual 
operating plans (incorporating volumes, access, quality and safety) within agreed budgets 
and with public reporting of performance, quality and safety measures. 
 
• Establish a strategy for cancer research across institutions (university, institution and 
foundation-based), including the integration of science and medicine towards achieving 
enhanced cancer control outcomes. 
 
• Act according to ethical and moral standards/principles consistent with ‘best practices’ of 
cancer control and optimal use of public funds for public health benefits. 
 
• Develop common infrastructure capabilities to facilitate population-based, outcomes 
focused cancer control, i.e. ICT, web-site, health records (EHR) etc. 
 
• Ensure that staff work within accepted/established norms of competence (as defined 
through programmes relating to professional disciplines of care, and including reporting 
relationships, manpower and workload standards and expectations of competence). 
Centres ensure the presence and application of procedures to ensure compliance. 
 
• Be committed to ‘outreach’ or provision of expertise across communities as a means of 
minimizing impacts of geography/distance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
The significant input of Dr Simon B. Sutcliffe, President, BC Cancer Agency, in assisting with the definition of 
Characteristics of a National Cancer Control Programme is acknowledged. 
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3. Operation of Managed Cancer Control Networks 
 
Managed Cancer Control Networks will facilitate the provision of care which is fully integrated 
between primary care, hospitals, palliative care, psycho-oncology and supportive care.  This will 
enable full advantage to be taken of the resources available to ensure the delivery of services 
that are of the highest quality and are equitable and accessible.  The emphasis in such a 
network will be on connection and partnership rather than isolation and self-sufficiency, on 
distribution of resources rather than centralisation, and on maximising the benefits for all patients. 
 
A Managed Cancer Control Network must feature the sharing of patients, expertise and 
resources.  It will allow, for example, hospitals to cooperate to provide services when the 
population base of each is too small for them to do this in isolation.  A good example will be 
radiotherapy which should exist in each network and provide access to patients from all centres 
within that region in a manner which is determined by clinical need as distinct from other 
considerations. 
 
The Health Service Executive will organise all the services it provides (primary, community and 
continuing care, as well as the National Hospitals Office) in four such networks on a national 
basis, each serving population catchments of approximately one million people.  This is a tried 
model for cancer care in that cancer control networks in other countries are organised around 
similar population sizes.  At this level each Managed Cancer Control Network should be self- 
sufficient in all but a small number of comparatively uncommon or complex cancers. 
 
Managed Cancer Control Networks will require capacity for Human Resources development, 
including education, training and post-graduate development across a range of professions 
related to cancer control (service delivery, academia, and support services); 
 
Managed Cancer Control Networks will require system capacity expansion potential – future 
opportunities to expand both national and regional capacity through: 
 
- Facilities expansion (new and/or modifications to existing) 
 
- Capital equipment expansion 
 
- Services expansion – both standard and sub-specialty services 
 
- Research capacity expansion (new facilities and/or modifications to existing clinical 
and/or university facilities) 
 
- HR training facilities expansion – technical/trade schools, academic facilities, 
professional ‘placement’ and training. 
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4. Criteria for the designation of Cancer Centres 
 
Successful cancer centre models elsewhere have been examined in conjunction with the 
Strategy.  On the basis of this examination the following criteria have been established for the 
designation and ongoing development of cancer centres: 
 
• Each Cancer Centre must serve a population of at least 500,000 
 
• In the Irish context each of the four HSE Regions will be required to have broad self 
sufficiency in respect of the most common cancers 
 
• Each HSE Region will have two Cancer Centres in a Managed Cancer Control Network. 
 
• Rare and complex cancers will be treated by a subset of the eight cancer centres, 
consistent with evidence based practice and likely population incidence 
 
• Centres will be designated for the treatment of rare and complex cancers based on an 
analysis of existing patterns of care and pre-existing resources within the limitations of the 
criteria outlined above. 
 
• Cancer Centres must be well supported by general medical and surgical infrastructure 
(including all general consultation services, including pathology, lab-medicine and 
radiology/imaging as well as support services, e.g. respiratory, physiotherapy, 
occupational therapy, rehabilitation, nutrition, palliative care) 
 
• Cancer Centres will require availability of critical surgical subspecialty services to support 
cancer control activity 
 
• Cancer Centres will require availability of medical oncology/systemic therapy support – 
consultation, therapy, curative and palliative therapies, clinical trials, etc. 
 
• Host hospitals must be receptive to and have the capacity to sustain a multi-disciplinary 
team environment engaging health professionals across common clinical services and 
academic endeavours 
 
• Cancer Centres will require host hospitals with an academic environment – availability of 
university and/or technical education facilities for education and specialty training for 
health professions 
 
• Cancer centres will require a research environment within the national network – 
availability of university facilities, research institutions and research infrastructure 
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5. Anatomical Site Specific Cancers and Cancer Centres 
 
Evidence related to cancer volumes and cancer outcomes has been reviewed in order to 
determine the number of centres that should be involved in the diagnosis and treatment of each 
form of cancer. 
 
Cancers have been categorised as follows: 
 
• Those requiring more than one Cancer Centre per Network; 
 
• Those requiring one Cancer Centre per Network; 
 
• Those requiring less than one site per network; 
 
• Those requiring one National Centre only. 
 
This process has been additionally informed by: 
 
• A “principles document” commissioned from the British Columbia Cancer Agency 
• Existing international recommendations for the organisation of individual anatomical site 
specific cancers (listed below), where they are available; 
• information on cancer incidence and mortality, cancer projections and hospital utilisation 
data; 
• Demography and hospital utilisation data 
• Expert opinion from the Advisory and Working Groups. 
 
The National Quality Assurance Standards for Symptomatic Breast Disease Services has also 
been reviewed.  An approach to the implementation of these standards has been developed and 
this has also served as a general template for the change management approach for other 
symptomatic services following the designation of the cancer centres. See section 6. 
 
Following designation, all acute sector cancer investment will be re-directed to the selected 
centres and away from existing fragmented services. 
 
It will be necessary to strengthen services at the eight centres to enable them to cope effectively 
with the workload which will be redirected from elsewhere.  It will also be necessary to develop 
mechanisms to enable appropriate expertise located outside the eight centres to be migrated 
into re-configured services. 
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The following are identified as core operating requirements for each Cancer Centre in respect of 
each tumour group: 
 
• All patients must be seen, reviewed, treatment decisions made, and treated by 
an MDT team prior to surgical or other intervention 
 
• Provision of national protocols for treatment options and follow-up care plans 
on a tumour by tumour basis 
 
• Specialist nursing 
 
• Dual / Tri modality care – access to pre and post op Radiation Oncology 
 
• Adequate access to appropriate radiology and pathology services as well as 
other laboratory services 
 
• Appropriate access to prosthetic and reconstructive services 
 
• Full participation in research including clinical trials 
 
• Undergraduate and postgraduate teaching in oncology 
 
• Rapid access clinics 
 
• Dietetic services 
 
• OT, physiotherapy and other support services on site 
 
• Counselling services 
 
• Access to genetic services 
 
• Availability of clinical and compounding pharmaceutical services 
 
• Psycho oncology services 
 
• Social work services 
 
• Community care services on discharge 
 
• Access to day bed/ambulatory care facilities during therapies 
 
• Access to specialist palliative care 
 
The National Programme will need sufficient resources to implement appropriate systems of 
clinical and other QA audit together with population based cancer surveillance. 
179 Report on the implementation of ‘A Strategy for Cancer Control in Ireland 2006’
Establishment of Managed Cancer Control Networks and Designation of Eight Cancer Centres 
11 
 
 
 
 
 
6. Designation of Cancer Centres 
 
Designated Cancer Centres will deliver diagnostic, surgical, medical (systemic) and radiation 
oncology services. 
 
The delivery of systemic therapy services (medical oncology/chemotherapy), once centrally 
planned, will be delivered within the Network under national protocols.  Patient support and 
palliative care services will also be provided at local level to ensure ease of access. 
 
Cancer Centres will be located and networked within each of the four HSE administration 
regions. 
 
The HSE Regions are: 
 
• HSE Dublin North East 
• HSE Dublin Mid Leinster 
• HSE South 
• HSE West 
 
The Managed Cancer Control Networks and  designated Cancer Centres within each Region will 
be as follows: 
 
Dublin North East 
1.  Beaumont Hospital, HSE Dublin North East 
2.  Mater Misericordiae Hospital, HSE Dublin North East 
 
Dublin Mid Leinster 
3.  St James’s Hospital, HSE Dublin Mid Leinster 
4.  St Vincent’s University Hospital, HSE Dublin Mid Leinster 
 
HSE South 
5.  Cork University Hospital, HSE South 
6.  Waterford Regional Hospital, HSE South 
 
HSE West 
7.  University College Hospital Galway, HSE West (with some linkage to 
Letterkenny see page 12) 
8.  Limerick Regional Hospital, HSE West 
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Linkage to Letterkenny 
 
There are particular and unique geographical circumstances applying to Donegal. This is 
reflected in north-south co-operation in the provision of radiotherapy from Belfast. 
 
On a sole exception basis, the Managed Cancer Control Network in the West will therefore be 
permitted to enter into outreach service delivery in Letterkenny as an  additional activity.  This 
exception is subject to: 
 
• The core case volumes at Galway meeting the minimum criteria (not taking into 
account any remote care caseload arising from this provision) 
 
• All other QA criteria being satisfied on the same basis as for care delivered in 
Galway 
 
• Services to be provided by staff attached to the Galway Cancer Centre 
 
• Integrated clinical governance provided by the Galway Centre 
 
• Outreach activity if undertaken, should be incorporated in rigorous process and 
outcome audit as though the activity took place at Galway to ensure that the 
provision of such an outreach service does not serve to place patients availing 
of it at any disadvantage compared with patients treated in Galway 
 
• The potential to meet the needs of cancer patents in Donegal through North- 
South initiatives, such as the Belfast Radiation Oncology service must be 
optimised and fully facilitated 
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7. The Configuration of services per Anatomical Site Specific Cancers is as 
follows. 
 
The section of the Report details the process of change in relation to each major 
anatomical site specific cancers. It specifies the number of centres which will be 
designated for the purpose of providing primary curative surgery in the context of full 
multi-disciplinary care.   For each of the anatomical site specific cancers to be treated at less 
than eight of the designated cancer centres, the National Cancer Control Programme will review 
data and other available evidence and designate centres accordingly. 
 
 
 
Breast 
There are currently about 2,000 breast cancers managed surgically in the public hospital system 
in Ireland.  It can be expected that BreastCheck, the National Breast Screening Programme will 
reduce this number of symptomatic presentations over time by between 33% and 50%.  Taking 
into account existing levels of activity in some larger Centres, and the minimum throughput (150 
new cases per year) in the report of the Expert Group chaired by Professor O’Higgins, this 
indicates that Ireland will require no more than eight such Centres. 
 
It has been concluded that the treatment of symptomatic breast disease will be delivered 
at all Eight (8) Cancer Centres. 
 
The implementation of the transition to eight centres outlined below illustrates the approach of 
the National Cancer Control Programme to the reorganisation of cancer services for each 
tumour group. 
 
Services will be withdrawn sequentially from hospitals which do not meet the defined criteria for 
delivery of symptomatic breast care, commencing with the lowest volume hospitals and 
ultimately including all hospitals which do not meet the Guideline standards  Arising from the 
designation of cancer centres, the HSE will direct the following hospitals with low case volumes 
to no longer provide multi-disciplinary symptomatic breast services and surgical treatment with 
immediate effect: 
 
1.  Naas General Hospital 
2.  Tullamore General Hospital 
3.  St Columcille's Hospital, Loughlinstown 
4.  Mallow General Hospital 
5.  Louth County Hospital 
6.  Cavan General Hospital 
7.  Our Lady’s Hospital, Navan 
8.  Mid Western Regional Hospital, Nenagh 
9.  Ennis General Hospital 
10. St Michael’s Hospital, Dun Laoghaire 
11. Roscommon County Hospital 
12. Portiuncula Hospital 
13. Mercy University Hospital, Cork (Cytology and Histopathology services in 
association with SIVUH exempted) 
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A number of these hospitals have in practice already discontinued symptomatic breast services. 
The National Hospitals Office has already planned the redirection of this symptomatic caseload. 
 
Additional groups of hospitals will be similarly directed, in line with the further development of 
quality assured capacity in the eight designated centres. 
 
It has also been concluded that it is necessary to ensure that HSE provided or funded facilities 
are no longer available to provide services, such as cytology and histopathology, to public or 
private sector hospitals and clinics which do not meet the O’Higgins guidelines, or in the 
absence of appropriate multi-disciplinary processes.  Independent verification of such 
compliance by private sector providers will be required. 
 
Colon 
It has been concluded that curative surgical treatment of primary colon and rectal cancers 
should be distinguished due to the high level of care and surgical skill required for the treatment 
of rectal disease. 
 
It has been concluded that the curative surgical treatment of primary colon cancers will be 
delivered at all Eight (8) Cancer Centres 
 
Colorectal 
The treatment of colorectal cancers was identified as a subset of colon cancers. 
 
It has been concluded that curative surgical treatment of primary colorectal cancer should be 
delivered in Four (4) Centres, one (1) within each Network. 
 
 
Thoracic 
It has been concluded that there is a need for Four (4) Centres nationally, one (1) within each 
Network, for the curative surgical treatment of primary thoracic cancers. 
 
Testicular 
It has been concluded that there is a need for Four (4) Centres nationally, one (1) within each 
Network, for the curative surgical treatment of primary testicular cancers 
 
Upper GI 
The Working Group concluded that there is a need for Two (2) Centres nationally for the 
curative surgical treatment of primary Upper GI cancers. 
 
Hepatobiliary including Pancreas 
It has been concluded that curative surgical treatment of primary Hepatobiliary cancers will be 
provided in One (1) National Centre. 
 
 
 
Gynaecological 
It has been concluded that there is a need for Four (4) Centres nationally, one (1) within each 
Network, for the curative surgical treatment of primary gynaecological cancers. 
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Brain and Other CNS 
It has been concluded that curative surgical treatment of primary Brain and Other CNS diseases 
will be provided in One (1) National Centre. 
 
Haematological 
It has been concluded that there is a need for Four (4) Centres nationally, one (1) within each 
Network, for the treatment of haematological cancers. 
 
Head and Neck 
It has been concluded that curative surgical treatment of complex primary Head and Neck 
diseases will be treated in One (1) National Centre. 
 
Paediatric Oncology 
It has been concluded that Paediatric Oncology will continue to be provided in One (1) National 
Centre. 
 
This model is already operating with considerable success.  Every child who develops cancer 
has their diagnosis established and treatment planned at the OLHSC in Crumlin.  This model of 
care has resulted in Ireland having a better performance for cancer care for children than adults, 
when compared to European benchmarks. 
 
OLHSC oncology services should continue until the new National Children’s Hospital is 
established and it should therefore be the appropriate centre for the delivery of paediatric 
oncology thereafter. 
 
Primary Bone and Soft Tissue Sarcomas 
It has been concluded that there is a need for One (1) National Centre for the treatment of 
Primary Bone and Soft Tissue Sarcomas. 
 
Skin 
It has been concluded that there is a need for Four (4) Centres nationally, one (1) within each 
Network, for the treatment of complex skin cancers, requiring multi disciplinary care. 
 
Urological 
It has been concluded that there is a need for Four (4) Centres nationally, one (1) within each 
Network, for the curative surgical treatment of primary urological cancer. 
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This Report and its recommendation has been accepted by the HSE and implemented as 
follows: 
 
 
8. How will these changes be implemented? 
 
The implementation of the Managed Cancer Control Networks will necessitate tapering in of 
additional capacity at the designated centres in tandem with the sequential withdrawal of 
services from other locations.  It will be necessary for the distribution of other acute services in 
the hospital sector to be rebalanced by the National Hospital’s Office. 
 
It is likely that those hospitals withdrawing from the provision of surgical oncology will be in a 
position to receive non-oncology services displaced from the designated cancer centres as a 
result of their increased oncology workloads and resulting demands on core services and 
facilities. 
 
In order to ensure the rapid transformation of cancer care in line with the Strategy for Cancer 
Control it will be necessary for the HSE to put in place arrangements which allow for: 
 
i.  Providing the Director of cancer control with full control over the use of 
funding for all cancer control activity within hospitals 
 
ii.  Non cancer related clinical activity to be moved, through the application of 
incentives by the HSE, from designated cancer centres to other locations 
thereby allowing capacity to be increased in the cancer centres 
 
iii.  The Director of cancer control to provide incentives for care to be provided 
through cancer centres, while applying financial disincentives to smaller 
facilities which are not designated as cancer centres to ensure that care 
does transfer to designated centres 
 
iv.  Development of standardised care pathways for individual cancer types to 
be applied to each managed cancer control network which reflect the 
designation of cancer centres 
 
v.  Publication and marketing of information for GPs and the public in general 
on care pathways, accessibility and referral criteria and on waiting times for 
such services to ensure that fully informed referral decisions are made by 
patients and general practitioners 
 
vi.  A structured programme of quality assurance, support and information 
services to underpin the re-organisation of services so as to ensure that 
cancer patients will receive quality services as close to home as possible. 
 
vii.  It will be a priority for the National Cancer Control Programme to establish 
detailed transition plans for the migration of services in accordance with 
quality assurance guidelines to be established for each tumour group. 
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It will take time for these arrangements to be fully developed and implemented.  The HSE has 
made initial decisions in respect of some cancers in smaller centres which will be implemented 
as follows: 
 
 
 
• 13 centres (see page 16) to stop doing breast cancer surgery immediately, to be followed by 
further staged reductions in the number of centres. 
 
• In addition to this, all non Cancer Centres will be directed not to conduct low volume, complex, 
elective cancer surgery for a number of primary cancers such as lung, pancreas, oesophagus, 
rectum etc.  The specific hospitals will be identified through analysis of surgical activity on a 
hospital specific basis with a view to enacting these changes by January 2008. 
 
• St Luke’s Hospital, Rathgar will be integrated in the Cancer Control Programme and 
continue in operation pending full implementation of the National Plan for Radiation 
Oncology. 
 
The HSE will actively inform the public of these decisions as they are made and will actively use 
financial incentives and other control measures to ensure that hospitals comply. 
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Appendix 2
ALL OESOPHAGEAL RESECTIONS
for Upper GI cancers
ALL GASTRECTOMIES
for Upper GI cancers
YEAR
Number (%) 
within a Cancer 
Centre
Number (%) 
outside a 
Cancer Centre
Total (%)
Number (%) 
within a Cancer 
Centre
Number (%) 
outside a 
Cancer Centre
Total (%)
2007 84 (62.7) 50 (37.3) 134 (100.0) 86 (55.5) 69 (44.5) 155 (100.0)
2008 100 (71.9) 39 (28.1) 139 (100.0) 106 (62.4) 64 (37.6) 170 (100.0)
2009 104 (73.8) 37 (26.2) 141 (100.0) 98 (59.4) 67 (40.6) 165 (100.0)
2010 104 (73.2) 38 (26.8) 142 (100.0) 124 (68.5) 57 (31.5) 181 (100.0)
2011 114 (73.5) 41 (26.5) 155 (100.0) 90 (62.9) 53 (37.1) 143 (100.0)
2012 96 (75.6) 31 (24.4) 127 (100.0) 90 (60.4) 59 (39.6) 149 (100.0)
2013 96 (77.4) 28 (22.6) 124 (100.0) 87 (66.4) 44 (33.6) 131 (100.0)
Source: HIPE, ESRI. Data generated by HIPE Portal. 
ALL RECTAL CANCER SURGERY ALL LUNG CANCER SURGERY
YEAR
Number (%) 
within a Cancer 
Centre
Number (%) 
outside a 
Cancer Centre
Total (%)
Number (%) 
within a Cancer 
Centre
Number (%) 
outside a 
Cancer Centre
Total (%)
2007 190 (43.4) 248 (56.6) 438 (100.0) 241 (100.0) 0 (0.0) 241 (100.0)
2008 199 (49.1) 206 (50.9) 405 (100.0) 272 (100.0) 0 (0.0) 272 (100.0)
2009 237 (51.7) 221 (48.3) 458 (100.0) 282 (100.0) 0 (0.0) 282 (100.0)
2010 249 (54.2) 210 (45.8) 459 (100.0) 297 (100.0) 0 (0.0) 297 (100.0)
2011 279 (66.4) 141 (33.6) 420 (100.0) 321 (100.0) 0 (0.0) 321 (100.0)
2012 311 (72.0) 121 (28.0) 432 (100.0) 401 (100.0) 0 (0.0) 401 (100.0)
2013 317 (76.6) 97 (23.4) 414 (100.0) 385 (100.0) 0 (0.0) 385 (100.0)
Source: HIPE, ESRI. Data generated by HIPE Portal. 
Cancer Surgery Activity within and without cancer centres 2007 – 2013
Distribution of discharges from public hospitals following primary surgical treatment of the following 
cancers: rectal, upper gastrointestinal, prostate, renal, testicular, bladder, breast, lung, ovarian, 
uterine and radical cervical resection for a cancer diagnosis. 
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ALL PROSTATE CANCER SURGERY ALL RENAL CANCER SURGERY
YEAR
Number (%) 
within a Cancer 
Centre
Number (%) 
outside a 
Cancer Centre
Total (%)
Number (%) 
within a Cancer 
Centre
Number (%) 
outside a 
Cancer Centre
Total (%)
2007 156 (60.9) 100 (39.1) 256 (100.0) 182 (68.9) 82 (31.1) 264 (100.0)
2008 139 (54.7) 115 (45.3) 254 (100.0) 192 (69.3) 85 (30.7) 277 (100.0)
2009 150 (57.7) 110 (42.3) 260 (100.0) 211 (75.6) 68 (24.4) 279 (100.0)
2010 186 (61.4) 117 (38.6) 303 (100.0) 228 (76.5) 70 (23.5) 298 (100.0)
2011 241 (68.9) 109 (31.1) 350 (100.0) 222 (75.3) 73 (24.7) 295 (100.0)
2012 247 (72.4) 94 (27.6) 341 (100.0) 258 (75.7) 83 (24.3) 341 (100.0)
2013 201 (69.3) 89 (30.7) 290 (100.0) 240 (77.9) 68 (22.1) 308 (100.0)
Source: HIPE, ESRI. Data generated by HIPE Portal. 
ALL BLADDER CANCER SURGERY ALL TESTICULAR CANCER SURGERY
YEAR
Number (%) 
within a Cancer 
Centre
Number (%) 
outside a 
Cancer Centre
Total (%)
Number (%) 
within a Cancer 
Centre
Number (%) 
outside a 
Cancer Centre
Total (%)
2007 239 (54.6) 199 (45.4) 438 (100.0) 65 (46.8) 74 (53.2) 139 (100.0)
2008 289 (57.1) 217 (42.9) 506 (100.0) 73 (54.1) 62 (45.9) 135 (100.0)
2009 376 (64.5) 207 (35.5) 583 (100.0) 61 (53.5) 53 (46.5) 114 (100.0) 
2010 370 (58.0) 268 (42.0) 638 (100.0) 77 (55.8) 61 (44.2) 138 (100.0)
2011 382 (61.9) 235 (38.1) 617 (100.0) 70 (53.8) 60 (46.2) 130 (100.0)
2012 369 (60.7) 239 (39.3) 608 (100.0) 80 (59.3) 55 (40.7) 135 (100.0)
2013 377 (59.7) 255 (40.3) 632 (100.0) 60 (53.6) 52 (46.4) 112 (100.0)
Source: HIPE, ESRI. Data generated by HIPE Portal. 
ALL BREAST CANCER SURGERY ALL PANCREATIC TUMOUR SURGERY
YEAR
Number (%) 
within a Cancer 
Centre
Number (%) 
outside a 
Cancer Centre
Total (%)
Number (%) 
within a Cancer 
Centre
Number (%) 
outside a 
Cancer Centre
Total (%)
2007 1237 (54.7) 1026 (45.3) 2263 (100.0) 45 (59.2) 31 (40.8) 76 (100.0)
2008 1490 (58.4) 1060 (41.6) 2550 (100.0) 58 (65.9) 30 (34.1) 88 (100.0)
2009 1917 (78.1) 539 (21.9) 2456 (100.0) 44 (57.1) 33 (42.9) 77 (100.0)
2010 2465 (99.4) 15 (0.6) 2480 (100.0) 65 (72.2) 25 (27.8) 90 (100.0)
2011 2421 (99.6) 10 (0.4) 2431 (100.0) 45 (58.4) 32 (41.6) 77 (100.0)
2012 2423 (99.1) 23 (0.9) 2446 (100.0) 76 (79.2) 20 (20.8) 96 (100.0)
2013 2209 (99.8) 4 (0.2) 2213 (100.0) 80 (93.0) 6 (7.0) 86 (100.0)
Source: HIPE, ESRI. Data generated by HIPE Portal. 
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ALL UTERINE CANCER SURGERY ALL OVARIAN CANCER SURGERY
YEAR
Number (%) 
within a Cancer 
Centre
Number (%) 
outside a 
Cancer Centre
Total (%)
Number (%) 
within a Cancer 
Centre
Number (%) 
outside a 
Cancer Centre
Total (%)
2007 105 (44.3) 132 (55.7) 237 (100.0) 117 (57.9) 85 (42.1) 202 (100.0)
2008 169 (60.6) 110 (39.4) 279 (100.0) 158 (68.7) 72 (31.3) 230 (100.0)
2009 225 (69.2) 100 (30.8) 325 (100.0) 163 (71.2) 66 (28.8) 229 (100.0)
2010 197 (67.9) 93 (32.1) 290 (100.0) 142 (76.8) 43 (23.2) 185 (100.0)
2011 179 (67.8) 85 (32.2) 264 (100.0) 129 (74.1) 45 (25.9) 174 (100.0) 
2012 198 (72.8) 74 (27.2) 272 (100.0) 179 (81.7) 40 (18.3) 219 (100.0)
2013 222 (80.4) 54 (19.6) 276 (100.0) 132 (88.6) 17 (11.4) 149 (100.0)
Source: HIPE, ESRI. Data generated by HIPE Portal. 
ALL RADICAL CERVICAL CANCER SURGERY ALL OTHER CERVICAL CANCER SURGERY
YEAR
Number (%) 
within a Cancer 
Centre
Number (%) 
outside a 
Cancer Centre
Total (%)
Number (%) 
within a Cancer 
Centre
Number (%) 
outside a 
Cancer Centre
Total (%)
2007 66 (55.9) 52 (44.1) 118 (100.0) 118 (10.6) 998 (89.4) 1116 (100.0) 
2008 78 (61.9) 48 (38.1) 126 (100.0) 272 (23.9) 867 (76.1) 1139 (100.0)
2009 117 (68.4) 54 (31.6) 171 (100.0) 474 (30.8) 1067 (69.2) 1541 (100.0)
2010 110 (72.8) 41 (27.2) 151 (100.0) 438 (25.3) 1295 (74.7) 1733 (100.0)
2011 100 (65.8) 52 (34.2) 152 (100.0) 771 (28.2) 1961 (71.8) 2732 (100.0)
2012 79 (65.3) 42 (34.7) 121 (100.0) 718 (27.8) 1865 (72.2) 2583 (100.0)
2013 65 (72.2) 25 (27.8) 90 (100.0) 630 (27.6) 1651 (72.4) 2281 (100.0)
Source: HIPE, ESRI. Data generated by HIPE Portal. 
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Data Definitions
Rectal cancer surgery is defined as any hospital 
discharge with a primary diagnosis of C19 
(malignant neoplasm of rectosigmoid junction), 
C20 (malignant neoplasm of rectum), D011 
(carcinoma in situ of rectosigmoid junction) or 
D012 (carcinoma in situ of rectum) AND any 
procedures in blocks 934 (rectosigmoidectomy or 
proctectomy), 935 (anterior resection of rectum) or 
936 (total proctocolectomy).
Oesophageal resections for upper GI cancer 
is defined as any hospital discharge with a 
primary discharge of C15 (malignant neoplasm 
of oesophagus), C16 (malignant neoplasm of 
stomach), D001 (carcinoma in situ of oesophagus) 
or D002 (carcinoma in situ of stomach) AND 
any procedures in blocks 858 (oesophagectomy 
by abdominal & thoracic mobilisation), 859 
(oesophagectomy by abdominal & cervical 
mobilisation), 860 (oesophagectomy by abdominal 
& transthoracic mobilisation) or 3029400 (cervical 
oesophagectomy).
Gastrectomy following upper GI cancer is defined 
as any hospital discharge with a primary discharge 
of C15 (malignant neoplasm of oesophagus), C16 
(malignant neoplasm of stomach), D001 (carcinoma 
in situ of oesophagus) or D002 (carcinoma in situ 
of stomach) AND any procedures in blocks 875 
(partial gastrectomy), 879 (other gastrectomy) or 
3052000 (local excision of lesion of stomach).
Lung cancer surgery is defined as any hospital 
discharge with a primary diagnosis of C33 
(malignant neoplasm of trachea), C34 (malignant 
neoplasm of bronchus & lung), D021 (carcinoma 
in situ of trachea) or D022 (carcinoma in situ of 
bronchus & lung) AND any procedures in blocks 
551 (partial resection of lung), 552 (lobectomy of 
lung) or 553 (pneumonectomy).
Prostate cancer surgery is defined as any 
hospital discharge with a primary diagnosis 
of C61 (malignant neoplasm of prostate) or 
D075 (carcinoma in situ of prostate) AND any 
of the following procedures: 3720900 (radical 
prostatectomy), 3721000 (radical prostatectomy 
with bladder neck reconstruction) or 3721100 
(radical prostatectomy with bladder neck 
reconstruction and pelvic lymphadenectomy)
Bladder cancer surgery is defined as any 
hospital discharge with a principal diagnosis of 
C67 (malignant neoplasm of bladder) or D090 
(carcinoma in situ of bladder) AND any of the 
following procedures in blocks 1100 (Endoscopic 
resection of bladder lesion or tissue), 1101 
(Endoscopic resection of bladder neck), 1102 
(Cystectomy) or 1103 (Other excision procedures 
on bladder).
Testicular cancer surgery is any hospital discharge 
with a principal diagnosis of C62 (malignant 
neoplasm of testis) AND with any of the following 
procedure block codes: 1184 (Orchidectomy) 
or 3760700 (Radical excision of retroperitoneal 
lymph nodes) or 3761000 (Radical excision of 
retroperitoneal lymph nodes, subsequent).
Renal cancer surgery is any hospital discharge 
with a principal diagnosis of C64 (malignant 
neoplasm of kidney, apart from renal pelvis) or 
C65 (malignant neoplasm of renal pelvis) AND 
with any of the following procedure block codes: 
1048 (partial nephrectomy), 1049 (complete 
nephrectomy) or 1053 (radical nephrectomy) or 
1054 (nephroureterectomy).
Breast cancer surgery is defined as any 
hospital discharge with a primary diagnosis of 
C50 (malignant neoplasm of breast) or D05 
(carcinoma in situ of breast) AND any procedures 
in blocks 1744 (excision of lesion of breast), 1747 
(subcutaneous mastectomy) or 1748 (simple 
mastectomy). 
Pancreatic tumour surgery is defined as any 
hospital discharge with a primary diagnosis of 
C24 – C25 (malignant neoplasm of other and 
unspecified parts of the biliary tract, malignant 
neoplasm of pancreas), D136 – D137 (Benign 
neoplasm of pancreas), C221 (Intrahepatic bile 
duct carcinoma), K862 – K863 (cyst and pseudocyst 
of pancreas) AND any procedures in block 978 
(pancreatectomy), 979 (other excisions procedures 
of pancreas), 3057800 (excision of lesion of 
pancreas or pancreatic duct) or 3045802 (local 
excision of lesion of bile ducts or sphincter of 
Oddi).
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Uterine cancer surgery is defined as any hospital 
discharge with a principal diagnosis of C54 
(malignant neoplasm of the corpus uteri) or C55 
(malignant neoplasm of uterus, part unspecified) 
AND any procedures in blocks 1268 (Abdominal 
hysterectomy), 1269 (Vaginal hysterectomy) or 
Pelvic Exenteration procedures - anterior (9045000) 
posterior (9045001) and total (9045002).
Ovarian cancer surgery is defined as any hospital 
discharge with a principal diagnosis of C56 
(malignant neoplasm of ovary) or C57 (malignant 
neoplasm of other and unspecified female genital 
organs) AND with any procedures in blocks 1243 
(Oophorectomy), 1252 (Salpingo-oophorectomy), 
1268 (Abdominal hysterectomy), 1269 (Vaginal 
hysterectomy) or Pelvic Exenteration procedures - 
anterior (9045000), posterior (9045001) and total 
(9045002).
Radical cervical cancer surgery is defined as any 
hospital discharge any hospital discharge with a 
principal diagnosis of C53 (malignant neoplasm 
of the cervix uteri) or D06 (carcinoma in situ of the 
cervix uteri) AND with any procedures in blocks 
1268 (Abdominal hysterectomy), 1269 (Vaginal 
hysterectomy) or Pelvic Exenteration procedures 
- anterior (9045000) posterior (9045001) and total 
(9045002).
All other cervical cancer surgery is defined as any 
hospital discharge with a principal diagnosis of C53 
(malignant neoplasm of the cervix uteri) or D06 
(carcinoma in situ of the cervix uteri) AND with any 
procedures in blocks 1275 (destruction procedures 
of the cervix) or 1276 (excision procedures of the 
cervix). 
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1 A third National 
Cancer Forum 
should be 
appointed by 
the Minister with 
terms of reference 
and composition 
reflecting the 
changed health 
system. 
Following the 2006 Strategy for Cancer Control, the National Cancer Control Programme was 
established in 2007 in the HSE. The NCCP is working to implement the Strategy which aims to 
achieve better cancer prevention, early detection (including screening programmes) and well 
organised programmes of treatment that maximise survival through a co-ordinated national 
service, based on international evidence and best practice. Regular ongoing meetings are 
held between the Department of Health and the NCCP on the monitoring of progress and the 
development of cancer policy
Appendix 3
Update on the implementation of the 55 Recommendations of the 2006 
Cancer Control Programme. June 2014
In the intervening years since the publication of the 2006 Cancer Strategy the roles and remits of many 
of the bodies referred to have changed so not all actions are now appropriate for the body identified. 
Many of the oversight/monitoring roles originally identified for HIQA have now been adopted by the 
NCCP or the NCRI (i.e. recommendations 40, 41, 43, 45, 46, 49). 
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2 The recommenda-
tions of the Review 
of the National 
Health Promotion 
Strategy, 2004 
should be imple-
mented across all 
sectors. 
The Department of Health is leading a new, whole-of-Government, whole-of-society, approach 
to health improvement, Healthy Ireland. The publication of Healthy Ireland – A Framework for 
Improved Health and Wellbeing 2013 - 2025 is a major milestone for the future provision of 
health and social care in Ireland. It provides the structure to enable service providers to influ-
ence major change in the development, implementation and delivery of health and social care 
for future generations. It emphasises the need for a collaborative approach between the health 
sector and other areas of Government and public services to work together, to affect improve-
ments in social protection, food safety, education, housing, transport and the environment. 
These are the key factors which influence health and social outcomes for the entire population. 
Tackling health inequalities, introducing preventative health measures and health promotion 
activities, to be delivered in the community, were the key messages in the consultative process 
which informed the publication of Healthy Ireland. It is widely recognised that these factors are 
economically more prudent than costly acute care and treating increasingly costly long-term 
chronic diseases.
The HSE National Service Plan 2014 identifies the reconfiguration and realignment of work prac-
tices, programmes and teams to deliver against the actions in Healthy Ireland as a key priority
	•		 Develop	a	cross-divisional	‘health	services’	3	year	implementation	plan	and	work	pro-
gramme for Healthy Ireland.
	•		 Review	workforce	capacity	commencing	with	community	dietetics	and	community	nursing	
services.
	•		 Review	programmes,	funding	strategies	and	activities	on	a	phased	basis	across	the	Divi-
sion to ensure they are a) evidence-based, sustainable and cost effective; b) orientated to 
promote health and reduce disease among communities and populations most at risk; and 
c) appropriately aligned to the work plans of the other Divisions.
	•		 Develop	Health	Intelligence	with	the	support	of	internal	and	external	partners.
Other national disease specific policies and strategies have been produced and resourced 
including:
	•		 HSE	Framework	for	Action	on	Obesity	(2008-2012)
	•		 The	Establishment	of	a	Ministerial	Special	Action	Group	on	Obesity
	•		 The	National	Tobacco	Control	Framework	(2010)
	•		 The	National	Drugs	Strategy	2009-2016	
	•		 Promoting	Physical	Activity	in	Ireland	(2009)
	•		 Building	Healthier	Hearts	(1999)	and	National	Cardiovascular	Health	Policy	2010-2019
	•		 The	National	Obesity	Task	Force	(2005).
	•		 The	HSE	established	a	Clinical	Programme	for	the	Prevention	of	Chronic	Diseases	
	•		 Roll	out	of	Health	Promoting	Schools	in	the	HSE-South
	•		 2	cities	in	the	South	and	1	in	the	West	established	as	WHO	designated	healthy	cities	–	
Cork, Waterford and Galway and the establishment of a National Network for Healthy 
Cities in Ireland 
The National Cancer Control Programme has a community oncology section which has a sig-
nificant focus on health promotion and works with the HSE Health and Wellbeing Division to 
promote healthy lifestyle and reduce cancer incidence.
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3 Compliance with 
all provisions 
of the Public 
Health (Tobacco) 
Acts, 2002 and 
2004 should be 
monitored. 
Tougher regulation of the tobacco industry and a proactive approach to law enforcement have 
been key pillars of government tobacco control policy since 2000.
The HSE Environmental Health Service is responsible for enforcing tobacco control legislation 
e.g. on smoking in the workplace, under-age sales of tobacco, point of sale restrictions and il-
legal promotions by the tobacco industry.
The HSE Environmental Health Service implements a national tobacco control inspection 
programme to assess and secure legislative compliance. In general, compliance with the Public 
Health (Tobacco) Act provisions has been high. However, significant problems remain in relation 
to smoking in the work place, (section 47 of the Act) particularly in relation to licensed premises 
and non-compliant smoking shelters and also in relation to sales of tobacco products to minors 
under the age of 18 (section 45 of the Act).
Since the commencement of Section 47 in 2004 until the end of 2013 a total of 251 prosecu-
tions were taken by the HSE resulting in 263 convictions. These prosecutions and convictions 
were mainly in respect of licensed premises including; pubs, night-clubs and hotels. In recent 
years more than 50% of prosecutions have related to smoking areas in licensed premises. A 
number of owners and proprietors have been prosecuted and convicted on multiple occasions.
In relation to the sale of tobacco to minors, the HSE undertakes compliance checks, also known 
as test purchases, in retail outlets to determine if retailers will sell tobacco products to minors. 
The EHS test purchase programme together with associated retail audits highlight a significant 
ongoing non-compliance issue. As a result there have been 43 prosecutions with 33 convictions 
between 2009 and 2013. 
The HSE operates a lo-call Compliance Line (1890 333 100) that offers an effective route 
through which the public can register complaints and concerns in respect of tobacco control. As 
a support mechanism for the National Tobacco Control Inspection Programme, the line plays an 
important role in building and maintaining compliance.
The HSE National Tobacco Control Office manages the register of tobacco retailers.
Compliance and enforcement of tobacco legislation is the responsibility of Environmental 
Health Officers of the HSE.  
The National Tobacco Control Inspection Programme outlines the priorities each year, based on 
available resources.  Compliance rates with tobacco legislation are generally very high.  Based 
on inspections undertaken in 2012, compliance with smoke-free workplace legislation is 98%.  
The HSE’s National Tobacco Control Office (formerly Office of Tobacco Control) undertakes 
periodic independent audit of retail premises to measure compliance with point-of-sale (POS) 
and sales to minor’s legislation. The most recent Audit was undertaken in 2011.  In 2011, 98% 
of premises surveyed were compliant with POS provisions.  73% of premises refused to sell 
cigarettes to minors.
The National Tobacco Control Office (NTCO) was established in January 2011 following the dis-
solution of the Office of Tobacco Control under the Public Health (Tobacco) (Amendment) Act 
2010.  The remit of the NTCO is to co-ordinate the tobacco control programme in the HSE.  It 
has responsibility for discharging the statutory functions prescribed under the Public Health (To-
bacco) Acts 2002-2012 and supporting and driving the delivery of the 61 actions in the Tobacco 
Control Framework 2010. 
	•		 Additional	undertaking	by	the	HSE/DOH	in	relation	to	Tobacco	Control	include:	
	•		 HSE	Tobacco	Control	Framework(2010):	WHO MPOWER model
	•		 Tobacco	Free	Campuses	Policy:	‘smoking by employees, patients, visitors and any other 
parties will be prohibited within all HSE campuses on or before 31st December 2015’
	•		 Public	Health	(Tobacco)	Acts	2002,	2004	&	2009:	Smoke free workplace / public places: 
cinemas, restaurants etc
	•		 HSE	Service	Plan	2013:	Training of staff in Brief Intervention
194Report on the implementation of ‘A Strategy for Cancer Control in Ireland 2006’
Recommendation Update June 2014
4 Excise duty on 
cigarettes should 
be substantially 
increased each year 
above the rate of 
inflation. To this 
end the National 
Cancer Forum 
should produce 
a pre – Budget 
submission to 
the Minister for 
Finance each year 
in order to continue 
advocating for 
price increases on 
tobacco. 
Excise increases on cigarettes were achieved in Budgets as follows:
2006 – 50c 
2007 – 30c 
2008 – 50c   
2009 – 25c 
2010 – 0     
2011 – 25c
2012 – 10c
2013 – 10c
5 Nicotine 
replacement 
therapy should be 
made available 
free of charge to 
all medical card 
holders. 
Completed 
6 The Report of 
the Strategic Task 
Force on Alcohol, 
2002 should be 
implemented in 
full. 
The Government recently approved an extensive package of measures to deal with alcohol 
misuse to be incorporated in a Public Health (Alcohol) Bill. These measures are based on the 
recommendations contained in the Steering Group Report on a National Substance Misuse 
Strategy, 2012. The package of measures to be implemented will include provision for:
•		 minimum	unit	pricing	for	alcohol	products;	
•		 the	regulation	of	advertising	and	marketing	of	alcohol;	
•		 structural	separation	of	alcohol	from	other	products	in	mixed	trading	outlets;	
•		 health	labelling	of	alcohol	products;	and	
•	 regulation	of	sports	sponsorship.
The Government also approved that:
Public health messaging relating to alcohol will be based on grams of alcohol. Weekly low-
risk drinking guidelines should be 168 grams (17 standard drinks) for men and 112 grams (11 
standard drinks) for women.
The other measures will be progressed by the relevant departments and organisations.
An Implementation Group for Alcohol has been established within the HSE to address the 
actions in the Report of the Steering Group on a National Substance Misuse Strategy for which 
the health service has responsibility. 
This Implementation Group is led by Social Inclusion (Primary Care Division) with a specific 
Health and Wellbeing sub group to progress all relevant actions. Work has commenced 
in regard to a communications strategy; actions in regard to prevention and enforcement. 
Environmental Health Services are actively working with the DOH in regard to regulations and 
legislation. 
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7 The recommenda-
tions of the Report 
of the National Task 
Force on Obesity, 
2005 should be 
implemented in 
full. In particular, 
there is a need for 
measures that raise 
the awareness of 
the links between 
diet and cancer. 
A review carried out in July 2011 found that of the 24 recommendations relevant to the Health 
Sector, 12 have been implemented in full, there is significant progress in 3, 8 are progressing 
and will remain ongoing and there was partial implementation of 1. No recommendation was 
outstanding. In 2013-14 significant progress has been made re the “partially implemented rec-
ommendation above i.e. re highlighting obesity on the undergrad and post grad curriculum of 
those in relevant Health Sciences (see details below).
In recent years there has been an increasing focus on obesity with the publication of the follow-
ing documents: 
* HSE Framework for Action on Obesity 2008 – 2012
*  DOHC –HSE Physical Activity Guidelines for Ireland
*  DOHC Changing Cardiovascular Health : National Cardiovascular Health Policy 2010 – 2012
*  DOHC National Nutrition Guidelines & Re-modelled Food Pyramid
*  HSE Childhood Obesity Surveillance Initiative (COSI) in the Republic of Ireland: Findings from  
2008, 2010 and 2012
The publication of Healthy Ireland underlines the importance of a healthy population as a major 
asset for Irish society however it also highlights adverse trends in relation to obesity, diabetes 
and physical activity. The HSE National Service Plan 2014 contains specific reference to further 
deliver on priority areas including diet and nutrition with a supporting package of obesity reduc-
tion programmes (€0.1m) targeted at key at risk groups. Examples of this is the expansion of 
the Smart Start Programme in Child Care facilities from 9 counties to 18 and the provision of 
funding to support W82GO programme for clinically obese children in the Children’s University 
Hospital, Temple Street, The introduction in Q4 2014 of school growth monitoring of 5-7 year 
olds in 4 pilot sites with communication of results to all parents, referral of parents of overweight 
children to self help resources & community prevention programmes with clinically obese (>98th 
centile) referred to the W82GO Lifestyle Intervention Programme provided by newly trained 
Multidisciplinary Teams in the community to support the 4 pilot sites. Clinical backup & training 
via Temple Street Hospital - Hub & Spoke approach. Approx 1,800 children in each of the 4 pi-
lot areas will be measured with approx 450 (25%) expected to be overweight or obese (moving 
from surveillance to screening), with a view to eventual national roll out if deemed appropriate 
following evaluation.
The NCCP also participates on the Royal College of Physicians Policy Group on Obesity. 
There has been significant ongoing work undertaken in regard to Obesity by the HSE in con-
junction with key stakeholders; 
ICGP has developed a whole segment on obesity management www.icgp.ie/weightmanage-
ment. 
The HSE – ICGP Weight Management Treatment Algorithm stresses the link of obesity to cancer 
- the benefits of 10% weight loss (for those with a BMI > 25) to a reduction in cancer deaths is 
stated. It is also recommended that cancer is addressed as part of the relevant medical history 
assessment.
Childhood obesity has been a major focus in 2013. The HSE-ICGP Weight Management Treat-
ment Algorithm for Children was published. In autumn 2013, Safefood launched a three year 
all island Childhood Obesity Social Marketing Campaign in partnership with the HSE and the 
Healthy Ireland Framework in the Republic of Ireland and the ‘Fitter Futures for All’ Implementa-
tion Plan in NI.
https://www.healthpromotion.ie/index.php/newsView/campaign_to_take_on_childhood_obesity
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7 Publications have been produced for both parents & health professionals and have been 
distributed nationwide to crèches, health centres, GP surgeries, public health nurses and 
local libraries. These are available to order under the obesity section of the health promotion 
website:
Your Child’s Weight a Guide to Preventing Childhood Obesity available to download from 
https://www.healthpromotion.ie/hp-files/docs/HPM00851.pdf Hard copies of this 20page A5 
booklet can be ordered from www.healthpronotion.ie Order Code: HPM00851
A Guide for Health Professionals: Assisting Parents and Guardians in communicating with 
their children about body weight. www.hse.ie/weightmanagement 
Other resources include Healthy Eating Schools Pack’, & Eat Smart Move More booklet and 
reward charts.
The HSE-ICGP Healthy Weight Management Guidelines Before, During and After Pregnancy 
were produced. It is hoped to launch these with an accompanying support resource for health 
professionals – Brief Intervention for Healthy Weight Management Before, During & After 
Pregnancy by year end.
The HSE has dedicated a section of its website to informing health professionals of 
the resources available to support healthy weight management: http://www.hse.ie/
weightmanagement/
In 2013, updated growth charts were launched and training provided to relevant HSE staff for 
use with growth monitoring of children – these include guidance on assessment of BMI charts 
for detection of childhood obesity. http://www.hse.ie/growthmonitoring/ By the end of 2014 
an elearning module on www.hseland.ie will be available. The ICGP (funded by Safefood & 
supported by the HSE) have developed a blended learning pack for primary care staff which 
includes growth monitoring.
The introduction of a tax on sugar-sweetened drinks and improved nutritional labelling are 
among the priorities being considered. A Health Impact Assessment, on the potential impact on 
obesity following introducing of a tax on sugar sweetened beverages was presented to SAGO. 
It was undertaken by the IPH under the chairmanship of Prof. Donal O Shea.
The NCCP itself has seconded a staff member from Health Promotion to support it in its work in 
educating health care professionals and the public on ways to reduce cancer.
A review of the implementation of the Report of the Taskforce on Obesity concluded that 
significant progress had been made however there were challenges in fostering non-health 
sectoral leadership and in the development of workable, meaningful and sustainable 
mechanisms for intersectoral cooperation at national, regional and local levels. 
The Special Advisory Group on Obesity has recently established a sub group to develop a new 
Obesity Strategy. 
The NCCP itself has seconded a staff member from Health Promotion to support it in its work in 
educating health care professionals and the public on ways to reduce cancer.
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8 The health services 
should work 
with the food 
industry in order 
to encourage it to 
produce, market 
and improve access 
to attractive and 
healthy options. 
•	 The	HSE	works	with	other	sectors	to	address	the	marketing	of	food	to	children.	See	Irish	Heart	
Foundation “Marketing of Food and Beverages To Children: Stakeholder views on policy 
options in Ireland. Findings from the PolMark Report Dec. 2009”. www.irishheart.ie/iopen24/
pub/full_polmark_reportjan5th_final.pdf
•	 The	Healthy	Catering	Guidelines	for	Staff	and	Visitors	in	Healthcare	Facilities	(DOHC)	is	being	
implemented via the Health Promoting Hospitals Network.
•	 The	HSE	Corporate	Catering	Event	Policy	is	being	implemented	within	the	HSE	and	is	shared	
with other organisations e.g. HSE Community Games.
•	 The	HSE	Salt	Procurement	Policy	has	had	implications	for	the	production	(reformulation)	of	
bread in companies seeking to supply HSE facilities.
•	 The	HSE	submitted	a	number	of	submissions	to	the	Broadcasting	Authority	of	Ireland.
•	 (BAI)	in	reviewing	its	code	of	standards	for	the	advertising	of	food	and	drink	to	children.	The	
revised code of standards, while not going far enough, will have an impact on the food and 
drink industry and hopefully will lead to product reformulations or new foods & drinks that are 
low in Fat, Salt & Sugar and higher in Fibre.
•	 In	conjunction	with	the	Irish	Heart	Foundation	the	HSE	promotes	Happy	Heart	Catering	
Awards in all catering facilities. The standards are currently being revised to include calorie 
posting.
•	 The	HSE	Healthy	Vending	Policy	has	been	signed	off	by	the	Senior	Management	Team.	The	
policy mandates a 60% “Better Choice” and 40% “Other” products in all vended offerings. 
This 60% Better Choice products can be revised upwards with authority given to local 
management to mandate 100% Better Choice products in key areas for vulnerable groups 
e.g. Paediatric wards & clinic areas & Diabetic Clinic waiting areas. Procurement plan to have 
a National Vending Contract in place by end September 2014.
•	 The	HSE	Expert	Group	on	Healthy	Vending	and	Calorie	Posting	are	working	on	a	HSE	Calorie	
Posting Policy to govern food provision in Staff Canteens, Visitor Restaurants & Coffee Shops. 
Calorie posting is already included in the HSE Healthy Vending Policy. Letterkenny General 
and Cherry Orchard Hospitals will form a pilot to inform the policy and provide learning for 
its implementation. The Policy should be signed off by end 2014. The IHF will include calorie 
posting as part of the standard requirements for the Happy Heart Catering Award.
•	 Currently	the	HSE,	DOH	(Hi),	DCYA	and	Safefood	are	cooperating	on	a	three	year	all	island	
childhood obesity social marketing campaign with the aim of working with parents of 0-12 yrs 
from low income groups to eat more healthy food, reduce consumption of food of little or no 
nutritional value and to become more physically active.
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9 The recommenda-
tions of the Report 
of the National Task 
Force on Obesity, 
2005 in relation to 
physical activity 
should be imple-
mented in full. 
Healthy Ireland emphasises the importance of increased physical activity to reduce chronic 
diseases and disabilities and underlines both the human and economic cost of overweight and 
obesity. A specific implementation plan for physical activity is currently being developed by the 
DOH in conjunction with key stakeholders (target date for final draft of the national physical 
activity plan March 2014).
The HSE National Service Plan 2014 reinforces the objectives of Healthy Ireland in the need 
for increased physical activity. In addition to maintaining current provision (examples below) it 
also provides for supporting the DOH in the development and implementation of the national 
physical activity plan and will increase Brief Intervention training to GPs and expand the Be 
Active After School Programme from 18 counties to 23. 
•	www.getirelandactive.ie has been developed to be a one-stop shop for the promotion of 
physical activity in all its forms from participation to competition. In addition the HSE has (in 
partnership with relevant codes) established www.getirelandwalking.ie, www.getirelandcycling 
and have signed a partnership deal with 8 other bodies to enhance participation in physical 
activity.
•	 The	GP	Exercise	Referral	Programme	and	Green	Prescription	are	being	rolled	out	throughout	
the country in a phased basis
•	 The	HSE	and	DOH	have	established	a	Healthy	Club	Programme	with	the	GAA
•	 The	HSE	has	developed	the	award	winning	Be	Active	After	Schools	Programme
•	 In	Partnership	with	ISC	and	Local	Sports	Partnership	embarked	on	encouraging	marginalised	
group to increase physical activity e.g. older people, people with disability, low income 
groups etc
•	 The	HSE	is	the	Title	Sponsor	of	Community	Games
•	 The	HSE	and	Special	Olympics	developed	a	Healthy	Athlete	Programme
•	 The	HSE	and	Border	Counties	Child	Care	Committees	Network	have	developed	a	national	
programme for all preschool facilities called Smart Start
The HSE formed a National Steering Group on Obesity. This group translated the Taskforce 
recommendations for which the health service has a lead role into the HSE Framework for 
Action on Obesity 2008–2012. The HSE Steering Group Annual Review for 2012 states that 
the HSE achieved all recommendations of the National Taskforce on Obesity as pertaining to 
physical activity and the HSE.
The HSE is currently working with the DoH and other stakeholders in regard to the development 
of a National Physical Activity Plan under the auspices of Healthy Ireland. A draft will be 
available for consultation in late August/early September. The plan takes a cross-sectoral 
approach as advocate din healthy Ireland and will focus on a life course approach with getting 
people more active through walking, running, and though improved interagency working. 
Communicating the message of increasing physical activity will form a key element of the plan.
10 In conjunction with 
campaigners to 
promote safe sun 
practices and to 
reduce exposure to 
ultraviolet radia-
tion, regulation of 
sunbed use, includ-
ing restriction to 
use by adults only, 
should be put in 
place. 
In December of 2013 the Government published the Public Health (Sunbeds) Bill. Under the 
Public Health (Sunbeds) Act 2014 from the 21st of July 2014,  it will be illegal for a sunbed 
operator to allow a person under 18 years of age to use a sunbed.  All sunbed operators will be 
required to provide training for staff and display health warnings on their premises.
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11 The public 
should be made 
aware that radon 
measurements can 
be undertaken by 
the Radiological 
Protection 
Institute of Ireland.  
Consideration 
should be given to 
providing financial 
support for testing 
in high-radon 
areas and for any 
necessary remedial 
work, on a means-
tested basis. 
The RPII have identified certain parts of the country, predominantly in the south east and the 
west as being at risk from radon.  A map showing these “High Radon Areas” is published on 
their website. http://www.rpii.ie/radon-map.aspx 
In February this year The National Radon Control Strategy for Ireland was launched by the 
Minister for the Environment, Community and Local Government.  The Strategy proposals which 
have a 4 year timeframe is set out under six general themes:
1. Radon prevention in new buildings; 
2. Use of property transactions (sales and rental) to drive action on radon; 
3. Raising radon awareness and encouraging individual action on radon;
4. Advice and guidance for individual householders and employers with high radon results;
5. Promoting confidence in radon services; and 
6. Addressing radon in workplaces and public buildings. 
The Strategy document is available at http://www.environ.ie/en/Publications/Environment/
EnvironmentalRadiation/FileDownLoad,35484,en.pdf
The RPII carry out public awareness campaigns of the dangers of exposure to radon in the 
home in these areas.  The objective of a campaign is to raise awareness of radon as a public 
health issue and to advise people to test their home and if high levels are found to reduce those 
levels.  Since March 2010 campaigns have been carried out in Sligo, Carlow, Waterford, South 
Tipperary, Galway, Kerry, Wexford, Louth and Kilkenny.   Details of campaigns are available at 
http://www.rpii.ie/Your-Home/Radon-Awareness-Campaigns.aspx. A further campaign will be 
carried out later this year.
Each year the RPII organises a National Radon Forum. The Forum provides an opportunity for 
those with a role to play in reducing the risk from radon in Ireland to meet and discuss radon 
activities and concerns.  This includes measurement companies, remediation companies, 
scientists, government representatives, local authorities, representatives of national agencies 
with responsibility for building standards, health and safety experts and the public.  The most 
recent forum was held in Kilkenny during February 2014. Details of previous fora are on the RPII  
website http://www.rpii.ie/Your-Environment/Radon-and-your-environment/National-Radon-
Forum.aspx
Since 2008 nearly 20,000 local authority homes have been measured for radon. This can 
compares with 56,000 private homes measured since the 1990s.  The continued work on radon 
by local is to be commended as it addresses the risk to tenants associated with high radon 
levels.  
The Home Renovation Incentive scheme, which was launched by the Government in March, 
includes work needed to reduce radon levels in a home. The scheme allows homeowners to 
qualify for tax credits at 13.5% of the cost of renovation, repair or improvement works. Full 
details of the scheme are available from Revenue here.
The Scheme of Housing Aid for Older People available to assist older people, generally over 
60 years, to have necessary repairs or improvements carried out to their homes.  Where a suite 
of works is being grant aided under this scheme, Local Authorities may also, as part of the 
package of works, assist with the provision of radon remediation works, where applicable. 
http://www.environ.ie/en/DevelopmentHousing/Housing/SpecialNeeds/OlderPeople/
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12 The HSE should 
put in place 
arrangements to 
monitor inequalities 
in cancer risks, 
cancer occurrence, 
cancer services and 
cancer outcomes. 
The National Cancer Registry of Ireland (NCRI) was established to record information on all 
cancer cases occurring in Ireland and has been collecting such data since 1994. Included within 
this remit is survival analysis. 
In 2011 The NCRI & the Northern Ireland Cancer Registry, published a report identifying major 
unexplained variations across the island in the risk of most common cancers. http://www.ncri.ie/
publications/cancer-atlases-and-geographic-studies/all-ireland-cancer-atlas-1995-2007 
Health Equity Audit incorporated into the Health Needs Assessment pilot for PCT’s 
Inequalities module added to the to the National Cancer Education Programme for Nurses 
Working in Primary Care
Resources and literature on cancer will be included in Health Inequalities Hub being developed 
in partnership with the Institute of Public Health in Ireland. 
A Tobacco-Free Future - An all-island report on tobacco, inequalities and childhood 2013 
reveals declines in smoking rates among both children and pregnant women over the past 
decade, both North and South of the border. This report published by the Institute of Public 
Health in Ireland (IPH) and the TobaccoFree Research Institute Ireland (TFRI), shows that while 
tobacco control measures are being successful, disadvantaged children are at particular risk of 
tobacco-related harms.
13 Population-
based screening 
programmes 
should only be 
introduced where 
their population 
health benefit can 
be demonstrated 
using the National 
Cancer Forum 
criteria.
Health Technology Assessments (HTA) are undertaken in advance of the proposed introduction 
of any screening programme approval.
In 2009 HIQA completed a HTA for the colorectal screening programme. 
 
14 Breast screening 
should be 
extended to 
include all women 
aged between 50 
and 69. 
The BreastCheck Programme provides free mammograms to all women aged 50-64. A priority 
of the BreastCheck Programme at present is to maximise national uptake in the 50-64 year age 
cohort. It also aims to extend the upper age range to include the 65-69 age cohort as soon as 
possible in line with available resources.
15 The national roll-
out of the Irish 
Cervical Screening 
Programme should 
be completed as a 
matter of priority. 
This programme was introduced nationally in September 2008. First three-year round was 
completed in 2011 and the report published in 2012. http://www.cervicalcheck.ie/_fileupload/
Publications/CervicalCheckprogrammereport1Sept2010-31August2011-Final.pdf 
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16 A colorectal cancer 
programme should 
be established to 
encompass popula-
tion screening, high 
risk screening and 
necessary develop-
ments in sympto-
matic colorectal 
cancer services. 
In preparation for 
this programme, 
the Department 
of Health and 
Children should 
establish a working 
group under aegis 
of the National 
Cancer Forum to 
address a range 
of implementation 
issues. 
BowelScreen, The national Bowel Screening programme commenced in 2012 commencing 
with men and women aged 60-69.
17 The Department 
of Health and 
Children in 
conjunction with 
the HSE and 
BreastCheck should 
plan the alignment 
of population-
based screening 
programmes.
The National Cancer Screening Service was established in January 2007. It currently delivers 
four national screening programmes. 
The National Cancer Screening Service encompasses  
BreastCheck - The National Breast Screening Programme, 
CervicalCheck - The National Cervical Screening Programme, 
BowelScreen - The National Bowel Screening Programme and  
Diabetic RetinaScreen – The National Diabetic Retinal Screening Programme.
18 Population-based 
prostate screening 
should NOT be in-
troduced in Ireland 
at present. The 
National Cancer 
Forum should keep 
emerging inter-
national evidence 
on population 
screening for pros-
tate cancer under 
review. 
International evidence does not suggest population based screening for prostate cancer.
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19 Opportunistic 
testing of 
asymptomatic 
individuals for 
cancer is not 
recommended. 
The NCCP has called for a ban on home PSA testing for prostate cancer. The NCCP has 
contacted the Irish Medicines Board in relation to its concerns and this is currently being 
addressed at European Commission level.
20 The HSE should 
develop specific 
programmes that 
promote early 
detection of cancer. 
Screening promotion incorporated into the National Cancer Screening programme plans.
Significant work is underway to liaise with primary care to promote early detect ion. 
Nationally there are three cancer screening programmes in operation; BreastCheck, 
CervicalCheck and BowelCheck. 
Rapid access breast, lung and prostate clinics have been established to facilitate early referrals 
from primary care to designated cancer centres for those with suspected cancer.
GP referral guidelines and forms have been developed for pigmented lesions
Work is ongoing with the ICGP to develop guidelines for improved detection of ovarian and 
head & neck cancers. 
A national hereditary cancer programme, in collaboration with the National Centre for Medical 
Genetics, Crumlin has been established to improve access to assessment and genetic testing 
for those patients whose cancer may have a hereditary component and their families. The 
programme focuses on hereditary breast, ovarian and bowel cancer, as well as rarer hereditary 
cancer syndromes.
21 All cancer care 
should be delivered 
through a national 
system of four 
Managed Cancer 
Control Networks, 
each serving a 
population of 
approximately one 
million people.
Cancer services are now centralised around 8 Designated Cancer Centres established in 4 
networks. Letterkenny Hospital is a satellite of University College Hospital Galway for breast 
cancer surgery. 
22 A Network 
Director should be 
appointed by the 
HSE as soon as 
possible to each 
Managed Cancer 
Control Network to 
support and direct 
implementation of 
cancer policy. 
There are two network manager posts within the NCCP. These posts cover all four cancer 
networks. 
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23 A lead clinician for 
each Cancer Centre 
should be appoint-
ed. In addition, a 
clinician should 
be appointed to 
lead the develop-
ment of cancer 
care pathways for 
each major site 
specific cancer in 
partnership with all 
stakeholders within 
the network. The 
Cancer Control 
Network Director 
should head this 
team of lead clini-
cians. 
National Lead Clinical Groups have been established for breast, urology, lung and 
gastrointestinal cancers in the eight cancer centres. There are also lead clinicians for upper 
gastrointestinal cancers in the four national centres. There are also national leads for pancreatic 
cancer, neuro-oncology, gynae cancers, colorectal cancers and neuro-endocrine cancers. 
The nominated clinicians are responsible for facilitating compliance with national standards 
and key performance indicators for the specific service and have a key role in contributing to 
the continuous development and improvement of the service in their own cancer centre and 
nationally through participation in NCCP processes, including national audit, quality and risk 
meetings. 
24 The HSE should 
develop care 
pathways for 
cancer care to 
link primary care 
services, hospital 
services and other 
relevant services. 
The NCCP has developed GP referral guidelines and pathways have been implemented for 
breast, lung, pigmented lesions and prostate cancers. 
Additional pathways have been developed for referral of patients from regional to tertiary 
centres for pancreatic cancers. Other care pathways are in development. 
25 Improved cancer 
information 
services should be 
available to primary 
care. 
Within the NCCP there is a Community Oncology Team whose role includes collaboration with 
and supporting of GPs and primary/community care nursing staff. 
The NCCP has developed GP and patient booklets have been produced on referral to the 
symptomatic breast clinic, prostate and lung rapid access clinics. 
NCSS provides information sessions to Primary Care for its screening programmes and provides 
free training programmes for smear-takers as part of its Cervical-check programme.
General Practice E-Learning programmes have been developed for a range of cancer related 
topics including smoking cessation and the ABC of early cancer detection. 
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26 The HSE 
should develop 
programmes that 
support primary 
care professionals 
in the provision of 
cancer services. 
Education and development programmes have been established for:
•	Nurses	who	work	in	primary	care
•	 An	intensive	skills	based	course	has	been	developed	for	public	health	nurses	to	enable	
them to provide some care to medical oncology patients in their own home. This service is 
integrated with the hospital specialist medical oncology service. A resource book has been 
published to support this service.
•	 A	Cancer	Nursing	Strategy	has	been	developed	to	provide	a	framework	for	the	professional	
development for all nurses who care for patients with cancer, from generalist to specialist 
settings.
Multiple meetings have taken place with GPs via their CME structures, in many locations around 
the country, to provide an update on NCCP developments and how to use the standardised 
referral procedures.
The NCCP has employed a GP and has worked closely with the Irish College of General 
Practitioners. E-learning programmes have been developed for a range of cancer related 
issues including brief interventions for smoking cessation, assessment of urological symptoms, 
management of breast problems in primary care and appropriate referral 
27 The HSE should 
ensure that 
systems are in 
place to identify 
and support a 
‘designated health 
professional’ as 
a contact person 
for each individual 
cancer patient who 
may require it. 
Designated cancer centres have their own internal systems in place to manage patient pathways 
and deal with individual queries. 
28 Cancer Centres 
that each serve 
a minimum 
population of 
500,000 should 
be designated by 
the HSE as soon as 
possible. Ireland 
will require about 
eight such centres. 
There are eight designated Cancer Centres (Letterkenny Hospital is a satellite of University 
College Hospital Galway for breast cancer surgery). 
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29 The HSE should 
conduct a needs 
assessment for 
cancer services 
with a particular 
emphasis on 
hospital-based 
cancer treatment 
that addresses the 
need for continued 
expansion in 
capacity and 
maximises the use 
of ambulatory care. 
Since the establishment of the NCCP there has been continued assessment of requirements 
for cancer services within hospitals. The NCCP has worked closely with the designated cancer 
centres to plan for the appropriate expansion in radiation oncology, medical oncology and 
surgical oncology facilities. 
The future capital requirements for radiotherapy have been identified under the National Plan 
for Radiation Oncology and expansion is underway in Cork & UCHG. In addition, the NCCP has 
worked with acute hospitals and HSE Estates to assess and prioritise expansion of oncology day 
facilities. 
Designation of in-patient beds for cancer patients is linked to the reconfiguration of acute 
hospital services. The NCCP has conducted a number of utilisation reviews of cancer facilities to 
ensure appropriate mix of ambulatory and inpatient services. 
30 The National 
Network for 
Radiation Oncology 
Services should be 
established by the 
HSE in accordance 
with the timelines 
set by Government. 
Since 2007 there has been a sustained investment in the development of a National Network of 
Radiation Oncology services on six hospital sites. The St. Luke’s Radiation Oncology Network 
has been established with radiotherapy delivered on three sites in Dublin. The units in Cork and 
Galway are managed directly by the host hospital. All radiotherapy centres are participating on 
the National Radiation Oncology Planning & Implementation Committee. 
31 Patients should 
have their 
diagnosis 
established and 
their treatment 
planned by 
site-specific 
multidisciplinary 
teams. 
Multidisciplinary team planning (MDT) meetings has become the standard for care for the 
majority of new patients.
32 The HSE should 
conduct a review 
of the number of 
centres required for 
the management of 
symptomatic breast 
disease to bring 
them into line with 
designated Cancer 
Centres. 
In 2007 eight designated Cancer Centres were selected by the HSE to improve patient care. 
The eight designated centres were to provide treatment and services for all cancer surgery 
including breast cancer, with a governance structure in place for systemic therapy which will 
continue to be delivered locally involving:
HIQA carried out a national quality review of the eight centres (plus the satellite centre in 
Letterkenny Symptomatic Breast Disease Services in 2009. http://www.hiqa.ie/system/files/
Symptomatic_Breast_Disease_Services_National_report_2010%20.pdf
33 The HSE should 
conduct a national 
needs assessment 
for rare cancers. 
In line with the European Union recommendations, a national policy for all rare diseases was 
published in July of 2014. The report makes specific recommendations and references to cancer. 
http://health.gov.ie/wp-content/uploads/2014/07/EditedFile.pdf 
206Report on the implementation of ‘A Strategy for Cancer Control in Ireland 2006’
Recommendation Update June 2014
34 A National 
Cancer Genetics 
Policy should be 
developed by the 
National Cancer 
Forum. 
The NCCP is developing a national strategy for familial cancer risk assessment and evaluation 
for genetic mutations that predispose to hereditary cancer. A national hereditary cancer 
programme, in collaboration with the National Centre for Medical Genetics, Crumlin has been 
established to improve access to assessment and genetic testing for patients and their families. 
The programme focuses on hereditary breast, ovarian and bowel cancer, as well as rarer 
hereditary cancer syndromes. 
Approval was given in June 2014 for the appointment of a national lead for hereditary cancer. 
35 The HSE should 
ensure that each 
Managed Cancer 
Centre Control 
Network has a 
comprehensive 
specialist palliative 
care service. 
Palliative Care services within the HSE are under the remit of the Acute Hospitals Division in 
consultation and collaboration with the National Clinical Programme for Palliative Care. A 
National Clinical Lead has been appointed. 
It is HSE policy to ensure that palliative care services are provided to all patients regardless of 
diagnosis. While deficits exist in some areas of the country, the HSE has a Framework in place to 
address these and is working to roll out services nationally. There are currently 38 acute hospital 
specialist palliative care teams (including in each of the Major Cancer Centres); 156 specialist 
in-patient beds across nine locations; Home care is provided in every county; and day care is 
available in 7 locations. In addition there are approximately 170 palliative care support beds 
across the country.
36 A formal linkage 
should be 
established 
between the 
National Cancer 
Forum and the 
National Council 
for Specialist 
Palliative Care. 
The National Council for Specialist Palliative Care is no longer in existence. Strategic planning 
and clinical responsibility for Palliative Care is under the remit of the National Clinical 
Programme. This is undertaken in collaboration with Palliative Care Services within the Acute 
Hospitals Division.
A Palliative Care Consultant participates on the NCCP the Steering Committee for Tumour 
Groups and on the NCCP Survivorship Group. 
37 The HSE should 
ensure that access 
to comprehensive 
psycho-oncology 
and psychosocial 
support is provided 
for cancer patients 
and their families 
in each Managed 
Cancer Control 
Network. 
Psycho-oncology is included within cancer nursing education programmes. 
Increasing emphasis is now placed on Survivorship and during 2014 the NCCP will develop 
a comprehensive survivorship programme to address communication issues and information 
needs of both cancer survivors and healthcare professionals.
38 A partnership 
framework should 
be developed 
between the HSE 
and the voluntary 
sector. 
Regular meetings take place between the NCCP and the Irish Cancer society, the Marie Keating 
Foundation and a number of other voluntary groups. 
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39 A code of 
practice should 
be developed for 
self-help groups, 
support groups and 
support centres. 
Following on from the publication of the 2006 strategy the Irish Cancer Society developed a 
code of practice for cancer support services and in 2011 it published ‘Guidelines for Cancer 
Support Services in Ireland’ http://www.cancer.ie/sites/default/files/contentat.tachments/ics_
support_groups_guidelines_2011.pdf
40 HIQA should 
establish a National 
Framework for 
Quality in Cancer 
Control. 
HIQA published national quality guidelines for Symptomatic Breast Disease in 2007. 
A national agreed monitoring programme for Symptomatic Breast Disease services is in place in 
all designated cancer centres to capture and monitor SBD standards and activity.  
HIQA developed Safer, Better Health Care as a quality framework for health services in 2012 – 
this will be applicable for all health services including cancer. However in order to implement 
Safer Better Heath care in Breast services the NCCP has specifically developed guidance for 
quality assurance in Symptomatic breast services. The 2007 Breast standards have now been 
subsumed into Safer Better Healthcare. 
The NCCP has developed a number of Key Performance indicators for cancer care which are 
captured and monitored monthly and reported quarterly. 
Annual Audit quality and Research days are now held for breast, prostate, pancreatic and lung 
tumour groups.and separately for medical and radiation oncology.
41 HIQA should 
establish 
site-specific 
multidisciplinary 
groups at a 
national level to 
develop guidelines 
for quality in major 
cancers. 
The NCCP has established expert National Tumour Groups for breast, lung, prostate, GI and 
gynaecological cancers. These tumour groups are developing multi disciplinary evidence‐based, 
guidelines for diagnosis, staging and treatment of the site specific cancers. The Royal College 
of Physicians and Surgeons have nominated expert consultants to lead this key initiative. These 
evidence‐based guidelines are being developed in line with international best practice and 
to meet the requirements of the National Clinical Effectiveness Committee (NCEC). Three 
completed draft guidelines (breast, prostate and gestational trophoblastic disease) have gone 
for stakeholder consultation. 
42 HIQA should 
develop a system 
of licensing and 
accreditation of 
Cancer Centres 
and services that 
should apply to 
both the public and 
private sectors. The 
systems of licensing 
and accreditation 
should be given 
statutory effect. 
Work is currently underway in the Department on legislative proposals relating to the 
development of a licensing framework for health facilities, including cancer centres. Such a 
framework will provide for a mandatory system of licensing for public and private health service 
providers. It will be designed to improve patient safety by ensuring that healthcare providers do 
not operate below core standards which are applied in a consistent and systematic way.
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43 HIQA should 
develop a cancer 
surveillance system 
that will build 
on the existing 
system of cancer 
registration. 
The National Cancer Registry of Ireland (NCRI) collects data on every new cancer in public and 
private hospitals in Ireland, it also has the remit for cancer outcomes such as survival analysis 
A cancer minimum dataset has been defined and communicated to all cancer centres. 
An agreed monitoring programme for symptomatic breast diseases (SBD) is in place and all 
centres have a data capture system for SBD. 
Some progress has been made in developing KPIs for other tumour groups and treatment 
modalities 
44 Mandatory 
notification of 
cancer should 
be put in 
place through 
appropriate 
legislation. 
Legislation has not been enacted to introduce mandatory notification of cancer. 
45 HIQA should 
ensure that a 
minimum national 
dataset should be 
collected for all 
cases of cancer. 
The NCRI collects data on every new cancer in public and private hospitals in Ireland and has a 
standard dataset that is collated on every cancer case. To align clinical datasets with NCRI data, 
a core national cancer dataset has been defined by the NCRI and accepted as policy by the 
NCCP.  This has been communicated to all cancer centres and key variables from this dataset 
form the basis of individual tumour clinical datasets. 
46 HIQA should 
ensure that the 
public has access 
to high-quality up 
to date information 
about all aspects of 
cancer. 
The NCCP has produced several booklets in relation to cancer prevention and treatment. The 
Irish Cancer Society has also produced many patient information booklets. The NCCP website 
is currently being updated and will include additional cancer related information. HIQA’s role at 
present is not focused on informing the public on health related issues.
47 General 
practitioners 
should have 
comprehensive 
information that 
enables informed 
referral and other 
management 
decisions. 
Standardised referral processes and referral guidelines have been produced for breast, lung and 
prostate cancers and for pigmented lesions. Electronic referral processes are in place for these 
cancers. Melanoma guidelines are being piloted in Cork pending national expansion although 
national rollout is not complete yet for pigmented lesions. Patient booklets have been produced 
for breast, prostate and lung cancers.
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48 Information 
systems and 
information 
technology should 
be developed by 
the HSE to support 
the management 
and delivery of 
cancer services. 
In primary care the NCCP has introduced a system of electronic referrals directly from GPs to 
designated cancer centres. National electronic referrals have now been embedded in all ICGP 
accredited software systems. 30% of all breast, prostate and lung cancer referrals are now sent 
electronically. 
It is estimated that by the end of 2013, 15,000 electronic referrals will have been received for 
breast, prostate and lung cancers. This is a 50% increase on 2012 and a seven fold increase 
since the scheme was introduced in 2010.  
A key information technology project being progressed by the NCCP’s Medical Oncology 
Programme is the development of a business case for a national medical oncology clinical 
information system for the optimal and safe delivery of systemic cancer treatment, including 
computerised ordering, prescribing and administration of these treatments in publicly funded 
hospitals. 
The National Cancer Registry of Ireland (NCRI) is a key source of information in relation to 
cancer incidence and prevalence in Ireland. There are a number of projects underway to 
improve timeliness of the NCRI data via the electronic transfer of histopathology data project.
Key Performance Indicators (KPIs) have been agreed for other tumour groups (including 
prostate, lung, rectal, pancreas and upper gastro intestinal cancers).  Collation of data for 
pancreatic and upper gastrointestinal cancers commenced in January 2012 and data collection 
for prostate, lung and rectal cancers is planned to commence in January 2014.   All cancer 
centres have the necessary IT infrastructure to collate data on these cancers though the cost of 
additional licenses and datasets is challenging for hospitals.  Supporting data collection remains 
a challenge for many hospitals. 
National collation of data on radiation oncology activity and timeliness commenced in 2012 and 
on medical oncology activity and timeliness in 2013.
Furthermore, there is increased use of other available routine data systems such as Hospital 
Inpatient Enquiry System (HIPE) and the Patient Treatment Register (PTR) to monitor cancer 
related activity.
49 HIQA should 
establish a Cancer 
Health Technology 
Assessment Panel. 
In 2011 the NCCP established a Technology Review Committee which is responsible for 
reviewing proposals received from industry or expert groups in Ireland for funding of new drugs, 
or expanded indications for existing drugs or related predictive laboratory tests.
The Committee reports to the Director of the National Cancer Control Programme and make 
recommendations on the priority for consideration of implementation of a new treatment or 
test. The recommendations are based on the degree of clinical effectiveness, the acute and 
chronic toxicity and the cost effectiveness of the proposed technology. A nominee from HIQA 
has been appointed to the membership of the Committee.
50 The HSE should 
develop a National 
Cancer Workforce 
Plan designed to 
fully implement 
national cancer 
policy. 
The NCCP has commenced work with the HSE Medical Education and Training (MET) Body 
regarding work force planning for cancer services. A strategy has been developed for expansion 
of medical oncology staffing. 
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51 The third National 
Cancer Forum, in 
partnership with 
the HRB, should 
advise on the 
development of 
a specific plan for 
cancer research. 
High-quality research is an important part of cancer control. The Health Research Board is the 
lead agency for supporting and funding health research. Funding is provided through the HRB 
for research areas including cancer incidence, causes and treatment.
Ireland is also a participating state in the International Agency for Research on Cancer, which 
provides valuable research into many aspects of cancer control.
52 There should be 
improved clinical 
trial entry for 
patients, both 
in terms of the 
number of trials 
conducted and the 
enrolment to them. 
The All Ireland Co-operative Oncology Research Group (ICORG) is a North-South organisation 
that brings cancer clinical research to Ireland. ICORG has succeeded in offering research options 
to over 10,300 patients in the last fifteen years. 
53 Ireland should 
establish a national 
tissue bio bank to 
support research 
and service 
delivery. 
The Action Plan for Jobs 2013 includes an action “to take steps to establish a national 
biobanking system and support infrastructure by 2016”. The HRB, in collaboration with other 
relevant stakeholders is engaged in ongoing discussion in relation to the model and funding for 
such a system.
54 The HRB should 
establish a national 
cancer research 
database. 
The HRB has a database of all funding grants which it has allocated, including cancer related 
research grants. Other awarding agencies include ICORG and the Irish Cancer Society.
55 The HSE should 
present a report on 
policy indicators 
each year to the 
National Cancer 
Forum. 
The NCCP captures monthly data on agreed national Key Performance indicators. These are 
published quarterly as part of the HSE Performance Reports on the Service Plan. 
The NCCP meets monthly with the Department of Health to provide updates on all relevant 
matters and to review progress on policy issues; 
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Cancer Development Funding
•	 The	increasing	incidence	of	cancer,	prolonged	survival	along	with	the	high	costs	of	novel	drugs	and	
technologies has resulted in significant challenges in funding cancer care. The majority of funding for 
cancer services is within the acute hospitals core budget or in the case of oncology drugs is held in 
primary care. 
•	 Dedicated	cancer	service	development	funding	and	staffing	was	provided	to	the	NCCP	and	NCSS	
between 2007 and 2014. This funding supplemented that which was already within the base funding of 
the acute hospitals and was allocated towards agreed service priorities.
•	 Critically,	all	cancer	development	funding	has	continued	to	remain	under	the	NCCP	and	is	allocated	to	
the relevant agencies on a once off basis each year. This approach has ensured that cancer funding has 
not been subjected to financial cuts imposed on hospital services. 
Dedicated Development Funding and Resources for the National Cancer Control Programme and the 
National Cancer Screening Services, 2007-2014
Agency Year WTEs
Budget 
(M)
Priorities for Funding 
National 
Cancer 
Control 
Programme 
2007 3.5 Symptomatic Breast Cancer Services 
2008 51 10.0 Symptomatic Breast Cancer Services
2009 88 13.3 Rapid Access Clinics & Neuro-oncology 
2010 25 8.0 Surgical and medical oncology&  dermatology 
2011 28 1.5 Theatre and critical care support 
2012 0 0
2013 0 17 Oncology Drug Funding 
2014 0 3.5 Oncology drug funding & molecular testing
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Agency Year WTEs
Budget 
(M)
Priorities for Funding 
National 
Programme 
for Radiation 
Oncology 
2007 0 3.25
2008 39 5.0
2009 12 1.7
2010 54 8.0
2011 0 8.0
2012 - -
After 2011 radiation oncology services were directly funded for 
development priorities
2013 - -
2014 - -
National 
Cancer 
Screening 
Services 
2007 - -
Prior to 2012 the NCSS were directly funded for development 
priorities
2008 - -
2009 - -
2010 - -
2011 - -
2012 20 3.4 BowelScreen & Diabetic RetinaScreen
2013 0 9.2 BowelScreen & Diabetic RetinaScreen
2014 0 6.5 BowelScreen & Diabetic RetinaScreen
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